Conditions: Non-Hodgkin Lymphoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 139
Healthy volunteers: no

Brief summary:
This open-label, single-arm study will evaluate the safety of rituximab subcutaneously (SC) administered during first line treatment for follicular non-Hodgkin's lymphoma (NHL) (Induction and/or Maintenance treatment plus 24 months of follow up), or diffuse large B-cell lymphoma (DLBCL) (treatment plus 24 months of follow-up).

Detailed description:

Arms:
arm 1: Participants with FL and DLBCL will receive rituximab SC 1400 milligrams (mg) once a month for a minimum of 4 cycles as induction therapy. Participants with FL will continue to receive rituximab once in 2 months for a minimum of 6 cycles as maintenance therapy according to local standards of care. Participants will also receive standard chemotherapy regimen (CHOP \[cyclophosphamide+doxorubicin+vincristine+prednisone\], CVP \[cyclophosphamide+vincristine+prednisone\] or FC \[fludarabine+cyclophosphamide\]) during induction.

Interventions: intervention 1: Rituximab intervention 2: Cyclophosphamide intervention 3: Doxorubicin intervention 4: Vincristine intervention 5: Prednisone intervention 6: Fludarabine
Intervention descriptions: intervention 1: Rituximab SC 1400 mg intervention 2: Cyclophosphamide will be administered as per standard local practice. intervention 3: Doxorubicin will be administered as per standard local practice. intervention 4: Vincristine will be administered as per standard local practice. intervention 5: Prednisone will be administered as per standard local practice. intervention 6: Fludarabine will be administered as per standard local practice.

Protocol document:
Prot_000.pdf: 
Official Title: 
An Open-Label, Multinational, Multicenter, Phase IIIB Study to 
Assess Safety of Rituximab Following Subcutaneous Administration 
in Patients With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 
3A 
NCT Number: 
NCT02406092 
Document Date: 
Protocol Version 3.1: 07-February-2016 


 
PROTOCOL 
TITLE:
AN OPEN-LABEL, MULTINATIONAL, 
MULTICENTER, PHASE IIIB STUDY TO ASSESS 
SAFETY OF RITUXIMAB FOLLOWING 
SUBCUTANEOUS ADMINISTRATION  IN 
PATIENTS WITH CD20+ DLBCL OR CD20+ 
FOLLICULAR NHL GRADE 1 TO 3A 
PROTOCOL NUMBER:
ML28964 
VERSION NUMBER:
3.1 
EUDRACT NUMBER:
 
IND NUMBER:
N/A 
TEST PRODUCT:
Rituximab (RO 45-2294) 
MEDICAL MONITOR:
 
SPONSOR:
Roche Algeria 
DATE FINAL:
See electronic date stamp below 
 
 
FINAL PROTOCOL APPROVAL 
Name: 
Signature: 
Date: 
 
  
  
 
 
 
 
Date 
 
 
 
 
 
 
Date 
 
 
 
CONFIDENTIAL STATEMENT 
 
This clinical study Mabrella program is being sponsored globally by F. Hoffmann-La 
Roche Ltd of Basel, Switzerland.  However, it may be implemented in individual 
countries by Roche’s local affiliates as daughter studies.  Thus the information 
contained in this document, especially any unpublished data, is the property of 
Roche Algeria spa. (or under its control) and therefore is provided to you in 
confidence as an investigator, potential investigator, or consultant, for review by you, 
your staff, and an applicable Ethics Committee or Institutional Review Board. It is 
understood that this information will not be disclosed to others without written 
authorization from Roche except to the extent necessary to obtain informed consent 
from persons to whom the drug may be administered. 


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
2 
TABLE OF CONTENTS 
1. 
BACKGROUND ........................................................................................... 20 
1.1 
Background on Non-Hodgkin’S Lymphoma ........................... 20 
1.1.1 
Epidemiology .......................................................................... 21 
1.1.2 
Current Management ............................................................. 22 
1.2 
Background on Rituximab ...................................................... 24 
1.2.1 
Rituximab IV ........................................................................... 25 
1.2.2 
Subcutaneous (SC) Rituximab ............................................... 32 
1.3 
Study Rationale and Benefit–Risk Assessment...................... 35 
2. 
OBJECTIVES .............................................................................................. 37 
2.1 
Primary Objective ................................................................... 37 
2.2 
Secondary Objectives ............................................................ 37 
2.3 
Patient-Reported Outcome Objectives ................................... 37 
2.4 
Healthcare ProfessIonal reported outcome 
objectıves ............................................................................... 37 
3. 
STUDY DESIGN .......................................................................................... 38 
3.1 
Description of Study ............................................................... 38 
3.1.1 
Overview ................................................................................ 38 
3.1.2 
Independent Review Committee ............................................ 41 
3.1.3 
Independent Data Monitoring Committee ............................... 41 
3.1.4 
Clinical Events Committee ..................................................... 41 
3.1.5 
Steering Committee ................................................................ 41 
3.2 
End of Study ........................................................................... 41 
3.3 
Rationale for Study Design ..................................................... 41 
3.3.1 
Rationale for Test Product Dosage ........................................ 41 
3.3.2 
Rationale for Patient Population and Analysis Group ............. 41 
3.3.3 
Rationale for Chemotherapy .................................................. 42 
3.3.4 
Rationale for Biomarker Assessments ................................... 42 
3.4 
Outcome Measures ................................................................ 42 
3.4.1 
Safety Outcome Measures ..................................................... 42 
3.4.2 
Efficacy Outcome Measures .................................................. 42 
3.4.3 
Exploratory Outcome Measures ............................................. 43 
3.4.4 
Pharmacodynamic and Pharmacokinetic Outcome 
Measures 43 


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
3 
3.4.5 
Pharmacoeconomic Outcome Measures ............................... 43 
3.4.6 
Patient-Reported Outcome (PRO) Measures ......................... 43 
3.4.7 
Healthcare Professional Reported Outcome 
Measures 43 
4. 
MATERIALS AND METHODS ..................................................................... 43 
4.1 
Patients .................................................................................. 43 
4.1.1 
Inclusion Criteria ..................................................................... 43 
4.1.2 
Exclusion Criteria ................................................................... 44 
4.2 
Method of Treatment Assignment and Blinding ...................... 45 
4.3 
Study Treatment ..................................................................... 45 
4.3.1 
Formulation, Packaging, and Handling ................................... 45 
4.3.2 
Dosage, Administration and Compliance ............................... 46 
4.3.3 
Investigational Medicinal Product Accountability .................... 47 
4.3.4 
Post-Trial Access to Rituximab SC ......................................... 47 
4.4 
Concomitant Therapy ............................................................. 47 
4.4.1 
Permitted Therapy .................................................................. 47 
4.4.2 
Prohibited Therapy ................................................................. 48 
4.4.3 
Prohibited Food ...................................................................... 49 
4.4.4 
Initiation of New Anti-lymphoma Treatment ............................ 49 
4.5 
Study Assessments ................................................................ 49 
4.5.1 
Description of Study Assessments ......................................... 49 
4.5.2 
Timing of Study Assessments ................................................ 52 
4.6 
Patient, Study, and Site Discontinuation ................................ 54 
4.6.1 
Patient Discontinuation ........................................................... 54 
4.6.2 
Study and Site Discontinuation............................................... 54 
5. 
ASSESSMENT OF SAFETY ....................................................................... 55 
5.1 
Safety Plan ............................................................................. 55 
5.1.1 
Adverse Events of Special Interest ......................................... 55 
5.1.2 
Interaction with Other Medicinal Products .............................. 55 
5.1.3 
Administration-Associated Reactions and their 
Management............................................................................................. 55 
5.2 
Safety Parameters and Definitions ......................................... 58 
5.2.1 
Adverse Events ...................................................................... 58 
5.2.2 
Serious Adverse Events (Immediately Reportable to 
the Sponsor) ............................................................................................. 59 


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
4 
5.2.3 
Non-Serious Adverse Events of Special Interest 
(Immediately Reportable to the Sponsor) ................................................. 59 
5.3 
Methods and Timing for Capturing and Assessing 
Safety Parameters .................................................................. 59 
5.3.1 
Adverse Event Reporting Period ............................................ 59 
5.3.2 
Eliciting Adverse Event Information ........................................ 60 
5.3.3 
Assessment of Severity of Adverse Events ............................ 60 
5.3.4 
Assessment of Causality of Adverse Events .......................... 61 
5.3.5 
Procedures for Recording Adverse Events ............................ 60 
5.4 
Immediate Reporting Requirements from Investigator 
to Sponsor .............................................................................. 65 
5.4.1 
Emergency Medical Contacts ................................................. 65 
5.4.2 
Reporting Requirements for Serious Adverse Events 
and Non-Serious Adverse Events of Special Interest ............................... 66 
5.4.3 
Reporting Requirements for Pregnancies .............................. 66 
5.5 
Follow-Up of Patients after Adverse Events ........................... 67 
5.5.1 
Investigator Follow-Up ............................................................ 67 
5.5.2 
Sponsor Follow-Up ................................................................. 67 
5.6 
Post-Study Adverse Events .................................................... 67 
5.7 
Expedited Reporting to Health Authorities, 
Investigators, Institutional Review Boards, and Ethics 
Committees ............................................................................ 68 
6. 
STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN........................ 68 
6.1 
Determination of Sample Size ................................................ 68 
6.2 
Summaries of Conduct of Study ............................................. 69 
6.3 
Summaries of PATIENT pOPULATION ................................. 69 
6.3.1 
Analysis Populations .............................................................. 69 
6.4 
Safety Analyses ...................................................................... 69 
6.5 
EFFICACY Analyses .............................................................. 70 
6.6 
Exploratory Analyses .............................................................. 70 
6.7 
Pharmacodynamic and Pharmacokinetic Analyses ................ 70 
6.8 
Pharmacoeconomic Analyses ................................................ 70 
6.9 
Patient-Reported Outcome Analyses ..................................... 70 
6.10 
Healthcare professıonal reported outcome analyses ............. 70 
6.11 
Interim Analyses ..................................................................... 70 
7. 
DATA COLLECTION AND MANAGEMENT ................................................ 70 


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
5 
7.1 
Data Quality Assurance .......................................................... 70 
7.2 
Electronic Case Report Forms ............................................... 70 
7.3 
Electronic Patient-Reported Outcome Data ........................... 72 
7.4 
Source Data Documentation .................................................. 72 
7.5 
Use of Computerized Systems ............................................... 72 
7.6 
Retention of Records .............................................................. 73 
8. 
ETHICAL CONSIDERATIONS .................................................................... 73 
8.1 
Compliance with Laws and Regulations ................................. 73 
8.2 
Informed Consent ................................................................... 73 
8.3 
Institutional Review Board or Ethics Committee ..................... 74 
8.4 
Confidentiality ......................................................................... 74 
8.5 
Financial Disclosure ............................................................... 74 
9. 
STUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRATION ...................................................................................... 74 
9.1 
Study Documentation ............................................................. 74 
9.2 
Site Inspections ...................................................................... 75 
9.3 
Publication of Data and Protection of Trade Secrets .............. 75 
9.4 
Protocol Amendments ............................................................ 75 
10. REFERENCES ............................................................................................ 76 
11. APPENDICES .............................................................................................. 80 
11.1 
Appendix 1 Schedule of Assessments ................................... 82 
11.2 
Appendix 2 Response Assessment According to the 
International Working Group Response Criteria ..................... 88 
11.3 
Appendix 3 Grading Systems and Scales .............................. 90 
11.3.1 
ECOG Performance status ..................................................... 90 
11.3.2 
International Prognostic Index (IPI) ........................................ 91 
11.3.3 
Follicular Lymphoma International Prognostic 
Index(FLIPI) .............................................................................................. 92 
11.4 
Appendix 4 Guidelines for Standard Rituximab SC 
Preparation and Administration .............................................. 93 
11.5 
Appendix 5 NCI Common Terminology Criteria for 
Adverse Events ...................................................................... 94 
11.6 
Appendix 6 rıtuxımab admınıstratıon Questıonnaıre 
(rasq-ıv and rasq-sc) .............................................................. 95 
11.7 
Appendıx 7 Healthcare ProfessIonal (HCP) 
questıonnaıre ....................................................................... 100 


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
6 
 
LIST OF TABLES 
Table 1 
Efficacy Summary of Phase III Randomized Controlled Trials of R-CHOP 
in Previously Untreated 
DLBCL……………………………………………………..25 
Table 2 
Efficacy Summary of Phase III Randomized Controlled Trials of Rituximab 
Plus Chemotherapy in Previously Untreated 
FL………………………….……27 
Table 3 
Safety Summary of Select Randomized Controlled Trials of R-CHOP in 
Previously Untreated 
DLBCL………………………………………………..……30 
Table 4 
Summary of Adverse Events from Stage 1 of Study 
BP22333……………….33 
Table 5 
Guidelines for Managing Specific Adverse Events related to R-CHOP 
treatment…………………………………………………………………………
…56 
Table 6 
Adverse Event Severity Grading 
Scale…………………………………………59 
 
LIST OF FIGURES 
Figure 1  
Study duration: Patients with CD20+ Follicular NHL…………………………….10 
Figure 2  
Study duration: Patients with CD20+ DLBCL…………………………………….10 
Figure 3  
Study duration: Patients with CD20+ Follicular NHL…………………………….40 
Figure 4  
Study duration: Patients with CD20+ DLBCL…………………………………….41 
 
 


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
7 
PROTOCOL ACCEPTANCE FORM 
TITLE:
AN OPEN-LABEL, MULTINATIONAL, 
MULTICENTER, PHASE IIIB STUDY TO ASSESS 
SAFETY OF RITUXIMAB FOLLOWING 
SUBCUTANEOUS ADMINISTRATION  IN 
PATIENTS WITH CD20+ DLBCL OR CD20+ 
FOLLICULAR NHL GRADE 1 TO 3A 
PROTOCOL NUMBER:
ML28964 
VERSION NUMBER:
3.1 
EUDRACT NUMBER:
{Number} 
IND NUMBER:
N/A 
TEST PRODUCT:
Rituximab (RO 45-2294) 
MEDICAL MONITOR:
 
SPONSOR:
Roche Algeria 
I agree to conduct the study in accordance with the current protocol. 
_______________________________________ 
Principal Investigator’s Name (print) 
_______________________________________ 
_________________________ 
Principal Investigator’s Signature 
 
 
 
 
 
 
Date 
Please return a copy of the form as instructed by your local study monitor. Please retain 
the original for your study files. 


5LWX[LPDE±5RFKH1RUWK$IULFD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±9±)HEUXDU\

35272&2/6<1236,6
7,7/(
$123(1/$%(/08/7,1$7,21$/08/7,&(17(5
3+$6(,,,%678'<72$66(666$)(7<2)5,78;,0$%
)2//2:,1*68%&87$1(286$'0,1,675$7,21,1
3$7,(176:,7+&''/%&/25&')2//,&8/$5
1+/*5$'(72$
35272&2/180%(5
0/
9(56,21180%(5

(8'5$&7180%(5
^1XPEHU`
,1'180%(5
1$
7(67352'8&7
5LWX[LPDE52
3+$6(
,,,E
,1',&$7,21
&'GLIIXVHODUJH%FHOOO\PSKRPDRU&'IROOLFXODUQRQ
+RGJNLQ¶VO\PSKRPDJUDGHWRD
6321625
5RFKH$OJHULD
2EMHFWLYHV
3ULPDU\2EMHFWLYH
•
7RHYDOXDWHWKHLQFLGHQFHRIDGPLQLVWUDWLRQDVVRFLDWHGUHDFWLRQV$$5VIROORZLQJPXOWLSOH
GRVHVRIVXEFXWDQHRXV6&ULWX[LPDEGXULQJ,QGXFWLRQDQGRU0DLQWHQDQFHWKHUDS\LQSDWLHQWV
ZLWK&'IROOLFXODUQRQ+RGJNLQ¶VO\PSKRPD1+/RU&'GLIIXVHODUJH%FHOOO\PSKRPD
'/%&/ZKRKDYHSUHYLRXVO\UHFHLYHGDWOHDVWRQHGRVHRILQWUDYHQRXV,9ULWX[LPDE

•
$$5VDUHGHILQHGDVDOODGYHUVHHYHQWV$(VRFFXUULQJZLWKLQKRXUVRIULWX[LPDE6&
DGPLQLVWUDWLRQDQGZKLFKDUHFRQVLGHUHGUHODWHGWRVWXG\GUXJ$$5VLQFOXGHLQIXVLRQLQMHFWLRQ
UHODWHGUHDFWLRQV,,55VLQMHFWLRQVLWHUHDFWLRQVDGPLQLVWUDWLRQVLWHFRQGLWLRQVDQGDOOV\PSWRPV
WKHUHRI
•

6HFRQGDU\2EMHFWLYHV
•
7RHYDOXDWHSDWLHQWUHSRUWHGRXWFRPHVLQWHUPVRI5LWX[LPDE$GPLQLVWUDWLRQ4XHVWLRQQDLUH
5$64
•
7RIXUWKHUHYDOXDWHWKHVDIHW\RIULWX[LPDE6&LQWHUPVRI
−*UDGH≥$(V
−*UDGH≥$$5V
−6HULRXVDGYHUVHHYHQWV6$(V
•
7RHYDOXDWHWKHHIILFDF\RIULWX[LPDE6&LQWHUPVRI
−HYHQWIUHHVXUYLYDO()6
−SURJUHVVLRQIUHHVXUYLYDO3)6
−2YHUDOOVXUYLYDO26
−GLVHDVHIUHHVXUYLYDO')6
−FRPSOHWHUHVSRQVH&5UDWHLQFOXGLQJFRPSOHWHUHVSRQVHXQFRQILUPHG&5XZHHNV
DIWHUWKHODVWGRVHRI,QGXFWLRQWUHDWPHQW
•7RHYDOXDWHKHDOWKFDUHSURIHVVLRQDORXWFRPHVLQWHUPVRI
− +&3+HDOWKFDUH3URIHVVLRQDO4XHVWLRQQDLUH

2WKHU2EMHFWLYHV
1RWDSSOLFDEOH
6WXG\'HVLJQ
'HVFULSWLRQRI6WXG\
7KLVLVDQRSHQODEHOVLQJOHDUPVWXG\WRHYDOXDWHWKHVDIHW\RIULWX[LPDE6&DGPLQLVWHUHGGXULQJ
ILUVWOLQHWUHDWPHQWIRU)/,QGXFWLRQDQGRU0DLQWHQDQFHWKHUDS\SOXVPRQWKVRIIROORZXSRU
'/%&/WUHDWPHQWSOXVPRQWKVRIIROORZXS


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
9 
This study will include adult patients with CD20+ DLBCL or CD20+ follicular NHL (grade 1 to 3a; 
NHL), who have already received at least one full dose of IV rituximab during first-line treatment, 
induction or maintenance.  
During administration of rituximab SC, patients will be assessed for safety and efficacy as detailed in 
the Schedule of Assessments (see Appendix 1). The Rituximab Administration Questionnaire 
(RASQ, Appendix 6) will be applied to patients and Healthcare Professional (HCP) Questionnaire 
(see Appendix 7) will be applied to health care professionals at the end of the study.  
Induction Therapy: 
NHL patients receiving Induction therapy prior to entry into the study must be eligible to receive at 
least four further cycles of rituximab SC (i.e. 4 additional months of Induction treatment). Patients 
with follicular NHL who will continue into Maintenance therapy (after staging at the end of Induction) 
can continue to receive rituximab SC during Maintenance (see below). 
Maintenance Therapy (patients with follicular NHL): 
NHL patients receiving Maintenance therapy prior to entry into the study must be eligible to receive 
at least six further cycles of rituximab SC (i.e. 12 additional months of Maintenance treatment). 
Patients who are continuing into Maintenance therapy following at least 4 (four) cycles of rituximab 
SC during Induction Therapy must also be eligible to receive at least six cycles of rituximab SC (i.e. 
12 additional months of Maintenance treatment). 
 




5LWX[LPDE±5RFKH1RUWK$IULFD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±9±)HEUXDU\


7DUJHW3RSXODWLRQ
7KHWDUJHWSRSXODWLRQZLOOFRQVLVWRIDGXOWVZLWK&''/%&/RU&'IROOLFXODU1+/JUDGHWR
DDFFRUGLQJWRWKH:RUOG+HDOWK2UJDQL]DWLRQ:+2FODVVLILFDWLRQV\VWHP
,QFOXVLRQ&ULWHULD
3DWLHQWVPXVWPHHWWKHIROORZLQJFULWHULDIRUVWXG\HQWU\
 6LJQHGZULWWHQLQIRUPHGFRQVHQWIRUP
 $JH≥DQG≤\HDUVDWWLPHRIHQUROPHQW
 +LVWRORJLFDOO\FRQILUPHG&''/%&/RU&'IROOLFXODU1+/JUDGHWRDDFFRUGLQJWR
WKH:+2FODVVLILFDWLRQV\VWHP
 &XUUHQWO\EHLQJWUHDWHGZLWKULWX[LPDE,9LQWKH,QGXFWLRQRU0DLQWHQDQFHVHWWLQJKDYLQJ
UHFHLYHGDWOHDVWRQHIXOOGRVHRIULWX[LPDE,9GHILQHGDVVWDQGDUGIXOOGRVHRIULWX[LPDE,9
PJPDGPLQLVWHUHGZLWKRXWLQWHUUXSWLRQRUHDUO\GLVFRQWLQXDWLRQEHFDXVHRIWROHUDELOLW\
LVVXHV
 ([SHFWDWLRQDQGFXUUHQWDELOLW\IRUWKHSDWLHQWWRUHFHLYHDWOHDVWIRXUDGGLWLRQDOF\FOHVRI
WUHDWPHQWGXULQJWKH,QGXFWLRQSKDVHDQGVL[DGGLWLRQDOF\FOHVRIWUHDWPHQWGXULQJWKH
0DLQWHQDQFHSKDVHSDWLHQWVZLWKIROOLFXODU1+/
 ,QGXFWLRQRQO\$Q,QWHUQDWLRQDO3URJQRVWLF,QGH[,3,VFRUHRIRU,3,VFRUHRIZLWK
EXON\GLVHDVHGHILQHGDVRQHOHVLRQ≥FPRU)ROOLFXODU/\PSKRPD,QWHUQDWLRQDO
3URJQRVWLF,QGH[)/,3,ORZLQWHUPHGLDWHRUKLJKULVNVHH$SSHQGL[
 ,QGXFWLRQRQO\$WOHDVWRQHELGLPHQVLRQDOO\PHDVXUDEOHOHVLRQGHILQHGDV≥FPLQLWV
ODUJHVWGLPHQVLRQRQFRPSXWHGWRPRJUDSK\&7VFDQ
 (DVWHUQ&RRSHUDWLYH2QFRORJ\*URXS(&2*SHUIRUPDQFHVWDWXV≤VHH$SSHQGL[
 3DWLHQWVZLWK&''/%&/HOLJLEOHIRU5&+23UHJLPHQ
3DWLHQWVZLWK/9()˃

([FOXVLRQ&ULWHULD
3DWLHQWVZKRPHHWDQ\RIWKHIROORZLQJFULWHULDZLOOEHH[FOXGHGIURPVWXG\HQWU\
&DQFHU5HODWHG&ULWHULD
 7UDQVIRUPHGO\PSKRPDLHKLVWRORJLFHYLGHQFHRIWUDQVIRUPDWLRQWRD%XUNLWWO\PSKRPDRU
IROOLFXODUO\PSKRPD)/*UDGH,,,%
 3ULPDU\FHQWUDOQHUYRXVV\VWHPO\PSKRPDSULPDU\HIIXVLRQO\PSKRPDSULPDU\PHGLDVWLQDO
'/%&/'/%&/RIWKHWHVWLVRUSULPDU\FXWDQHRXV'/%&/
 +LVWRU\RIRWKHUPDOLJQDQF\WKDWFRXOGDIIHFWFRPSOLDQFHZLWKWKHSURWRFRORULQWHUSUHWDWLRQRI
UHVXOWV7KLVLQFOXGHVDPDOLJQDQF\WKDWKDVEHHQWUHDWHGEXWQRWZLWKFXUDWLYHLQWHQWXQOHVVWKH
PDOLJQDQF\KDVEHHQLQUHPLVVLRQZLWKRXWWUHDWPHQWIRU≥\HDUVSULRUWRGRVLQJ1RWH3DWLHQWV
ZLWKDKLVWRU\RIFXUDWLYHO\WUHDWHGEDVDORUVTXDPRXVFHOOFDUFLQRPDRUPHODQRPDRIWKHVNLQRU
LQVLWXFDUFLQRPDRIWKHFHUYL[DUHHOLJLEOHIRUWKHVWXG\
3ULRURU&RQFRPLWDQW7UHDWPHQWV
 2QJRLQJFRUWLFRVWHURLGXVH!PJGD\RISUHGQLVRQHRUHTXLYDOHQW1RWHSDWLHQWV
UHFHLYLQJFRUWLFRVWHURLGWUHDWPHQWZLWK≤PJGD\RISUHGQLVRQHRUHTXLYDOHQWPXVWEH
GRFXPHQWHGWREHRQDVWDEOHGRVHRIDWOHDVWZHHNV¶GXUDWLRQSULRUWRGRVLQJ
/DERUDWRU\$VVHVVPHQWVDW6FUHHQLQJ
 ,QDGHTXDWHUHQDOIXQFWLRQGHILQHGDV
−&UHDWLQLQH!WLPHVWKHXSSHUOLPLWRIQRUPDO8/1XQOHVVQRUPDOFUHDWLQLQHFOHDUDQFH
RUFDOFXODWHGFUHDWLQLQHFOHDUDQFHP/PLQXVLQJWKH&RFNFURIW*DXOWIRUPXOD
 ,QDGHTXDWHKHPDWRORJLFIXQFWLRQGHILQHGDV
−+HPRJORELQJG/
−$EVROXWHQHXWURSKLOFRXQW[/
−3ODWHOHWFRXQW[/


5LWX[LPDE±5RFKH1RUWK$IULFD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±9±)HEUXDU\

 ,QDGHTXDWHKHSDWLFIXQFWLRQGHILQHGDV
−$VSDUWDWHDPLQRWUDQVIHUDVH$67RUDODQLQHDPLQRWUDQVIHUDVH$/7![8/1
−7RWDOELOLUXELQ≥[8/11RWHSDWLHQWVZLWKGRFXPHQWHG*LOEHUWGLVHDVHPD\EHHQUROOHG
LIWRWDOELOLUXELQLV≤[8/1
2WKHU3ULRURU&XUUHQW0HGLFDO&RQGLWLRQVRU7UHDWPHQWV
 +LVWRU\RIVHYHUHDOOHUJLFRUDQDSK\ODFWLFUHDFWLRQVWRKXPDQL]HGRUPXULQHPRQRFORQDO
DQWLERGLHVRUNQRZQVHQVLWLYLW\RUDOOHUJ\WRPXULQHSURGXFWV
 )RUSDWLHQWVZLWK)/DQG'/%&/&RQWUDLQGLFDWLRQWRDQ\RIWKHLQGLYLGXDOFRPSRQHQWVRI
&+23F\FORSKRVSKDPLGHYLQFULVWLQHGR[RUXELFLQDQGSUHGQLVRQHLQFOXGLQJSULRUUHFHLSWRI
DQWKUDF\FOLQHV
2WKHUVHULRXVXQGHUO\LQJPHGLFDOFRQGLWLRQVZKLFKLQWKH,QYHVWLJDWRU¶VMXGJPHQWFRXOG
LPSDLUWKHDELOLW\RIWKHSDWLHQWWRSDUWLFLSDWHLQWKHVWXG\HJVLJQLILFDQWFDUGLRYDVFXODU
GLVHDVHXQFRQWUROOHGGLDEHWHVPHOOLWXVJDVWULFXOFHUVDFWLYHDXWRLPPXQHGLVHDVH
5HFHQWPDMRUVXUJHU\ZLWKLQZHHNVSULRUWRGRVLQJRWKHUWKDQIRUGLDJQRVLV
$FWLYHDQGRUVHYHUHEDFWHULDOYLUDOIXQJDOP\FREDFWHULDOSDUDVLWLFRURWKHULQIHFWLRQ
H[FOXGLQJIXQJDOLQIHFWLRQVRIQDLOEHGVRUDQ\PDMRUHSLVRGHRILQIHFWLRQUHTXLULQJ
WUHDWPHQWZLWK,9DQWLELRWLFVRUKRVSLWDOL]DWLRQUHODWLQJWRWKHFRPSOHWLRQRIWKHFRXUVHRI
DQWLELRWLFVH[FHSWLIIRUWXPRXUIHYHUZLWKLQZHHNVSULRUWRGRVLQJ
$FWLYHKHSDWLWLV%YLUXV+%9RUDFWLYHKHSDWLWLV&YLUXV+&9LQIHFWLRQPXVWEHUXOHGRXW
GXULQJ6FUHHQLQJ
+LVWRU\RIKXPDQLPPXQRGHILFLHQF\YLUXV+,9VHURSRVLWLYHVWDWXV
*HQHUDO&ULWHULD
,QDELOLW\WRSURYLGHLQIRUPHGFRQVHQWDQGFRPSO\ZLWKSURWRFROUHTXLUHPHQWV
/LIHH[SHFWDQF\RIOHVVWKDQPRQWKV
$SRVLWLYHVHUXPSUHJQDQF\WHVWLQZRPHQRIFKLOGEHDULQJSRWHQWLDOZLWKLQGD\VSULRUWR
GRVLQJRUZLWKLQGD\VLIZLWKDFRQILUPDWRU\XULQHSUHJQDQF\WHVWZLWKLQGD\VSULRUWR
GRVLQJ:RPHQRIFKLOGEHDULQJSRWHQWLDODUHGHILQHGDVSUHPHQRSDXVDOZRPHQRUZRPHQ
ZKRDUH\HDUVDIWHUWKHRQVHWRIPHQRSDXVHDQGDUHQRWVXUJLFDOO\VWHULOH
)HUWLOHPHQRUZRPHQRIFKLOGEHDULQJSRWHQWLDOZKRGRQRWDJUHHWRXVHDKLJKO\HIIHFWLYH
PHDVXUHRIFRQWUDFHSWLRQVXFKDVRUDOFRQWUDFHSWLYHVLQWUDXWHULQHGHYLFHRUEDUULHUPHWKRG
RIFRQWUDFHSWLRQLQFRQMXQFWLRQZLWKVSHUPLFLGDOMHOO\RUVXUJLFDOO\VWHULOHWKURXJKRXWWKH
VWXG\DQGIRUDWOHDVWPRQWKVDIWHUWKHODVWGRVHRIULWX[LPDE
/HQJWKRI6WXG\
$VVHVVPHQWVRIWKLVVWXG\ZLOOEHSHUIRUPHGDFFRUGLQJWRWKHW\SHRIO\PSKRPDHLWKHU)/RU
'/%&/6LQFHDVVHVVPHQWVIRU)/SDWLHQWVDUHH[SHFWHGWREHRQVWXG\ORQJHUWKLVSRUWLRQRIWKH
VWXG\ZLOOEHGHWHUPLQDWLYHIRUWKHOHQJWKRIWKHVWXG\)RU)/SDWLHQWVWKHVWXG\LVHVWLPDWHGWRWDNH
DSSUR[LPDWHO\\HDUVPRQWKVEDVHGRQDQDSSUR[LPDWHO\PRQWKRIUHFUXLWPHQWSHULRG
PRQWKVRILQGXFWLRQDQGPRQWKVRIPDLQWHQDQFHWUHDWPHQWDQGPRQWKVRIIROORZXSSHULRG
2QWKHRWKHUKDQG'/%&/SDWLHQWVDUHH[SHFWHGWREHRQVWXG\IRUDVKRUWHUSHULRGRIWLPH
DSSUR[LPDWHO\LQ\HDUVEDVHGRQDSSUR[LPDWHO\PRQWKUHFUXLWPHQWPRQWKVRIWUHDWPHQW
DQGPRQWKVIROORZXSSHULRG
(QGRI6WXG\
7KHHQGRIWKHVWXG\GHILQHGDVODVWSDWLHQWODVWYLVLW/3/9ZLOORFFXUPRQWKVDIWHUWKHODVW6&
ULWX[LPDEWUHDWPHQWIRUWKHODVW)/RU'/%&/SDWLHQWZKLFKHYHUFRPHVODWHU
•
)/SDWLHQWVZKRFRPSOHWHLQGXFWLRQWUHDWPHQWZLOOWKHQHQWHUWKHPDLQWHQDQFHSKDVH
)ROORZLQJWKHODVW6&ULWX[LPDEDGPLQLVWUDWLRQ)/SDWLHQWVZLOOEHIROORZHGXSIRUPRQWKV
•
'/%&/SDWLHQWVZKRUHFHLYHWKHLUODVW6&ULWX[LPDEWUHDWPHQWZLOOWKHQHQWHUWKHSRVW
WUHDWPHQWIROORZXSSKDVH
•
3DWLHQWVZLWK6'RU3'DWVWDJLQJZLOOEHZLWKGUDZQIURPVWXG\WUHDWPHQWDQGZLOORQO\EH
IROORZHG$(VDQGIRUVXUYLYDOXQWLOWKHHQGRIWKHVWXG\
•
3DWLHQWVZKRGRQRWFRPSOHWHWKH,QGXFWLRQWUHDWPHQWSHUSURWRFROZLOOXQGHUJRHQGRI
WUHDWPHQWDVVHVVPHQWZLWKLQZHHNVDIWHUWKHODVWGRVHRI,QGXFWLRQWUHDWPHQWDQGZLOOEH
IROORZHGXQWLOWKHHQGRIWKHZKROHVWXG\DFFRUGLQJWRORFDOSUDFWLFHIRU$(VWXPRXUUHVSRQVH


5LWX[LPDE±5RFKH1RUWK$IULFD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±9±)HEUXDU\

SURJUHVVLRQLI3'QRW\HWGRFXPHQWHGVXUYLYDODQGGRFXPHQWDWLRQRIDQ\QHZDQWL
O\PSKRPDWUHDWPHQW
•
3DWLHQWVZKRFRPSOHWHWKHVWXG\RUGLVFRQWLQXHIURPWKHVWXG\HDUO\ZLOOEHDVNHGWRUHWXUQWR
WKHFOLQLFDIWHUGD\VRUDWOHDVWKDOIOLYHVRIDQ\QRQULWX[LPDE,03VZKLFKHYHU
ORQJHUDIWHUWKHODVWGRVHRIVWXG\GUXJIRUDIROORZXSYLVLW
6DIHW\2XWFRPH0HDVXUHV
6DIHW\RXWFRPHVZLOOLQFOXGH$$5VGHILQHGDVDOOUHODWHG$(VRFFXUULQJZLWKLQKRXUVRIULWX[LPDE
6&DGPLQLVWUDWLRQLQFOXGLQJ,,55VDGPLQLVWUDWLRQVLWHFRQGLWLRQVDQGDOOV\PSWRPVWKHUHRIJUDGH≥
$(VDQG6$(V2WKHUVDIHW\DVVHVVPHQWVLQFOXGHURXWLQHVDIHW\ODERUDWRU\WHVWVYLWDOVLJQV
PHDVXUHPHQWVDQGFKDQJHVLQFRQFRPLWDQWPHGLFDWLRQV$OOFOLQLFDO$(VDQG6$(VDVZHOODV
ODERUDWRU\DEQRUPDOLWLHVZLOOEHUHFRUGHGUHJDUGOHVVRIWKHLULQWHQVLW\JUDGLQJ*UDGLQJZLOOEH
FRPSOHWHGDFFRUGLQJWRWKH1DWLRQDO&DQFHU,QVWLWXWH1&,&RPPRQ7HUPLQRORJ\&ULWHULDIRU
$GYHUVH(YHQWV&7&$(YHUVLRQ
(IILFDF\2XWFRPH0HDVXUHV
7XPRXUDVVHVVPHQWVZLOOEHGRQHDFFRUGLQJWRWKHSURWRFROVFKHGXOHRIDVVHVVPHQWV6HH
$SSHQGL[$SSHQGL[
7XPRXUDVVHVVPHQWVZLOOEHEDVHGRQ&7VFDQVRIWKHQHFNFKHVWDEGRPHQDQGRUSHOYLVLI
GHWHFWDEOHE\WKHVHWHFKQLTXHVRURWKHUGLDJQRVWLFPHDQVHJPDJQHWLFUHVRQDQFHLPDJLQJ>05,@
ZKHUHDSSOLFDEOH2WKHUPHWKRGVHJ05,DUHDFFHSWDEOHIRUSDWLHQWVLQZKRP&7VFDQVDUH
FRQWUDLQGLFDWHG7KH&7VFDQXVHGIRUHOLJLELOLW\DVVHVVPHQWVPD\EHSHUIRUPHGXSWRGD\VSULRU
WRGRVLQJ
5HVSRQVHDVVHVVPHQWVZHHNVDIWHUWKHODVWGRVHRI,QGXFWLRQWUHDWPHQWZLOOEHEDVHGRQWKH
,QYHVWLJDWRU¶VDVVHVVPHQWFRPSOHWHGDFFRUGLQJWRWKH,QWHUQDWLRQDO:RUNLQJ*URXS,:*UHVSRQVH
FULWHULD&KHVRQHWDOVHH$SSHQGL[
7KHHIILFDF\RIULWX[LPDE6&ZLOOEHHYDOXDWHGGXULQJ,QGXFWLRQDQGRU0DLQWHQDQFHLQWHUPVRI()6
3)626&5&5XDQG')6
7KHHQGSRLQWVRI()63)6DQG26ZLOOEHGHILQHGDQGDQDO\VHGWZLFHXVLQJWZRGLIIHUHQWVWDUWLQJ
SRLQWVIRUWKHWLPHWRHYHQWFDOFXODWLRQV7KHILUVWVWDUWLQJSRLQWZLOOEHILUVWGRVHRIULWX[LPDE,9DQG
WKHVHFRQGZLOOEHILUVWGRVHRIULWX[LPDE6&
()6LVGHILQHGDVWKHWLPHIURPILUVWGRVHRIULWX[LPDEDQDO\VHGXVLQJERWKILUVWGRVHRI,9DQGILUVW
GRVHRI6&WRILUVWRFFXUUHQFHRISURJUHVVLRQRUUHODSVHDFFRUGLQJWRWKH,:*UHVSRQVHFULWHULD
&KHVRQHWDOVHH$SSHQGL[RULQLWLDWLRQRIDQRQ±SURWRFROVSHFLILHGDQWLO\PSKRPD
WKHUDS\RUGHDWKZKLFKHYHURFFXUVILUVW
3)6LVGHILQHGDVWKHWLPHIURPILUVWGRVHRIULWX[LPDEDQDO\VHGXVLQJERWKILUVWGRVHRI,9DQGILUVW
GRVHRI6&WRWKHILUVWRFFXUUHQFHRISURJUHVVLRQRUUHODSVHDFFRUGLQJWRWKH,:*UHVSRQVHFULWHULD
&KHVRQHWDOVHH$SSHQGL[RUGHDWKIURPDQ\FDXVH
26LVGHILQHGDVWKHWLPHIURPILUVWGRVHRIULWX[LPDEDQDO\VHGXVLQJERWKILUVWGRVHRI,9DQGILUVW
GRVHRI6&WRGHDWKIURPDQ\FDXVH
')6ZLOOEHDVVHVVHGLQSDWLHQWVDFKLHYLQJ&5&5XDQGLVGHILQHGDVWKHSHULRGIURPWKHGDWHRIWKH
LQLWLDO&5&5XXQWLOWKHGDWHRIUHODSVHRUGHDWKIURPDQ\FDXVH
&5&5XLVFRPSOHWHUHVSRQVHRUFRPSOHWHUHVSRQVHXQFRQILUPHGDQGLVPHDVXUHGZHHNVDIWHU
WKHODVWGRVHRI,QGXFWLRQWUHDWPHQW
([SORUDWRU\2XWFRPH0HDVXUHV
1RWDSSOLFDEOH
3KDUPDFRG\QDPLFDQG3KDUPDFRNLQHWLF2XWFRPH0HDVXUHV
1RWDSSOLFDEOH
3KDUPDFRHFRQRPLF2XWFRPH0HDVXUHV
1RWDSSOLFDEOH
3DWLHQW5HSRUWHG2XWFRPH0HDVXUHV
3DWLHQWVDWLVIDFWLRQZLWKDGPLQLVWUDWLRQRIWUHDWPHQWZLOOEHHYDOXDWHGXVLQJWKH5$64VHH$SSHQGL[
DIWHUWKHULWX[LPDE,9DGPLQLVWUDWLRQDIWHUODVW5LWX[LPDE6&LQLQGXFWLRQDQGDIWHUODVW5LWX[LPDE
6&LQPDLQWHQDQFH7KH5$64ZLOOEHFRPSOHWHGLPPHGLDWHO\DIWHUULWX[LPDEDGPLQLVWUDWLRQDQG
EHIRUHFKHPRWKHUDS\DGPLQLVWUDWLRQLQFDVHWKHSDWLHQWZLOOUHFHLYHFKHPRWKHUDS\3DWLHQWV
SUHPDWXUHO\GLVFRQWLQXLQJWUHDWPHQWGXULQJWKHVWXG\VKRXOGFRPSOHWHWKHTXHVWLRQQDLUHDWWLPHRI


5LWX[LPDE±5RFKH1RUWK$IULFD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±9±)HEUXDU\

GLVFRQWLQXDWLRQDVORQJDVWKH\KDGEHHQDGPLQLVWHUHGDWOHDVWRQHGRVHRIWUHDWPHQWYLDERWK
DGPLQLVWUDWLRQURXWHV
+HDOWKFDUH3URIHVVLRQDO5HSRUWHG2XWFRPH0HDVXUHV
$WWKHHQGRIWKHVWXG\KHDOWKFDUHSURIHVVLRQDO+&3TXHVWLRQQDLUHVHH$SSHQGL[ZLOOEHDSSOLHG
WRKHDOWKFDUHSURIHVVLRQDOVVXFKDVKHPDWRORJLVWVLQWHUQLVWVQXUVHVRURWKHUKHDOWKFDUHSURIHVVLRQDOV
ZKRDGPLQLVWHUHGULWX[LPDE6&
6WXG\'UXJDQG6WXG\7UHDWPHQW
7KHWHUPVWXG\GUXJZLOOEHXVHGWKURXJKRXWWKHSURWRFROWRUHIHUWRULWX[LPDE6&7KHWHUPVWXG\
WUHDWPHQWZLOOEHXVHGWRUHIHUWRSURWRFROPDQGDWHGWUHDWPHQWDOVRLQFOXGLQJEDFNJURXQG
FKHPRWKHUDS\DQGRURWKHUSUHPHGLFDWLRQV
,QYHVWLJDWLRQDO0HGLFLQDO3URGXFWV
7HVW3URGXFW
5LWX[LPDE6&7KHULWX[LPDE6&GRVHLVPJIRUDOOSDWLHQWVLQGHSHQGHQWRISDWLHQWERG\
VXUIDFHDUHD%6$7KLVWUDQVODWHVLQWRDQLQMHFWLRQYROXPHRIP/
(DFKDGPLQLVWUDWLRQZLOOFRQVLVWRIDVLQJOH6&LQMHFWLRQRIULWX[LPDEPJLQGHSHQGHQWRI%6$
,QGXFWLRQWKHUDS\ULWX[LPDE6&ZLOODOZD\VEHDGPLQLVWHUHGSULRUWRWKHVHOHFWHGFKHPRWKHUDS\
UHJLPHQZLWKWKHH[FHSWLRQRIWKHFRUWLFRVWHURLGFRPSRQHQWLQ&+23UHJLPHQVRQDYHUDJHRI
RQFHDPRQWKIRUDPLQLPXPRIIRXUF\FOHV
0DLQWHQDQFHWKHUDS\SDWLHQWVZLWKIROOLFXODU1+/ULWX[LPDE6&ZLOOEHDGPLQLVWHUHGDWPRQWK
LQWHUYDOVIRUDPLQLPXPRIVL[F\FOHVDFFRUGLQJWRORFDOVWDQGDUGVRIFDUH

&RPSDUDWRU
1RWDSSOLFDEOH
1RQ,QYHVWLJDWLRQDO0HGLFLQDO3URGXFWV
%DFNJURXQGWKHUDS\&RPPHUFLDOO\DYDLODEOHFKHPRWKHUDS\ZLOOEHXVHGLQFRPELQDWLRQZLWK
ULWX[LPDE6&DVSHUVWDQGDUGORFDOSUDFWLFH)RUIXUWKHUGHWDLOVVHHWKHORFDOSUHVFULELQJLQIRUPDWLRQ
IRU&+23&93RU)&
&RQFRPLWDQWWKHUDS\3DWLHQWVVKRXOGUHFHLYHIXOOVXSSRUWLYHFDUHVXFKDVJUDQXORF\WHFRORQ\
VWLPXODWLQJIDFWRU*&6)VXSSRUWWUDQVIXVLRQVRIEORRGDQGEORRGSURGXFWVSURSK\ODFWLFDQWLYLUDO
PHGLFDWLRQDQWLELRWLFVDQWLHPHWLFVRUORFDODSSOLFDWLRQRIUDGLRWKHUDS\IRUFRQVROLGDWLRQDIWHU
LQGXFWLRQDVDSSOLFDEOHDQGDFFRUGLQJWRLQVWLWXWLRQDOVWDQGDUGV0HVQD0HUFDSWR(WKDQH
6XOIRQDWHVRGLXPPD\EHXVHGDVSURSK\OD[LVRIKDHPRUUKDJLFF\VWLWLV
3UHPHGLFDWLRQ,QRUGHUWRUHGXFHWKHLQFLGHQFHDQGVHYHULW\RI,,55VLWLVUHFRPPHQGHGWKDWDOO
SDWLHQWVUHFHLYHWKHIROORZLQJSUHPHGLFDWLRQDGPLQLVWHUHGPLQXWHVSULRUWRHDFKULWX[LPDE
DGPLQLVWUDWLRQ
•
SDUDFHWDPRODFHWDPLQRSKHQ
•
GLSKHQK\GUDPLQHK\GURFKORULGHRUDOWHUQDWLYHDQWLKLVWDPLQH
7XPRU/\VLV6\QGURPH3URSK\OD[LV7/6SUHYHQWLRQPD\LQFOXGHK\GUDWLRQDQGSURSK\ODFWLF
UDVEXULFDVHUHFRPELQDQWXUDWHR[LGDVHLQKLJKULVNSDWLHQWVK\GUDWLRQSOXVDOORSXULQRORU
UDVEXULFDVHIRULQWHUPHGLDWHULVNSDWLHQWVDQGFORVHPRQLWRULQJRIHOHFWURO\WHDEQRUPDOLWLHVIRUORZ
ULVNSDWLHQWV3ULPDU\PDQDJHPHQWRIHVWDEOLVKHG7/6LQYROYHVVLPLODUUHFRPPHQGDWLRQVZLWKWKH
DGGLWLRQRIDJJUHVVLYHK\GUDWLRQDQGGLXUHVLVSOXVDOORSXULQRORUUDVEXULFDVHIRUK\SHUXULFHPLD
6WDWLVWLFDO0HWKRGV
7KHDQDO\VLVRIWKLVVWXG\ZLOOEHH[SORUDWRU\DQGZLOOSULPDULO\PDNHXVHRIGHVFULSWLYHVWDWLVWLFDO
PHWKRGV,QDGGLWLRQH[SORUDWRU\VWDWLVWLFDOWHVWLQJDQGPRGHOLQJZLOOEHXVHGWRKLJKOLJKWLQWHUHVWLQJ
DVSHFWVRIWKHGDWD$OOWHVWVZLOOEHWZRVLGHGDQGFDUULHGRXWZLWKDαHUURUUDWHZLWKRXW
FRUUHFWLRQIRUPXOWLSOLFLW\
$OOHQUROOHGSDWLHQWVZKRUHFHLYHDWOHDVWRQHGRVHRIVWXG\PHGLFDWLRQZLOOEHLQFOXGHGLQWKH6DIHW\
3RSXODWLRQZKLFKZLOOEHWKHSULPDU\DQDO\VLVSRSXODWLRQIRUVDIHW\SDUDPHWHUV$OOHQUROOHGSDWLHQWV
ZLOOEHLQFOXGHGLQWKH,QWHQWWR7UHDW3RSXODWLRQZKLFKZLOOEHWKHSULPDU\DQDO\VLVSRSXODWLRQIRU
HIILFDF\SDUDPHWHUV2WKHUDQDO\VLVSRSXODWLRQVPD\EHGHILQHGEDVHGRQPRUHUHVWULFWLYHFULWHULD
VXFKDVIXOILOOPHQWRIHOLJLELOLW\FULWHULDRUDPLQLPXPGXUDWLRQRIWKHREVHUYDWLRQSHULRG


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
15 
Endpoint and Analysis 
Safety will be assessed on the following safety parameters: AARs, including IIRRs, AEs, AEs of 
grade  3, SAEs, routine laboratory parameters, vital signs, concomitant medications, premature 
withdrawal from the study and from study medication due to AEs or ECOG performance status.  
The incidence of AARs AEs, AEs leading to premature discontinuation or interruption of study 
treatment, SAEs, grade  3 AEs will be estimated with 95%-Clopper-Pearson confidence intervals. 
The incidence of each AE will be summarized by the primary system-organ class and by preferred 
term. The incidence of deaths and cause of deaths will be listed and summarized. 
Laboratory parameters will be summarized and selected laboratory parameters may also be 
displayed graphically.  
Vital signs will be summarized over time. 
ECOG performance status will be summarized by frequency tables over time and percentage of 
patients in different categories will be presented by bar charts at different time points. 
Concomitant medication will be coded according to the WHO DRUG dictionary and tabulated in 
summary tables.  
All safety analyses will be based on the Safety population. 
The analysis of endpoints measured as a time to event (EFS, PFS, OS and DFS) is based on the 
survivor function, which is the probability of remaining event-free beyond a certain point in time.  The 
survivor function will be estimated using Kaplan-Meier methodology and summarized using the 
range, the 25th and 75th percentiles and median survival along with a 95% confidence interval for 
median survival.  
Endpoints resulting in an incidence rate (e.g. CR/CRu) will be summarized with a 95% Clopper-
Pearson confidence interval. 
Determination of Sample Size  
A sample size of 110 patients is deemed sufficient for this study. In this study, all planned statistical 
analysis will be exploratory in nature as the study will not be powered to address any pre-defined 
statements and only descriptive statistical evaluations will be carried out primarily for safety (and 
efficacy) parameters. Additionally, no published reference is available on administration-associated 
reactions (AARs) following multiple doses of subcutaneous (SC) rituximab during induction and/or 
maintenance therapy in patients with CD20+ follicular non-Hodgkin’s lymphoma (NHL) or CD20+ 
diffuse large B-cell lymphoma (DLBCL). However, with 110 patients a 95% Clopper-Pearson CI for 
the incidence of AARs will be no wider than +/- 9.7%. This width of interval is deemed sufficiently 
precise to draw valid conclusions around the incidence of ARRs. Additionally, enrolment of more 
than 110 patients within the specified indications could also be difficult in participating countries. 
Due to the fact of exploratory nature of the study, drop out patients will not be replaced. 
Interim Analyses  
Not applicable 
Study Procedures  
See Schedule of Assessments, Appendix 1 and Appendix 2.  
 


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
16 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
 
Abbreviation
Definition
aaIPI
Age-adjusted International Prognostic Index 
AAR
Administration-associated reaction 
AE
adverse event 
ALT (SGPT)
alanine aminotransferase 
aPTT
Activated Partial Thromboplastin Time 
AST (SGOT)
aspartate aminotransferase 
BSA
body surface area 
BUN
blood urea nitrogen 
CEC
Clinical Events Committee 
CHO
Chinese hamster ovary 
CHOP
cyclophosphamide, oncovine (vincristine), doxorubicin, 
prednisone/prednisolone  
CHOP-21
CHOP given every 21 days  
CHOP-14
CHOP given every 14 days 
CHVP
cyclophosphamide, doxorubicin, etoposide, 
prednisone/prednisolone 
CI
confidence interval 
CLL
chronic lymphocytic leukaemia 
CR
complete response 
CRF
Case report form 
CRu
complete response unconfirmed 
CRO
contract research organization 
CT
Computed tomography  
CTCAE
Common Terminology Criteria for Adverse Events 
Ctrough
Minimal plasma concentration prior to next drug administration 
CVP
cyclophosphamide, vincristine, prednisone/prednisolone 
DFS
disease-free survival 
DLBCL
diffuse large B-cell lymphoma 
EC
Ethics Committee 
ECG
Electrocardiogram 
ECOG
Eastern Cooperative Oncology Group 
eCRF
electronic Case Report Form 
EDC
electronic data capture 


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
17 
Abbreviation
Definition
EFS
event-free survival 
EGSG
East German Study Group 
EU
FC
FC 28
European Union 
Fludarabine, cyclophosphamide 
FC given every 28 days 
FDA
Food and Drug Administration 
FDG-PET
[18F]deoxyglucose positron emission tomography 
FFS
failure-free survival 
FL
follicular lymphoma 
FLIPI
Follicular Lymphoma International Prognostic Index 
G-CSF
granulocyte colony-stimulating factor 
GELA
Groupe d’Etude des Lymphomes de l’Adulte  
GLSG
German Low-Grade Lymphoma Study Group 
HACA
human antichimeric antibody 
HAMA
human anti-mouse antibody 
HBV
hepatitis B virus  
HCV
hepatitis C virus  
HIPAA
Health Insurance Portability and Accountability Act 
HIV
Human Immunodeficiency Virus 
IB
Investigator’s Brochure 
ICF
informed consent form 
ICH
International Conference on Harmonisation 
IDMC
Independent Data Monitoring Committee 
IDSMB
Independent Data Safety Monitoring Board 
IFN
interferon- 
IMP
investigational medicinal product 
INR
International Normalized Ratio  
IPI
International Prognostic Index 
IRC
Independent Review Committee 
IRF
Independent Review Facility 
IRR
Infusion-related reaction 
IIRR
infusion/injection-related reaction 
ITT
Intent-to-treat  
IV
intravenous(ly) 


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
18 
Abbreviation
Definition
IWG
International Working Group 
LDH
lactate dehydrogenase  
LPLV
last patient, last visit 
MCP
mitoxantrone, chlorambucil, prednisone/prednisolone 
MedDRA
Medical Dictionary for Regulatory Activities 
MInT
MabThera international trial  
MRI
magnetic resonance imaging 
NCI
National Cancer Institute 
NCI CTCAE
National Cancer Institute Common Terminology Criteria for 
Adverse Events  
NHL
Non-Hodgkin’s Lymphoma 
NIMP
Non-investigational medicinal product 
ORR
overall response rate 
OS
overall survival 
PD
progressive disease (disease progression)  
PD
pharmacodynamics 
PET
positron emission tomography 
PFS
progression-free survival 
PK
Pharmacokinetic 
PML
Progressive Multifocal Leukoencephalopathy 
PR
partial response 
PRO
patient-reported outcome 
PT
Prothrombin Time 
RBC
red blood cell count  
RCR
Roche Clinical Repository 
R-CHOP
rituximab plus CHOP chemotherapy 
RCT
randomized controlled trial 
R-CVP
rituximab plus CVP chemotherapy 
R-CHVP
R-FC
rituximab plus CHVP chemotherapy 
Rituximab plus FC chemotherapy 
rHuPH20
recombinant human hyaluronidase 
SAE
serious adverse event 
SAP
Statistical Analysis Plan 
SC
subcutaneous(ly) 
SD
stable disease 


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
19 
Abbreviation
Definition
SEER
Surveillance, Epidemiology, and End Results 
SPD
sum of the products of the greatest diameters 
SUSAR
Suspected Unexpected Serious Adverse Reactions 
SWT
Satisfaction with Therapy  
TLS
Tumour lysis syndrome 
TNLT
time to next lymphoma treatment 
TTF
time to treatment failure 
TTP
time to tumour progression 
ULN
upper limit of normal 
WBC
White blood cell 
WHO
World Health Organization 


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
20 
1. 
BACKGROUND 
1.1 
BACKGROUND ON NON-HODGKIN’S LYMPHOMA 
Non-Hodgkin’s lymphoma (NHL), a heterogeneous group of lymphoproliferative 
malignancies, is one of the leading causes of cancer death in the United States (US) 
and Europe. NHL accounted for 3.2% of new cancer cases and 2.8% of cancer 
deaths in Europe in 2006, making it the 8th leading cause of new cancer cases and 
the 10th leading cause of cancer deaths (Ferlay et al, 2007).  
In Northen Africa, tha age adjusted incidence rate of NHL is 8.4 per 100,000. It’s 
ranked the 3rd cancer of most common cancer in males and females. NHL represent 
the 5th leading cause of cancer deaths in males and the 4th leading cause of cancer 
deaths in women (Globocan 2008).  Among North African countries, Egypt has the 
highest incidence rate of lymphoma, mainly NHL; which is higher than even the 
United States (Ferlay J, et al, 2010). In Morocco, Lymphoma represents 4% of all 
cancers among both Men and women, it’s ranked 5th cancer, with an increasing 
incidence over the last 3 decades. In the following North African countries (Algeria, 
Morocco and Tunisia), the incidence of NHL is higher in males than females 
(Lamchahab M, Quessar A, Maghrebian congress 2012). As with other lymphoid 
neoplasms, its aetiology remains largely unknown, although risk factors include 
certain infections as well as treatments and diseases that cause severe 
immunosuppression. NHL has been classified into two types: aggressive (i.e. fast 
growing) and indolent (i.e. slow growing) (Landis et al. 1999). Categorizing the 
various lymphoid neoplasms has proven to be enormously challenging and has 
resulted in the evolution of numerous classification schemes over the past 50 years. 
In 2001, the World Health Organization (WHO) introduced a new system for 
classifying haematopoietic neoplasms, which, in addition to morphology, 
incorporates immunophenotype, cytogenetic and molecular features, clinical 
behaviour, and some known aspects of aetiology and pathogenesis into the 
definition of each disease subtype (Jaffe et al. 2001). Indolent NHL comprises a 
group of incurable, generally slow-growing lymphomas that are highly responsive to 
initial therapy and are characterized by a relapsing and progressive course. Diffuse 
large B-cell lymphoma (DLBCL) is the most common histologic subtype of NHL 
(Swerdlow S et al, 2008). 
Follicular lymphoma (FL) is the most common of the indolent NHLs (Friedberg, 
2008), accounting for 20-25% of all lymphomas. The disease generally manifests 
with hypertrophy of peripheral and deep lymph nodes and splenomegaly, together 
with bone marrow infiltration. FL is characterized by initial responsiveness to therapy 
followed by repeated relapses and sometimes with histological progression into high-
grade NHL (Horning, 1993). In the WHO classification the histology is further 
classified into grade 1, 2 or 3 FL, depending on the percentage of large cells seen on 
high-power field microscopy (Nathwani et al, 2001). Grade 3 FL is further subdivided 
into 3a and 3b, where 3b may represent a distinct biological entity more similar to 
DLBCL (Nathwani et al, 2001). Biologically, FL has been associated with the 
translocation of chromosomes 14 and 18 [t(14;18)], which results in constitutive 
activation of the bcl-2 oncogene and the subsequent inhibition of apoptosis of 
lymphoid cancer cells (Bordeleau and Berinstein, 2000). Given that FL is currently 
incurable with standard treatment options, there is a need to improve the clinical 
outcomes. 


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
21 
1.1.1 
Epidemiology 
NHLs account for almost 5% of all cancers occurring in the US, with an estimated 
70,130 new diagnoses (38,160 men and 31,970 women) in the year 2012. Based on 
cases diagnosed in 2005-2009 from 18 Surveillance, Epidemiology and End Results 
(SEER) geographic areas, the age-adjusted incidence rate for NHL was 19.6 per 
100,000 men and women per year and the age-adjusted death rate was 6.6 per 
100,000 men and women per year (Howlander et al. 2012). In Algeria and Tunisia, 
the reported age-adjusted incidence rate was <5.3 per 100,000 but in Morocco, it 
was <6.8 per 100,000 (Boffetta P Ann Oncol 2011;22:iv27-iv31).  
A recent study of incidence of NHL has been carried out in Algeria but it contains 
data from Pathology based laboratories from predominantly urban areas. The 
incidence was 3.8 per 100,000 in general with 3.2 per 100,000 in women and 4,4 per 
100,000 in men with a predominance of large B-cell lymphoma.  
In Morocco, the first report of cancer incidence done in Rabat from a population-
based cancer registry for the period 2006–2008 showed 271 malignant 
haemopathies recorded between 2006 and 2008, 11% of all cases, and their 
incidence rate is significantly higher in men than in women (ASR: 18.2 vs. 
10.5/100,000). The most frequent was NHL (43%). The NHL was nodal in 43% of 
cases, while the most frequent extranodal sites were the stomach (12%) and 
nasopharynx (6%). Nearly half of the NHL cases were large B-cell lymphoma (Tazi 
M.A. et al. ecancer 2013) 
The incidence and mortality rates for NHL were reported to have risen steadily in the 
US (with an estimated 50% increase in age-adjusted incidence of NHL from 1970 to 
1990) and in other populations over several decades. Although further reports 
suggested that the steep rise in incidence may have slowed in the late 1990s, this 
group of closely related diseases is still an important contributor to the overall cancer 
burden (Morton et al. 2006; Cartwright 1999; Eltorn et al. 2002; Clarke and Glazer 
2002). Cancer incidence and mortality patterns vary remarkably across regions 
within Africa because of the substantial regional differences in economic 
development and social, cultural, and other environmental factors, including major 
known risk factors (Globocan 2008). 
Among the NHL cases included in the SEER database, B-cell NHL accounted for 
90.4%, T-cell NHL accounted for 6.8%, and NHL of unknown cell lineage accounted 
for 2.8%.  
Based on other reports, FL accounts for 20-25% of all cases of NHL (ILSG 1997). Its 
incidence is rapidly increasing in Western countries and has nearly doubled within 
the past three decades. Like many lymphomas, it is increasing in incidence with over 
24,000 new cases diagnosed each year. It remains incurable with standard 
treatment options. 
DLBCL constitutes 25-30% of NHL cases, and its incidence increases with 
advancing age, such that the disease represents 54% of NHL cases among patients 
older than 75 years (Michallet and Coiffier, 2009; Niitsu 2010). A crude incidence of 
3-4 cases/100,000/year was reported in the European Union, increasing from 0.3 
cases/100,000/year in patients aged 35-39 years to 26.6 cases/100,000/year in 
patients aged 80-84 years (Tilly and Dreyling, 2010). In the US, the incidence of 
DLBCL is approximately 7 cases per 100,000 person years and varies by ethnicity, 
with Caucasian Americans having higher rates than African Americans, Asians, and 
American Indian or Alaska Natives, in order of decreasing incidence (Morton et al, 
2006). 


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
22 
Patients with DLBCL typically present with a rapidly enlarging symptomatic mass, 
most usually nodal enlargement in the neck or abdomen. The median age at 
presentation is approximately 65 years, and it is slightly more common in males than 
females. In appreciation of rapid lymph node enlargement, systemic "B" symptoms 
(i.e. fever, weight loss, drenching night sweats) are present in approximately 30% of 
patients. About 40% of DLBCLs occur from extranodal sites, most commonly the 
gastrointestinal canal. Among DLBCL cases, 11-27% have bone marrow infiltration, 
approximately 50% have elevated serum lactate dehydrogenase (LDH), and about 
half have advanced stage (stage III/IV) disease (Niitsu N, 2010). Bone marrow 
involvement in DLBCL can also be detected after histologic transformation from most 
other types of B-cell lymphoma. In general, patients who have undergone histologic 
transformation have a poorer response to therapy and prognosis than those with a 
de novo appearance (Swerdlow S et al, 2008; Niitsu N, 2010). 
1.1.2 
Current Management 
The CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone) 
regimen, administered every 21 days (and every 14 days in some countries), has 
been the standard therapy for DLBCL for over three decades (Michallet and Coiffier, 
2009; Niitsu 2010). However, the cure rate with CHOP is considered suboptimal, 
with 3-year progression-free survival (PFS) and overall survival (OS) rates of about 
40% and 50%, respectively (Fisher et al. 1993). Rituximab, a genetically engineered 
chimeric monoclonal antibody that specifically binds to CD20, is the first monoclonal 
antibody approved for the treatment of B-cell lymphoma. The addition of rituximab to 
chemotherapy has improved PFS and OS of patients with DLBCL (Niitsu 2010). 
Based on randomized controlled trials (RCTs) demonstrating that the addition of 
rituximab to CHOP (R-CHOP) improved disease-free survival (DFS), event-free 
survival (EFS) and OS, R-CHOP has become the standard of care in DLBCL. 
Rituximab administration on Day 1 of each treatment cycle is also convenient 
(Habermann 2007). 
Since approval was granted for the use of rituximab in the first-line treatment of 
patients with CD20+ DLBCL in combination with CHOP or other anthracycline-based 
chemotherapy regimens, rituximab has been recommended in relevant guidelines as 
standard therapy in the treatment of DLBCL (Tilly and Dreyling 2010; Keating 2010; 
NCCN 2011). 
The scale of therapeutic options for FL is wide and ranges from a watch-and-wait 
policy to aggressive alternatives, such as haematopoietic stem cell transplant. There 
are several reports of significant improvements in the clinical course of the disease 
over the past decades (Swenson et al 2005; Fisher et al, 2005). However, the most 
striking outcome improvement has been achieved with the introduction of anti-CD20 
monoclonal antibodies in combination with standard chemotherapy as demonstrated 
in several phase III studies (Marcus et al, 2005; Marcus et al, 2008; Hiddemann et al, 
2005; Herold et al, 2007; Salles et al, 2008) and registry data (Pulte et al, 2008). The 
combination of rituximab with chemotherapy as first-line treatment has become the 
standard Induction therapy. 
Initial treatment of NHL with chemotherapy (such as alkylating agents, 
prednisone/prednisolone, anthracyclines, vinca alkaloids, purine analogues), 
combined with interferon or monoclonal antibodies such as rituximab is associated 
with a high rate of clinical response, although typically followed by relapse. Patients 
with aggressive B-cell lymphoma are potentially curable when treated with multi-
agent chemotherapy such as CHOP (Fisher et al, 1993). In 30-70% of the FL cases, 
the disease eventually transforms to aggressive lymphoma, responding only to 


Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
23 
combination chemotherapies usually employed for aggressive disease, such as 
anthracyclines or cytosine arabinoside-containing regimens or high-dose 
chemotherapy with autologous stem cell transplantation (Lossos 2005). The 
standard of care for patients with aggressive lymphoma has changed recently with 
the implementation of therapy with the chimeric anti-CD20 monoclonal antibody 
rituximab (Boye et al, 2003). Combination treatment with R-CHOP or similar 
regimens has resulted in superior treatment outcomes compared with multi-agent 
chemotherapy alone, making combined immunochemotherapy with rituximab the 
new standard of care for this group of patients (Feugier et al, 2005). The combination 
of cyclophosphamide, vincristine, and prednisone/prednisolone (CVP) is one of 
several standard treatment options for advanced FL. Similar to other 
chemotherapeutic regimens; this combination induces response rates of 60-80%, 
with median response duration of under 2 years (Marcus et al, 2005).  
A recently published large, prospective, longitudinal, observational study to identify 
current patterns of care of FL in the US (conducted between 2004 and 2007) found 
that amongst the 2728 patients enrolled, the most common initial therapeutic 
strategy was chemotherapy plus rituximab (51.9%), followed by observation (17.7%), 
rituximab monotherapy (13.9%), clinical trial-related interventions (6.1%), radiation 
therapy (5.6%) and chemotherapy alone (3.2%). Chemotherapy plus rituximab 
regimens were R-CHOP (55.0%), rituximab plus CVP (R-CVP, 23.1%), rituximab 
plus fludarabine based-chemotherapy (15.5%), and other (6.4%). The choice to 
initiate therapy rather than observation only was associated with age, Follicular 
Lymphoma International Prognostic Index (FLIPI), stage, and grade (p < 0.01) 
(Friedberg et al, 2009). 
Toxicity of rituximab is mild and occurs most frequently during the first infusion. 
Importantly, it does not produce treatment-related cytopenias or severe cumulative 
toxicity (Sousou and Friedberg, 2010). Compared to single-agent cytotoxic therapy, 
single-agent rituximab was better tolerated and had similar efficacy (McLaughlin et al, 
1998). Several Phase II and Phase III multicentre RCTs demonstrated that the 
addition of rituximab to various chemotherapy regimens in patients with FL 
significantly improves outcomes when compared with standard chemotherapy 
regimens, without adding significant toxicity (Sousou and Friedberg, 2010). In clinical 
trials with rituximab monotherapy given for 4 weeks, haematological abnormalities 
occurred in a minority of patients and were usually mild and reversible. Severe 
(grade 3/4) neutropenia was reported in 4.2%, anaemia in 1.1% and 
thrombocytopenia in 1.7% of the patients. During rituximab Maintenance treatment 
for up to 2 years, grade 3/4 leucopenia (5% vs. 2%, grade 3/4) and neutropenia 
(10% vs. 4%, grade 3/4) were reported at a higher incidence when compared to 
observation. In studies with rituximab in combination with chemotherapy, grade 3/4 
leucopenia, neutropenia, and pancytopenia were reported higher frequencies when 
compared to chemotherapy alone. However, the higher incidence of neutropenia in 
patients treated with rituximab and chemotherapy was not associated with a higher 
incidence of infections and infestations compared to patients treated with 
chemotherapy alone and the neutropenia was not prolonged in the rituximab group. 
There were no differences reported for the incidence of thrombocytopenia or 
anaemia (Rituximab Summary of Product Characteristics). 
Rituximab, an anti-CD20 antibody, has had a large impact on the treatment of 
indolent NHL. Its effectiveness as a single agent and in conjunction with known 
chemotherapy regimens has made it a standard of care in the treatment of NHL. 
Analysis of data obtained from NHL clinical trials, as well as data from the National 


5LWX[LPDE±5RFKH1RUWK$IULFD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±9±)HEUXDU\

&DQFHU,QVWLWXWH1&,LQGLFDWHWKDWWKH26RISDWLHQWVZLWKLQGROHQW1+/KDV
LPSURYHGZLWKWKHXVHRIULWX[LPDEDQGWKDWJLYHQLWVHIIHFWLYHQHVVDQGWROHUDELOLW\
ULWX[LPDELVFXUUHQWO\EHLQJLQYHVWLJDWHGDVDPDLQWHQDQFHDJHQWZLWKHQFRXUDJLQJ
UHVXOWV6RXVRXDQG)ULHGEHUJ

%$&.*5281'215,78;,0$%
5LWX[LPDE52LVDFKLPHULFPXULQHKXPDQPRQRFORQDODQWLERG\WKDW
VSHFLILFDOO\ELQGVWR&'DK\GURSKRELFWUDQVPHPEUDQHSURWHLQSUHVHQWRQWKH
VXUIDFHRI%O\PSKRF\WHV7HGGHUDQG(QJHO,QSUHFOLQLFDOVWXGLHVULWX[LPDE
ZDVVKRZQWRLQGXFHERWKFRPSOHPHQWPHGLDWHGDQGDQWLERG\GHSHQGHQWFHOO
PHGLDWHGO\VHVRI&'FHOOV5HIIHWDO5LWX[LPDEKDVDOVREHHQUHSRUWHG
WRKDYHGLUHFWDQWLWXPRXUDFWLYLW\LQGHSHQGHQWRIWKHKRVWLPPXQHV\VWHPDV
LQGLFDWHGE\WKHLQGXFWLRQRIDSRSWRVLVRIKXPDQ%FHOOOLQHV,QDGGLWLRQLWVHQVLWL]HV
GUXJUHVLVWDQWKXPDQ%FHOOO\PSKRPDFHOOOLQHVWRWKHF\WRWR[LFHIIHFWVRIVRPH
FKHPRWKHUDSHXWLFDJHQWV0DORQH\HWDO'HPLGHPHWDO
7KHPRGHRIDFWLRQRIULWX[LPDELVPHGLDWHGWKURXJKELQGLQJWR&'7KHVSHFLILF
DQGVDWXUDEOHLQWHUDFWLRQRIDQWLERGLHVZLWKWKHLUUHFHSWRULQIOXHQFHVWKH
SKDUPDFRNLQHWLF3.GLVSRVLWLRQ2QFHWDUJHWVLWHVDUHVDWXUDWHGOLQHDU
SKDUPDFRNLQHWLFVDUHREVHUYHG0DJHU3.RIWKHFXUUHQWO\DSSURYHG
LQWUDYHQRXV,9GRVHLQGLFDWHVWKDWWDUJHWVLWHVDUHVDWXUDWHG,WLVH[SHFWHGWKDW
PD[LPDOFOLQLFDOEHQHILWLVDFKLHYHGDWWKHVHFRQFHQWUDWLRQOHYHOV<LQHWDO
$6&2
6HYHUDO5&7VKDYHHVWDEOLVKHGWKHHIILFDF\DQGVDIHW\RIULWX[LPDE,9DGPLQLVWHUHG
DVPRQRWKHUDS\RULQFRPELQDWLRQZLWKFKHPRWKHUDS\LQ1+/)/DQG'/%&/DQG
FKURQLFO\PSKRF\WLFOHXNDHPLD&//OHDGLQJWRPDUNHWLQJDSSURYDOVLQPRUHWKDQ
FRXQWULHV,PSRUWDQWO\WKHDGGLWLRQRIULWX[LPDEWR&+23UHVXOWHGLQDQ
DSSUR[LPDWHO\DEVROXWHLQFUHDVHLQVXUYLYDOEHJLQQLQJDWRQH\HDUIURPLQLWLDWLRQ
RIWKHUDS\LQSDWLHQWVRIDOODJHVZLWKPLQLPDOFOLQLFDOO\UHOHYDQWLQFUHDVHVLQWR[LFLW\
3HWWHQJHOODQG/LQFK%DGLQDQG+D\VOLS5&7VHYDOXDWLQJWKHHIILFDF\
DQGVDIHW\RIULWX[LPDE,9LQSDWLHQWVZLWKXQWUHDWHG'/%&/DUHVXPPDUL]HGLQ
6HFWLRQ
5LWX[LPDELVPDUNHWHGXQGHUWKHEUDQGQDPHV0DE7KHUDDQG5LWX[DQ5LWX[LPDE
ZDVILUVWDSSURYHGLQWKH86XQGHUWKHEUDQGQDPH5LWX[DQLQIRUWKH
WUHDWPHQWRIUHODSVHGRUUHIUDFWRU\LQGROHQW%FHOOO\PSKRPDV&XUUHQWO\ULWX[LPDELV
DSSURYHGIRUWUHDWPHQWRIUHODSVHGRUFKHPRUHVLVWDQWORZJUDGHRUIROOLFXODU
&'%FHOO1+/LQRYHUFRXQWULHVLQFOXGLQJWKH(XURSHDQ8QLRQ(8DQGWKH
86DQGIRUWUHDWPHQWRIUKHXPDWRLGDUWKULWLVLQWKH86DQG(8
7KHDSSURYHGRQFRORJ\LQGLFDWLRQVIRUULWX[LPDELQWKH(8LQFOXGHWKHWUHDWPHQWRI
1+/)/DQG'/%&/DQG&//DVIROORZV
•
)RUSUHYLRXVO\XQWUHDWHGSDWLHQWVZLWKVWDJH,,,,9)/LQFRPELQDWLRQZLWK
FKHPRWKHUDS\
•
$V0DLQWHQDQFHWUHDWPHQWIRU)/UHVSRQGLQJWR,QGXFWLRQWKHUDS\
•
)RU&''/%&/LQFRPELQDWLRQZLWK&+23FKHPRWKHUDS\
•
$VPRQRWKHUDS\IRUWUHDWPHQWRISDWLHQWVZLWKVWDJH,,,,9)/ZKRDUHFKHPR
UHVLVWDQWRUDUHLQWKHLUVHFRQGRUVXEVHTXHQWUHODSVHDIWHUFKHPRWKHUDS\
•
)RUSUHYLRXVO\XQWUHDWHGRUUHODSVHGUHIUDFWRU\&//LQFRPELQDWLRQZLWK
FKHPRWKHUDS\
2YHUWKHSDVWGHFDGHWKHXVHRIULWX[LPDEKDVUDGLFDOO\FKDQJHGWKHWUHDWPHQWRI
1+/DQGKDVEHFRPHVWDQGDUGLQWKHPDQDJHPHQWRISDWLHQWVVXIIHULQJIURPYDULRXV
%FHOOPDOLJQDQFLHVLQFOXGLQJ)/'/%&/DQG&//,WKDVEHHQREVHUYHGWKDWWKH




Rituximab – Roche North Africa (Algeria, Morocco &Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016 
26 
Abbreviations: aaIPI: age-adjusted International Prognostic Index (score); CR: complete response; CRu: 
complete response unconfirmed; FU: follow-up; GELA: Groupe d’Etude des Lymphomes de l’Adulte; IPI: 
International Prognostic Index (score); Med: median; mo: months; MInT: MabThera International Trial; NR: not 
reported; yrs: years 
1.2.1.2 
Efficacy of Rituximab IV Plus Chemotherapy in the Treatment of 
FL 
Several multicentre RCTs have demonstrated that the addition of rituximab to first-
line therapy for FL significantly improves clinical outcomes when compared with 
standard chemotherapy regimens of varying intensities, without adding significant 
toxicity. See details in Table 2. 












Rituximab – Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
32 
and 97% vs. 88% respectively), but the incidence of grade 2 to 4 infections was only 
slightly higher (46% in the R-CHOP arm compared to 42% in the CHOP arm). 
1.2.1.3.3 
Other toxicities 
Tumour Lysis Syndrome (TLS) has been reported to occur after the first rituximab 
infusion in patients with a high tumour burden or high numbers of circulating 
malignant lymphocytes during Induction treatment.  
Pulmonary events were also reported. They have included hypoxia, pulmonary 
infiltrates, and acute respiratory failure.  
In studies evaluating rituximab in combination with chemotherapy, the incidence of 
grade 3 and 4 cardiac arrhythmias, predominantly supraventricular arrhythmias such 
as tachycardia and atrial flutter/fibrillation, was higher in the R-CHOP group (14 
patients, 6.9%) as compared to the CHOP group (3 patients, 1.5%) (Rituximab 
Summary of Product Characteristics). 
Very rare cases of hepatitis B reactivation, including reports of fulminant hepatitis, 
have been reported in patients receiving rituximab, although these reports are 
confounded by both underlying disease and exposure to other cytotoxic 
chemotherapy. Patients with a history of hepatitis B infection should be carefully 
monitored for signs of active hepatitis B infection when rituximab is used in 
association with cytotoxic chemotherapy. 
Use of rituximab may be associated with an increased risk of Progressive Multifocal 
Leukoencephalopathy (PML). Patients must be monitored at regular intervals for any 
new or worsening neurological symptoms or signs that may be suggestive of PML. If 
PML is suspected, further dosing must be suspended until PML has been excluded. 
Some patients who were treated with rituximab and chemotherapy have developed 
gastrointestinal perforation.  
Immunization following rituximab treatment in the oncology setting has been 
evaluated in controlled studies. Impaired response to tetanus, influenza, and the 
neo-antigen keyhole limpet hemocyanin were observed. It is recommended that any 
course of immunization for patients should be completed at least 4 weeks before 
starting rituximab Maintenance therapy and patients should not receive any 
vaccinations that contain live or attenuated organisms during the study. 
Further information concerning rituximab safety can be found in the current version 
of the IB for rituximab IV, Summary of Product Characteristics and local prescribing 
information. 
1.2.2 
Subcutaneous (SC) Rituximab 
In contrast to the IV infusion, the rituximab SC injection takes only 5-6 minutes, and 
could thus significantly reduce the time a patient spends in the hospital and could 
eliminate hospital burdens associated with IV administration (e.g., nursing time for IV 
dosing, clinic space and utilities). It is therefore envisaged that an SC formulation of 
rituximab could bring significant clinically-meaningful benefits to patients and 
considerable economic reductions to healthcare providers. 
Until now, the relatively large volume of the established rituximab IV dose has 
hindered the SC administration route for rituximab. By concentrating the IV rituximab 
formulation 12-fold and by adding recombinant human hyaluronidase (rHuPH20) as 
a novel excipient and a permeation enhancer, the injectable volume is no longer 
considered to be an issue. rHuPH20 hydrolyses hyaluronic acid fibres of the 
interstitial matrix allowing the installation of volumes larger than 2-3 mL and 
increasing the dispersion of locally injected drugs across a broad range of molecular 
weights without tissue distortion. rHuPH20 improves the PK profiles of large 
biopharmaceuticals administered via the interstitial route and drives the PK profile 




Rituximab – Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
34 
CTC: common terminology criteria; SAE: serious adverse event; SC: subcutaneous  
* One additional SAE (major depression) was subsequently downgraded to a non-serious event. 
Data available on clinical database as of September 28, 2010 
 
Four serious adverse events (SAEs) were reported in four patients (appendicitis 
[Cohort A], hospitalization for transluminal angioplasty [Cohort C], major depression 
[Cohort A], subsequently downgraded to a non-serious event, and angina pectoris 
[Cohort D]). All were considered unrelated to study treatment. There have been no 
reports of serious or severe infections. There were no AEs leading to death, 
withdrawal or treatment discontinuation. 
The most commonly documented AE was local administration-associated reactions 
(AARs; N = 30). AARs are defined as all AEs occurring within 24 hours of rituximab 
administration and considered related to study drug. AARs included IRRs, injection-
site reactions, administration site conditions and all symptoms thereof. After AARs, 
the most common events were mild infections (N = 18) and gastrointestinal disorders 
(N = 17). The majority of AARs (85%) and of AEs overall (68%) were assessed as 
mild (National Cancer Institute Common Terminology Criteria for Adverse Events 
[NCI CTCAE] grade 1), 27% of AEs as moderate (CTC grade 2) and the remaining 
5% as severe (CTC grade 3), all of which resolved. 
Safety data is now available from the comparative part of study BP22333 (Salar et 
al, 2012). Results showed that the incidence and intensity of AEs were generally 
balanced, as 79% of patients in each arm experienced AEs. Serious AEs were 
observed in 12% and 14% of patients in the SC and IV arms, respectively.  No SAE 
occurred in > 1 patient in either treatment arm. Grade 3/4 AEs occurred in 18% and 
17% of patients in the SC and IV arms, respectively.  Neutropenia (2 patients in each 
arm) and arthralgia (2 patients in the IV arm) was the only grade 3/4 AE occurring 
in > 1 patient in either treatment arm. ARRs were the most frequent AE and had a 
higher incidence in the SC arm (31% of SC vs. 4% of IV patients). ARRs consisted 
mostly or local reactions, and the most common in the SC arm were erythema (13%), 
injection site erythema (5%), and myalgia (5%). 
Ongoing Clinical Studies 
Two additional clinical studies with rituximab SC have started recently. Study 
BO22334 (NCT01200758), investigating the PK, safety and efficacy of rituximab SC 
in combination with chemotherapy followed by rituximab SC Maintenance therapy in 
530 patients with FL and study BO25431 (NCT01292603), investigating the PK and 
safety of rituximab SC in 200 patients with CLL. First interim results were presented 
at the American Society of Haematology (ASH) conference 2012. 
Lastly, three phase IIIb trials have been initiated. 
MO25455 will evaluate the efficacy in terms of PFS after randomization of rituximab 
SC in 770 patients with relapsed or refractory, indolent NHL who responded to 
induction and initial two years maintenance therapy (Maintenance I), and were 
randomized to either prolonged rituximab maintenance until progression 
(Maintenance II) or observation. First interim results are expected in Q4/2013. 
MO28107 will investigate the efficacy of the combination of subcutaneous rituximab 
in combination with chemotherapy in patients with previously untreated DLBCL. First 
interim results are expected in Q4/2013. 
MO28457 will evaluate patient preference with subcutaneous administration of 
rituximab versus intravenous rituximab in previously untreated patients with DLBCL 
or follicular lymphoma. First interim results are expected in Q1/2014. 
Refer to the current rituximab SC IB for further details on nonclinical and clinical 
studies of rituximab SC. 


Rituximab – Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
35 
1.3 
STUDY RATIONALE AND BENEFIT–RISK ASSESSMENT 
1.3.1.1 
Benefits of Rituximab 
The efficacy and safety of rituximab IV is well established. Rituximab IV is 
administered as an infusion over 3 to 4 hours. Frequently observed IRRs may 
require prolonging the infusion time further. These long infusion times and the side 
effects related to the infusion were cited by some patients as uncomfortable 
consequences of the current therapeutic treatment. Furthermore, the required 
procedure to establish IV access is considered invasive and can be painful, 
particularly in patients with malignant diseases who are treated repeatedly. 
Rituximab for SC administration has been developed to address these limitations (i.e. 
IIRRs, long administration times, hospital facilities requirements, difficulty treating 
patients with poor venous access). SC administration of rituximab takes significantly 
less time (5-6 minutes) compared to IV infusion and this is expected to improve 
treatment convenience, patient satisfaction and compliance.  
Based on modelling and simulation of PK data from Stage 1 of the dose-finding 
study BP22333 (Salar A et al. 2010), a fixed rituximab SC dose of 1400 mg has been 
found non-inferior to the rituximab IV dose of 375 mg/m2 and selected for further 
investigation. BP22333 was the first-in-human adaptive two-stage study (Stage 1 
and Stage 2) for selecting a rituximab SC dose that achieves non-inferior trough 
concentrations compared to those of rituximab IV, and comparing exposure and 
safety for the IV and SC formulations in patients with FL. Preliminary safety data 
collected for 108 patients treated with a single SC dose and 16 patients receiving 
standard rituximab IV in Stage 1 of study BP22333 indicate that rituximab SC was 
well tolerated, with an AE profile comparable to that of the IV formulation. A total of 
65 patients experienced 157 AEs in the 4 cohorts combined, including 57 of the 108 
patients receiving rituximab SC. Observed AEs were mostly mild to moderate and 
none required discontinuation of treatment. A total of 3 SAEs were reported, none of 
which were considered related to rituximab (SC or IV). Further details about the 
BP22333 study design, as well as PK and preliminary safety findings are provided in 
Section  1.2.2. 
The safety profile and the efficacy of the rituximab SC formulation containing 
rHuPH20 are expected to be similar to those of the IV formulation. Preclinical, clinical 
and extensive post-marketing experience with the rHuPH20 excipient used in the SC 
formulation has shown the component to be well-tolerated. In addition, the SC route 
of administration may reduce the risk and intensity of IIRRs compared to IV 
administration. For other monoclonal antibodies in other clinical settings the switch 
from IV to SC administration has resulted in an improved tolerability with less IIRRs, 
increased patient-convenience and improved cost-effectiveness (Stilgenbauer et al. 
2009; Wynne et al. 2010; Moreau et al. 2011). For example, the administration of 
alemtuzumab by the IV route resulted in a significant proportion of patients 
experiencing IRRs; however these were rare or absent following SC administration 
(Stilgenbauer et al. 2009). 
1.3.1.2 
Mitigation of the Known Safety Risks of Rituximab  
The safety of rituximab IV in patients with haematologic malignancies, including 
previously untreated DLBCL or follicular NHL is well characterised.  
The contraindications for rituximab administration in NHL (known hypersensitivity to 
the active substance or to any of the excipients or to murine proteins, active, severe 
infections and severely immunocompromised state) are specified as exclusion 
criteria for the current study. The risk of hypersensitivity reaction to rituximab after 
SC injection is minimized by administering the rituximab SC formulation only to 


Rituximab – Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
36 
patients that have been previously treated with rituximab IV and who, consequently, 
are unlikely to have relevant quantities of circulating B-cells that may induce IIRRs, 
such as fever, or hypotension, upon their destruction through rituximab. In the event 
of an allergic reaction during administration of rituximab, standard treatment for 
hypersensitivity reactions (e.g. epinephrine [adrenaline], antihistamines and 
glucocorticoids), should be available for immediate use. 
Rituximab is associated with IIRRs, which may be related to release of cytokines 
and/or other chemical mediators. Severe IIRRs might be clinically indistinguishable 
from hypersensitivity reactions or cytokine release syndrome. Severe IRRs with fatal 
outcome have been reported with rituximab IV during post-marketing use. Severe 
IIRRs usually manifested within 30 minutes to 2 hours after starting the first rituximab 
IV infusion, were characterized by pulmonary events and included, in some cases, 
rapid tumour lysis and features of TLS in addition to fever, chills, rigors, hypotension, 
urticaria, angioedema and other symptoms (Rituximab IV IB). In order to reduce the 
incidence and severity of IIRRs, it is recommended that all patients receive 
premedication with paracetamol (acetaminophen) and diphenhydramine 
hydrochloride (or alternative antihistamine), administered 30-60 minutes prior to 
each rituximab administration (see Section  4.4.1.1). Recommendations for TLS 
prophylaxis are also provided (see Section  4.4.1.2). Patients who were not able to 
receive the full dose of rituximab at Cycle 1 as a result of IIRRs will not continue in 
the study. 
Use of rituximab may be associated with an increased risk of neurotoxicity, including 
PML. If PML is suspected based on any new or worsening neurological, cognitive or 
psychiatric symptoms or signs, further dosing will be suspended until PML has been 
excluded. The protocol provides guidance for management of neurotoxicity (see 
Section  5.1.3).  
Although rituximab is not myelosuppressive when given as monotherapy, decreased 
red blood cell (RBC), leucocyte and platelet counts have been reported with the R-
CHOP combination regimens. Therefore, only patients with adequate haematological 
function (defined as haemoglobin  9 g/dL, absolute neutrophil count  1.5 x 109/L 
and platelet counts of  75 x 109/L), will be enrolled in the study. The protocol also 
provides guidance for management of haematological toxicities (see Section  5.1.3). 
Angina pectoris or cardiac arrhythmia (such as atrial flutter and fibrillation), heart 
failure and myocardial infarction have occurred in patients treated with rituximab IV. 
Prospective study patients will therefore undergo an electrocardiogram (ECG) 
assessment at baseline, to rule out clinically significant abnormalities. 
The potential risk of side effects at the injection site is minimized by instructing the 
study personnel and Investigators to pay special attention to the injection site and to 
report any findings in the case report form (CRF).  
Patients treated with monoclonal antibodies may develop antibodies against these 
monoclonal antibodies potentially resulting in hypersensitivity reactions or 
attenuation of therapeutic effects. Patients with human anti-mouse antibody (HAMA) 
or human antichimeric antibody (HACA) titres may develop allergic or 
hypersensitivity reactions when treated with other diagnostic or therapeutic 
monoclonal antibodies (Kornbrot et al. 1994). The development of such antibodies is 
a rare event. In an integrated review of data from 356 patients, four patients 
developed a HACA response following treatment with rituximab IV. Two of these 
patients were retreated without problems. No correlation was seen between HACA 
response and loss of, or interference with, response to treatment.  


5LWX[LPDE±5RFKH1RUWK$IULFD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\

,QVXPPDU\WKH6&IRUPXODWLRQLVH[SHFWHGWREULQJVLJQLILFDQWDQGFOLQLFDOO\
PHDQLQJIXOEHQHILWVWRSDWLHQWVLQWHUPVRILPSURYHGWROHUDELOLW\ZLWKSRWHQWLDOO\IHZHU
DQGOHVVVHYHUH,,55V7KLVH[SHFWDWLRQLVEDVHGRQWKHORZHUSHDNVHUXP
FRQFHQWUDWLRQVDIWHUDGPLQLVWUDWLRQZKLFKDUHDWWDLQHGPRUHVORZO\DVZHOODVDQ
LPSURYHGWUHDWPHQWFRQYHQLHQFHGXHWRWKHIDVWHUDQGPRUHFRQYHQLHQW6&
DGPLQLVWUDWLRQ7KHUHIRUHWKHRYHUDOOULVNEHQHILWDVVHVVPHQWRIWKLVVWXG\LV
FRQVLGHUHGWREHSRVLWLYH

2%-(&7,9(6

35,0$5<2%-(&7,9(
3ULPDU\REMHFWLYHVIRUWKLVVWXG\DUHDVIROORZV
•
7RHYDOXDWHWKHLQFLGHQFHRI$$5VIROORZLQJPXOWLSOHGRVHVRIULWX[LPDE6&
GXULQJ,QGXFWLRQDQGRU0DLQWHQDQFHWKHUDS\LQSDWLHQWVZLWK&'IROOLFXODU
1+/RU&''/%&/ZKRKDYHSUHYLRXVO\UHFHLYHGDWOHDVWRQHGRVHRI
ULWX[LPDE,9
•
7RHYDOXDWHSDWLHQWUHSRUWHGRXWFRPHVLQWHUPVRI5$645LWX[LPDE
$GPLQLVWUDWLRQ4XHVWLRQQDLUH


6(&21'$5<2%-(&7,9(6
6HFRQGDU\REMHFWLYHVIRUWKLVVWXG\DUHDVIROORZV
•
7RIXUWKHUHYDOXDWHWKHVDIHW\RIULWX[LPDE6&LQWHUPVRI
− *UDGH≥$(V
− *UDGH≥,,55V
− 6$(V
•
7RHYDOXDWHWKHHIILFDF\RIULWX[LPDE6&LQWHUPVRI
− ()6
− 3)6
− 26
− ')6
− FRPSOHWHUHVSRQVH&5UDWHLQFOXGLQJFRPSOHWHUHVSRQVHXQFRQILUPHG
&5XZHHNVDIWHUWKHODVWGRVHRI,QGXFWLRQWUHDWPHQW
• 7RHYDOXDWHKHDOWKFDUHSURIHVVLRQDOUHODWHGRXWFRPHVLQWHUPVRI
− +&3+HDOWKFDUH3URIHVVLRQDO4XHVWLRQQDLUH

3$7,(175(3257('287&20(2%-(&7,9(6
7KHSDWLHQWUHSRUWHGRXWFRPH352PHDVXUHVDUHSDUWRIWKHVHFRQGDU\REMHFWLYHV
RIWKLVVWXG\DQGWKH\ZLOOEHDVVHVVHGXVLQJ5LWX[LPDE$GPLQLVWUDWLRQ4XHVWLRQQDLUH
5$64VHH$SSHQGL[

+($/7+&$5(352)(66,21$/5(3257('287&20(
2%-(&7,9(6
+HDOWKFDUH3URIHVVLRQDOUHSRUWHGPHDVXUHVDUHSDUWRIWKHVHFRQGDU\REMHFWLYHVRI
WKLVVWXG\+HDOWKFDUH3URIHVVLRQDOV¶H[SHULHQFHVDERXWULWX[LPDE6&DGPLQLVWUDWLRQ
DQGLW¶VFRQYHQLHQFHZLOOEHHYDOXDWHGXVLQJ+HDOWKFDUH3URIHVVLRQDO+&3
4XHVWLRQQDLUHVHH$SSHQGL[ZKLFKZLOOEHFRPSOHWHGE\WKHKHDOWKFDUH
3URIHVVLRQDOVVXFKDVKHPDWRORJLVWVLQWHUQLVWVQXUVHVRURWKHUKHDOWKFDUH
SURIHVVLRQDOVZKRDGPLQLVWHUHGULWX[LPDE6&WRWKHVXEMHFWV


Rituximab – Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
38 
3. 
STUDY DESIGN 
3.1 
DESCRIPTION OF STUDY 
3.1.1 
Overview 
This is an open-label, single-arm study to evaluate the safety of rituximab SC 
administered during first line treatment for FL (Induction and/or Maintenance), or DLBCL 
(treatment plus 24 months of follow-up). 
This study will include adult patients with CD20+ DLBCL or CD20+ follicular NHL 
(grade 1 to 3a; NHL), who have already received at least one full dose of IV 
rituximab during induction or maintenance. Patients receiving Induction therapy must 
be able to receive at least 4 cycles of rituximab SC in addition to standard 
chemotherapy. FL Patients receiving Maintenance therapy must be able to receive at 
least 6 cycles of rituximab SC. 
During administration of rituximab SC, patients will be assessed for safety and 
efficacy as detailed in the Schedule of Assessments (see Appendix 1). RASQ (see 
Appendix 6) will be applied to patients at the end of the study after rituximab 
administration. Healthcare Professional  (HCP) Questionnaire (see Appendix 7) will 
be applied at the end of the study to health care professionals. 
Induction Therapy: 
Patients receiving Induction therapy prior to entry into the study must be eligible to 
receive at least four further cycles of rituximab SC (i.e. 4 additional months of 
Induction treatment). Patients with follicular NHL who will continue into Maintenance 
therapy (after staging at the end of Induction) can continue to receive rituximab SC 
during Maintenance (see below). 
Maintenance Therapy (patients with follicular NHL): 
Patients receiving Maintenance therapy prior to entry into the study must be eligible 
to receive at least six further cycles of rituximab SC (i.e. 12 additional months of 
Maintenance treatment). Patients who are continuing into Maintenance therapy 
following at least four cycles of rituximab SC during Induction Therapy must also be 
eligible to receive at least six cycles of rituximab SC (i.e. 12 additional months of 
Maintenance treatment). 
 
Study Design Schemes 
 






5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\



,QGHSHQGHQW5HYLHZ&RPPLWWHH
1RWDSSOLFDEOH

,QGHSHQGHQW'DWD0RQLWRULQJ&RPPLWWHH
1RWDSSOLFDEOH

&OLQLFDO(YHQWV&RPPLWWHH
1RWDSSOLFDEOH

6WHHULQJ&RPPLWWHH
1RWDSSOLFDEOH

(1'2)678'<
7KHHQGRIWKHVWXG\GHILQHGDVODVWSDWLHQWODVWYLVLW/3/9ZLOORFFXUPRQWKV
DIWHUWKHODVW6&ULWX[LPDEWUHDWPHQWIRUWKHODVW)/RU'/%&/SDWLHQWZKLFKHYHU
FRPHVODWHU)RUFRQWLQXHGULWX[LPDE6&WUHDWPHQWDIWHUWKHHQGRIVWXG\SOHDVH
UHIHUWR6HFWLRQ
•
)/SDWLHQWVZKRFRPSOHWHLQGXFWLRQWUHDWPHQWZLOOWKHQHQWHUWKHPDLQWHQDQFHSKDVH
)ROORZLQJWKHODVW6&ULWX[LPDEDGPLQLVWUDWLRQ)/SDWLHQWVZLOOEHIROORZHGXSIRU
PRQWKV
•
'/%&/SDWLHQWVZKRUHFHLYHWKHLUODVW6&ULWX[LPDEWUHDWPHQWZLOOWKHQHQWHUWKH
SRVWWUHDWPHQWIROORZXSSKDVH
• 3DWLHQWVZLWK6'RU3'DWVWDJLQJZLOOEHZLWKGUDZQIURPVWXG\WUHDWPHQWDQG
ZLOORQO\EHIROORZHGIRU$(VDQGIRUVXUYLYDOXQWLOWKHHQGRIWKHVWXG\
• 3DWLHQWVZKRGRQRWFRPSOHWHWKH,QGXFWLRQWUHDWPHQWSHUSURWRFROZLOO
XQGHUJRHQGRIWUHDWPHQWDVVHVVPHQWZLWKLQZHHNVDIWHUWKHODVWGRVHRI
,QGXFWLRQWUHDWPHQWDQGZLOOEHIROORZHGXQWLOWKHHQGRIWKHZKROHVWXG\
DFFRUGLQJWRORFDOSUDFWLFHIRU$(VWXPRXUUHVSRQVHSURJUHVVLRQLI3'QRW
\HWGRFXPHQWHGVXUYLYDODQGGRFXPHQWDWLRQRIDQ\QHZDQWLO\PSKRPD
WUHDWPHQW
• 3DWLHQWVZKRFRPSOHWHWKHVWXG\RUGLVFRQWLQXHIURPWKHVWXG\HDUO\ZLOOEH
DVNHGWRUHWXUQWRWKHFOLQLFDIWHUGD\VRUDWOHDVWKDOIOLYHVRIDQ\QRQ
ULWX[LPDE,03VZKLFKHYHUORQJHUDIWHUWKHODVWGRVHRIVWXG\GUXJIRUD
IROORZXSYLVLW


5$7,21$/()25678'<'(6,*1

5DWLRQDOHIRU7HVW3URGXFW'RVDJH
0RGHOOLQJDQGVLPXODWLRQRI3.GDWDIURP6WDJHDQGLQLWLDOUHVXOWVRI6WDJHRIWKH
DIRUHPHQWLRQHGVWXG\%31&76DODUHWDO6DODUHWDO
LQGLFDWHWKDWWKHIL[HGGRVHRIPJULWX[LPDE6&DFKLHYHVWURXJKOHYHOVWKDWDUH
QRQLQIHULRUWRWKHULWX[LPDE,9GRVHRIPJPLQSDWLHQWVZLWKSUHYLRXVO\WUHDWHG
RUXQWUHDWHG)/JUDGHRUD5LWX[LPDE6&ZDVZHOOWROHUDWHGZLWKDQ$(
SURILOHFRPSDUDEOHWRWKDWRIULWX[LPDE,91R6$(VUHODWHGWRULWX[LPDE6&ZHUH
UHSRUWHG$IL[HG6&GRVHRIPJKDVWKHUHIRUHEHHQVHOHFWHGIRUIXUWKHUFOLQLFDO
WHVWLQJRIULWX[LPDE6&LQWKLVVWXG\DVZHOODVRQJRLQJUHJLVWUDWLRQDOVWXGLHV

5DWLRQDOHIRU3DWLHQW3RSXODWLRQDQG
$QDO\VLV*URXS
&XUUHQWO\ULWX[LPDE,9ZKLFKLVLQGLFDWHGLQ)/DQG'/%&/LVDSSURYHGLQPDQ\
FRXQWULHV,QWKLVVWXG\ZHDUHDLPLQJWRDVVHVVVDIHW\LQFLGHQFHRI$$5VRI
ULWX[LPDE6&LQWKHVDPHWDUJHWSRSXODWLRQ3DWLHQWVZLWK&'1+/DQG&'


5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\

'/%&/ZLOOEHUHFUXLWHGLQWKLVVWXG\DQGSDWLHQWVZKRUHFHLYHGDWOHDVWRQHGRVHRI
ULWX[LPDE6&ZLOOEHLQFOXGHGLQWKHDQDO\VLVSRSXODWLRQ

5DWLRQDOHIRU&KHPRWKHUDS\
&KHPRWKHUDS\UHJLPHQVLQWKHDIRUHPHQWLRQHGSLYRWDOWULDOVLQSUHYLRXVO\XQWUHDWHG
'/%&/LQFOXGHG&+23&+23RU&+23OLNHFKHPRWKHUDS\IRUVL[RUHLJKW
F\FOHV7KRVHLQSUHYLRXVO\XQWUHDWHGIROOLFXODU1+/LQFOXGHG&+23&93DQG)&
IRUVL[RUHLJKWF\FOHV,QNHHSLQJZLWKWKHUHVXOWVRIWKHSLYRWDOWULDOVDVZHOODVWKH
DSSURYHGLQGLFDWLRQVIRUULWX[LPDE,9DQGFXUUHQWVWDQGDUGSUDFWLFHVVLPLODU
EDFNJURXQGFKHPRWKHUDS\UHJLPHQVZLOOEHXVHGLQWKLVVWXG\

5DWLRQDOHIRU%LRPDUNHU$VVHVVPHQWV
1RWDSSOLFDEOH

287&20(0($685(6

6DIHW\2XWFRPH0HDVXUHV
6DIHW\RXWFRPHPHDVXUHVZLOOLQFOXGH$$5VGHILQHGDVDOOUHODWHG$(VRFFXUULQJ
ZLWKLQKRXUVRIULWX[LPDE6&DGPLQLVWUDWLRQLQFOXGLQJ,,55VLQMHFWLRQVLWH
UHDFWLRQVDGPLQLVWUDWLRQVLWHFRQGLWLRQVDQGDOOV\PSWRPVWKHUHRIJUDGH≥$(V
DQG6$(V2WKHUVDIHW\DVVHVVPHQWVLQFOXGHURXWLQHVDIHW\ODERUDWRU\WHVWVYLWDO
VLJQVPHDVXUHPHQWVDQGFKDQJHVLQFRQFRPLWDQWPHGLFDWLRQV$OOFOLQLFDO$(VDQG
6$(VDVZHOODVODERUDWRU\DEQRUPDOLWLHVZLOOEHUHFRUGHGUHJDUGOHVVRIWKHLU
LQWHQVLW\JUDGLQJ*UDGLQJZLOOEHFRPSOHWHGDFFRUGLQJWRWKH1&,&7&$(YHUVLRQ
VHH$SSHQGL[

(IILFDF\2XWFRPH0HDVXUHV
7KHHIILFDF\RIULWX[LPDEZLOOEHHYDOXDWHGDWWKHHQGRILQGXFWLRQWUHDWPHQWIRU)/SDWLHQWVDQGDW
WKHHQGRIWKHODVWF\FOHIRU'/%&/SDWLHQWVLQWHUPVRI()63)626&5&5XDQG')67KH
HQGSRLQWVRI()63)6DQG26ZLOOEHGHILQHGDQGDQDO\VHGWZLFHXVLQJWZRGLIIHUHQWVWDUWLQJSRLQWV
IRUWKHWLPHWRHYHQWFDOFXODWLRQV7KHILUVWVWDUWLQJSRLQWZLOOEHILUVWGRVHRIULWX[LPDE,9DQGWKH
VHFRQGZLOOEHILUVWGRVHRIULWX[LPDE6&
• ()6LVGHILQHGDVWKHWLPHIURPILUVWGRVHRIULWX[LPDEDQDO\VHGXVLQJERWK
ILUVWGRVHRI,9DQGILUVWGRVHRI6&WRILUVWRFFXUUHQFHRISURJUHVVLRQRU
UHODSVHDFFRUGLQJWRWKH,:*UHVSRQVHFULWHULD&KHVRQHWDOVHH
$SSHQGL[RURWKHUFRXQWU\VWDQGDUGVRULQLWLDWLRQRIDQRQ±SURWRFRO
VSHFLILHGDQWLO\PSKRPDWKHUDS\RUGHDWKZKLFKHYHURFFXUVILUVW
• 3)6LVGHILQHGDVWKHWLPHIURPILUVWGRVHRIULWX[LPDEDQDO\VHGXVLQJERWK
ILUVWGRVHRI,9DQGILUVWGRVHRI6&WRWKHILUVWRFFXUUHQFHRISURJUHVVLRQRU
UHODSVHDFFRUGLQJWRWKH,:*UHVSRQVHFULWHULD&KHVRQHWDOVHH
$SSHQGL[RURWKHUFRXQWU\VWDQGDUGVRUGHDWKIURPDQ\FDXVH
• 26LVGHILQHGDVWKHWLPHIURPILUVWGRVHRIULUWX[LPDEDQDO\VHGXVLQJERWK
ILUVWGRVHRI,9DQGILUVWGRVHRI6&XQWLOGHDWKIURPDQ\FDXVH
• ')6ZLOOEHDVVHVVHGDWWKHHQGRILQGXFWLRQWUHDWPHQWLQSDWLHQWVDFKLHYLQJ
&5&5XDQGLVGHILQHGDVWKHSHULRGIURPWKHGDWHRIWKHLQLWLDO&5&5XXQWLO
WKHGDWHRIUHODSVHRUGHDWKIURPDQ\FDXVH
•
&5&5X5HVSRQVHDVVHVVPHQWVZHHNVDIWHUWKHODVWGRVHRI,QGXFWLRQ
WUHDWPHQWZLOOEHEDVHGRQWKH,QYHVWLJDWRU¶VDVVHVVPHQWFRPSOHWHG
DFFRUGLQJWRWKHRULJLQDO,QWHUQDWLRQDO:RUNLQJ*URXS,:*UHVSRQVHFULWHULD
IRUUHVSRQVHDVVHVVPHQWRIO\PSKRPD&KHVRQHWDOVHH$SSHQGL[
7XPRXUDVVHVVPHQWVZLOOEHEDVHGRQFRPSXWHGWRPRJUDSK\&7VFDQVRIWKHQHFN
FKHVWDEGRPHQDQGRUSHOYLVLIGHWHFWDEOHE\WKHVHWHFKQLTXHVRURWKHUGLDJQRVWLF
PHDQVHJPDJQHWLFUHVRQDQFHLPDJLQJ>05,@3(7&7ZKHUHDSSOLFDEOH2WKHU
PHWKRGVHJ05,DUHDFFHSWDEOHIRUSDWLHQWVLQZKRP&7VFDQVDUH


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
43 
contraindicated. The CT scan used for eligibility assessments may be performed up 
to 28 days prior to dosing. 
3.4.3 
Exploratory Outcome Measures 
Not applicable 
3.4.4 
Pharmacodynamic and Pharmacokinetic 
Outcome Measures 
Not applicable 
3.4.5 
Pharmacoeconomic Outcome Measures 
Not applicable 
3.4.6 
Patient-Reported Outcome (PRO) 
Measures 
Patient satisfaction with administration of treatment will be evaluated by all patients 
using the RASQ (see Appendix 6) after last Rituximab SC in induction and after last 
Rituximab SC in maintenance. The RASQ will be completed immediately after 
rituximab administration and before chemotherapy administration in case the patient 
will receive chemotherapy. Patients prematurely discontinuing treatment during the 
study should complete the questionnaire at time of discontinuation, as long as they 
had been administered at least one dose of treatment via both administration routes. 
3.4.7 
Healthcare Professional Reported 
Outcome Measures 
Healthcare Professionals’ experiences about rituximab SC administration and it’s 
convenience will be evaluated using Healthcare Professional (HCP) Questionnaire 
(see Appendix 7). Questionnaire will be completed at the end of the study by the 
healthcare Professionals such as hematologists, internists, nurses or other 
healthcare professionals who administered rituximab SC to the subjects. 
4. 
MATERIALS AND METHODS  
4.1 
PATIENTS 
The target population will consist of adults with CD20+ DLBCL or CD20+ follicular 
NHL grade 1 to 3a, according to the WHO classification system. 
4.1.1 
Inclusion Criteria 
Patients must meet the following criteria for study entry: 
1. 
Signed, written informed consent form 
2. 
Age  18 and  80 years at time of enrolment 
3. 
Histologically confirmed, CD20+ DLBCL or CD20+ follicular NHL grade 1 to 3a, 
according to the WHO classification system 
4. 
Currently being treated with rituximab IV in the Induction or Maintenance setting, having 
received at least one full dose of rituximab IV, defined as standard full dose of rituximab 
IV 375 mg/m2 administered without interruption or early discontinuation because of 
tolerability issues 
5. 
Expectation and current ability for the patient to receive at least four additional cycles of 
treatment during the Induction phase or six additional cycles of treatment during the 
Maintenance phase (patients with follicular NHL) 
6. 
Induction only: An International Prognostic Index (IPI) score of 1-4 or IPI score of 0 with 
bulky disease, defined as one lesion  7.5 cm, or FLIPI (low, intermediate or high risk) 
(see Appendix 3) 


5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\


,QGXFWLRQRQO\$WOHDVWRQHELGLPHQVLRQDOO\PHDVXUDEOHOHVLRQGHILQHGDV≥FPLQ
LWVODUJHVWGLPHQVLRQRQ&7VFDQ

(DVWHUQ&RRSHUDWLYH2QFRORJ\*URXS(&2*SHUIRUPDQFHVWDWXV≤VHH$SSHQGL[

3DWLHQWVZLWK&''/%&/HOLJLEOHIRU5&+23UHJLPHQ
 3DWLHQWVZLWK/9()˃
 

([FOXVLRQ&ULWHULD
3DWLHQWVZKRPHHWDQ\RIWKHIROORZLQJFULWHULDZLOOEHH[FOXGHGIURPVWXG\HQWU\
&DQFHU5HODWHG&ULWHULD

7UDQVIRUPHGO\PSKRPDRU)/,,,%

3ULPDU\FHQWUDOQHUYRXVV\VWHPO\PSKRPDKLVWRORJLFHYLGHQFHRIWUDQVIRUPDWLRQWRD
%XUNLWWO\PSKRPDSULPDU\HIIXVLRQO\PSKRPDSULPDU\PHGLDVWLQDO'/%&/'/%&/RI
WKHWHVWLVRUSULPDU\FXWDQHRXV'/%&/

+LVWRU\RIRWKHUPDOLJQDQF\WKDWFRXOGDIIHFWFRPSOLDQFHZLWKWKHSURWRFRORU
LQWHUSUHWDWLRQRIUHVXOWV7KLVLQFOXGHVDPDOLJQDQF\WKDWKDVEHHQWUHDWHGEXWQRWZLWK
FXUDWLYHLQWHQWXQOHVVWKHPDOLJQDQF\KDVEHHQLQUHPLVVLRQZLWKRXWWUHDWPHQWIRU≥
\HDUVSULRUWRGRVLQJ
1RWH3DWLHQWVZLWKDKLVWRU\RIFXUDWLYHO\WUHDWHGEDVDORUVTXDPRXVFHOOFDUFLQRPDRU
PHODQRPDRIWKHVNLQRULQVLWXFDUFLQRPDRIWKHFHUYL[DUHHOLJLEOHIRUWKHVWXG\
3ULRURU&RQFRPLWDQW7UHDWPHQWV

2QJRLQJFRUWLFRVWHURLGXVH!PJGD\RISUHGQLVRQHRUHTXLYDOHQW1RWHSDWLHQWV
UHFHLYLQJFRUWLFRVWHURLGWUHDWPHQWZLWK≤PJGD\RISUHGQLVRQHRUHTXLYDOHQWPXVWEH
GRFXPHQWHGWREHRQDVWDEOHGRVHRIDWOHDVWZHHNV¶GXUDWLRQSULRUWRGRVLQJ
/DERUDWRU\$VVHVVPHQWVDW6FUHHQLQJ

,QDGHTXDWHUHQDOIXQFWLRQGHILQHGDV
− &UHDWLQLQH!WLPHVWKHXSSHUOLPLWRIQRUPDO8/1XQOHVVQRUPDO
FUHDWLQLQHFOHDUDQFHRUFDOFXODWHGFUHDWLQLQHFOHDUDQFHP/PLQXVLQJ
WKH&RFNFURIW*DXOWIRUPXOD

,QDGHTXDWHKHPDWRORJLFIXQFWLRQGHILQHGDV
− +DHPRJORELQJG/
− $EVROXWHQHXWURSKLOFRXQW[/
− 3ODWHOHWFRXQW[/

,QDGHTXDWHKHSDWLFIXQFWLRQGHILQHGDV
− $VSDUWDWHDPLQRWUDQVIHUDVH$67RUDODQLQHDPLQRWUDQVIHUDVH$/7![
8/1
− 7RWDOELOLUXELQ≥[8/11RWHSDWLHQWVZLWKGRFXPHQWHG*LOEHUWGLVHDVH
PD\EHHQUROOHGLIWRWDOELOLUXELQLV≤[8/1
2WKHU3ULRURU&XUUHQW0HGLFDO&RQGLWLRQVRU7UHDWPHQWV

+LVWRU\RIVHYHUHDOOHUJLFRUDQDSK\ODFWLFUHDFWLRQVWRKXPDQL]HGRUPXULQHPRQRFORQDO
DQWLERGLHVRUNQRZQVHQVLWLYLW\RUDOOHUJ\WRPXULQHSURGXFWV

)RUSDWLHQWVZLWK'/%&/&RQWUDLQGLFDWLRQWRDQ\RIWKHLQGLYLGXDOFRPSRQHQWVRI
&+23LQFOXGLQJSULRUUHFHLSWRIDQWKUDF\FOLQHV


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
45 
10. Other serious underlying medical conditions, which, in the Investigator’s judgment, could 
impair the ability of the patient to participate in the study (e.g., significant cardiovascular 
disease, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease) 
11. Recent major surgery (within 4 weeks prior to dosing, other than for diagnosis 
12. Active and/or severe bacterial, viral, fungal, mycobacterial, parasitic, or other infection 
(excluding fungal infections of nail beds) or any major episode of infection requiring 
treatment with IV antibiotics or hospitalization (relating to the completion of the course of 
antibiotics except if for tumour fever) within 4 weeks prior to dosing 
13. Active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection (must be ruled 
out during Screening) 
14. History of human immunodeficiency virus (HIV) seropositive status 
General Criteria 
15. Inability to provide informed consent and comply with protocol requirements.  
16. Life expectancy of less than 6 months 
17. A positive serum pregnancy test in women of childbearing potential within 7 days prior 
to dosing or within 14 days if with a confirmatory urine pregnancy test within 7 days prior 
to dosing. Women of childbearing potential are defined as pre-menopausal women or 
women who are < 2 years after the onset of menopause and are not surgically sterile 
18. Fertile men or women of childbearing potential who do not agree to use a highly 
effective measure of contraception (such as oral contraceptives, intrauterine device or 
barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) 
throughout the study and for at least 12 months after the last dose of rituximab.  
4.2 
METHOD OF TREATMENT ASSIGNMENT AND BLINDING  
Not applicable. 
4.3 
STUDY TREATMENT  
4.3.1 
Formulation, Packaging, and Handling 
4.3.1.1 
Rituximab SC 
Rituximab for SC administration (MabThera® SC; RO 45-2294) is supplied as a 
ready-to-use liquid formulation with rituximab at a concentration of 120 mg/mL. 
Rituximab must not be diluted prior to administration. Furthermore, rituximab SC 
contains rHuPH20 as an excipient at a concentration of 2000 U/mL (manufactured in 
a Chinese Hamster Ovary [CHO] cell line) acting as a permeation enhancer, 
histidine/histidine-HCl (buffer), ,-trehalose (bulking agent), methionine (stabilizer), 
and polysorbate 80 (surfactant) in water for injection at a pH of 5.5. The drug product 
is a sterile, colourless to yellowish, clear to opalescent liquid.  
The rituximab SC dose is 1400 mg for all patients, independent of patient body 
surface area (BSA). This translates into an injection volume of 11.7 mL. 
Rituximab SC will be supplied by Roche, with a study specific package labeled 
according to local applicable regulations in each participating country and shipped to 
the pharmacist of each centre by the local Roche affiliate or contract research 
organization (CRO) designee.  Upon arrival of investigational products at the site, 
site personnel should check them for damage and verify proper identity, quantity, 
integrity of seals and temperature conditions, and report any deviations or product 
complaints to the monitor upon discovery. 
For further details, see the rituximab SC IB and Appendix 4. 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
46 
4.3.1.2 
Background Treatment 
Commercially available chemotherapy will be used in combination with rituximab SC, 
as per standard local practice. For further details, see the local prescribing 
information for CHOP, CVP or FC. 
4.3.2 
Dosage, Administration and Compliance 
Patients entering the study will already be receiving rituximab IV in the Induction or 
Maintenance setting.  Where possible, rituximab SC should start in alignment with the 
next planned cycle start date. 
Rituximab is always administered prior to chemotherapy (with the exception of the 
corticosteroid component). The day of rituximab administration in all cycles will be 
considered as ‘Day 1’. 
4.3.2.1 
Rituximab SC 
Each cycle will consist of a single SC injection of rituximab administered at a fixed 
dose of 1400 mg.  
For each injection, 11.7 mL of the solution should be withdrawn from the vial. The 27 
gauge injection needle will be inserted using sterile technique in the SC tissue of the 
abdomen. The needle should be fully inserted, being careful that the tip of the needle 
is deeper than the dermis but not as deep as the underlying muscle. The goal of the 
placement angle and needle depth is to achieve uniform placement into every 
patient’s SC tissue. Study drug should not be injected into moles, scars, or bruises. 
The skin should be pinched and needle inserted before the skin is released and the 
pressure on the syringe can be applied. 
The injection should be manually pushed at a flow rate of approximately 2 mL/min, 
therefore an administration volume of 11.7 mL should take approximately 5-6 
minutes. If there is a request by the patient to interrupt the injection, the pressure on 
the syringe should initially be eased to alleviate the pain. If the pain is not alleviated 
the injection should be stopped and the patient should be asked when they are 
comfortable to resume the injection. 
Refer to Appendix 4 for additional details. 
Rituximab SC must be administered in outpatient setting in this study. There is no 
specific recommendation regarding the observation period after rituximab SC 
injections; medical judgment should be utilized.  
No dose modification should be made for rituximab SC. If chemotherapy is delayed, 
rituximab administration must also be delayed. Fourteen days will be considered an 
acceptable delay of a cycle. In a patient experiences more than 14 days of delay, the 
Medical Monitor must be consulted before the patient can resume treatment. 
4.3.2.2 
Background Treatment 
Commercially available chemotherapy will be used in combination with rituximab SC, 
as per standard local practice. 
Guidelines for dosage modification and treatment interruption or discontinuation are 
provided in Section 5.1. All Background therapy (e.g., CHOP for patients with DLBCL, 
or CHOP, CVP, or FC for patients with follicular NHL) should be recorded on the 
eCRF. 
Before starting a new treatment cycle, toxicity related to the previous cycle must 
have resolved. 
4.3.2.3 
Additional Required Medication 
For premedications, prophylactic treatments and any additional required medications 
see Section 4.4. 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
47 
4.3.3 
Investigational Medicinal Product 
Accountability 
Rituximab SC will be supplied by Roche and shipped to the pharmacist of each 
centre by the local Roche affiliate or contract research organization (CRO) designee.  
In accordance with the requirements of national regulatory agencies and of local 
health authorities, the Investigator or the responsible local pharmacist will be held 
accountable for proper storage and dispensing of the IMPs. All drug supplies that will 
be used in the study must be maintained securely. All study drugs shall be 
dispensed in accordance with the Investigator's prescription. The site pharmacy must 
not release rituximab if the patient’s enrolment number is not on the prescription 
received. Under no circumstances will the Investigator supply study drug to a third 
party, or allow the study drug to be used, destroyed or disposed in other ways than 
as directed by this protocol. Adequate records for the disposition of the study drug 
(e.g. Drug Dispensing Log) must be maintained. Accountability will be assessed by 
monitoring drug dispensing and return records and the IMP stored on-site. All 
records and drug supplies must be available for inspection by the Monitor at every 
monitoring visit.  
All supplies, including partially used or empty containers and copies of the 
dispensing and inventory logs, must be returned to the Monitor at the end of the 
study, unless alternate destruction has been authorized by Roche, or is required by 
local or institutional regulations. 
The electronic case report form (eCRF) and clinic records will be checked for 
consistency with site-administered chemotherapy agents used during Induction 
treatment. 
4.3.4 
Post-Trial Access to Rituximab SC 
Currently, Roche does not have any plans to provide rituximab SC to patients after 
conclusion of the study or any earlier patient withdrawal. Roche will evaluate the 
appropriateness of continuing to provide rituximab SC to study patients after 
evaluating the primary efficacy outcome measure and safety data gathered in the 
study. These analyses may be conducted prior to completion of the study. If these 
data are medically significant, Roche may amend the protocol to continue to provide 
rituximab SC in an open-label extension study to patients who have shown a 
demonstrable benefit from rituximab SC treatment during this study as measured by 
primary and secondary endpoints. This open-label extension study will continue until 
rituximab SC is commercially available to the participating patients in their countries 
or until Roche ceases producing or studying rituximab SC. 
4.4 
CONCOMITANT THERAPY 
Concomitant therapy includes any medication (e.g. prescription drugs, over the 
counter drugs, herbal/homeopathic remedies, nutritional supplements) used by a 
patient from 7 days prior to Screening to the study completion/early termination visit. 
All concomitant medications should be reported to the Investigator and recorded on 
the Concomitant Medications eCRF.  
Background therapy (e.g., CHOP for patients with DLBCL, or CHOP, CVP, or FC for 
patients with follicular NHL) should also be recorded on the eCRF. 
4.4.1 
Permitted Therapy  
Patients should receive full supportive care, such as granulocyte colony-stimulating 
factor (G-CSF) support, transfusions of blood and blood products, prophylactic 
antiviral medication, antibiotics, anti-emetics, or local application of radiotherapy for 
consolidation after induction, as applicable and according to institutional standards. 


5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\

5HJXODUDSSOLFDWLRQRI*&6)LVQRWJHQHUDOO\UHFRPPHQGHG+RZHYHULWVKRXOGEH
DSSOLHGDFFRUGLQJWRWKH$PHULFDQ6RFLHW\RI&OLQLFDO2QFRORJ\JXLGHOLQHVHVSHFLDOO\
LQFDVHRILQIHFWLRQVDQGSURORQJHGQHXWURSHQLDLQSUHYLRXVF\FOHV6PLWKHWDO
0HVQD0HUFDSWR(WKDQH6XOIRQDWHVRGLXPPD\EHXVHGDVSURSK\OD[LVRI
KDHPRUUKDJLFF\VWLWLV7KHUHDVRQVIRUWUHDWPHQWGRVDJHDQGGDWHVRIWUHDWPHQW
PXVWEHUHFRUGHGLQWKHH&5)
3DWLHQWVZKRXVHRUDOFRQWUDFHSWLYHVKRUPRQHUHSODFHPHQWWKHUDS\RURWKHU
PDLQWHQDQFHWKHUDS\VKRXOGFRQWLQXHWKHLUXVH

3UHPHGLFDWLRQ
,QRUGHUWRUHGXFHWKHLQFLGHQFHDQGVHYHULW\RI,,55VLWLVUHFRPPHQGHGWKDWDOO
SDWLHQWVUHFHLYHWKHIROORZLQJSUHPHGLFDWLRQDGPLQLVWHUHGPLQXWHVSULRUWR
HDFKULWX[LPDEDGPLQLVWUDWLRQ
•
SDUDFHWDPRODFHWDPLQRSKHQ
•
GLSKHQK\GUDPLQHK\GURFKORULGHRUDOWHUQDWLYHDQWLKLVWDPLQH
,QVWLWXWLRQVVKRXOGIROORZWKHLUVWDQGDUGSUHPHGLFDWLRQSURFHGXUHVUHJDUGLQJRWKHU
VXSSRUWLYHFDUHLQFOXGLQJWUDQVIXVLRQVRIEORRGDQGEORRGSURGXFWVRU*&6)
,IJLYHQWKHVHPHGLFDWLRQVPXVWEHGRFXPHQWHGRQWKH&RQFRPLWDQW0HGLFDWLRQV
H&5)

7XPRXU/\VLV6\QGURPH3URSK\OD[LV
7/6GHVFULEHVWKHPHWDEROLFGHUDQJHPHQWVWKDWRFFXUZLWKWXPRXUEUHDNGRZQ
IROORZLQJWKHLQLWLDWLRQRIF\WRWR[LFWKHUDS\7KHPHWDEROLWHVUHOHDVHGLQ7/6FDQ
RYHUZKHOPWKHERG\
VQRUPDOKRPHRVWDWLFPHFKDQLVPVFDXVHK\SHUXULFDHPLD
K\SHUNDODHPLDK\SRSKRVSKDWHPLDK\SRFDOFDHPLDDQGXUDHPLDDQGOHDGWRDFXWH
UHQDOIDLOXUH3URSK\OD[LVDJDLQVW7/6PD\EHJLYHQDVSHULQVWLWXWLRQDOSUDFWLFHDQG
VKRXOGEHGRFXPHQWHGRQWKH&RQFRPLWDQW0HGLFDWLRQVH&5)DFFRUGLQJO\
7KHPDLQVWD\VRI7/6SUHYHQWLRQLQFOXGHK\GUDWLRQDQGSURSK\ODFWLFUDVEXULFDVH
UHFRPELQDQWXUDWHR[LGDVHLQKLJKULVNSDWLHQWVK\GUDWLRQSOXVDOORSXULQRORU
UDVEXULFDVHIRULQWHUPHGLDWHULVNSDWLHQWVDQGFORVHPRQLWRULQJRIHOHFWURO\WH
DEQRUPDOLWLHVIRUORZULVNSDWLHQWV3ULPDU\PDQDJHPHQWRIHVWDEOLVKHG7/6LQYROYHV
VLPLODUUHFRPPHQGDWLRQVZLWKWKHDGGLWLRQRIDJJUHVVLYHK\GUDWLRQDQGGLXUHVLVSOXV
DOORSXULQRORUUDVEXULFDVHIRUK\SHUXULFHPLD$ONDOLQL]DWLRQLVQRWUHFRPPHQGHG
&DLURDQG%LVKRS&RLIILHUHWDO

3URKLELWHG7KHUDS\
7KHIROORZLQJWUHDWPHQWVDUHSURKLELWHGGXULQJVWXG\WUHDWPHQW
•
,QYHVWLJDWLRQDORUXQOLFHQVHGXQDSSURYHGDJHQWVRIDQ\W\SH
•
2WKHUFRQFRPLWDQWDQWLWXPRXUDJHQWVQRWGHILQHGLQWKLVSURWRFRODVVWXG\
WUHDWPHQWLQFOXGLQJO\PSKRPDWKHUDSHXWLFGRVHVRIJOXFRFRUWLFRVWHURLGV
3DWLHQWVUHFHLYLQJDQ\RIWKHSURKLELWHGWKHUDSLHVZLOOEHGLVFRQWLQXHGDQGIROORZHG
IRUVXUYLYDO
3DWLHQWVVKRXOGQRWUHFHLYHORQJWHUPWUHDWPHQW!PRQWKZLWKFRUWLFRVWHURLGV
RWKHUWKDQLQWHUPLWWHQWGH[DPHWKDVRQHWRFRQWURORUSUHYHQWQDXVHDRUYRPLWLQJRU
FRUWLFRVWHURLGVIRUQRQLQIHFWLYHH[DFHUEDWLRQVRIDVWKPDRUUHVSLUDWRU\GLVHDVH
1RQVWHURLGDOKRUPRQHVDGPLQLVWHUHGIRUQRQO\PSKRPDUHODWHGFRQGLWLRQVHJ
LQVXOLQIRUGLDEHWHVDUHSHUPLWWHG
,WLVUHFRPPHQGHGWKDWDQ\FRXUVHRILPPXQL]DWLRQIRUSDWLHQWVVKRXOGEHFRPSOHWHG
DWOHDVWZHHNVEHIRUHVWDUWLQJULWX[LPDEDQGSDWLHQWVVKRXOGQRWUHFHLYHDQ\
YDFFLQDWLRQVWKDWFRQWDLQOLYHRUDWWHQXDWHGRUJDQLVPVGXULQJWKHVWXG\


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
49 
4.4.3 
Prohibited Food 
There’s no limitation of food unless it’s deemed necessary by the investigator due to 
any background treatment. 
4.4.4 
Initiation of New Anti-lymphoma 
Treatment  
New anti-lymphoma treatment is defined as start of any radiation therapy (even focal 
radiation), chemotherapy or immunotherapy, alone or in any combination of them, 
which is instituted for lymphoma treatment and is not planned in the protocol. 
New anti-lymphoma treatment should be started at any time of documented disease 
progression if this progression is symptomatic and/or if the Investigator considers 
that a new treatment is necessary for the patient’s benefit. Disease progression 
should be documented. If the new anti-lymphoma treatment was initiated during the 
rituximab-based Induction treatment, the patient will undergo end-of-study assessment and 
subsequently only be followed for survival until the end of the study. 
Data on treatment at progression will be recorded in the eCRF. If a new anti-
lymphoma treatment has been started, the therapy used and the response to therapy 
should be documented in the eCRF. 
4.5 
STUDY ASSESSMENTS  
4.5.1 
Description of Study Assessments 
Study-mandated assessments are summarised in the Schedule of Assessments 
(see Appendix 1). 
For details on the timing of each assessment listed in this section, refer to Section 
4.5.2.  
4.5.1.1 
Medical History and Demographic Data 
Medical history includes clinically significant diseases within the last 5 years, surgeries, 
cancer history (including prior cancer therapies and procedures), smoking history, use 
of alcohol and drugs of abuse, and all medications (e.g. prescription drugs, over-the-
counter drugs, herbal/homeopathic remedies, nutritional supplements) used by the 
patient within 30 days prior to the Screening visit. 
Demographic data will include age, sex and ethnicity. 
4.5.1.2 
Vital Signs 
Vital signs measurements will include resting (sitting) heart rate, systolic and 
diastolic blood pressure, and body temperature and will be performed at every study 
visit. 
4.5.1.3 
Physical Examinations 
A complete Screening/Baseline physical examination should include an evaluation of 
the head, eye, ear, nose, and throat, and the cardiovascular, dermatological, 
musculoskeletal, respiratory, gastrointestinal, genitourinary, and neurological 
systems. In addition, as part of tumour assessments, physical examinations should also 
include the evaluation of the presence and degree of enlarged lymph nodes, hepatomegaly, 
and splenomegaly. Any abnormality identified at Screening/Baseline should be 
recorded on the General Medical History and Baseline Conditions eCRF. At 
subsequent study visits, limited, symptom-directed physical examinations should be 
performed. Changes from baseline abnormalities should be recorded in patient notes. 
New or worsened abnormalities should be recorded as AEs on the Adverse Event 
eCRF. As part of physical exams, SC injection sites will also be checked at every 
applicable treatment visit. 
Patients should be assessed at every visit for presence of active infections 
throughout the treatment period.  


5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\


7XPRXUDQG5HVSRQVH(YDOXDWLRQV
7XPRXUDVVHVVPHQWDW6FUHHQLQJ%DVHOLQHDQGZHHNVDIWHUWKHODVWGRVHRI
,QGXFWLRQWUHDWPHQWVWDJLQJZLOOEHEDVHGRQ&7VFDQVRIWKHQHFNFKHVWDEGRPHQ
DQGSHOYLVDVDSSOLFDEOH&7VFDQZLWKFRQWUDVWLVWKHUHFRPPHQGHGWHFKQLTXH
+RZHYHU05,VRIWKHFKHVWDEGRPHQDQGSHOYLVZLWKDQRQFRQWUDVW&7VFDQPD\
EHXVHGLQSDWLHQWVIRUZKRP&7VFDQVZLWKFRQWUDVWDUHFRQWUDLQGLFDWHGLH
SDWLHQWVZLWKFRQWUDVWDOOHUJ\RULPSDLUHGUHQDOFOHDUDQFH&RQYHQWLRQDO&7RU05,
VKRXOGEHSHUIRUPHGDFFRUGLQJWRLQVWLWXWLRQDOVWDQGDUGV
&7DQG05,DUHFXUUHQWO\WKHEHVWDYDLODEOHDQGPRVWUHSURGXFLEOHPHWKRGVIRU
PHDVXULQJWDUJHWOHVLRQVVHOHFWHGIRUUHVSRQVHDVVHVVPHQW7KHVDPHUDGLRJUDSKLF
SURFHGXUHXVHGDW6FUHHQLQJ%DVHOLQHPXVWEHXVHGWKURXJKRXWWKHVWXG\HJ&7
ZLWKWKHVDPHFRQWUDVWSURWRFRORU05,ZLWKRUZLWKRXWDQRQFRQWUDVW&77KH
WXPRXUDVVHVVPHQWPD\EHUHSHDWHGDWDQ\WLPHDWWKH,QYHVWLJDWRU¶VGLVFUHWLRQLI
SURJUHVVLYHGLVHDVH3'LVVXVSHFWHG'XHWRWKHSRVVLEOHOLPLWHGDYDLODELOLW\RI
>)@GHR[\JOXFRVHSRVLWURQHPLVVLRQWRPRJUDSK\)'*3(7VFDQQHUVDQ)'*
3(7VFDQFDQQRWEHPDQGDWHGEXWFDQEHSHUIRUPHGDFFRUGLQJWRORFDOLQVWLWXWLRQDO
VWDQGDUGV
7KH&7VFDQXVHGIRUHOLJLELOLW\DVVHVVPHQWVPD\EHSHUIRUPHGXSWRGD\VSULRUWR
GRVLQJ7KHHQGRIWUHDWPHQWUHVSRQVHDVVHVVPHQWLQFOXGLQJUDGLRORJ\LPDJLQJ
UHSRUWPXVWEHREWDLQHG±ZHHNVDIWHUWKHODVWGRVHRI,QGXFWLRQWUHDWPHQW
5HVSRQVHVKRXOGEHGHWHUPLQHGRQWKHEDVLVRIUDGLRJUDSKLFDQGFOLQLFDOHYLGHQFHRI
GLVHDVHDFFRUGLQJWKH,:*JXLGHOLQHV&KHVRQHWDOVHH$SSHQGL[RULIQRW
DSSOLFDEOHLQVWLWXWLRQDOVWDQGDUGVVKRXOGEHXVHGIRUWXPRXUHYDOXDWLRQ'LVHDVH
SURJUHVVLRQZLOOEHHYDOXDWHGE\WKH,QYHVWLJDWRUDFFRUGLQJWRWKH,:*UHVSRQVH
FULWHULDIRU1+/&KHVRQHWDOVHH$SSHQGL[RURWKHUFRXQWU\VWDQGDUGV
XQWLO3'3DWLHQWVZLWKVWDEOHGLVHDVH6'RU3'DWVWDJLQJZLOOEHZLWKGUDZQIURP
VWXG\WUHDWPHQWDQGZLOORQO\EHIROORZHGIRUUHVROXWLRQRI6$(VUHODWHGWRULWX[LPDE
WKHUDS\DVDSSOLFDEOHDQGIRUVXUYLYDOXQWLOWKHHQGRIWKHVWXG\
6FUHHQLQJ%DVHOLQHERQHPDUURZH[DPLQDWLRQVVKRXOGLQFOXGHELRSV\DQGDVSLUDWH
IRUPRUSKRORJ\IORZVWXGLHVDUHRSWLRQDOIRUVWDJLQJSXUSRVHVXQOHVVLWKDVEHHQ
SHUIRUPHGZLWKLQPRQWKVSULRUWRGRVLQJDQGZDVGRQHIRUWKHSXUSRVHRIGLDJQRVLV
DQGVWDJLQJRI'/%&/6XEVHTXHQWERQHPDUURZDVVHVVPHQWVDUHUHTXLUHGWR
FRQILUPDQ\&5LQSDWLHQWVZLWKERQHPDUURZLQYROYHPHQWDWEDVHOLQH

'LVHDVH6SHFLILF6FUHHQLQJ%DVHOLQH$VVHVVPHQWV
6FUHHQLQJDQGSUHWUHDWPHQW%DVHOLQHHYDOXDWLRQVZLOOLQFOXGHWKHIROORZLQJ
•
'/%&/RUIROOLFXODU1+/GLDJQRVLV1RWHWKHGLDJQRVLVRI'/%&/RUIROOLFXODU
1+/EHIRUHULWX[LPDE6&WUHDWPHQWPXVWKDYHLQFOXGHGKLVWRORJLFDOGLDJQRVLV
DQGLQLWLDO&'H[SUHVVLRQFRQILUPDWLRQ
•
(&2*SHUIRUPDQFHVWDWXVVHH$SSHQGL[IRUGHWDLOV1RWH(&2*
SHUIRUPDQFHVWDWXVQHHGVWREH≤IRULQFOXVLRQRIWKHSDWLHQWLQWRWKHVWXG\
•
,3,VFRUHDFFRUGLQJWR6KLSSHWDODQGRU)/,3,VFRUH6RODO&HOLJQ\HWDO
VHH$SSHQGL[GHWHUPLQHGDW%DVHOLQHSULRUWR&\FOH7KH,3,VFRUH
DFFRUGLQJWR6KLSSHWDOLVDEOHWRGLIIHUHQWLDWHSDWLHQWVLQWRIRXU
SURJQRVWLFJURXSVORZULVNORZLQWHUPHGLDWHULVNKLJKLQWHUPHGLDWHULVNDQGKLJK
ULVN:KHUHSRVVLEOHWKHEDVHOLQH,3,DQGRU)/,3,VFRUHVKRXOGEHFDOFXODWHG
IURPWKHSDWLHQWQRWHV0LVVLQJ,3,)/,3,VFRUHVZLOOQRWSUHFOXGHHQUROPHQW

/DERUDWRU\$VVHVVPHQWV
6DPSOHVIRUWKHODERUDWRU\WHVWVOLVWHGEHORZZLOOEHDQDO\VHGORFDOO\7KHUHVXOWVIURP
WKHVDIHW\ODERUDWRU\DVVHVVPHQWVPXVWEHDYDLODEOHRQWUHDWPHQWGD\VSULRUWRWKH
ULWX[LPDEDGPLQLVWUDWLRQV


5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\

$OOODERUDWRU\DVVHVVPHQWVZLOOEHSHUIRUPHGORFDOO\DFFRUGLQJWRORFDOVWDQGDUGV
1RUPDOUDQJHVIRUWKHVWXG\ODERUDWRU\SDUDPHWHUVPXVWEHVXSSOLHGWR5RFKH
EHIRUHWKHVWXG\VWDUWV
•
+DHPDWRORJ\SDUDPHWHUVZLOOLQFOXGHKDHPRJORELQ5%&FRXQWZKLWHEORRGFHOO
:%&FRXQWDQGGLIIHUHQWLDODQGSODWHOHWFRXQW
•
%LRFKHPLVWU\SDUDPHWHUVDW6FUHHQLQJZLOOLQFOXGHVRGLXPSRWDVVLXP
$/76*37$676*27WRWDOELOLUXELQVHUXPFUHDWLQLQHDONDOLQHSKRVSKDWDVH
DOEXPLQEORRGXUHDQLWURJHQ%81&UHDFWLYHSURWHLQDQG/'+%LRFKHPLVWU\
SDUDPHWHUVDWDQ\IXUWKHUWLPHSRLQWGXULQJWKHVWXG\ZLOOLQFOXGHVRGLXP
SRWDVVLXP$/76*37$676*27WRWDOELOLUXELQDQGVHUXPFUHDWLQLQH
•
&RDJXODWLRQWHVWVZLOOLQFOXGH,QWHUQDWLRQDO1RUPDOL]HG5DWLR,153URWKURPELQ
7LPH37$FWLYDWHG3DUWLDO7KURPERSODVWLQ7LPHD377
•
3UHJQDQF\WHVWZRPHQRIFKLOGEHDULQJSRWHQWLDOGHILQHGDVSUHPHQRSDXVDO
ZRPHQRUZRPHQZKRDUH\HDUVDIWHUWKHRQVHWRIPHQRSDXVHDQGQRW
VXUJLFDOO\VWHULOHPXVWXQGHUJRVHUXPSUHJQDQF\WHVWZLWKLQGD\VSULRUWR
GRVLQJRUZLWKLQGD\VLIZLWKDFRQILUPDWRU\XULQHSUHJQDQF\WHVWZLWKLQGD\V
SULRUWRGRVLQJ,IDXULQHSUHJQDQF\WHVWLVSRVLWLYHLWPXVWEHFRQILUPHGE\D
VHUXPSUHJQDQF\WHVW
•
9LUDOVHURORJ\DQGGHWHFWLRQVKRXOGEHSHUIRUPHGEHIRUHWKHILUVWVWXG\GUXJ
DGPLQLVWUDWLRQDFFRUGLQJWRFOLQLFDOMXGJPHQWDQGPD\LQFOXGHWKHIROORZLQJWHVWV
− +%9KHSDWLWLV%VXUIDFHDQWLJHQDQGWRWDOKHSDWLWLV%FRUHDQWLERG\
− +&9+&9DQWLERG\
− +,9DQWLERG\WHVWLQJ
3DWLHQWVNQRZQRUIRXQGWRKDYH+,9+&9RUDFWLYH+%9LQIHFWLRQPXVWQRWEH
LQFOXGHGLQWKHVWXG\/RFDOJXLGHOLQHVIRUSDWLHQWFRQVHQWWRYLUDOWHVWLQJPXVWEH
DGKHUHGWR

(OHFWURFDUGLRJUDPV
$VWDQGDUGUHVWLQJOHDG(&*QHHGVWREHSHUIRUPHGDW6FUHHQLQJ%DVHOLQHDV
SDUWRIWKHHOLJLELOLW\DVVHVVPHQWV%RG\SRVLWLRQVKRXOGEHFRQVLVWHQWO\PDLQWDLQHG
IRUHDFK(&*HYDOXDWLRQWRSUHYHQWFKDQJHVLQKHDUWUDWH(&*VVKRXOGEH
SHUIRUPHGSULRUWRYLWDOVLJQPHDVXUHPHQWVDQGEORRGGUDZV
7KH,QYHVWLJDWRURUGHVLJQHHPXVWUHYLHZVLJQDQGGDWHDOO(&*WUDFLQJV3DSHU
FRSLHVZLOOEHNHSWDVSDUWRIWKHSDWLHQW
VSHUPDQHQWVWXG\ILOHDWWKHVLWH

3DWLHQW5HSRUWHG2XWFRPHV352
352GDWDZLOOEHHOLFLWHGIURPWKHSDWLHQWVLQWKLVVWXG\WRPRUHIXOO\FKDUDFWHUL]HWKH
FOLQLFDOSURILOHRIULWX[LPDE7KH352LQVWUXPHQWVWUDQVODWHGDVUHTXLUHGLQWKHORFDO
ODQJXDJHZLOOEHGLVWULEXWHGE\VLWHUHVHDUFKSHUVRQQHODQGFRPSOHWHGLQWKHLU
HQWLUHW\E\WKHSDWLHQW

3DWLHQW6DWLVIDFWLRQZLWK7KHUDS\
3DWLHQWVDWLVIDFWLRQZLWK6&RU,9DGPLQLVWUDWLRQRIULWX[LPDEZLOOEHDVVHVVHGXVLQJ
WKH5$64VHH$SSHQGL[LPPHGLDWHO\DIWHUWKHULWX[LPDEDGPLQLVWUDWLRQDQG
EHIRUHFKHPRWKHUDS\DGPLQLVWUDWLRQLQFDVHWKHSDWLHQWZLOOUHFHLYHFKHPRWKHUDS\
3DWLHQWVSUHPDWXUHO\GLVFRQWLQXLQJWUHDWPHQWGXULQJWKHVWXG\VKRXOGFRPSOHWHWKH
TXHVWLRQQDLUHDWWLPHRIGLVFRQWLQXDWLRQDVORQJDVWKH\KDGEHHQDGPLQLVWHUHGDW
OHDVWRQHGRVHRIWUHDWPHQWYLDERWKDGPLQLVWUDWLRQURXWHV
7KH5$64FRQWDLQVTXHVWLRQVRIZKLFKKDYHILYHUHVSRQVHRSWLRQVWZRKDYH
WKUHHUHVSRQVHRSWLRQVDQGRQHTXHVWLRQUHTXLUHVD<HV1RDQVZHU7ZRDOPRVW
LGHQWLFDOYHUVLRQVRIWKHTXHVWLRQQDLUHZLOOEHXVHGLQWKHFXUUHQWVWXG\RQHUHIHUULQJ
WRULWX[LPDE6&DQGRQHUHIHUULQJWRULWX[LPDE,9VHH$SSHQGL[7KH
TXHVWLRQVFRYHUYDULRXVDUHDVRIWUHDWPHQWVDWLVIDFWLRQDQGSUHIHUHQFHLQFOXGLQJ


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
52 
satisfaction with the rituximab (SC or IV) treatment, rating of injection site-related and 
administration-related side effects, anxiety about the treatment and disease, 
confidence in the treatment, treatment convenience, time required and time lost for 
the treatment administrations, how much the treatment interferes or limits daily 
activities, impact of treatment on the ability to talk to the nurse and/or doctor, (no) 
preference for IV or SC administration of rituximab and whether the patient would 
recommend rituximab (SC or IV) treatment to others. 
4.5.1.9 
Healthcare Professional Reported Outcomes 
Healthcare Professionals’ experiences about rituximab SC administration and it’s 
convenience will be evaluated using Healthcare Professional (HCP) Questionnaire 
(see Appendix 7). Questionnaire will be completed at the end of the study treatment 
by the healthcare Professionals such as hematologists, internists, nurses or other 
HCP who administered rituximab SC to the subjects. The HCP Questionnaire 
contains 14 questions evaluating how much time does the rituximab SC 
administration take, administration related complications/reactions and convenience 
of administering the treatment. 
4.5.1.10 
Mandatory Samples 
Not applicable 
4.5.2 
Timing of Study Assessments 
4.5.2.1 
Screening and Pre-treatment Assessments 
Written informed consent for participation in the study must be obtained before 
performing any study-specific screening tests or evaluations. Informed Consent 
Forms (ICFs) for enrolled patients and for patients who were screened but not 
subsequently enrolled will be maintained at the study site.  
Screening tests and evaluations will be performed within 28 days prior to start of 
treatment. Standard-of-care tests or examinations performed prior to obtaining 
informed consent and within 28 days prior to start of treatment do not need to be 
repeated for Screening. All sites of known disease should be documented at 
Screening/Baseline in order to provide an accurate basis for future assessments. All 
screening evaluations must be completed and reviewed to confirm that patients meet 
all eligibility criteria before study enrolment. Patients who are suspected of 
progressing between their Screening/Baseline tumour assessments and first dose 
should be re-screened and re-assessed for their suitability for the trial. The 
Investigator will maintain a screening log in accordance with local study file 
documentation requirements to record details of all patients screened and to confirm 
eligibility or record reasons for screening failures. 
Please see Appendix 1 for the schedule of Screening and pre-treatment 
assessments. 
4.5.2.2 
Assessments during Treatment Visits  
All assessments must be performed on the day of the specified visit, unless a time 
window is specified in the Schedule of Assessments (see Appendix 1). 
Assessments scheduled on the day of study treatment administration should be 
performed prior to administration of study treatment, unless otherwise noted in the 
Schedule of Assessments. 
Please see Appendix 1 for the Schedule of Assessments performed during the 
treatment period. 
The RASQ (see Appendix 6) will be applied at the end of the study. Patients will be 
asked to assess their satisfaction with the study treatment using RASQ immediately 
after rituximab administration and before chemotherapy administration in case the 
patient will receive chemotherapy. 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
53 
Patients with SD or PD at staging after induction therapy for FL or first-line therapy 
for DLBCL will be withdrawn from study treatment and will only be followed for 
resolution of SAEs related to rituximab therapy (as applicable) and for survival until 
the end of the study. 
Patients who do not complete the Induction treatment per protocol will undergo end-
of-treatment assessment within 4 weeks after the last dose of Induction treatment 
and will be followed until the end of the whole study according to local practice for 
resolution of SAEs related to rituximab SC therapy (as applicable), tumour response 
/ progression (if PD not yet documented), survival, and documentation of any new 
anti-lymphoma treatment. 
4.5.2.3 
Post-Treatment Follow-up (Observation) Period  
After the study completion/early termination visit, AEs should be followed as outlined 
in Sections 5.5 and 5.6. 
Please see Appendix 1 for the schedule of follow-up assessments. 
All patients who complete Induction treatment will then enter the post-treatment 
follow-up phase until the end of study. Patients with SD at staging will be 
permanently discontinued from study treatment and will enter the post-treatment 
follow-up phase. Patients with PD at staging (or at any time during treatment) will be 
permanently discontinued from study treatment and will be followed only for survival 
and related SAES until the end of study. Patients who receive at least one dose of 
study drug but do not complete the study as per protocol will undergo the early 
treatment termination assessments within 4 weeks after the last dose of (Induction or 
Maintenance) treatment and will enter the post-treatment follow-up phase until the 
end of study for resolution of SAEs related to rituximab therapy, tumour response / 
progression (if PD not yet documented), new treatments for lymphoma, and survival. 
Follow-up of patients after Induction treatment will occur every 3 months for the first 
year and then every 6 months (± 2 weeks) until the end of the study, as detailed in 
Appendix 1 (Schedule of Assessments). In countries where it is not feasible to 
perform a CT scan every 3 months (± 2 weeks) for 1 year, it is acceptable to perform 
a CT scan every 6 months (± 2 weeks) for 2 years instead.  
4.5.2.4 
Assessments at Study Completion/Early Termination Visit 
Patients who complete the study or discontinue from the study early will be asked to 
return to the clinic (after 28 days or at least 5 half-lives of any non-rituximab IMPs, 
whichever longer) after the last dose of study drug for a follow-up visit. 
Please see Appendix 1 for the Schedule of Assessments performed at the study 
completion/early termination visit. 
Patient satisfaction with administration of treatment will be evaluated by all patients 
using the RASQ (see Appendix 6) after last Rituximab SC in induction and after last 
Rituximab SC in maintenance. The RASQ will be completed immediately after 
rituximab administration and before chemotherapy administration. Patients 
prematurely discontinuing treatment during the study should complete the 
questionnaire at time of discontinuation, as long as they had been administered at 
least one dose of treatment via both administration routes. 
Healthcare professionals such as haematologist, internists, nurses or other 
healthcare professionals who administered rituximab SC will complete Healthcare 
Professional (HCP) questionnaire (see Appendix 7) at the end of the study. 
4.5.2.5 
Unplanned Visits 
Assessments other than those specified in Appendix 1, Schedule of Assessments, 
may be performed as clinically indicated. These assessments should be adequately 
documented. 


5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\


3$7,(17678'<$1'6,7(',6&217,18$7,21

3DWLHQW'LVFRQWLQXDWLRQ
7KH,QYHVWLJDWRUKDVWKHULJKWWRGLVFRQWLQXHDSDWLHQWIURPVWXG\WUHDWPHQWRU
ZLWKGUDZDSDWLHQWIURPWKHVWXG\DWDQ\WLPH,QDGGLWLRQSDWLHQWVKDYHWKHULJKWWR
YROXQWDULO\GLVFRQWLQXHVWXG\WUHDWPHQWRUZLWKGUDZIURPWKHVWXG\DWDQ\WLPHIRUDQ\
UHDVRQ5HDVRQVIRUGLVFRQWLQXDWLRQRIVWXG\WUHDWPHQWPD\LQFOXGHEXWDUHQRW
OLPLWHGWRWKHIROORZLQJ
•
$Q\PHGLFDOFRQGLWLRQWKDWWKH,QYHVWLJDWRURU6SRQVRUGHWHUPLQHVPD\
MHRSDUGLVHWKHSDWLHQW¶VVDIHW\LIKHRUVKHFRQWLQXHVVWXG\WUHDWPHQW
•
3UHJQDQF\
•
0DMRUSURWRFROYLRODWLRQ
5HDVRQVIRUZLWKGUDZDOIURPWKHVWXG\PD\LQFOXGHEXWDUHQRWOLPLWHGWRWKH
IROORZLQJ
•
3DWLHQWZLWKGUDZDORIFRQVHQWDWDQ\WLPH,QLQVWDQFHVZKHUHFRQVHQWLV
ZLWKGUDZQWKH,QYHVWLJDWRUPXVWFODULI\DQGGRFXPHQWZKHWKHUWKHSDWLHQWLV
ZLOOLQJWRFRQWLQXHWREHIROORZHGLHIRUVXUYLYDO
•
,QYHVWLJDWRURU6SRQVRUGHWHUPLQHVLWLVLQWKHEHVWLQWHUHVWRIWKHSDWLHQW
•
3DWLHQWQRQFRPSOLDQFH
•
3DWLHQWORVWWRIROORZXS
•
0DMRUSURWRFROYLRODWLRQ
•
7ULDOWHUPLQDWLRQE\WKH6SRQVRU5HJXODWRU\$XWKRULWLHV
•
7ULDOWHUPLQDWLRQDWVLWHE\,QYHVWLJDWRURU(&

'LVFRQWLQXDWLRQIURP6WXG\'UXJ
3DWLHQWVZKRGLVFRQWLQXHVWXG\WUHDWPHQWSUHPDWXUHO\ZLOOEHDVNHGWRUHWXUQWRWKH
FOLQLFIRUDVWXG\FRPSOHWLRQHDUO\WHUPLQDWLRQYLVLWVHH6HFWLRQDQGPD\
XQGHUJRIROORZXSDVVHVVPHQWVVHH6HFWLRQ7KHSULPDU\UHDVRQIRU
SUHPDWXUHVWXG\GUXJWUHDWPHQWGLVFRQWLQXDWLRQVKRXOGEHGRFXPHQWHGRQWKH
DSSURSULDWHH&5)
3DWLHQWVZKRGLVFRQWLQXHVWXG\GUXJSUHPDWXUHO\ZLOOQRWEHUHSODFHG

:LWKGUDZDOIURP6WXG\
(YHU\HIIRUWVKRXOGEHPDGHWRREWDLQLQIRUPDWLRQRQSDWLHQWVZKRZLWKGUDZIURPWKH
VWXG\7KHSULPDU\UHDVRQIRUZLWKGUDZDOIURPWKHVWXG\VKRXOGEHGRFXPHQWHGRQ
WKHDSSURSULDWHH&5)3DWLHQWVZLOOQRWEHIROORZHGIRUDQ\UHDVRQDIWHULQIRUPHG
FRQVHQWKDVEHHQZLWKGUDZQDOWKRXJKGDWHRIGHDWKVKRXOGEHUHFRUGHGZKHUH
DSSOLFDEOH3DWLHQWVZKRZLWKGUDZIURPWKHVWXG\ZLOOQRWEHUHSODFHG

6WXG\DQG6LWH'LVFRQWLQXDWLRQ
7KH6SRQVRUKDVWKHULJKWWRWHUPLQDWHWKLVVWXG\DWDQ\WLPH5HDVRQVIRU
WHUPLQDWLQJWKHVWXG\PD\LQFOXGHEXWDUHQRWOLPLWHGWRWKHIROORZLQJ
•
7KHLQFLGHQFHRUVHYHULW\RI$(VLQWKLVRURWKHUVWXGLHVLQGLFDWHVDSRWHQWLDO
KHDOWKKD]DUGWRSDWLHQWV
•
3DWLHQWHQUROPHQWLVXQVDWLVIDFWRU\
7KH6SRQVRUZLOOQRWLI\WKH,QYHVWLJDWRULIWKHSDWLHQWHQUROPHQWLVSODFHGRQKROGRU
LIWKH6SRQVRUGHFLGHVWRGLVFRQWLQXHWKHVWXG\RUGHYHORSPHQWSURJUDP
7KH6SRQVRUKDVWKHULJKWWRUHSODFHDVLWHDWDQ\WLPH5HDVRQVIRUUHSODFLQJDVLWH
PD\LQFOXGHEXWDUHQRWOLPLWHGWRWKHIROORZLQJ
•
([FHVVLYHO\VORZUHFUXLWPHQW
•
3RRUSURWRFRODGKHUHQFHDQGRUUHSHDWHGSURWRFROYLRODWLRQV


5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\

•
5HSHWLWLYHODWHLQDFFXUDWHRULQFRPSOHWHGDWDUHFRUGLQJRUIDLOXUHWRUHVROYHGDWD
TXHULHVLQWKHH&5)
•
1RQFRPSOLDQFHZLWKWKH,QWHUQDWLRQDO&RQIHUHQFHRQ+DUPRQLVDWLRQ,&+
JXLGHOLQHIRU*RRG&OLQLFDO3UDFWLFH

$66(660(172)6$)(7<

6$)(7<3/$1
3DWLHQWVZLOOEHDVVHVVHGE\SULRUPHGLFDOKLVWRU\YLWDOVLJQVLQFOXGLQJUHVWLQJEORRG
SUHVVXUHKHDUWUDWHDQGERG\WHPSHUDWXUHZHLJKWDQGKHLJKWSK\VLFDO
H[DPLQDWLRQ$(VDQGFRQFRPLWDQWPHGLFDWLRQV$FRPSOHWHPHGLFDOKLVWRU\
LQFOXGLQJSULRUWUHDWPHQWVIRUFDQFHUZLOOEHGRFXPHQWHGDW6FUHHQLQJ%DVHOLQH$
JHQHUDOSK\VLFDOH[DPZLWKLQIHFWLRQDVVHVVPHQWZLOOEHSHUIRUPHGDW
6FUHHQLQJ%DVHOLQHDQGDWHYHU\WUHDWPHQWDQGSRVWWUHDWPHQWIROORZXSYLVLWVHH
$SSHQGL[6FKHGXOHRI$VVHVVPHQWV$VSDUWRISK\VLFDOH[DPV6&LQMHFWLRQ
VLWHVZLOOEHFKHFNHGDWHYHU\WUHDWPHQWYLVLW$OOSDWLHQWVZLOOXQGHUJRURXWLQHVDIHW\
ODERUDWRU\WHVWV
$(VZLOOEHPRQLWRUHGDQGGRFXPHQWHGFRQWLQXRXVO\GXULQJWKHVWXG\DWHDFKRQ
WUHDWPHQWYLVLWDQGGXULQJWKHSRVWWUHDWPHQWIROORZXSDVGHWDLOHGLQ6HFWLRQ
UHIHUWR6HFWLRQVDQGIRUGHWDLOVRQ6$(UHSRUWLQJDQGIROORZXS
UHTXLUHPHQWVUHVSHFWLYHO\$OO$(VDQG6$(VLQFOXGLQJSDWLHQWV¶V\PSWRPVDQG
VLJQVRIWR[LFLW\DQGFOLQLFDOO\VLJQLILFDQWKDHPDWRORJLFDODQGELRFKHPLFDOSDUDPHWHUV
ZLOOEHJUDGHGDFFRUGLQJWR1&,&7&$(YHUVLRQVHH$SSHQGL[
&KDQJHVLQFRQFRPLWDQWPHGLFDWLRQZLOOEHUHFRUGHGDWHDFKVWXG\YLVLW5HFRUGLQJRI
FRQFRPLWDQWWUHDWPHQWVDQGWKHUDSLHVZLOOLQFOXGHDQ\QHZDQWLO\PSKRPDWUHDWPHQW
LQLWLDWHGDIWHUWKH%DVHOLQHYLVLW

$GYHUVH(YHQWVRI6SHFLDO,QWHUHVW
$(VRIVSHFLDOLQWHUHVWLQFOXGH$$5VKHSDWRWR[LFLW\HOHYDWHG$/7RU$67LQ
FRPELQDWLRQZLWKHLWKHUDQHOHYDWHGELOLUXELQRUFOLQLFDOMDXQGLFHDVGHILQHGLQ
6HFWLRQDQGVXVSHFWHGWUDQVPLVVLRQRIDQLQIHFWLRXVDJHQWE\WKHVWXG\GUXJ
VHH6HFWLRQ

,QWHUDFWLRQZLWK2WKHU0HGLFLQDO3URGXFWV
$WSUHVHQWWKHUHDUHOLPLWHGGDWDRQSRVVLEOHGUXJLQWHUDFWLRQVZLWKULWX[LPDE7KH
WROHUDELOLW\RIWKHVLPXOWDQHRXVRUVHTXHQWLDOFRPELQDWLRQRIULWX[LPDE6&ZLWK
FKHPRWKHUDS\DJHQWVWKDWDUHOLDEOHWRFDXVHGHSOHWLRQRIQRUPDO%FHOOVLVZHOO
GHILQHG
3DWLHQWVZLWK+$0$RU+$&$WLWHUVPD\GHYHORSDOOHUJLFRUK\SHUVHQVLWLYLW\UHDFWLRQV
ZKHQWUHDWHGZLWKRWKHUGLDJQRVWLFRUWKHUDSHXWLFPRQRFORQDODQWLERGLHV

$GPLQLVWUDWLRQ$VVRFLDWHG5HDFWLRQVDQG
WKHLU0DQDJHPHQW
$(VRIVSHFLDOLQWHUHVWLQFOXGH$$5V$$5VDUHGHILQHGDVDOO$(VRFFXUULQJZLWKLQ
KRXUVRIULWX[LPDEDGPLQLVWUDWLRQDQGFRQVLGHUHGE\WKHLQYHVWLJDWRUWREHUHODWHG
WRVWXG\GUXJ$$5VLQFOXGH,,55VLQMHFWLRQVLWHUHDFWLRQVDGPLQLVWUDWLRQVLWH
FRQGLWLRQVDQGDOOV\PSWRPVWKHUHRI7KHLQFLGHQFHRIFXWDQHRXVDQGVRIWWLVVXH
$$5VZLOODGGLWLRQDOO\EHPHDVXUHGIRUWKRVHWKDWDUHGHILQHGDVORFDOL]HGDQGWKRVH
WKDWDUHGHILQHGDVQRQORFDOL]HG,,55VFDQSUHVHQWZLWKRQHRUPRUHRIWKH
IROORZLQJV\PSWRPVDOOHUJLFUHDFWLRQDUWKUDOJLDEURQFKRVSDVPFKLOOVFRXJK
GL]]LQHVVG\VSQHDKHDGDFKHK\SHUWHQVLRQK\SRWHQVLRQP\DOJLDQDXVHDSUXULWXV
S\UH[LDUDVKWDFK\FDUGLDXUWLFDULDYRPLWLQJ


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
56 
All AARs must be recorded on the Adverse Event eCRF. Cutaneous and soft-tissue 
AARs will be classified in the eCRF as either localized at the injection site, or non-
localized reactions (including generalized reactions). In order to capture potential 
differences in terms of clinical relevance of these events, it is important to report and 
assess the intensity of all individual symptoms of the AARs. 
Signs and symptoms suggestive of an IIRR were reported in more than 50% of 
patients who received rituximab IV in clinical trials, and were predominantly seen 
during the first infusion. Severe IIRRs occurred in up to 12% of all patients at the 
time of the first treatment cycle with rituximab in combination with chemotherapy. 
These included cases of cytokine release syndrome accompanied by hypotension 
and bronchospasm. The incidence of infusion-related symptoms decreased 
substantially with subsequent infusions and is <1% of patients by the eighth cycle. 
Infusion reaction symptoms are usually reversible with interruption of the infusion. 
Treatment of infusion-related symptoms with an anti-pyretic (e.g. acetaminophen), 
an antihistaminic (such as diphenhydramine) is recommended. Additional treatment 
with bronchodilators, oxygen or IV saline may be indicated. In most cases, the 
infusion can be resumed at a 50% reduction in rate (e.g. from 100 mg/hour to 50 
mg/hour) when symptoms have completely resolved. 
Patients who develop severe cytokine release syndrome or severe pulmonary events 
should have their infusion interrupted immediately and should receive aggressive 
symptomatic treatment. Since initial improvement of clinical symptoms may be 
followed by deterioration, these patients should be closely monitored until TLS and 
pulmonary infiltration have been resolved or ruled out. 
Hypersensitivity reactions typically occur within minutes after starting rituximab 
infusion. Medicinal products for the treatment of hypersensitivity reactions (e.g. 
epinephrine (adrenaline), antihistamines and glucocorticoids), should be available for 
immediate use in the event of an allergic reaction during administration of rituximab. 
If PML is suspected based on any new or worsening neurological, cognitive or 
psychiatric symptoms or signs, further dosing must be suspended until PML has 
been excluded. The Investigator should evaluate the patient to determine if the 
symptoms are indicative of neurological dysfunction, and if so, whether these 
symptoms are possibly suggestive of PML. 
Guidelines for managing of specific haematologic and non-haematologic AEs 
associated with R-CHOP treatment are summarized in Table 5 below.  






5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\


6HULRXV$GYHUVH(YHQWV,PPHGLDWHO\
5HSRUWDEOHWRWKH6SRQVRU
$Q6$(LVDQ\$(WKDWPHHWVDQ\RIWKHIROORZLQJFULWHULD
•
)DWDOLHWKH$(DFWXDOO\FDXVHVRUOHDGVWRGHDWK
•
/LIHWKUHDWHQLQJLHWKH$(LQWKHYLHZRIWKH,QYHVWLJDWRUSODFHVWKHSDWLHQWDW
LPPHGLDWHULVNRIGHDWK
7KHWHUPOLIHWKUHDWHQLQJLQWKHGHILQLWLRQRIVHULRXVUHIHUVWRDQHYHQWLQ
ZKLFKWKHSDWLHQWZDVDWULVNRIGHDWKDWWKHWLPHRIWKHHYHQWLWGRHVQRW
UHIHUWRDQHYHQWZKLFKK\SRWKHWLFDOO\PLJKWKDYHFDXVHGGHDWKLILWZHUH
PRUHVHYHUH
•
5HTXLUHVRUSURORQJVLQSDWLHQWKRVSLWDOL]DWLRQVHH6HFWLRQ
•
5HVXOWVLQSHUVLVWHQWRUVLJQLILFDQWGLVDELOLW\LQFDSDFLW\LHWKH$(UHVXOWVLQ
VXEVWDQWLDOGLVUXSWLRQRIWKHSDWLHQW¶VDELOLW\WRFRQGXFWQRUPDOOLIHIXQFWLRQV
•
&RQJHQLWDODQRPDO\ELUWKGHIHFWLQDQHRQDWHLQIDQWERUQWRDPRWKHUH[SRVHGWR
VWXG\GUXJ
•
6LJQLILFDQWPHGLFDOHYHQWLQWKH,QYHVWLJDWRU
VMXGJPHQWHJPD\MHRSDUGL]HWKH
SDWLHQWRUPD\UHTXLUHPHGLFDOVXUJLFDOLQWHUYHQWLRQWRSUHYHQWRQHRIWKH
RXWFRPHVOLVWHGDERYH
7KHWHUPV³VHYHUH´DQG³VHULRXV´DUHQRWV\QRQ\PRXV6HYHULW\UHIHUVWRWKHLQWHQVLW\
RIDQ$(UDWHGDVPLOGPRGHUDWHRUVHYHUHRUDFFRUGLQJWR1&,&7&$(FULWHULD
VHH6HFWLRQDQG$SSHQGL[WKHHYHQWLWVHOIPD\EHRIUHODWLYHO\PLQRU
PHGLFDOVLJQLILFDQFHVXFKDVVHYHUHKHDGDFKHZLWKRXWDQ\IXUWKHUILQGLQJV
6HYHULW\DQGVHULRXVQHVVQHHGWREHLQGHSHQGHQWO\DVVHVVHGIRUHDFK$(UHFRUGHG
RQWKHH&5)
6$(VDUHUHTXLUHGWREHUHSRUWHGE\WKH,QYHVWLJDWRUWRWKH6SRQVRUZLWKLQKRXUV
DIWHUOHDUQLQJRIWKHHYHQWVHH6HFWLRQIRUUHSRUWLQJLQVWUXFWLRQV

1RQ6HULRXV$GYHUVH(YHQWVRI6SHFLDO
,QWHUHVW,PPHGLDWHO\5HSRUWDEOHWRWKH
6SRQVRU
1RQVHULRXV$(VRIVSHFLDOLQWHUHVWDUHUHTXLUHGWREHUHSRUWHGE\WKH,QYHVWLJDWRUWR
WKH6SRQVRUZLWKLQKRXUVDIWHUOHDUQLQJRIWKHHYHQWVHH6HFWLRQIRU
UHSRUWLQJLQVWUXFWLRQV$(VRIVSHFLDOLQWHUHVWIRUWKLVVWXG\LQFOXGHWKHIROORZLQJ
• &DVHVRIDQHOHYDWHG$/7RU$67LQFRPELQDWLRQZLWKHLWKHUDQHOHYDWHG
ELOLUXELQRUFOLQLFDOMDXQGLFHDVGHILQHGLQ6HFWLRQ
• 6XVSHFWHGWUDQVPLVVLRQRIDQLQIHFWLRXVDJHQWE\WKHVWXG\GUXJ
• $55

0(7+2'6$1'7,0,1*)25&$3785,1*$1'$66(66,1*
6$)(7<3$5$0(7(56
7KH,QYHVWLJDWRULVUHVSRQVLEOHIRUHQVXULQJWKDWDOO$(VVHH6HFWLRQIRU
GHILQLWLRQDUHUHFRUGHGRQWKH$(H&5)DQGUHSRUWHGWRWKH6SRQVRULQDFFRUGDQFH
ZLWKLQVWUXFWLRQVSURYLGHGLQWKLVVHFWLRQDQGLQ6HFWLRQV−
)RUHDFK$(UHFRUGHGRQWKH$(H&5)WKH,QYHVWLJDWRUZLOOPDNHDQDVVHVVPHQWRI
VHULRXVQHVVVHH6HFWLRQIRUVHULRXVQHVVFULWHULDVHYHULW\VHH6HFWLRQ
DQGFDXVDOLW\VHH6HFWLRQ

$GYHUVH(YHQW5HSRUWLQJ3HULRG
,QYHVWLJDWRUVZLOOVHHNLQIRUPDWLRQRQ$(VDWHDFKSDWLHQWFRQWDFW$OO$(VZKHWKHU
UHSRUWHGE\WKHSDWLHQWRUQRWHGE\VWXG\SHUVRQQHOZLOOEHUHFRUGHGLQWKHSDWLHQW¶V
PHGLFDOUHFRUGDQGRQWKH$GYHUVH(YHQWH&5)




5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\


$VVHVVPHQWRI&DXVDOLW\RI$GYHUVH
(YHQWV
,QYHVWLJDWRUVVKRXOGXVHWKHLUNQRZOHGJHRIWKHSDWLHQWWKHFLUFXPVWDQFHV
VXUURXQGLQJWKHHYHQWDQGDQHYDOXDWLRQRIDQ\SRWHQWLDODOWHUQDWLYHFDXVHVWR
GHWHUPLQHZKHWKHURUQRWDQ$(LVFRQVLGHUHGWREHUHODWHGWRWKHVWXG\GUXJ
LQGLFDWLQJ\HVRUQRDFFRUGLQJO\7KHIROORZLQJJXLGDQFHVKRXOGEHWDNHQLQWR
FRQVLGHUDWLRQ
•
7HPSRUDOUHODWLRQVKLSRIHYHQWRQVHWWRWKHLQLWLDWLRQRIVWXG\GUXJ
•
&RXUVHRIWKHHYHQWFRQVLGHULQJHVSHFLDOO\WKHHIIHFWVRIGRVHUHGXFWLRQ
GLVFRQWLQXDWLRQRIVWXG\GUXJRUUHLQWURGXFWLRQRIVWXG\GUXJZKHUHDSSOLFDEOH
•
.QRZQDVVRFLDWLRQRIWKHHYHQWZLWKWKHVWXG\GUXJRUZLWKVLPLODUWUHDWPHQWV
•
.QRZQDVVRFLDWLRQRIWKHHYHQWZLWKWKHGLVHDVHXQGHUVWXG\
•
3UHVHQFHRIULVNIDFWRUVLQWKHSDWLHQWRUXVHRIFRQFRPLWDQWPHGLFDWLRQVNQRZQ
WRLQFUHDVHWKHRFFXUUHQFHRIWKHHYHQW
•
3UHVHQFHRIQRQWUHDWPHQWUHODWHGIDFWRUVWKDWDUHNQRZQWREHDVVRFLDWHGZLWK
WKHRFFXUUHQFHRIWKHHYHQW
)RUSDWLHQWVUHFHLYLQJFRPELQDWLRQWKHUDS\FDXVDOLW\ZLOOEHDVVHVVHGLQGLYLGXDOO\IRU
HDFKSURWRFROPDQGDWHGWKHUDS\

3URFHGXUHVIRU5HFRUGLQJ
$GYHUVH(YHQWV
,QYHVWLJDWRUVVKRXOGXVHFRUUHFWPHGLFDOWHUPLQRORJ\FRQFHSWVZKHQUHFRUGLQJ$(V
RQWKH$GYHUVH(YHQWH&5)&ROORTXLDOLVPVDQGDEEUHYLDWLRQVVKRXOGEHDYRLGHG
2QO\RQH$(WHUPVKRXOGEHUHFRUGHGLQWKHHYHQWILHOGRQWKH$GYHUVH(YHQWH&5)

'LDJQRVLVYHUVXV6LJQVDQG6\PSWRPV
5HDFWLRQV7HPSRUDOO\$VVRFLDWHGZLWKWKH5LWX[LPDE,QMHFWLRQV
$(VWKDWRFFXUGXULQJRUZLWKLQKRXUVDIWHUVWXG\GUXJDGPLQLVWUDWLRQVKRXOGEH
FDSWXUHGDVLQGLYLGXDOVLJQVDQGV\PSWRPVUDWKHUWKDQDGLDJQRVLVRIDOOHUJLF
UHDFWLRQRULQIXVLRQUHDFWLRQ
2WKHU$GYHUVH(YHQWV
)RU$(VRWKHUWKDQ,,55VDGLDJQRVLVLINQRZQVKRXOGEHUHFRUGHGRQWKH$GYHUVH
(YHQWH&5)UDWKHUWKDQLQGLYLGXDOVLJQVDQGV\PSWRPVHJUHFRUGRQO\OLYHUIDLOXUH
RUKHSDWLWLVUDWKHUWKDQMDXQGLFHDVWHUL[LVDQGHOHYDWHGWUDQVDPLQDVHV+RZHYHULI
DFRQVWHOODWLRQRIVLJQVDQGRUV\PSWRPVFDQQRWEHPHGLFDOO\FKDUDFWHUL]HGDVD
VLQJOHGLDJQRVLVRUV\QGURPHDWWKHWLPHRIUHSRUWLQJHDFKLQGLYLGXDOHYHQWVKRXOG
EHUHFRUGHGRQWKH$GYHUVH(YHQWH&5),IDGLDJQRVLVLVVXEVHTXHQWO\HVWDEOLVKHG
DOOSUHYLRXVO\UHSRUWHG$(VEDVHGRQVLJQVDQGV\PSWRPVVKRXOGEHQXOOLILHGDQG
UHSODFHGE\RQH$(UHSRUWEDVHGRQWKHVLQJOHGLDJQRVLVZLWKDVWDUWLQJGDWHWKDW
FRUUHVSRQGVWRWKHVWDUWLQJGDWHRIWKHILUVWV\PSWRPRIWKHHYHQWXDOGLDJQRVLV

$GYHUVH(YHQWV2FFXUULQJ6HFRQGDU\WR2WKHU(YHQWV
,QJHQHUDO$(VRFFXUULQJVHFRQGDU\WRRWKHUHYHQWVHJFDVFDGHHYHQWVRUFOLQLFDO
VHTXHODHVKRXOGEHLGHQWLILHGE\WKHLUSULPDU\FDXVHZLWKWKHH[FHSWLRQRIVHYHUHRU
VHULRXVVHFRQGDU\HYHQWV+RZHYHUPHGLFDOO\VLJQLILFDQW$(VRFFXUULQJVHFRQGDU\
WRDQLQLWLDWLQJHYHQWWKDWDUHVHSDUDWHGLQWLPHVKRXOGEHUHFRUGHGDVLQGHSHQGHQW
HYHQWVRQWKH$GYHUVH(YHQWH&5))RUH[DPSOH
•
,IYRPLWLQJUHVXOWVLQPLOGGHK\GUDWLRQZLWKQRDGGLWLRQDOWUHDWPHQWRQO\YRPLWLQJ
VKRXOGEHUHSRUWHGRQWKHH&5)
•
,IYRPLWLQJUHVXOWVLQVHYHUHGHK\GUDWLRQERWKHYHQWVVKRXOGEHUHSRUWHG
VHSDUDWHO\RQWKHH&5)


5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\

•
,IDVHYHUHJDVWURLQWHVWLQDOKDHPRUUKDJHOHDGVWRUHQDOIDLOXUHERWKHYHQWV
VKRXOGEHUHSRUWHGVHSDUDWHO\RQWKHH&5)
•
,IGL]]LQHVVOHDGVWRDIDOODQGVXEVHTXHQWIUDFWXUHDOOWKUHHHYHQWVVKRXOGEH
UHSRUWHGVHSDUDWHO\RQWKHH&5)
•
,IQHXWURSHQLDLVDFFRPSDQLHGE\DPLOGQRQVHULRXVLQIHFWLRQRQO\QHXWURSHQLD
VKRXOGEHUHSRUWHGRQWKHH&5)
•
,IQHXWURSHQLDLVDFFRPSDQLHGE\DVHYHUHRUVHULRXVLQIHFWLRQERWKHYHQWV
VKRXOGEHUHSRUWHGVHSDUDWHO\RQWKHH&5)
$OO$(VVKRXOGEHUHFRUGHGVHSDUDWHO\RQWKH$GYHUVH(YHQWH&5)LILWLVXQFOHDUDV
WRZKHWKHUWKHHYHQWVDUHDVVRFLDWHG

3HUVLVWHQWRU5HFXUUHQW$GYHUVH(YHQWV
$SHUVLVWHQW$(LVRQHWKDWH[WHQGVFRQWLQXRXVO\ZLWKRXWUHVROXWLRQEHWZHHQSDWLHQW
HYDOXDWLRQWLPHSRLQWV6XFKHYHQWVVKRXOGRQO\EHUHFRUGHGRQFHRQWKH$GYHUVH
(YHQWH&5)7KHLQLWLDOVHYHULW\RIWKHHYHQWVKRXOGEHUHFRUGHGDQGWKHVHYHULW\
VKRXOGEHXSGDWHGWRUHIOHFWWKHPRVWH[WUHPHVHYHULW\DQ\WLPHWKHHYHQWZRUVHQV
,IWKHHYHQWEHFRPHVVHULRXVWKH$GYHUVH(YHQWH&5)VKRXOGEHXSGDWHGWRUHIOHFW
WKLV
$UHFXUUHQW$(LVRQHWKDWUHVROYHVEHWZHHQSDWLHQWHYDOXDWLRQWLPHSRLQWVDQG
VXEVHTXHQWO\UHFXUV(DFKUHFXUUHQFHRIDQ$(VKRXOGEHUHFRUGHGVHSDUDWHO\RQ
WKH$GYHUVH(YHQWH&5)

$EQRUPDO/DERUDWRU\9DOXHV
1RWHYHU\ODERUDWRU\DEQRUPDOLW\TXDOLILHVDVDQ$($ODERUDWRU\WHVWUHVXOWVKRXOG
EHUHSRUWHGDVDQ$(LILWPHHWVDQ\RIWKHIROORZLQJFULWHULD
•
$FFRPSDQLHGE\FOLQLFDOV\PSWRPV
•
5HVXOWVLQDFKDQJHLQVWXG\WUHDWPHQWHJGRVDJHPRGLILFDWLRQWUHDWPHQW
LQWHUUXSWLRQRUWUHDWPHQWGLVFRQWLQXDWLRQ
•
5HVXOWVLQDPHGLFDOLQWHUYHQWLRQHJSRWDVVLXPVXSSOHPHQWDWLRQIRU
K\SRNDOHPLDRUDFKDQJHLQFRQFRPLWDQWWKHUDS\
•
&OLQLFDOO\VLJQLILFDQWLQWKH,QYHVWLJDWRU¶VMXGJPHQW
•
:RUVHQLQJYDOXHFRPSDUHGWREDVHOLQH
,WLVWKH,QYHVWLJDWRU¶VUHVSRQVLELOLW\WRUHYLHZDOOODERUDWRU\ILQGLQJV0HGLFDODQG
VFLHQWLILFMXGJPHQWVKRXOGEHH[HUFLVHGLQGHFLGLQJZKHWKHUDQLVRODWHGODERUDWRU\
DEQRUPDOLW\VKRXOGEHFODVVLILHGDVDQ$(
,IDFOLQLFDOO\VLJQLILFDQWODERUDWRU\DEQRUPDOLW\LVDVLJQRIDGLVHDVHRUV\QGURPH
HJDONDOLQHSKRVSKDWDVHDQGELOLUXELQILYHWLPHVWKH8/1DVVRFLDWHGZLWK
FKROHF\VWLWLVRQO\WKHGLDJQRVLVLHFKROHF\VWLWLVVKRXOGEHUHFRUGHGRQWKH
$GYHUVH(YHQWH&5)
,IDFOLQLFDOO\VLJQLILFDQWODERUDWRU\DEQRUPDOLW\LVQRWDVLJQRIDGLVHDVHRUV\QGURPH
WKHDEQRUPDOLW\LWVHOIVKRXOGEHUHFRUGHGRQWKH$GYHUVH(YHQWH&5)DORQJZLWKD
GHVFULSWRULQGLFDWLQJLIWKHWHVWUHVXOWLVDERYHRUEHORZWKHQRUPDOUDQJHHJ
HOHYDWHGSRWDVVLXPDVRSSRVHGWRDEQRUPDOSRWDVVLXP,IWKHODERUDWRU\
DEQRUPDOLW\FDQEHFKDUDFWHUL]HGE\DSUHFLVHFOLQLFDOWHUPSHUVWDQGDUGGHILQLWLRQV
WKHFOLQLFDOWHUPVKRXOGEHUHFRUGHGDVWKH$()RUH[DPSOHDQHOHYDWHGVHUXP
SRWDVVLXPOHYHORIP(T/VKRXOGEHUHFRUGHGDV³K\SHUNDOHPLD´
2EVHUYDWLRQVRIWKHVDPHFOLQLFDOO\VLJQLILFDQWODERUDWRU\DEQRUPDOLW\IURPYLVLWWR
YLVLWVKRXOGQRWEHUHSHDWHGO\UHFRUGHGRQWKH$GYHUVH(YHQWH&5)XQOHVVWKH
DHWLRORJ\FKDQJHV7KHLQLWLDOVHYHULW\RIWKHHYHQWVKRXOGEHUHFRUGHGDQGWKH
VHYHULW\RUVHULRXVQHVVVKRXOGEHXSGDWHGDQ\WLPHWKHHYHQWZRUVHQV


5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\


$EQRUPDO9LWDO6LJQ9DOXHV
1RWHYHU\YLWDOVLJQDEQRUPDOLW\TXDOLILHVDVDQ$($YLWDOVLJQUHVXOWVKRXOGEH
UHSRUWHGDVDQ$(LILWPHHWVDQ\RIWKHIROORZLQJFULWHULD
•
$FFRPSDQLHGE\FOLQLFDOV\PSWRPV
•
5HVXOWVLQDFKDQJHLQVWXG\WUHDWPHQWHJGRVDJHPRGLILFDWLRQWUHDWPHQW
LQWHUUXSWLRQRUWUHDWPHQWGLVFRQWLQXDWLRQ
•
5HVXOWVLQDPHGLFDOLQWHUYHQWLRQRUDFKDQJHLQFRQFRPLWDQWWKHUDS\
•
&OLQLFDOO\VLJQLILFDQWLQWKH,QYHVWLJDWRU¶VMXGJPHQW
,WLVWKH,QYHVWLJDWRU¶VUHVSRQVLELOLW\WRUHYLHZDOOYLWDOVLJQILQGLQJV0HGLFDODQG
VFLHQWLILFMXGJPHQWVKRXOGEHH[HUFLVHGLQGHFLGLQJZKHWKHUDQLVRODWHGYLWDOVLJQ
DEQRUPDOLW\VKRXOGEHFODVVLILHGDVDQ$(
,IDFOLQLFDOO\VLJQLILFDQWYLWDOVLJQDEQRUPDOLW\LVDVLJQRIDGLVHDVHRUV\QGURPHHJ
KLJKEORRGSUHVVXUHRQO\WKHGLDJQRVLVLHK\SHUWHQVLRQVKRXOGEHUHFRUGHGRQ
WKH$GYHUVH(YHQWH&5)
2EVHUYDWLRQVRIWKHVDPHFOLQLFDOO\VLJQLILFDQWYLWDOVLJQDEQRUPDOLW\IURPYLVLWWRYLVLW
VKRXOGQRWEHUHSHDWHGO\UHFRUGHGRQWKH$GYHUVH(YHQWH&5)XQOHVVWKHDHWLRORJ\
FKDQJHV7KHLQLWLDOVHYHULW\RIWKHHYHQWVKRXOGEHUHFRUGHGDQGWKHVHYHULW\RU
VHULRXVQHVVVKRXOGEHXSGDWHGDQ\WLPHWKHHYHQWZRUVHQV

$EQRUPDO/LYHU)XQFWLRQ7HVWV
7KHILQGLQJRIDQHOHYDWHG$/7RU$67×8/1LQFRPELQDWLRQZLWKHLWKHUDQ
HOHYDWHGWRWDOELOLUXELQ×8/1RUFOLQLFDOMDXQGLFHLQWKHDEVHQFHRIFKROHVWDVLV
RURWKHUFDXVHVRIK\SHUELOLUXELQHPLDLVFRQVLGHUHGWREHDQLQGLFDWRURIVHYHUHOLYHU
LQMXU\7KHUHIRUH,QYHVWLJDWRUVPXVWUHSRUWWKHRFFXUUHQFHRIHLWKHURIWKHIROORZLQJ
DVDQ$(
•
7UHDWPHQWHPHUJHQW$/7RU$67×8/1YDOXHLQFRPELQDWLRQZLWKWRWDO
ELOLUXELQ×8/1RIZKLFKLVGLUHFWELOLUXELQ
•
7UHDWPHQWHPHUJHQW$/7RU$67×8/1YDOXHLQFRPELQDWLRQZLWKFOLQLFDO
MDXQGLFH
7KHPRVWDSSURSULDWHGLDJQRVLVRULIDGLDJQRVLVFDQQRWEHHVWDEOLVKHGWKH
DEQRUPDOODERUDWRU\YDOXHVVKRXOGEHUHFRUGHGRQWKH$GYHUVH(YHQWH&5)
VHH6HFWLRQDQGUHSRUWHGWRWKH6SRQVRULPPHGLDWHO\LHQRPRUHWKDQ
KRXUVDIWHUOHDUQLQJRIWKHHYHQWHLWKHUDVDQ6$(RUDQRQVHULRXVDGYHUVHHYHQWV
RIVSHFLDOLQWHUHVWVHH6HFWLRQ

'HDWKV
)RUWKLVSURWRFROPRUWDOLW\LVDQHIILFDF\HQGSRLQW'HDWKVVHH6HFWLRQWKDW
DUHDWWULEXWHGE\WKH,QYHVWLJDWRUVROHO\WRSURJUHVVLRQRIWKHXQGHUO\LQJFRQGLWLRQ
'/%&/RUIROOLFXODU1+/VKRXOGEHUHFRUGHGRQO\RQWKH6WXG\&RPSOHWLRQ(DUO\
'LVFRQWLQXDWLRQH&5)$OORWKHURQVWXG\GHDWKVUHJDUGOHVVRIUHODWLRQVKLSWRVWXG\
GUXJPXVWEHUHFRUGHGRQWKH$GYHUVH(YHQWH&5)DQGUHSRUWHGWRWKH6SRQVRU
ZLWKLQKRXUVVHH6HFWLRQ
'HDWKVKRXOGEHFRQVLGHUHGDQRXWFRPHDQGQRWDGLVWLQFWHYHQW7KHHYHQWRU
FRQGLWLRQWKDWFDXVHGRUFRQWULEXWHGWRWKHIDWDORXWFRPHVKRXOGEHUHFRUGHGDVWKH
VLQJOHPHGLFDOFRQFHSWRQWKH$GYHUVH(YHQWH&5)*HQHUDOO\RQO\RQHVXFKHYHQW
VKRXOGEHUHSRUWHG7KHWHUP³VXGGHQGHDWK´VKRXOGRQO\EHXVHGIRUWKHRFFXUUHQFH
RIDQDEUXSWDQGXQH[SHFWHGGHDWKGXHWRSUHVXPHGFDUGLDFFDXVHVLQDSDWLHQWZLWK
RUZLWKRXWSUHH[LVWLQJKHDUWGLVHDVHZLWKLQKRXURIWKHRQVHWRIDFXWHV\PSWRPV
RULQWKHFDVHRIDQXQZLWQHVVHGGHDWKZLWKLQKRXUVDIWHUWKHSDWLHQWZDVODVW
VHHQDOLYHDQGVWDEOH,IWKHFDXVHRIGHDWKLVXQNQRZQDQGFDQQRWEHDVFHUWDLQHGDW
WKHWLPHRIUHSRUWLQJ³XQH[SODLQHGGHDWK´VKRXOGEHUHFRUGHGRQWKH$GYHUVH(YHQW


5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\

H&5),IWKHFDXVHRIGHDWKODWHUEHFRPHVDYDLODEOHHJDIWHUDXWRSV\
³XQH[SODLQHGGHDWK´VKRXOGEHUHSODFHGE\WKHHVWDEOLVKHGFDXVHRIGHDWK
'XULQJVWXG\VXUYLYDOIROORZXSGHDWKVDWWULEXWHGWRSURJUHVVLRQRIWKHXQGHUO\LQJ
FRQGLWLRQVKRXOGEHUHFRUGHGRQWKH6WXG\&RPSOHWLRQ(DUO\'LVFRQWLQXDWLRQH&5)
)RUDQ\GHDWKVRFFXUULQJDIWHUVWXG\FORVXUHUHIHUWR6HFWLRQ

3UHH[LVWLQJ0HGLFDO&RQGLWLRQV
$SUHH[LVWLQJPHGLFDOFRQGLWLRQLVRQHWKDWLVSUHVHQWDWWKH6FUHHQLQJ%DVHOLQHYLVLW
IRUWKLVVWXG\6XFKFRQGLWLRQVVKRXOGEHUHFRUGHGRQWKH*HQHUDO0HGLFDO+LVWRU\
DQG%DVHOLQH&RQGLWLRQVH&5)
$SUHH[LVWLQJPHGLFDOFRQGLWLRQVKRXOGEHUHFRUGHGDVDQ$(RQO\LIWKHIUHTXHQF\
VHYHULW\RUFKDUDFWHURIWKHFRQGLWLRQZRUVHQVGXULQJWKHVWXG\:KHQUHFRUGLQJ
VXFKHYHQWVRQWKH$GYHUVH(YHQWH&5)LWLVLPSRUWDQWWRFRQYH\WKHFRQFHSWWKDW
WKHSUHH[LVWLQJFRQGLWLRQKDVFKDQJHGE\LQFOXGLQJDSSOLFDEOHGHVFULSWRUV
HJ³PRUHIUHTXHQWKHDGDFKHV´

/DFNRI(IILFDF\RU:RUVHQLQJRIWKH8QGHUO\LQJ&RQGLWLRQ
(YHQWVWKDWDUHFOHDUO\FRQVLVWHQWZLWKWKHH[SHFWHGSDWWHUQRISURJUHVVLRQRIWKH
XQGHUO\LQJFRQGLWLRQ'/%&/RUIROOLFXODU1+/VKRXOGQRWEHUHFRUGHGDV$(V
7KHVHGDWDZLOOEHFDSWXUHGDVHIILFDF\DVVHVVPHQWGDWDRQO\,QPRVWFDVHVWKH
H[SHFWHGSDWWHUQRISURJUHVVLRQZLOOEHEDVHGRQWKHRULJLQDO,:*IRUUHVSRQVH
DVVHVVPHQWRIO\PSKRPD&KHVRQHWDO$SSHQGL[RURWKHUFRXQWU\
VWDQGDUGV,QUDUHFDVHVWKHGHWHUPLQDWLRQRIFOLQLFDOSURJUHVVLRQZLOOEHEDVHGRQ
V\PSWRPDWLFGHWHULRUDWLRQ+RZHYHUHYHU\HIIRUWVKRXOGEHPDGHWRGRFXPHQW
SURJUHVVLRQXVLQJREMHFWLYHFULWHULD,IWKHUHLVDQ\XQFHUWDLQW\DVWRZKHWKHUDQHYHQW
LVGXHWRGLVHDVHSURJUHVVLRQLWVKRXOGEHUHSRUWHGDVDQ$(

+RVSLWDOL]DWLRQRU3URORQJHG+RVSLWDOL]DWLRQ
$Q\$(WKDWUHVXOWVLQKRVSLWDOL]DWLRQRUSURORQJHGKRVSLWDOL]DWLRQVKRXOGEH
GRFXPHQWHGDQGUHSRUWHGDVDQ6$(SHUWKHGHILQLWLRQRIDQ6$(LQ6HFWLRQ
H[FHSWDVRXWOLQHGEHORZ
7KHIROORZLQJKRVSLWDOL]DWLRQVFHQDULRVDUHQRWFRQVLGHUHGWREH6$(V
•
+RVSLWDOL]DWLRQIRUUHVSLWHFDUH
•
3ODQQHGKRVSLWDOL]DWLRQUHTXLUHGE\WKHSURWRFROHJIRUVWXG\GUXJ
DGPLQLVWUDWLRQRULQVHUWLRQRIDFFHVVGHYLFHIRUVWXG\GUXJDGPLQLVWUDWLRQ
•
+RVSLWDOL]DWLRQIRUDSUHH[LVWLQJFRQGLWLRQSURYLGHGWKDWDOORIWKHIROORZLQJ
FULWHULDDUHPHW
− 7KHKRVSLWDOL]DWLRQZDVSODQQHGSULRUWRWKHVWXG\RUZDVVFKHGXOHGGXULQJ
WKHVWXG\ZKHQHOHFWLYHVXUJHU\EHFDPHQHFHVVDU\EHFDXVHRIWKHH[SHFWHG
QRUPDOSURJUHVVLRQRIWKHGLVHDVH
− 7KHSDWLHQWKDVQRWVXIIHUHGDQ$(
•
+RVSLWDOL]DWLRQGXHVROHO\WRSURJUHVVLRQRIWKHXQGHUO\LQJFRQGLWLRQ'/%&/RU
IROOLFXODU1+/

2YHUGRVHV
6WXG\GUXJRYHUGRVHLVWKHDFFLGHQWDORULQWHQWLRQDOXVHRIWKHGUXJLQDQDPRXQW
KLJKHUWKDQWKHGRVHEHLQJVWXGLHG$QRYHUGRVHRULQFRUUHFWDGPLQLVWUDWLRQRIVWXG\
GUXJLVQRWDQ$(XQOHVVLWUHVXOWVLQXQWRZDUGPHGLFDOHIIHFWV
$Q\VWXG\GUXJRYHUGRVHRULQFRUUHFWDGPLQLVWUDWLRQRIVWXG\GUXJVKRXOGEHQRWHG
RQWKH6WXG\'UXJ$GPLQLVWUDWLRQH&5)
$OO$(VDVVRFLDWHGZLWKDQRYHUGRVHRULQFRUUHFWDGPLQLVWUDWLRQRIVWXG\GUXJVKRXOG
EHUHFRUGHGRQWKH$GYHUVH(YHQWH&5),IWKHDVVRFLDWHG$(IXOILOVVHULRXVQHVV
FULWHULDWKHHYHQWVKRXOGEHUHSRUWHGWRWKH6SRQVRULPPHGLDWHO\LHQRPRUHWKDQ
KRXUVDIWHUOHDUQLQJRIWKHHYHQWVHH6HFWLRQIRUUHSRUWLQJLQVWUXFWLRQV


5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\


3DWLHQW5HSRUWHG2XWFRPHVDV6DIHW\'DWD
$(UHSRUWVZLOOQRWEHGHULYHGIURP352GDWD+RZHYHULIDQ\SDWLHQWUHVSRQVHV
VXJJHVWLYHRIDSRVVLEOH$(DUHLGHQWLILHGGXULQJVLWHUHYLHZRIWKH352
TXHVWLRQQDLUHVVLWHVWDIIZLOODOHUWWKH,QYHVWLJDWRUZKRZLOOGHWHUPLQHLIWKHFULWHULD
IRUDQ$(KDYHEHHQPHWDQGZLOOGRFXPHQWWKHRXWFRPHRIWKLVDVVHVVPHQWLQWKH
SDWLHQW
VPHGLFDOUHFRUGSHUVLWHSUDFWLFH,IWKHHYHQWPHHWVWKHFULWHULDIRUDQ$(LW
ZLOOEHUHSRUWHGRQWKH$GYHUVH(YHQWH&5)

+HDOWKFDUH3URIHVVLRQDO5HSRUWHG2XWFRPHVDV6DIHW\'DWD
'DWDFROOHFWHGWKURXJK+HDOWKFDUH3URIHVVLRQDO+&34XHVWLRQQDLUHZLOOQRWEH
DVVHVVHGLQWHUPVRI$(VVLQFHWKHTXHVWLRQQDLUHLVDLPLQJWRKDYHDQRYHUYLHZRI
WKHKHDOWKFDUHSURIHVVLRQDOVDERXWWKHFRQYHQLHQFHRIWKHULWX[LPDE6&
DGPLQLVWUDWLRQ

,00(',$7(5(3257,1*5(48,5(0(176)520,19(67,*$725
726321625
&HUWDLQHYHQWVUHTXLUHLPPHGLDWHUHSRUWLQJWRDOORZWKH6SRQVRUWRWDNHDSSURSULDWH
PHDVXUHVWRDGGUHVVSRWHQWLDOQHZULVNVLQDFOLQLFDOWULDO7KH,QYHVWLJDWRUPXVW
UHSRUWVXFKHYHQWVWRWKH6SRQVRULPPHGLDWHO\XQGHUQRFLUFXPVWDQFHVVKRXOG
UHSRUWLQJWDNHSODFHPRUHWKDQKRXUVDIWHUWKH,QYHVWLJDWRUOHDUQVRIWKHHYHQW
7KHIROORZLQJLVDOLVWRIHYHQWVWKDWWKH,QYHVWLJDWRUPXVWUHSRUWWRWKH6SRQVRUZLWKLQ
KRXUVDIWHUOHDUQLQJRIWKHHYHQWUHJDUGOHVVRIUHODWLRQVKLSWRVWXG\GUXJ
•
6$(V
•
1RQVHULRXV$(VRIVSHFLDOLQWHUHVW
•
3UHJQDQFLHV
7KH,QYHVWLJDWRUPXVWUHSRUWQHZVLJQLILFDQWIROORZXSLQIRUPDWLRQIRUWKHVHHYHQWVWR
WKH6SRQVRUZLWKLQKRXUVDIWHUEHFRPLQJDZDUHRIWKHLQIRUPDWLRQ1HZVLJQLILFDQW
LQIRUPDWLRQLQFOXGHVWKHIROORZLQJ
•
1HZVLJQVRUV\PSWRPVRUDFKDQJHLQWKHGLDJQRVLV
•
6LJQLILFDQWQHZGLDJQRVWLFWHVWUHVXOWV
•
&KDQJHLQFDXVDOLW\EDVHGRQQHZLQIRUPDWLRQ
•
&KDQJHLQWKHHYHQW¶VRXWFRPHLQFOXGLQJUHFRYHU\
•
$GGLWLRQDOQDUUDWLYHLQIRUPDWLRQRQWKHFOLQLFDOFRXUVHRIWKHHYHQW
,QYHVWLJDWRUVPXVWDOVRFRPSO\ZLWKORFDOUHTXLUHPHQWVIRUUHSRUWLQJ6$(VWRWKH
ORFDOKHDOWKDXWKRULW\DQG(WKLFV&RPPLWWHH(&
$OOSDUWLFLSDWLQJ,QYHVWLJDWRUVDQGWKHUHVSHFWLYH(&ZLOOEHQRWLILHGRIDOO6XVSHFWHG
8QH[SHFWHG6HULRXV$GYHUVH5HDFWLRQV686$5VWKDWDUHUHSRUWHGGXULQJWKH
VWXG\VHH6HFWLRQ

(PHUJHQF\0HGLFDO&RQWDFWV
7KHSULPDU\HPHUJHQF\FRQWDFWIRUHDFKFRXQWU\ZLOOEHDVVLJQHGE\WKHORFDO5RFKH
DIILOLDWH
7RHQVXUHWKHVDIHW\RIVWXG\SDWLHQWVDQ(PHUJHQF\0HGLFDO&DOO&HQWUH+HOS'HVN
ZLOODFFHVVWKH5RFKH0HGLFDO(PHUJHQF\/LVWHVFDODWHHPHUJHQF\PHGLFDOFDOOV
SURYLGHPHGLFDOWUDQVODWLRQVHUYLFHLIQHFHVVDU\FRQQHFWWKH,QYHVWLJDWRUZLWKD
5RFKH0HGLFDO0RQLWRUDQGWUDFNDOOFDOOV7KH(PHUJHQF\0HGLFDO&DOO&HQWUH+HOS
'HVNZLOOEHDYDLODEOHKRXUVSHUGD\GD\VSHUZHHN7ROOIUHHQXPEHUVIRUWKH
+HOS'HVNDQG0HGLFDO0RQLWRUFRQWDFWLQIRUPDWLRQZLOOEHGLVWULEXWHGWRDOO
,QYHVWLJDWRUVVHH3URWRFRO$GPLQLVWUDWLYHDQG&RQWDFW,QIRUPDWLRQ	/LVWRI
,QYHVWLJDWRUV


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
66 
5.4.2 
Reporting Requirements for Serious 
Adverse Events and Non-Serious 
Adverse Events of Special Interest 
For reports of SAEs and non-serious AEs of special interest, Investigators should 
record all case details that can be gathered within 24 hours on the Adverse Event 
eCRF and submit the report via the electronic data capture (EDC) system. A report 
will be generated and sent to Roche Safety Risk Management by the EDC system. 
In the event that the EDC system is unavailable, a paper Serious Adverse 
Event/Non-Serious Adverse Event of Special Interest CRF and Fax Coversheet 
should be completed and faxed to Roche Safety Risk Management or its designee 
within 24 hours after learning of the event, using the fax numbers provided to 
Investigators (see Protocol Administrative and Contact Information & List of 
Investigators). Once the EDC system is available, all information will need to be 
entered and submitted via the EDC system.  
5.4.3 
Reporting Requirements for Pregnancies 
5.4.3.1 
Pregnancies in Female Patients 
Female patients of childbearing potential will be instructed to immediately inform the 
Investigator if they become pregnant during the study or within 12 months after the 
last dose of study drug. A Pregnancy Report eCRF should be completed by the 
Investigator within 24 hours after learning of the pregnancy and submitted via the 
EDC system. Details of the course and outcome of any pregnancy will be collected 
and reported.  A pregnancy report will automatically be generated and sent to Roche 
Safety Risk Management. Pregnancy should not be recorded on the Adverse Event 
eCRF. The Investigator should discontinue study drug and counsel the patient, 
discussing the risks of the pregnancy and the possible effects on the foetus. 
Monitoring of the patient should continue until conclusion of the pregnancy. 
In the event that the EDC system is unavailable, a Pregnancy Report worksheet and 
Pregnancy Fax Coversheet should be completed and faxed to Roche Safety Risk 
Management or its designee within 24 hours after learning of the pregnancy, using 
the fax numbers provided to Investigators (see Protocol Administrative and Contact 
Information & List of Investigators). 
5.4.3.2 
Pregnancies in Female Partners of Male Patients 
Male patients will be instructed through the ICF to immediately inform the 
Investigator if their partner becomes pregnant during the study or within 90 days after 
the last dose of study drug. A Pregnancy Report eCRF should be completed by the 
Investigator within 24 hours after learning of the pregnancy and submitted via the 
EDC system. Attempts should be made to collect and report details of the course 
and outcome of any pregnancy in the partner of a male patient exposed to study 
drug. The pregnant partner will need to sign an Authorization for Use and Disclosure 
of Pregnancy Health Information to allow for follow-up on her pregnancy. Once the 
authorization has been signed, the Investigator will update the Pregnancy Report 
eCRF with additional information on the course and outcome of the pregnancy. An 
Investigator who is contacted by the male patient or his pregnant partner may 
provide information on the risks of the pregnancy and the possible effects on the 
foetus, to support an informed decision in cooperation with the treating physician 
and/or obstetrician. 
In the event that the EDC system is unavailable, the reporting instructions provided 
in Section 5.4.3.1 should be followed. 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
67 
5.4.3.3 
Abortions 
Any spontaneous abortion should be classified as an SAE (as the Sponsor considers 
spontaneous abortions to be medically significant events), recorded on the Adverse 
Event eCRF, and reported to the Sponsor within 24 hours after learning of the event 
(see Section 5.4.2).  
5.4.3.4 
Congenital Anomalies / Birth Defects 
Any congenital anomaly/birth defect in a child born to a female patient or female 
partner of a male patient exposed to study drug should be classified as an SAE, 
recorded on the Adverse Event eCRF, and reported to the Sponsor within 24 hours 
after learning of the event (see Section 5.4.2). 
5.5 
FOLLOW-UP OF PATIENTS AFTER ADVERSE EVENTS 
5.5.1 
Investigator Follow-Up 
The Investigator should follow each AE until the event has resolved to baseline 
grade or better, the event is assessed as stable by the Investigator, the patient is lost 
to follow up, or the patient withdraws consent. Every effort should be made to follow 
all SAEs until a final outcome can be reported. 
During the study period, resolution of AEs (with dates) should be documented on the 
Adverse Event eCRF and in the patient’s medical record to facilitate source data 
verification. If, after follow-up, return to baseline status or stabilization cannot be 
established, an explanation should be recorded on the Adverse Event eCRF.  
In the event of medically significant unexplained abnormal laboratory test values, the 
tests should be repeated and followed up until they have returned to the normal 
range or baseline state and/or an adequate explanation of the abnormality is found. 
If a clear explanation is established it should be recorded on the eCRF. 
All pregnancies reported during the study should be followed until pregnancy 
outcome. If the EDC system is not available at the time of pregnancy outcome, follow 
reporting instructions provided in Section 5.4.3.1. 
5.5.2 
Sponsor Follow-Up 
For SAEs, non-serious AEs of special interest, and pregnancies, the Sponsor or a 
designee may follow up by telephone, fax, electronic mail, and/or a monitoring visit to 
obtain additional case details and outcome information (e.g. from hospital discharge 
summaries, consultant reports, autopsy reports) in order to perform an independent 
medical assessment of the reported case. 
5.6 
POST-STUDY ADVERSE EVENTS 
At the End of Study / Early Treatment Termination visit, the Investigator should instruct each 
patient to report to the Investigator any subsequent adverse events. After the study has 
ended the Sponsor should be notified if the investigator becomes aware of any death, 
serious adverse event, or other non-serious adverse event of special interest which are 
considered to be related to the study drug, occurring at any time after a patient has 
discontinued study participation. The Investigator is not required to actively monitor patients 
after the study has ended. 
The Sponsor should also be notified if the Investigator becomes aware of the development 
of cancer or a congenital anomaly/birth defect in a subsequently conceived offspring of a 
patient that participated in this study. 
The Investigator should report these events to Roche Safety Risk Management on 
the Adverse Event eCRF.  If the Adverse Event eCRF is no longer available, the 


5LWX[LPDE±5RFKH$OJHULD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±Y±)HEUXDU\

LQYHVWLJDWRUVKRXOGUHSRUWWKHHYHQWGLUHFWO\WR5RFKH6DIHW\5LVN0DQDJHPHQWYLD
WHOHSKRQHVHH3URWRFRO$GPLQLVWUDWLYHDQG&RQWDFW,QIRUPDWLRQ	/LVWRI
,QYHVWLJDWRUV


(;3(',7('5(3257,1*72+($/7+$87+25,7,(6
,19(67,*$7256,167,787,21$/5(9,(:%2$5'6$1'
(7+,&6&200,77((6
7RGHWHUPLQHUHSRUWLQJUHTXLUHPHQWVIRUVLQJOH$(FDVHVWKH6SRQVRUZLOODVVHVV
WKHH[SHFWHGQHVVRIWKHVHHYHQWVXVLQJ
•
WKH0DEWKHUD5LWX[LPDE6&,%
7KH6SRQVRUZLOOVXPPDUL]HWKHVHYHULW\RIHDFKHYHQWDQGWKHFXPXODWLYHHYHQW
IUHTXHQF\UHSRUWHGIRUWKHVWXG\ZLWKWKHVHYHULW\DQGIUHTXHQF\UHSRUWHGLQWKH
DSSOLFDEOHUHIHUHQFHGRFXPHQW
5HSRUWLQJUHTXLUHPHQWVZLOODOVREHEDVHGRQWKH,QYHVWLJDWRU
VDVVHVVPHQWRI
FDXVDOLW\DQGVHULRXVQHVVZLWKDOORZDQFHIRUXSJUDGLQJE\WKH6SRQVRUDVQHHGHG
$OOSDUWLFLSDWLQJ,QYHVWLJDWRUVDQGWKHUHVSHFWLYH(&ZLOOEHQRWLILHGRIDOO686$5V
WKDWDUHUHSRUWHGGXULQJWKHVWXG\$Q$(RQO\TXDOLILHVDVD686$5ZKHQDOORIWKH
IROORZLQJFRQGLWLRQVDUHPHW
•
7KHHYHQWLVVHULRXV6$(
•
7KHHYHQWLVGHHPHGUHODWHGWRWKHVWXG\GUXJDFFRUGLQJWRWKHFULWHULDSURYLGHG
LQ6HFWLRQ1RWHDQ\VXVSLFLRQRIDFDXVDOUHODWLRQVKLSVKRXOGOHDGWRDQ
DVVHVVPHQWRIµUHODWHG¶
•
:KHQDVVHVVHGDJDLQVWWKHNQRZQVDIHW\SURILOHRIULWX[LPDEDVGHVFULEHGLQWKH
,%IRUULWX[LPDE6&WKHHYHQWLVFRQVLGHUHGXQH[SHFWHGLHQRWIRUHVHHQLQWKH
,%
,QGLYLGXDO686$5UHSRUWVRULJLQDWLQJLQWKLVWULDOLQFOXGLQJ686$5VFRQVLGHUHG
EHLQJDVLJQLILFDQWVDIHW\LVVXHDQGRUZKLFKUHVXOWLQ5RFKHUHFRPPHQGLQJD
FKDQJHWRWKH,&)ZLOOEHIRUZDUGHGWRDOOSDUWLFLSDWLQJ,QYHVWLJDWRUVDQGWKH(&
DVVRFLDWHGZLWKWKHLUVLWHVRQDQH[SHGLWHGEDVLV686$5UHSRUWVRULJLQDWLQJIURP
RWKHUWULDOVXVLQJWKHVDPH,03ZLOOEHSURYLGHGDVVL[PRQWKO\686$55HSRUWVWRDOO
,QYHVWLJDWRUVDQG(&

67$7,67,&$/&216,'(5$7,216$1'$1$/<6,63/$1

'(7(50,1$7,212)6$03/(6,=(
$VDPSOHVL]HRISDWLHQWVLVGHHPHGVXIILFLHQWIRUWKLVVWXG\,QWKLVVWXG\DOO
SODQQHGVWDWLVWLFDODQDO\VLVZLOOEHH[SORUDWRU\LQQDWXUHDVWKHVWXG\ZLOOQRWEH
SRZHUHGWRDGGUHVVDQ\SUHGHILQHGVWDWHPHQWVDQGRQO\GHVFULSWLYHVWDWLVWLFDO
HYDOXDWLRQVZLOOEHFDUULHGRXWSULPDULO\IRUVDIHW\DQGHIILFDF\SDUDPHWHUV
$GGLWLRQDOO\QRSXEOLVKHGUHIHUHQFHLVDYDLODEOHRQDGPLQLVWUDWLRQDVVRFLDWHG
UHDFWLRQV$$5VIROORZLQJPXOWLSOHGRVHVRIVXEFXWDQHRXV6&ULWX[LPDEGXULQJ
LQGXFWLRQDQGRUPDLQWHQDQFHWKHUDS\LQSDWLHQWVZLWK&'IROOLFXODUQRQ
+RGJNLQ¶VO\PSKRPD1+/RU&'GLIIXVHODUJH%FHOOO\PSKRPD'/%&/
+RZHYHUZLWKSDWLHQWVD&ORSSHU3HDUVRQ&,IRUWKHLQFLGHQFHRI$$5VZLOO
EHQRZLGHUWKDQ7KLVZLGWKRILQWHUYDOLVGHHPHGVXIILFLHQWO\SUHFLVHWR
GUDZYDOLGFRQFOXVLRQVDURXQGWKHLQFLGHQFHRI$55V$GGLWLRQDOO\HQUROOPHQWRI
PRUHWKDQSDWLHQWVZLWKLQWKHVSHFLILHGLQGLFDWLRQVFRXOGDOVREHGLIILFXOWLQ
SDUWLFLSDWLQJFRXQWULHV'XHWRWKHIDFWRIH[SORUDWRU\QDWXUHRIWKHVWXG\GURSRXW
SDWLHQWVZLOOQRWEHUHSODFHG


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
69 
6.2 
SUMMARIES OF CONDUCT OF STUDY 
This is a prospective, open-label, single-arm study to evaluate the safety of rituximab 
SC administered as Induction and/or Maintenance therapy. The study will include at 
least 100 adult patients with CD20+ DLBCL or CD20+ follicular NHL (grade 1 to 3a; 
NHL), who are currently undergoing Induction and/or Maintenance therapy with 
rituximab IV. Patients receiving Induction therapy must be able to receive at least 4 
cycles of rituximab SC in addition to standard chemotherapy. Patients with follicular 
NHL receiving Maintenance therapy must be able to receive at least 6 cycles of 
rituximab SC. 
Induction Therapy: 
Patients receiving Induction therapy prior to entry into the study must be eligible to 
receive at least four further cycles of rituximab SC (i.e. 4 additional months of 
Induction treatment). Patients with follicular NHL who will continue into Maintenance 
therapy (after staging at the end of Induction) can continue to receive rituximab SC 
during Maintenance (see below). 
Maintenance Therapy (patients with follicular NHL): 
Patients receiving Maintenance therapy prior to entry into the study must be eligible 
to receive at least six further cycles of rituximab SC (i.e. 12 additional months of 
Maintenance treatment). Patients who are continuing into Maintenance therapy 
following at least four cycles of rituximab SC during Induction Therapy must also be 
eligible to receive at least six cycles of rituximab SC (i.e. 12 additional months of 
Maintenance treatment).  
6.3 
SUMMARIES OF PATIENT POPULATION 
Baseline characteristics will be summarized, as well as the demographic profile, 
medical history, IPI score (according to Shipp et al. 1993) and/or FLIPI score (see 
Appendix 3), concomitant medication use and serum pregnancy test at 
Screening/Baseline using appropriate descriptive statistics: mean, standard deviation, 
median and range (minimum and maximum) for the continuous variables, and 
number/percentage of patients for the categorical variables. 
Exposure to study treatment (rituximab) and chemotherapy, including the number of 
cycles administered, duration of treatment exposure (calculated from date of first 
treatment date to the last treatment date) and dosing information (e.g. dose 
interruptions, modifications and delays) will be summarized.  
The number of patients who prematurely discontinue study treatment and the 
number of patients who withdrew from the study will be summarized and reasons for 
withdrawal will be displayed. 
Further details about the planned analyses will be presented in the Statistical 
Analysis Plan (SAP). 
6.3.1 
Analysis Populations 
The Intent-To-Treat (ITT) population will include all patients enrolled into the study. 
The Safety population will include all patients who have received at least one dose of 
rituximab. The Safety data will be summarized based on the safety set.  Efficacy 
endpoints will be summarized based on the ITT population. 
6.4 
SAFETY ANALYSES 
Safety will be assessed by AEs, AEs of grade  3, SAEs, AARs including IIRRs, AEs 
within the MedDRA SMQ ‘Anaphylactic reactions’ (wide), safety laboratory 
parameters, vital signs, concomitant medications, premature withdrawal from the 
study and from study medication due to AEs and ECOG performance status. All 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
70 
clinical AEs and SAEs as well as laboratory abnormalities will be recorded and 
graded according to the NCI-CTCAE version 4.0. 
The analysis of AEs will focus on treatment-emergent adverse events, i.e. AEs 
occurring on the day of or after the first administration of study drug and up to 28 
days after the last dose. Non-treatment emergent AEs (i.e. those occurring before 
commencement of study medication) will only be listed. Adverse events will be 
coded using the Medical Dictionary for Regulatory Activities (MedDRA). 
The incidence of AARs, AEs, AEs leading to premature discontinuation or 
interruption of study treatment, SAEs, grade  3 AEs will be computed with 95% 
Confidence Interval. The incidence of each AE will be summarized according to the 
primary system-organ class and by preferred term. The incidence of cutaneous and 
soft tissue AARs will additionally be summarised for those that are defined as 
localized and those that are defined as non-localized. The incidence of deaths and 
cause of deaths will be listed and summarized.  
Safety laboratory parameters (haematology, biochemistry, coagulation tests, as 
defined in Section  4.5.1.6), will be presented in shift tables of NCI CTCAE grade at 
baseline against worst grade recorded during the treatment period. Laboratory 
parameters will be summarized and selected laboratory parameters may also be 
displayed graphically.  
Vital signs will be summarized over time. 
ECOG performance status will be summarized by frequency tables over time and 
percentage of patients in different categories will be presented by bar charts at 
different time points. 
Concomitant medication will be coded according to the WHO DRUG dictionary and 
tabulated in summary tables. New anti-lymphoma treatment (chemotherapy, 
radiotherapy, immunotherapy), initiated after the Baseline visit will be presented in 
summary tables. 
All safety analyses will be based on the Safety population.  
Further details about the planned safety analyses will be presented in the SAP. 
6.5 
EFFICACY ANALYSES 
The analyses will include all enrolled patients. 
Efficacy endpoints include EFS, PFS, OS, DFS, CR/CRu rate and will be analysed for 
the ITT population. 
Response assessments will be based on the Investigator’s assessment, completed 
according to the IWG response criteria (Cheson et al 1999, see Appendix 2) or 
other country standards.  The endpoints of EFS, PFS and OS will be defined and 
analysed twice using two different starting points for the time-to-event calculations.  
The first starting point will be first dose of rituximab IV and the second will be first 
dose of rituximab SC. 
EFS is defined as the time from first dose of rituximab (analysed using both first dose 
of IV and first dose of SC) to first occurrence of progression or relapse, according to 
the IWG response criteria (Cheson et al 1999, see Appendix 2) or other country 
standards, or initiation of a non–protocol-specified anti-lymphoma therapy or death, 
whichever occurs first.  
PFS is defined as the time from first dose of rituximab (analysed using both first dose 
of IV and first dose of SC) to the first occurrence of progression or relapse, according 
to the IWG response criteria (Cheson et al 1999, see Appendix 2) or other country 
standards, or death from any cause.  
OS is defined as the time from first dose of rituximab (analysed using both first dose 
of IV and first dose of SC) until death from any cause. 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
71 
DFS will be assessed in patients achieving CR/CRu and is defined as the period 
from the date of the initial CR/CRu until the date of relapse or death from any cause.  
CR/CRu rate at 4-6 weeks after the last dose of Induction treatment will be 
summarized and presented with the corresponding 95% two-sided Pearson-Clopper 
CI by treatment group and overall. 
Endpoints resulting in a incidence rate (e.g. CR/CRu) will be summarised with a 95% 
Clopper-Pearson confidence interval. 
The analysis of endpoints measured as a time to event (e.g. EFS, PFS, OS and DFS) 
is based on the survivor function, which is the probability of remaining event free 
beyond a certain point in time. The survivor function will be estimated using Kaplan-
Meier methodology and summarized using the range, the 25th and 75th percentiles 
and median survival along with a 95% confidence interval for median survival. 
Patients who have experienced none of these events at the time of analysis (clinical-
cut off) and patients who are lost to follow up will be censored at their last clinical 
assessment date.  Patients without post-baseline tumour assessments will be 
censored at the time of their baseline visit except if death occurs prior to their first 
scheduled tumour assessment. 
6.6 
EXPLORATORY ANALYSES 
Not applicable 
6.7 
PHARMACODYNAMIC AND PHARMACOKINETIC ANALYSES 
Not applicable 
6.8 
PHARMACOECONOMIC ANALYSES 
Not applicable 
6.9 
PATIENT-REPORTED OUTCOME ANALYSES 
Descriptive statistics will be computed for the questions assessing patient responses 
regarding convenience, satisfaction and preference for rituximab SC as compared to 
rituximab IV. Specifically, frequencies and percentages will be presented, for the 
total sample and by country.  
Further details about RASQ analyses will be presented in the SAP. 
6.10 
HEALTHCARE PROFESSIONAL REPORTED OUTCOME 
ANALYSES 
Healthcare Professional (HCP) Questionnaire will be evaluated with descriptive 
statistics. Frequencies and percentages will be presented for the total sample and by 
country. Further details will be presented in the SAP. 
6.11 
INTERIM ANALYSES 
Not applicable 
7. 
DATA COLLECTION AND MANAGEMENT 
7.1 
DATA QUALITY ASSURANCE 
A CRO will be responsible for the data management of this study, including quality 
checking of the data. Data entered manually will be collected via EDC using eCRFs. 
Sites will be responsible for data entry into the EDC system. In the event of 
discrepant data, the CRO will request data clarification from the sites, which the sites 
will resolve electronically in the EDC system.  
Roche will supervise the data management of this study. Roche will produce an EDC 
Study Specification document that describes the quality checking to be performed on 
the data. Laboratory data and/or other electronic data will be sent directly to the CRO, 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
72 
using the CRO’s standard procedures to handle and process the electronic transfer of 
these data. 
Electronic CRFs and correction documentation will be maintained in the EDC 
system’s audit trail. System backups for data stored at Roche and records retention 
for the study data will be consistent with Roche’s standard procedures. 
Data from paper PRO questionnaires will be entered into the EDC system by site 
staff. 
7.2 
ELECTRONIC CASE REPORT FORMS  
eCRFs are to be completed using a Sponsor-designated EDC system. Sites will 
receive training and a have access to a manual for appropriate eCRF completion. 
eCRFs will be submitted electronically to the Sponsor and should be handled in 
accordance with instructions from the Sponsor. 
All eCRFs should be completed by designated, trained site staff. eCRFs should be 
reviewed and electronically signed and dated by the Investigator or a designee. 
At the end of the study, the Investigator will receive patient data for his or her site in 
a readable format on a compact disc that must be kept with the study records. 
Acknowledgement of receipt of the compact disc is required. 
7.3 
ELECTRONIC PATIENT-REPORTED OUTCOME DATA 
Not applicable 
7.4 
SOURCE DATA DOCUMENTATION 
Study monitors will perform ongoing source data verification to confirm that critical 
protocol data (i.e., source data) entered into the eCRFs by authorized site personnel 
are accurate, complete, and verifiable from source documents.  
Source documents (paper or electronic) are those in which patient data are recorded 
and documented for the first time. They include, but are not limited to, hospital 
records, clinical and office charts, laboratory notes, memoranda, PROs, evaluation 
checklists, pharmacy dispensing records, recorded data from automated instruments, 
copies of transcriptions that are certified after verification as being accurate and 
complete, microfiche, photographic negatives, microfilm or magnetic media, X-rays, 
patient files, and records kept at pharmacies, laboratories, and medico-technical 
departments involved in a clinical trial. 
Before study initiation, the types of source documents that are to be generated will 
be clearly defined in the Trial Monitoring Plan. This includes any protocol data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) 
and considered source data. 
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained 
per the policy for retention of records described in Section 7.6. 
To facilitate source data verification, the Investigators and institutions must provide 
the Sponsor direct access to applicable source documents and reports for 
trial-related monitoring, Sponsor audits, and EC review. The investigational site must 
also allow inspection by applicable health authorities. 
7.5 
USE OF COMPUTERIZED SYSTEMS 
When clinical observations are entered directly into an investigational site’s 
computerized medical record system (i.e., in lieu of original hardcopy records), the 
electronic record can serve as the source document if the system has been validated 
in accordance with health authority requirements pertaining to computerized systems 
used in clinical research. An acceptable computerized data collection system allows 
preservation of the original entry of data. If original data are modified, the system 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
73 
should maintain a viewable audit trail that shows the original data as well as the 
reason for the change, name of the person making the change, and date of the 
change. 
7.6 
RETENTION OF RECORDS 
Records and documents pertaining to the conduct of this study and the distribution of 
IMP, including eCRFs, ePRO data (if applicable), ICFs, laboratory test results, and 
medication inventory records, must be retained by the Principal Investigator for at 
least 15 years after completion or discontinuation of the study, or for the length of 
time required by relevant national or local health authorities, whichever is longer. 
After that period of time, the documents may be destroyed, subject to local 
regulations.  
No records may be disposed of without the written approval of the Sponsor. Written 
notification should be provided to the Sponsor prior to transferring any records to 
another party or moving them to another location. 
8. 
ETHICAL CONSIDERATIONS 
8.1 
COMPLIANCE WITH LAWS AND REGULATIONS 
This study will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice and the principles of the Declaration of Helsinki, or the laws and 
regulations of the country in which the research is conducted, whichever affords the 
greater protection to the individual. The study will comply with the requirements of 
the ICH E2A guideline (Clinical Safety Data Management: Definitions and Standards 
for Expedited Reporting) and the EU Clinical Trial Directive (2001/20/EC). 
8.2 
INFORMED CONSENT 
Roche sample ICF (and any applicable ancillary sample ICFs such as a Child’s 
Assent or Caregiver's ICF, if applicable) will be provided to each site. If applicable, it 
will be provided in a certified translation of the local language. Roche or its designee 
must review and approve any proposed deviations from Roche sample ICFs or any 
alternate consent forms proposed by the site (collectively, the “Consent Forms”) 
before EC submission. The final EC-approved Consent Forms must be provided to 
Roche for health authority submission purposes according to local requirements. 
The Consent Forms must be signed and dated by the patient or the patient’s legally 
authorised representative before his or her participation in the study. The case 
history or clinical records for each patient shall document the informed consent 
process and that written informed consent was obtained prior to participation in the 
study. 
The Consent Forms should be revised whenever there are changes to study 
procedures or when new information becomes available that may affect the 
willingness of the patient to participate. The final revised EC-approved Consent 
Forms must be provided to Roche for health authority submission purposes. 
Patients must be re-consented to the most current EC-approved version of the 
Consent Forms (or to a significant new information/findings addendum in accordance 
with applicable laws and EC policy) during their participation in the study. For any 
updated or revised Consent Forms, the case history or clinical records for each 
patient shall document the informed consent process and that written informed 
consent was obtained using the updated/revised Consent Forms for continued 
participation in the study. 
A copy of each signed Consent Form must be provided to the patient or the patient’s 
legally authorised representative. All signed and dated Consent Forms must remain 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
74 
in each patient’s study file or in the site file and must be available for verification by 
study monitors at any time. 
8.3 
INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE 
This protocol, the ICFs, any information to be given to the patient, and relevant 
supporting information must be submitted to the EC by the Principal Investigator or, 
as applicable, the Country Study Manager and reviewed and approved by the EC 
before the study is initiated. In addition, any patient recruitment materials must be 
approved by the EC.  
The Principal Investigator or, as applicable, the Country Study Manager is 
responsible for providing written summaries of the status of the study to the EC 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by the EC. Investigators or, as applicable, the Country Study 
Manager are/is also responsible for promptly informing the EC of any protocol 
amendments (see Section 9.5). 
In addition to the requirements for reporting all AEs to the Sponsor, Investigators 
must comply with requirements for reporting SAEs to the local health authority and 
EC. Investigators may receive written IND safety reports or other safety-related 
communications from Roche. Investigators are responsible for ensuring that such 
reports are reviewed and processed in accordance with health authority 
requirements and the policies and procedures established by their EC, and archived 
in the site’s study file.  
8.4 
CONFIDENTIALITY 
Roche maintains confidentiality standards by coding each patient enrolled in the 
study through assignment of a unique patient identification number. This means that 
patient names are not included in data sets that are transmitted to any Roche 
location. 
Patient medical information obtained by this study is confidential and may only be 
disclosed to third parties as permitted by the ICF (or separate authorisation for use 
and disclosure of personal health information) signed by the patient, unless 
permitted or required by law. 
Medical information may be given to a patient’s personal physician or other 
appropriate medical personnel responsible for the patient’s welfare, for treatment 
purposes. 
Data generated by this study must be available for inspection upon request by 
representatives of the US FDA and other national and local health authorities, Roche 
monitors, representatives, and collaborators, and the EC for each study site, as 
appropriate. 
8.5 
FINANCIAL DISCLOSURE 
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate health 
authorities. Investigators are responsible for providing information on financial 
interests during the course of the study and for 1 year after completion of the study 
(i.e. LPLV). 
9. 
STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION 
9.1 
STUDY DOCUMENTATION 
The Investigator must maintain adequate and accurate records to enable the 
conduct of the study to be fully documented, including but not limited to the protocol, 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
75 
protocol amendments, ICFs, and documentation of EC and governmental approval. 
In addition, at the end of the study, the Investigator will receive the patient data, 
which includes an audit trail containing a complete record of all changes to data. 
9.2 
SITE INSPECTIONS 
Site visits will be conducted by Roche or an authorised representative for inspection 
of study data, patients’ medical records, and eCRFs. The Investigator will permit 
national and local health authorities, Roche monitors, representatives, and 
collaborators, and the ECs to inspect facilities and records relevant to this study. 
9.3 
PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS 
The results of this study may be published or presented at scientific meetings. If this 
is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the 
Sponsor prior to submission. This allows the Sponsor to protect proprietary 
information and to provide comments based on information from other studies that 
may not yet be available to the Investigator. 
The Sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicentre trials only in their entirety and not as individual 
centre data. In this case, a coordinating Investigator will be designated by mutual 
agreement. 
Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements. Any formal 
publication of the study in which contribution of Sponsor personnel exceeded that of 
conventional monitoring will be considered as a joint publication by the Investigator 
and the appropriate Sponsor personnel. 
Any inventions and resulting patents, improvements, and/or know-how originating 
from the use of data from this study will become and remain the exclusive and 
unburdened property of the Sponsor, except where agreed otherwise. 
9.4 
PROTOCOL AMENDMENTS 
Any protocol amendments will be prepared by the Sponsor. Protocol amendments 
will be submitted to the EC and to regulatory authorities in accordance with local 
regulatory requirements.  
Approval must be obtained from the EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g. change in Medical Monitor or contact information). 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
76 
10. 
REFERENCES  
Badin F, Hayslip J. Rituximab in the treatment of B-cell non-Hodgkin lymphoma, 
focus on outcomes and comparative effectiveness. Clinicoecon Outcomes Res 
2010;2:37-45. 
Bookbinder LH, Hofer A, Haller MF et al. A recombinant human enzyme for 
enhanced interstitial transport of therapeutics. J Control Release 2006;114(2):230-41. 
Bordeleau L, Berinstein NL. Molecular diagnostics in follicular non-Hodgkin's 
lymphoma: a review. Semin Oncol 2000;27(Suppl 12):42-52. 
Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 
monoclonal antibody rituximab. Ann Oncol 2003;14:520-35. 
Cairo M, Bishop M. Tumor lysis syndrome: new strategies and classification. Br J 
Hematol 2004;127(1):3-11. 
Cartwright RA. Time trends in incidence of haematological malignancies and related 
conditions. Br J Haematol 1999;106:281-95. 
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to 
standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored 
International Working Group. J Clin Oncol 1999;17(4):1244. 
Clarke CA, Glaser SL. Changing incidence of non-Hodgkin’s lymphomas in the 
United States. Cancer 2002;94:2015-23. 
Coiffier B, Altman A, Pui CH et al. Guidelines for the management of pediatric and 
adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008 Jun 
1;26(16):2767-78. 
Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared 
with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J 
Med 2002;346(4):235-42. 
Coiffier B, Thieblemont C, Van Den Neste E et al. Long-term outcome of patients in 
the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to 
standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes 
des Lymphomes de l'Adulte. Blood 2010;116(12):2040-5. 
Cunningham D, Smith P, Mouncey P et al. R-CHOP14 versus R-CHOP21: Result of 
a randomized phase III trial for the treatment of patients with newly diagnosed diffuse 
large B-cell non-Hodgkin lymphoma. J Clin Oncol 2011;29(15, suppl):abstr 8000. 
Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal 
antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J 
Clin Oncol 2000;18(17):3135-43. 
Davis TA, White CA, Grillo-Lopez AJ et al. Single-agent monoclonal antibody 
efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J 
Clin Oncol 1999;17(6):1851-7. 
Delarue R, Tilly H, Salles G et al. R-CHOP-14 compared to R-CHOP-21 in elderly 
patients with diffuse large B-cell lymphoma (DLBCL): Results of the second interim 
analysis of the LNH03-6B GELA study. Ann Oncol 2011;22(suppl 4):117 abstract 
106. 
Del Nagro CJ, Mao CP, Brovarney M et al. Comparison of B cell depletion mediated 
by intravenous (IV) Rituxan(R) and Rituxan given subcutaneous (SC) in cynomolgus 
monkeys. Blood (ASH Annual Meeting Abstracts) 2010;116(21): abstract 3980. 
Demidem A, Lam T, Alan S et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal 
antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. 
Cancer Biother Radiopharm 1997;12:177-86. 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
77 
Eltom MA, Jemal A, Mbulaiteye SM et al. Trends in Kaposi's sarcoma and non-
Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl 
Cancer Inst. 2002;94:1204-10. 
Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in 
Europe in 2006. Ann Oncol 2007;18:581-92. 
Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in 
the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the 
Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117-26. 
Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) 
with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. 
New Engl J Med 1993;328:1002-6. 
Fisher RI, LeBlanc M, Press OW et al: New treatment options have changed the 
survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-52. 
Friedberg JW. Treatment of follicular non-Hodgkin's lymphoma: the old and the new. 
Semin Hematol 2008;45(3 suppl 2):S2-6. 
Friedberg JW, Taylor MD, Cerhan JR et al. Follicular lymphoma in the United States: 
first report of the national LymphoCare study. J Clin Oncol 2009;27(8):1202-8. 
Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for 
subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4(4):427-
40. 
Habermann TM. Antibody therapy in aggressive lymphomas. Hematology Am Soc 
Hematol Educ Program 2007:257-64. 
Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone 
or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J 
Clin Oncol 2006;24(19):3121-7. 
Herold M, Dölken G, Fiedler F et al. Ongoing clinical studies – randomized phase III 
study for the treatment of advanced indolent NHL and MCL: chemotherapy versus 
chemotherapy plus Rituximab. Ann Hematol 2003;82:77-9. 
Herold M, Haas A, Srock S et al. Rituximab added to first-line mitoxantrone, 
chlorambucil, and prednisolone chemotherapy followed by interferon maintenance 
prolongs survival in patients with advanced follicular lymphoma: An East German 
study group hematology and oncology study. J Clin Oncol 2007;25(15):1986-92. 
Hiddemann W, Kneba M, Dreyling M et al: Frontline therapy with rituximab added to 
the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone 
(CHOP) significantly improves the outcome for patients with advanced-stage 
follicular lymphoma compared with therapy with CHOP alone: Results of a 
prospective randomized study of the German low-grade lymphoma study group. 
Blood 2005;106:3725-32. 
Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. 
Semin Oncol 1993;20(Suppl 5):75-88. 
Howlader N, Noone AM, Krapcho M et al. (eds). SEER Cancer Statistics Review, 
1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, 
http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER 
data submission, posted to the SEER web site, 2012. 
[ILSG] The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of 
the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. 
Blood 1997;89:3909-18. 
Investigator Brochure MabThera®, Rituxan®, Fifteenth Edition, July 2010 (Rituximab 
IV), and Second Edition, October 2010 (Rituximab SC). 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
78 
Jaffe ES, Harris NL, Stein H et al. (eds). World Health Organization classification of 
tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. 
Lyon, France: IARC Press; 2001. 
Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-
grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 
2010;70(11):1445-76. 
Kornbrot B, Kobayashi RH, Singer A et al. Hypersensitivity to therapeutic murine 
monoclonal antibodies. Nebr Med J 1994;79(12):393-8. 
Landis SH, Murray T, Bolden S et al. Cancer Statistics, 1999. CA Cancer J Clin 
1999;49(1):8-31. 
Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and 
cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves 
response and time to treatment failure, but not long-term outcome in patients with 
previously untreated mantle cell lymphoma: Results of a prospective randomized trial 
of the German low grade lymphoma study group (GLSG). J Clin Oncol 
2005;23(9):1984-92. 
Lossos IS. Higher-grade transformation of follicular lymphoma - a continuous enigma. 
Leukemia 2005;19(8):1331-3. 
Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-
mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507-32. 
Maloney D, Smith B, Appelbaum F. The anti-tumor effect of monoclonal anti-CD20 
antibody (MAB) therapy includes direct anti-proliferative activity and induction of 
apopthosis in CD20 positive non-Hodgkin’s lymphoma (NHL) cell lines. Blood 
1996;88:637a. 
Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with 
CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-
23. 
Marcus R, Imrie K, Solal-Celigny P et al. Phase III study of R-CVP compared with 
cyclophosphamide, vincristine, and prednisone alone in patients with previously 
untreated advanced follicular lymphoma. J Clin Oncol 2008;26(28):4579-86. 
McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric anti-CD20 
monoclonal antibody therapy for relapsed indolent lymphoma: half of patients 
respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33. 
Michallet AS, Coiffier B. Recent developments in the treatment of aggressive non-
Hodgkin lymphoma. Blood Rev 2009;23(1):11-23. 
Moreau P, Pylypenko H, Grosicki S et al. Subcutaneous versus intravenous 
administration of bortezomib in patients with relapsed multiple myeloma: a 
randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12(5):431-40. 
Morton LM, Wang SS, Devesa SS et al. Lymphoma incidence patterns by WHO 
subtype in the United States, 1992-2001. Blood 2006;107(1):265–76. 
Nathwani BN, Harris NL, Weisenburger D et al. Follicular lymphoma. In Jaffe ES, 
Harris NL, Stein H et al. (eds). World Health Organization classification of tumors. 
Pathology and genetics of tumors of haematopoietic and lymphoid tissues. IARC 
Press: Lyon 2001;162-7. 
National Cancer Center Network Guidelines, v3 2011 (www.nccn.org) 
Niitsu N. Current treatment strategy of diffuse large B-cell lymphomas. Int J Hematol 
2010;92(2):231-7. 
Pettengell R, Linch D. Position paper on the therapeutic use of rituximab in CD20-
positive diffuse large B-cell non-Hodgkin’s lymphoma. Br J Haematol 
2003;121(1):44-8. 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
79 
Pfreundschuh M, Schubert J, Ziepert M et al. German high-grade non-Hodgkin 
lymphoma study group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 
with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: 
a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9(2):105-16. 
Pfreundschuh M, Trümper L, Osterborg A et al. MabThera international trial group. 
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in 
young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised 
controlled trial by the MabThera international trial (MInT) group. Lancet Oncol 
2006;7(5):379-91. 
Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients 
diagnosed as having non-Hodgkin’s lymphoma from the 1990s to the early 21st 
century. Arch Intern Med 2008;168:469-76. 
Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric 
mouse human monoclonal antibody to CD20. Blood 1994;83:435-45. 
Rituximab Summary of Product Characteristics 
Salar A, Bouabdallah R, McIntyre C et al. A two-stage phase Ib study to investigate 
the pharmacokinetics, safety and tolerability of subcutaneous rituximab in patients 
with follicular lymphoma as part of maintenance treatment. Blood (ASH Annual 
Meeting Abstracts) 2010;116(21): abstract 2858. 
Salar A, et al. Final Results of the BP22333 Study Demonstrate Non-Inferior 
Pharmacokinetics and Safety of Subcutaneous Administration of Rituximab 
Compared with Intravenous Administration As Maintenance Therapy in Patients with 
Follicular Lymphoma (ASH Annual Meeting Abstracts) 2012. Abstract 1641.  Full 
citation pending. 
Salles G, Mounier N, de Guibert S et al: Rituximab combined with chemotherapy and 
interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 
study. Blood 2008;112:4824-31. 
Shipp MA, Harrington DP et al. A predictive model for aggressive non-Hodgkin’s 
lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. N 
Engl J Med 1993;329(14):987-94. 
Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for 
the use of white blood cell growth factors: an evidence-based clinical practice 
guideline. J Clin Oncol 2006;24(19):3187-205. 
Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international 
prognostic index. Blood 2004;104(5):1258-65. 
Sousou T, Friedberg J. Rituximab in indolent lymphomas. Semin Hematol 
2010;47(2):133-42. 
Stilgenbauer S, Zenz T, Winkler D et al; German chronic lymphocytic leukemia study 
group. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic 
leukemia: Clinical results and prognostic marker analyses from the CLL2H study of 
the German chronic lymphocytic leukemia study group. J Clin Oncol 
2009;27(24):3994-4001. 
Swenson WT, Wooldridge JE, Lynch CF et al. Improved survival of follicular 
lymphoma patients in the United States. J Clin Oncol 2005;23:5019-26. 
Swerdlow SH, Campo E, Harris NL et al. WHO classification of tumours of 
haematopoietic and lymphoid tissues, 4th edition, IARC Press, 2008. 
Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. 
Immunol Today 1994;15:450-4. 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
80 
Tilly H, Dreyling M; ESMO guidelines working group. Diffuse large B-cell non-
Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and 
follow-up. Ann Oncol 2010;21(suppl 5):v172-4. 
Wynne C, Harvey V, Schwabe C et al. The development of a formulation of 
trastuzumab for subcutaneous administration. Ann Oncol 2010;21(8):viii78–viii95, 
abstract 218PD. 
Yin A, Li J, Hurst D et al. Population pharmacokinetics (PK) and association of PK 
and clinical outcomes of rituximab in patients with non-Hodgkin's lymphoma. J Clin 
Oncol 2010;28:(suppl; abstract e13108) [Published in conjunction with the ASCO 
2010 Annual Meeting]. 


Rituximab – Roche Algeria (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – v3.1 – 07 February 2016  
81 
11. 
APPENDICES 
 






 
Rituximab – Roche North Africa (Algeria, Morocco & Tunisia)  
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016  
84 
i. 
Women of childbearing potential (defined as pre-menopausal women or women who are < 2 years after the onset of menopause and not surgically sterile) must undergo 
serum pregnancy test within 7 days prior to first dose or within 14 days if with a confirmatory urine pregnancy test within 7 days prior to dosing.  
j. 
Haematology parameters will include haemoglobin, RBC, WBC count and differential, and platelet count. Biochemistry parameters at Screening will include sodium, 
potassium, ALT/SGPT, AST/SGOT, total bilirubin, serum creatinine, alkaline phosphatase, albumin, BUN, C-reactive protein and LDH. Biochemistry parameters at any 
further timepoint during the study will include sodium, potassium, ALT/SGPT, AST/SGOT, total bilirubin, and serum creatinine. Coagulation tests will include: INR, PT, and 
aPTT. The results from the safety laboratory assessments must be available on treatment days, prior to the rituximab administrations. 
k. 
After informed consent has been obtained but prior to dosing, only SAEs caused by a protocol-mandated intervention should be reported (e.g. SAEs related to invasive 
procedures such as biopsies). All clinical and laboratory AEs reported during the study will be documented and graded using the NCI CTCAE criteria, version 4.0. Special 
attention should be given to any acute infusion-related toxicities. After initiation of study drug, all AEs/SAEs, regardless of relationship to study drug, will be reported until 
study closure.  
l. 
Patient reported outcomes: All patients will be required to complete the Rituximab Administration Questionnaire (RASQ, see Appendix 6) at the end of the study. Patients 
prematurely discontinuing study treatment should complete the questionnaire at time of discontinuation, as long as they had taken at least one dose via each treatment 
route (IV and SC) post-randomization. RASQ will be completed immediately after rituximab administration and before chemotherapy administration. 
m. Healthcare Professional (HCP) Questionnaire (see Appendix 7) will be completed at the end of the study by healthcare professionals such as haematologists, internists, 
nurses or other healthcareprofessionals who administered rituximab SC during the study. 
 






 
Rituximab – Roche North Africa (Algeria, Morocco & Tunisia)  
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016  
87 
further timepoint during the study will include sodium, potassium, ALT/SGPT, AST/SGOT, total bilirubin, and serum creatinine. Coagulation tests will include: INR, PT, and 
aPTT. The results from the safety laboratory assessments must be available on treatment days, prior to the rituximab administrations. 
k. 
After informed consent has been obtained but prior to dosing, only SAEs caused by a protocol-mandated intervention should be reported (e.g. SAEs related to invasive 
procedures such as biopsies). All clinical and laboratory AEs reported during the study will be documented and graded using the NCI CTCAE criteria, version 4.0. Special 
attention should be given to any acute infusion-related toxicities. After initiation of study drug, all AEs/SAEs, regardless of relationship to study drug, will be reported until 
study closure. 
l. 
Patient reported outcomes: All patients will be required to complete the Rituximab Administration Questionnaire (see Appendix 6) at the end of the study. Patients 
prematurely discontinuing study treatment should complete the questionnaire at time of discontinuation, as long as they had taken at least one dose via each treatment 
route (IV and SC) post-randomization. RASQ will be comleted immediately after rituximab administration and before chemotherapy administration. 
m. Healthcare Professional (HCP) Questionnaire (see Appendix 7) will be completed at the end of the study by healthcare professionals such as haematologists, internists, 
nurses or other healthcareprofessionals who administered rituximab SC during the study. 
 
 
.  


 
Rituximab – Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016   
88 
11.2 
APPENDIX 2 RESPONSE ASSESSMENT ACCORDING TO THE 
INTERNATIONAL WORKING GROUP RESPONSE CRITERIA 
Complete response (CR) requires the following: 
1. 
Complete disappearance of all detectable clinical and radiographic evidence of disease and 
disappearance of all disease-related symptoms if present before therapy, and normalization of 
those biochemical abnormalities (e.g., LDH) definitely assignable to NHL. 
2. 
All lymph nodes and nodal masses must have regressed to normal size ( 1.5 cm in their 
greatest transverse diameter for nodes > 1.5 cm before therapy). Previously involved nodes 
that were 1.1 to 1.5 cm in their greatest transverse diameter before treatment must have 
decreased to  1 cm in their greatest transverse diameter after treatment, or by more than 
75% in the sum of the products of the greatest diameters (SPD). 
3. 
The spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have 
regressed in size and must not be palpable on physical examination. However, no normal size 
can be specified because of the difficulties in accurately evaluating splenic and hepatic size. 
For instance, spleens thought to be of normal size may contain lymphoma, whereas an 
enlarged spleen may not necessarily reflect the presence of lymphoma but variations in 
anatomy, blood volume, the use of hematopoietic growth factors, or other causes. The 
determination of splenic volume or splenic index by CT scan is cumbersome and not widely 
used. Any macroscopic nodules in any organs detectable on imaging techniques should no 
longer be present. Similarly, other organs considered to be enlarged before therapy due to 
involvement by lymphoma, such as liver and kidneys, must have decreased in size. 
4. 
If the bone marrow was involved by lymphoma before treatment, the infiltrate must be cleared 
on repeat bone marrow aspirate and biopsy of the same site. The sample on which this 
determination is made must be adequate ( 20 mm biopsy core). Flow cytometric, molecular, 
or cytogenetic studies are not considered part of routine assessment to document persistent 
disease at the present time. These studies should only be incorporated into trials examining 
important research questions. 
CR/unconfirmed (CRu) includes those patients who fulfil criteria 1 and 3 above, but with 
one or more of the following features: 
1. 
A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has 
regressed by more than 75% in the SPD. Individual nodes that were previously confluent must 
have regressed by more than 75% in their SPD compared with the size of the original mass. 
2. 
Indeterminate bone marrow (increased number or size of aggregates without cytologic or 
architectural atypia). 
Partial response (PR) requires the following: 
1. 
 50% decrease in SPD of the six largest dominant nodes or nodal masses. These nodes or 
masses should be selected according to the following features: (a) they should be clearly 
measurable in at least two perpendicular dimensions, (b) they should be from as disparate 
regions of the body as possible, and (c) they should include mediastinal and retroperitoneal 
areas of disease whenever these sites are involved. 
2. 
No increase in the size of the other nodes, liver, or spleen. 
3. 
Splenic and hepatic nodules must regress by at least 50% in the SPD. 






 
Rituximab – Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016   
91 
11.3.2 
International Prognostic Index (IPI) 
Five adverse prognostic factors were selected: 
1. 
Age (> 60) 
2. 
ECOG/Zubrod performans status (2-4) 
3. 
Stage (III-IV) 
4. 
Serum LDH level (> normal) 
5. 
Extranodal site (>1) 
Four risk groups were defined: 
1. 
LOW RISK (0-1 adverse factor) 
2. 
LOW INTERMEDIATE RISK (2 adverse factors) 
3. 
HIGH INTERMEDIATE RISK (3 adverse factors) 
4. 
HIGH RISK ( 3 adverse factors) 
Source: Shipp MA, Harrington DP, Anderson JR et al. A predictive model for aggressive 
NHL: The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J 
Med 329:987, 1993 
 


 
Rituximab – Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016   
92 
11.3.3 
Follicular Lymphoma International Prognostic 
Index (FLIPI)  
 
Five adverse prognostic factors were selected: 
1. 
Age (> 60 vs.  60) 
2. 
Ann Arbor Stage (III-IV vs. I-II) 
3. 
Haemoglobin level (< 12 g/dl vs.  12 d/dl) 
4. 
Number of nodal areas (> 4 vs.  4) 
5. 
Serum LDH level (> normal vs.  normal) 
Three risk groups were defined: 
6. 
LOW RISK (0-1 adverse factor) 
7. 
INTERMEDIATE RISK (2 adverse factors) 
8. 
POOR RISK ( 3 adverse factors) 
Source: Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international 
prognostic index. Blood 2004;104(5):1258-65. 


 
Rituximab – Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016   
93 
11.4 
APPENDIX 4 GUIDELINES FOR STANDARD RITUXIMAB SC 
PREPARATION AND ADMINISTRATION 
HOW SUPPLIED 
Rituximab SC for the subcutaneous administration (MabThera SC; Ro 045-2294) is 
supplied as a ready to use liquid formulation with a nominal content of 120 mg/mL 
rituximab in an 11.7 mL vial and must not be diluted prior to administration. The drug 
product contains 2,000 U/mL rHuPH20 (manufactured in a CHO cell line) acting as a 
permeation enhancer, histidine/histidine-HCl (buffer), ,-trehalose (bulking agent), 
methionine (stabilizer), and polysorbate 80 (surfactant) in water for injection (WFI) at a pH 
of 5.5. The drug product is a sterile, colourless to yellowish, clear to opalescent liquid in 
colourless 11.7 mL vials. 
STABILITY AND STORAGE 
The recommended storage condition for rituximab SC is 2°C to 8°C, protected from light. 
Once transferred from the vial to the syringe, the solution of Mabthera SC formulation is 
physically and chemically stable for 48 hours at 2°C to 8°C, and subsequently 8 hours at 
30°C in diffuse daylight. The hypodermic injection needle must only be attached to the 
syringe immediately prior to administration to avoid any potential needle clogging. From a 
microbiological point of view the product should be used immediately after first opening. If 
not used immediately, in-use storage times and conditions prior to use are the 
responsibility of the user. The product should be handled gently and foaming avoided. It 
should not be shaken. Batch specific details and information on shelf-life are given on the 
packaging label. 
PREPARATION OF RITUXIMAB FOR SC ADMINISTRATION 
Patients receiving SC rituximab will be administered at a dose of 1400 mg. 
1. 
Withdraw 11.7 mL of solution from the vial. 
2. 
Insert the injection needle (25 or 27 gauge) using sterile technique in the subcutaneous tissue 
of the abdomen.  
Note: The needle should be fully inserted, being careful that the tip of the needle is deeper 
than the dermis but not as deep as the underlying muscle. The goal of the placement 
angle and needle depth is to achieve uniform placement into every patient’s subcutaneous 
tissue. Study drug should not be injected into moles, scars, or bruises. The skin should be 
pinched and needle inserted before the skin is released and the pressure on the syringe 
can be applied. 
3. 
Push the injection manually at a flow rate of approximately 2 mL/min; administration of the 
11.7 mL volume should take approximately 5 to 6 minutes.  
4. 
If there is a request by the patient to interrupt the injection, initially ease the pressure on the 
syringe to alleviate the pain. If the pain is not alleviated, stop the injection and ask the patient 
when he/she is comfortable to resume the injection. The remaining content of the syringe 
should be administered at the same injection site. 


 
Rituximab – Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016   
94 
11.5 
APPENDIX 5 NCI COMMON TERMINOLOGY CRITERIA FOR ADVERSE 
EVENTS 
In the present study, toxicities will be recorded according to the NCI CTCAE, version 4.0. 
At the time this protocol was issued, the full CTC document was available on the NCI site, 
at the following address: http://ctep.cancer.gov  
Investigators who do not have access to Internet can contact the Data Centre to receive a 
hard copy of this document by mail. 
 
 


 
Rituximab – Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016   
95 
11.6 
APPENDIX 6 RITUXIMAB ADMINISTRATION QUESTIONNAIRE (RASQ-
IV AND RASQ-SC) 
RASQ-IV 
Instructions: Please complete the following questions based on your Rituximab treatment. Your 
Rituximab was given through a thin plastic tube and a needle that was put directly into a vein in 
your arm, called an intravenous or IV infusion. Your Rituximab treatment was given BEFORE your 
chemotherapy medicine. Please answer the questions based on your most recent Rituximab IV 
infusion. 
1. Thinking about the Rituximab IV infusion, how satisfied or dissatisfied are you with the IV 
infusion? 
Very satisfied 
Satisfied 
Neither  satisfied 
nor dissatisfied 
Dissatisfied 
Very dissatisfied 
2. Thinking about the Rituximab IV infusion, how do you rate the pain, swelling, or redness you 
experienced at the site of the drug injection? 
None
Mild
Moderate
Severe
Very Severe
3. Thinking about the Rituximab IV infusion, how do you rate the pain you experience with the IV 
infusion process? 
None
Mild
Moderate
Severe
Very Severe
4. Thinking about the Rituximab IV infusion, are the side effects of the IV infusion as you 
expected? 
Much better than 
expected 
Somewhat better 
than expected 
Met my 
expectations 
Some what 
worse than my 
expectations 
Much worse than 
my expectations 
5. Before you receive the Rituximab IV infusion do you feel anxious about having the infusion? 
Not at all
A little bit
Somewhat
Quite a bit
Very much
6. When you receive the Rituximab IV infusion do you worry that your condition would get worse?
Not at all
A little bit
Somewhat
Quite a bit
Very much
7. When you receive the Rituximab IV infusion do you feel anxious thinking about your disease? 
Not at all
A little bit
Somewhat
Quite a bit
Very much
8. Thinking about the Rituximab IV infusion, how confident are you that the Rituximab IV infusion 
is treating your disease? 
Not at all
A little bit
Somewhat
Quite a bit
Very much
9. When you receive the Rituximab treatment do you feel restricted by the IV infusion? 
Not at all
A little bit
Somewhat
Quite a bit
Very much



5LWX[LPDE±5RFKH1RUWK$IULFD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±9±)HEUXDU\


7KLQNLQJDERXWWKH5LWX[LPDE,9LQIXVLRQKRZFRQYHQLHQWLVLWIRU\RXWRJHW\RXU,9LQIXVLRQ"
9HU\FRQYHQLHQW
&RQYHQLHQW
1HLWKHU
FRQYHQLHQWQRU
LQFRQYHQLHQW
,QFRQYHQLHQW
9HU\LQFRQYHQLHQW
7KLQNLQJDERXWWKH5LWX[LPDE,9LQIXVLRQKRZGR\RXIHHODERXWWKHDPRXQWRIWLPHLWWDNHV
WRJHW\RXU,9LQIXVLRQ"

7RRVKRUW
-XVWULJKW
7RRORQJ

7KLQNLQJDERXWWKH5LWX[LPDE,9LQIXVLRQGR\RXIHHOWKDWWKHOHQJWKRIWLPHWRJHW\RXU,9
LQIXVLRQZDVDV\RXH[SHFWHG"
0XFKVKRUWHU
WKDQH[SHFWHG
6RPHZKDW
VKRUWHUWKDQ
H[SHFWHG
$VH[SHFWHG
6RPHZKDW
ORQJHUWKDQ
H[SHFWHG
0XFKORQJHU
WKDQH[SHFWHG
7KLQNLQJDERXWWKH5LWX[LPDE,9LQIXVLRQKRZERWKHUHGDUH\RXE\WKHDPRXQWRIWLPHLWWDNHV
WRJHWWKHLQIXVLRQ"
1RWDWDOO
ERWKHUHG
$OLWWOHERWKHUHG
0RGHUDWHO\
ERWKHUHG
4XLWHERWKHUHG
9HU\ERWKHUHG
+RZPXFKGRHVWKH5LWX[LPDE,9LQIXVLRQ
D ,QWHUIHUHZLWK\RXUXVXDORUGDLO\DFWLYLWLHV"
1RWDWDOO
$OLWWOHELW
6RPHZKDW
4XLWHDELW
9HU\PXFK
E /LPLW\RXUGDLO\DFWLYLWLHV"
1HYHU
5DUHO\
6RPHWLPHV
0RVWRIWKHWLPH
$OZD\V
%HFDXVHRIWKHOHQJWKRIWLPHWRDSSO\WKH5LWX[LPDE,9LQIXVLRQGR\RXIHHOWKDW\RXKDYH
ORVWRUJDLQHGWLPHIRURWKHUWKLQJV"
/RVWORWRIWLPH
/RVWVRPHWLPH
1HLWKHUORVWQRW
JDLQHGWLPH
*DLQHGVRPH
WLPH
*DLQHGDORWRI
WLPH
:KHQ\RXUHFHLYHGWKH5LWX[LPDEWUHDWPHQWDUH\RXDEOHWRWDONWR\RXUQXUVHDQGRU
'RFWRUDVPXFKDV\RXZRXOGOLNHDERXW\RXULOOQHVV"SOHDVHFKHFNRQHDQVZHU
•
<HV,KDGPRUHWKDQHQRXJKWLPHWRWDONWRP\QXUVHDQGRUGRFWRU
•
<HVEXW,ZRXOGKDYHOLNHGPRUHWLPHWRWDONWRP\QXUVHDQGRUGRFWRU
•
,WGRHVQRWPDWWHUWRPHLI,KDYHWLPHWRWDONWRP\QXUVHDQGRUGRFWRUGXULQJP\
WUHDWPHQW
•
1R,GLGQRWKDYHHQRXJKWLPHWRWDONWRP\QXUVHDQGRUGRFWRU
•
1R,GLGQRWWDONWRP\QXUVHDQGRUGRFWRUDWDOO




5LWX[LPDE±5RFKH1RUWK$IULFD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±9±)HEUXDU\


'RHVWKH5LWX[LPDE,9LQIXVLRQLPSDFWWKH DPRXQWRIWLPH \RXKDYHWRWDON WR\RXUQXUVH
DQGRUGRFWRUDERXW\RXULOOQHVVDQGRWKHUFRQFHUQV"

<HV

1R

7KLQNLQJDERXWWKH5LWX[LPDEWUHDWPHQWLIJLYHQWKHRSWLRQ ZKLFK ZRXOG \RXSUHIHUERWK
RSWLRQVWUHDW\RXUGLVHDVHLQWKHVDPHZD\"3OHDVHFKHFNRQH
•
3UHIHULQWUDYHQRXV,9LQIXVLRQJLYHQWKURXJKDWKLQSODVWLFWXEHDQGDQHHGOHLQWR
\RXUYHLQ,9GULS7KLVWUHDWPHQWRSWLRQXVXDOO\WDNHVWRKRXUV
•
3UHIHUVXEFXWDQHRXV6&LQMHFWLRQDSSOLHGZLWKDV\ULQJHDQGQHHGOHLQWRWKHVNLQ
RIWKHDEGRPHQRUEHOO\ 7KLVWUHDWPHQWRSWLRQLVXVXDOO\WDNHVWRPLQXWHV
•
1RSUHIHUHQFHIRUWUHDWPHQWRSWLRQ
7KLQNLQJDERXWWKH5LWX[LPDEWUHDWPHQWZRXOG\RXUHFRPPHQGWKHZD\\RXUHFHLYHGWKH
WUHDWPHQW,9LQIXVLRQWRDQRWKHUSDWLHQW"
'HILQLWHO\\HV
3UREDEO\\HV
,GRQ¶WNQRZ
3UREDEO\QRW
'HILQLWHO\QRW



 
Rituximab – Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016   
98 
 
RASQ-SC 
Instructions: Please complete the following questions based on your Rituximab treatment. Your 
Rituximab was given through a needle injected into your abdomen (or belly) area, called a 
subcutaneous or SC injection. Your Rituximab treatment was given BEFORE your chemotherapy 
medicine. Please answer the questions based on your most recent Rituximab SC injection. 
 
1. Thinking about the Rituximab SC injection, how satisfied or dissatisfied are you with the SC 
injection? 
Very satisfied 
Satisfied 
Neither  satisfied 
nor dissatisfied 
Dissatisfied 
Very dissatisfied 
2. Thinking about the Rituximab SC injection, how do you rate the pain, swelling, or redness 
you experienced at the site of the drug injection? 
None
Mild
Moderate
Severe
Very Severe
3. Thinking about the Rituximab SC injection, how do you rate the pain you experience with the 
SC injection process?  
None
Mild
Moderate
Severe
Very Severe
4. Thinking about the Rituximab SC injection, are the side effects of the SC injection as you 
expected? 
Much better than 
expected 
Somewhat better 
than expected 
Met my 
expectations 
Some what 
worse than my 
expectations 
Much worse than 
my expectations 
5. Before you receive the SC injection do you feel anxious about having the injection? 
Not at all
A little bit
Somewhat
Quite a bit
Very much
6. When you receive the SC injection do you worry that your condition would get worse? 
Not at all
A little bit
Somewhat
Quite a bit
Very much
7. When you receive the SC injection do you feel anxious thinking about your disease? 
Not at all
A little bit
Somewhat
Quite a bit
Very much
8. Thinking about the Rituximab SC injection, how confident are you that Rituximab SC injection 
is treating your disease? 
Not at all
A little bit
Somewhat
Quite a bit
Very much
9. When you receive the Rituximab treatment do you feel restricted by the SC injection? 
Not at all
A little bit
Somewhat
Quite a bit
Very much
 



5LWX[LPDE±5RFKH1RUWK$IULFD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±9±)HEUXDU\


7KLQNLQJ DERXW WKH 5LWX[LPDE 6& LQMHFWLRQ KRZ FRQYHQLHQW LV LW IRU \RX WR JHW \RXU 6&
LQMHFWLRQ"
9HU\FRQYHQLHQW
&RQYHQLHQW
1HLWKHU
FRQYHQLHQWQRU
LQFRQYHQLHQW
,QFRQYHQLHQW
9HU\LQFRQYHQLHQW
7KLQNLQJDERXWWKH5LWX[LPDE6&LQMHFWLRQKRZGR\RXIHHODERXWWKHDPRXQWRIWLPHLWWDNHV
WRJHW\RXU6&LQMHFWLRQ"

7RRVKRUW
-XVWULJKW
7RRORQJ

7KLQNLQJDERXWWKH5LWX[LPDE6&LQMHFWLRQGR\RXIHHOWKDWWKHOHQJWKRIWLPHWRJHW\RXU6&
LQMHFWLRQLVDV\RXH[SHFWHG"
0XFKVKRUWHU
WKDQH[SHFWHG
6RPHZKDW
VKRUWHUWKDQ
H[SHFWHG
$VH[SHFWHG
6RPHZKDW
ORQJHUWKDQ
H[SHFWHG
0XFKORQJHU
WKDQH[SHFWHG
7KLQNLQJDERXWWKH5LWX[LPDE6&LQMHFWLRQKRZERWKHUHGDUH\RXE\WKHDPRXQWRIWLPHLW
WDNHVWRJHWLQMHFWLRQ"
1RWDWDOO
ERWKHUHG
$OLWWOHERWKHUHG
0RGHUDWHO\
ERWKHUHG
4XLWHERWKHUHG
9HU\ERWKHUHG
+RZPXFKGRHVWKH5LWX[LPDE6&LQMHFWLRQ
D ,QWHUIHUHZLWK\RXUXVXDORUGDLO\DFWLYLWLHV"
1RWDWDOO
$OLWWOHELW
6RPHZKDW
4XLWHDELW
9HU\PXFK
E /LPLW\RXUGDLO\DFWLYLWLHV"
1HYHU
5DUHO\
6RPHWLPHV
0RVWRIWKHWLPH
$OZD\V
%HFDXVHRIWKHOHQJWKRIWLPHWRDSSO\WKH5LWX[LPDE6&LQMHFWLRQGR\RXIHHOWKDW\RXKDYH
ORVWRUJDLQHGWLPHIRURWKHUWKLQJV"
/RVWORWRIWLPH
/RVWVRPHWLPH
1HLWKHUORVWQRW
JDLQHGWLPH
*DLQHGVRPH
WLPH
*DLQHGDORWRI
WLPH
:KHQ\RXUHFHLYHWKH5LWX[LPDEWUHDWPHQWDUH\RXDEOHWRWDONWR\RXUQXUVHDQGRUGRFWRU
DVPXFKDV\RXZRXOGOLNHDERXW\RXULOOQHVV"SOHDVHRQO\FKHFN21(DQVZHU
•
<HV,KDGPRUHWKDQHQRXJKWLPHWRWDONWRP\QXUVHDQGRUGRFWRU
•
<HVEXW,ZRXOGKDYHOLNHGPRUHWLPHWRWDONWRP\QXUVHDQGRUGRFWRU
•
,WGRHVQRWPDWWHUWRPHLI,KDYHWLPHWRWDONWRP\QXUVHDQGRUGRFWRUGXULQJP\
WUHDWPHQW
•
1R,GLGQRWKDYHHQRXJKWLPHWRWDONWRP\QXUVHDQGRUGRFWRU
•
1R,GLGQRWWDONWRP\QXUVHDQGRUGRFWRUDWDOO



5LWX[LPDE±5RFKH1RUWK$IULFD$OJHULD0RURFFR	7XQLVLD
0DEUHOOD0/'DXJKWHU3URWRFRO±9±)HEUXDU\


'RHVWKH5LWX[LPDE6&LQMHFWLRQLPSDFWWKHDPRXQWRIWLPH\RXKDYHWRWDONWR\RXUQXUVH
DQGRUGRFWRUDERXW\RXULOOQHVVDQGRWKHUFRQFHUQV"

<HV

1R

7KLQNLQJDERXWWKH5LWX[LPDEWUHDWPHQWLIJLYHQWKHRSWLRQ ZKLFK ZRXOG \RXSUHIHUERWK
RSWLRQVWUHDW\RXUGLVHDVHLQWKHVDPHZD\"3OHDVHFKHFNRQH
•
3UHIHULQWUDYHQRXV,9LQIXVLRQJLYHQWKURXJKDWKLQSODVWLFWXEHDQGDQHHGOHLQWR
\RXUYHLQ,9GULS7KLVWUHDWPHQWRSWLRQXVXDOO\WDNHVWRKRXUV
•
3UHIHUVXEFXWDQHRXV6&LQMHFWLRQDSSOLHGZLWKDV\ULQJHDQGQHHGOHLQWRWKHVNLQ
RIWKHDEGRPHQRUEHOO\ 7KLVWUHDWPHQWRSWLRQLVXVXDOO\WDNHVWRPLQXWHV
•
1RSUHIHUHQFHIRUWUHDWPHQWRSWLRQ
7KLQNLQJDERXWWKH5LWX[LPDEWUHDWPHQWZRXOG\RXUHFRPPHQGWKHZD\\RXUHFHLYHGWKH
WUHDWPHQW6&LQMHFWLRQWRDQRWKHUSDWLHQW"
'HILQLWHO\\HV
3UREDEO\\HV
,GRQ¶WNQRZ
3UREDEO\QRW
'HILQLWHO\QRW







 
Rituximab – Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol – V3.1 – 07 February 2016   
103 
 
Thank you very much for your time 
 

SAP_001.pdf: 
 
Official Title: 
An Open-Label, Multinational, Multicenter, Phase IIIB Study to 
Assess Safety of Rituximab Following Subcutaneous Administration 
in Patients With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 
3A 
NCT Number: 
NCT02406092 
Document Date: 
SAP Version 1: 04-January-2022 
 
 


STATISTICAL ANALYSIS PLAN APPROVAL 
 
[This space is reserved for the electronic signature] 
CONFIDENTIAL 
 
This is F. Hoffmann-La Roche Ltd local affiliates document that contains confidential information.  
Nothing herein is to be disclosed without written consent from F. Hoffmann-La Roche Ltd. 
 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
Statistical Analysis Plan ML28964 
STATISTICAL ANALYSIS PLAN 
TITLE: 
AN OPEN-LABEL, MULTINATIONAL, MULTICENTER, 
PHASE IIIB STUDY TO ASSESS SAFETY OF RITUXIMAB 
FOLLOWING SUBCUTANEOUS ADMINISTRATION IN 
PATIENTS WITH CD20+ DLBCL OR CD20+ FOLLICULAR 
NHL GRADE 1 TO 3A 
PROTOCOL NUMBER: 
ML28964 
STUDY DRUG: 
Rituximab 
VERSION NUMBER: 
1.0 
IND NUMBER: 
N/A 
EUDRACT NUMBER: 
N/A 
SPONSOR: 
Roche Algeria 
PLAN PREPARED BY: 
  
  
SPARC Consulting (on behalf of IQVIA), Milan - Italy 
DATE FINAL: 
See electronic date stamp below 
DATE(S) AMENDED: 
N/A 


Rituxibam— Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
2/Statistical Analysis Plan ML28964 
STATISTICAL ANALYSIS PLAN HISTORY 
Version 
Date Release 
0.1 
15DEC2021 
0.2 
22DEC2021 
1.0 
04JAN2022 
 
 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
3/Statistical Analysis Plan ML28964 
 
TABLE OF CONTENTS 
STATISTICAL ANALYSIS PLAN HISTORY ......................................................... 2 
1. 
BACKGROUND .......................................................................................... 21 
2. 
STUDY DESIGN ......................................................................................... 21 
2.1 
Protocol Synopsis .................................................................. 22 
2.2 
Outcome Measures ............................................................... 22 
2.2.1 
Safety Outcome Measures .................................................... 22 
2.2.2 
Efficacy Outcome Measures .................................................. 22 
2.2.3 
Exploratory Outcome Measures ............................................ 23 
2.2.4 
Pharmacokinetic Outcome Measures .................................... 23 
2.3 
Determination of Sample Size ............................................... 23 
2.3.1 
Sample Size for the China Extension Period ......................... 23 
2.4 
Analysis Timing ..................................................................... 24 
2.4.1 
Analysis Timing for the China Subgroup Analysis ................. 24 
3. 
STUDY CONDUCT ..................................................................................... 24 
3.1 
Randomization ....................................................................... 24 
3.2 
Independent Review Facility .................................................. 24 
3.3 
Data Monitoring ..................................................................... 24 
4. 
STATISTICAL METHODS .......................................................................... 24 
4.1 
Analysis Populations ............................................................. 25 
4.1.1 
Randomized Population......................................................... 25 
4.1.2 
Per Protocol Population ......................................................... 25 
4.1.3 
Pharmacokinetic-Evaluable Population ................................. 25 
4.1.4 
Safety Population .................................................................. 25 
4.1.5 
Intent-To-Treat Population ..................................................... 26 
4.2 
Analysis of Study Conduct ..................................................... 26 
4.2.1 
Definition of Baseline ............................................................. 26 
4.3 
Analysis of Treatment Group Comparability .......................... 26 
4.3.1 
Medical History ...................................................................... 26 
4.3.2 
Surgery and Procedures History ............................................ 27 
4.3.3 
Physical Examination ............................................................ 27 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
4/Statistical Analysis Plan ML28964 
4.3.4 
Previous and Concomitant Therapies .................................... 27 
4.3.5 
Viral Serology ........................................................................ 28 
4.4 
Efficacy Analysis .................................................................... 28 
4.4.1 
Primary Efficacy Endpoint ...................................................... 29 
4.4.2 
Secondary Efficacy Endpoints ............................................... 29 
4.4.3 
Exploratory Efficacy Endpoints .............................................. 30 
4.4.4 
Sensitivity Analyses ............................................................... 30 
4.4.5 
Subgroup Analyses ............................................................... 30 
4.5 
Pharmacokinetic and Pharmacodynamic 
Analyses ................................................................................ 30 
4.6 
Patient-Reported Outcome Analyses .................................... 30 
4.7 
Healthcare Professional Reported Outcome 
Analyses ................................................................................ 31 
4.8 
Safety Analyses ..................................................................... 32 
4.8.1 
Exposure of Study Medication ............................................... 32 
4.8.2 
Adverse Events ..................................................................... 32 
4.8.3 
Laboratory Data ..................................................................... 36 
4.8.4 
Vital Signs .............................................................................. 36 
4.8.5 
ECOG Performance Status ................................................... 36 
4.9 
Missing Data .......................................................................... 36 
4.10 
Interim Analyses .................................................................... 37 
5. 
CHINA SUBGROUP ANALYSIS ................................................................. 38 
6. 
REFERENCES ........................................................................................... 39 
Appendix 1 - Protocol Synopsis .................................................................. 46 
Appendix 2 - Schedule of Assessments ...................................................... 54 
Appendix 3 - Table and Listing Shells ......................................................... 60 
TABLE 14.1.1. ENROLLED BY COUNTRY AND SITE (ITT 
POPULATION) ....................................................................... 61 
TABLE 14.1.2. SUMMARY OF PATIENT DISPOSITION 
(ITT POPULATION) ............................................................ 62 
TABLE 14.1.3. SUMMARY OF PROTOCOL DEVIATIONS 
(ITT POPULATION) ............................................................ 63 
TABLE 14.1.4. SUMMARY OF DEMOGRAPHICS (ITT 
POPULATION) ....................................................................... 64 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
5/Statistical Analysis Plan ML28964 
TABLE 14.1.5. SERUM PREGNANCY TEST AT SCREENING 
(SAFETY POPULATION) ...................................................... 65 
TABLE 14.1.6. SUMMARY OF BASELINE 
CHARACTERISTICS – PART #1 (ITT 
POPULATION) ....................................................................... 66 
TABLE 14.1.7. SUMMARY OF BASELINE 
CHARACTERISTICS – PART #2 (ITT 
POPULATION) ....................................................................... 67 
TABLE 14.1.8. DLBCL DIAGNOSIS (SAFETY 
POPULATION) ....................................................................... 68 
TABLE 14.1.9. FOLLICULAR LYMPHOMA DIAGNOSIS 
(SAFETY POPULATION) ...................................................... 69 
TABLE 14.1.10. SUMMARY OF BONE MARROW AT 
BASELINE (ITT POPULATION) ......................................... 70 
TABLE 14.1.11. LEAD ECG AT SCREENING (SAFETY 
POPULATION) ....................................................................... 71 
TABLE 14.1.12. VIRAL SEROLOGY AT SCREENING 
(SAFETY POPULATION) ...................................................... 72 
TABLE 14.1.13. SUMMARY OF PREVIOUS DISEASE (ITT 
POPULATION) ....................................................................... 73 
TABLE 14.1.14. SUMMARY OF CONCOMITANT DISEASE 
(ITT POPULATION) ............................................................ 74 
TABLE 14.1.15. SUMMARY OF PHYSICAL EXAMINATION 
(SAFETY POPULATION) ...................................................... 75 
TABLE 14.1.16. SUMMARY OF PREVIOUS THERAPIES 
(SAFETY POPULATION) ...................................................... 76 
TABLE 14.1.17. SUMMARY OF CONCOMITANT THERAPIES 
(SAFETY POPULATION) ...................................................... 77 
TABLE 14.1.18. SUMMARY OF PREVIOUS IV RITUXIMAB 
DOSE FOR DLBCL (SAFETY POPULATION) ...................... 78 
TABLE 14.1.19. SUMMARY OF PREVIOUS IV RITUXIMAB 
DOSE FOR FL (SAFETY POPULATION) ............................ 79 
TABLE 14.1.20. EXPOSURE TO RITUXIMAB SC – 
ADMINISTRATION SUMMARY (SAFETY 
POPULATION) ....................................................................... 80 
TABLE 14.1.21. EXPOSURE TO RITUXIMAB SC – 
ADMINISTRATION DETAILS (SAFETY 
POPULATION) ....................................................................... 81 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
6/Statistical Analysis Plan ML28964 
TABLE 14.1.22. EXPOSURE TO RITUXIMAB SC – 
ADMINISTRATION DETAILS (SAFETY 
POPULATION) ....................................................................... 82 
TABLE 14.1.23. TYPE OF CHEMOTHERAPY (SAFETY 
POPULATION) ....................................................................... 83 
TABLE 14.1.24. EXPOSURE TO CHEMOTHERAPY (SAFETY 
POPULATION) ....................................................................... 84 
TABLE 14.1.25. EXPOSURE TO NEW ANTI – LYMPHOMA 
TREATMENT CHEMO/IMMUNO THERAPY 
(SAFETY POPULATION) ...................................................... 85 
TABLE 14.1.26. INITIAL CHOP REGIMEN DOSAGE 
(SAFETY POPULATION) ...................................................... 86 
TABLE 14.1.27. INITIAL CVP REGIMEN DOSAGE 
(SAFETY POPULATION) ...................................................... 87 
TABLE 14.1.28. INITIAL FLUDARABINE DOSAGE 
(SAFETY POPULATION) ...................................................... 88 
TABLE 14.1.29. EXPOSURE TO NEW ANTI – LYMPHOMA 
TREATMENT RADIOTHERAPY (SAFETY 
POPULATION) ....................................................................... 89 
TABLE 14.2.1. OVERALL SUMMARY OF PATIENTS 
EXPERIENCING EACH CLASS OF TREATMENT 
EMERGENT ADVERSE EVENT (SAFETY 
POPULATION) ....................................................................... 90 
TABLE 14.2.2. PROPORTION OF TREATMENT EMERGENT 
ADVERSE EVENT BY SYSTEM ORGAN CLASS 
AND PREFERRED TERM (SAFETY 
POPULATION) ....................................................................... 91 
TABLE 14.2.3. PROPORTION OF SERIOUS TREATMENT 
EMERGENT ADVERSE EVENT BY SYSTEM 
ORGAN CLASS AND PREFERRED TERM 
(SAFETY POPULATION) ...................................................... 92 
TABLE 14.2.4. PROPORTION OF LOCALIZED 
ADMINISTRATION ASSOCIATED REACTIONS 
BY SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ........................................... 93 
TABLE 14.2.5. PROPORTION OF NON-LOCALIZED 
ADMINISTRATION ASSOCIATED REACTIONS 
BY SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ........................................... 94 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
7/Statistical Analysis Plan ML28964 
TABLE 14.2.6. PROPORTION OF TREATMENT-EMERGENT 
ADVERSE EVENTS WITH GRADE >=3+ AES 
BY SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ........................................... 95 
TABLE 14.2.7. PROPORTION OF TREATMENT-EMERGENT 
ADVERSE EVENTS WITH GRADE >=3+ SAES 
BY SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ........................................... 96 
TABLE 14.2.8. PROPORTION OF TREATMENT-EMERGENT 
ADVERSE EVENTS WITH GRADE >=3+ AARS 
BY SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ........................................... 97 
TABLE 14.2.9. PROPORTION OF TREATMENT-EMERGENT 
ADVERSE EVENTS LEADING TO RITUXIMAB 
DRUG INTERRUPTED/DRUG DELAYED BY 
SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ........................................... 98 
TABLE 14.2.10. PROPORTION OF TREATMENT-EMERGENT 
ADVERSE EVENTS LEADING TO RITUXIMAB 
DOSE DISCONTINUATION BY SYSTEM ORGAN 
CLASS AND PREFERRED TERM (SAFETY 
POPULATION) ....................................................................... 99 
TABLE 14.2.11. PROPORTION OF TREATMENT-EMERGENT 
ADVERSE EVENTS LEADING TO 
CHEMOTHERAPY DOSE MODIFICATION BY 
SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ......................................... 100 
TABLE 14.2.12. PROPORTION OF TREATMENT-EMERGENT 
ADVERSE EVENTS LEADING TO 
CHEMOTHERAPY DOSE DISCONTINUATION BY 
SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ......................................... 101 
TABLE 14.2.13. PROPORTION OF TREATMENT-EMERGENT 
ADVERSE EVENTS LEADING TO DEATH BY 
SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ......................................... 102 
TABLE 14.2.14. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS BY SYSTEM ORGAN CLASS 
AND PREFERRED TERM (SAFETY 
POPULATION) ..................................................................... 103 
TABLE 14.2.15. SUMMARY OF SERIOUS TREATMENT-
EMERGENT ADVERSE EVENTS BY SYSTEM 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
8/Statistical Analysis Plan ML28964 
ORGAN CLASS AND PREFERRED TERM 
(SAFETY POPULATION) .................................................... 104 
TABLE 14.2.16. SUMMARY OF ADVERSE EVENTS OF 
SPECIAL INTEREST BY SYSTEM ORGAN 
CLASS AND PREFERRED TERM (SAFETY 
POPULATION) ..................................................................... 105 
TABLE 14.2.17. SUMMARY OF ADMINISTRATION 
ASSOCIATED REACTIONS BY SYSTEM ORGAN 
CLASS AND PREFERRED TERM (SAFETY 
POPULATION) ..................................................................... 106 
TABLE 14.2.18. SUMMARY OF INFUSION/INJECTION-
RELATED REACTIONS BY SYSTEM ORGAN 
CLASS AND PREFERRED TERM (SAFETY 
POPULATION) ..................................................................... 107 
TABLE 14.2.19. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS WITH GRADE >=3+ AES 
BY SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ......................................... 108 
TABLE 14.2.20. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS WITH GRADE >=3+ SAES 
BY SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ......................................... 109 
TABLE 14.2.21. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS WITH GRADE >=3+ AESI 
BY SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ......................................... 110 
TABLE 14.2.22. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS WITH GRADE >=3+ AARS 
BY SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ......................................... 111 
TABLE 14.2.23. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS WITH GRADE >=3+ IIRRS 
BY SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ......................................... 112 
TABLE 14.2.24. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS WITHIN THE MEDDRA SMQ 
`ANAPHYLACTIC REACTIONS’ (WIDE)  BY 
SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ......................................... 113 
TABLE 14.2.25. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS LEADING TO RITUXIMAB 
DRUG INTERRUPTED/DRUG DELAYED BY 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
9/Statistical Analysis Plan ML28964 
SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ......................................... 114 
TABLE 14.2.26. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS LEADING TO RITUXIMAB 
DOSE DISCONTINUATION BY SYSTEM ORGAN 
CLASS AND PREFERRED TERM (SAFETY 
POPULATION) ..................................................................... 115 
TABLE 14.2.27. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS LEADING TO 
CHEMOTHERAPY DOSE MODIFICATION BY 
SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ......................................... 116 
TABLE 14.2.28. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS LEADING TO 
CHEMOTHERAPY DOSE DISCONTINUATION BY 
SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ......................................... 117 
TABLE 14.2.29. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS LEADING TO DEATH BY 
SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ......................................... 118 
TABLE 14.2.30. SUMMARY OF CUTANEOUS AND SOFT 
TISSUE AARS (LOCALIZED) BY SYSTEM 
ORGAN CLASS AND PREFERRED TERM 
(SAFETY POPULATION) .................................................... 119 
TABLE 14.2.31. SUMMARY OF CUTANEOUS AND SOFT 
TISSUE AARS (NON-LOCALIZED) BY 
SYSTEM ORGAN CLASS AND PREFERRED 
TERM (SAFETY POPULATION) ......................................... 120 
TABLE 14.2.32. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS WITH AN INCIDENCE OF 
>=5% BY SYSTEM ORGAN CLASS AND 
PREFERRED TERM (SAFETY POPULATION) .................... 121 
TABLE 14.2.33. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS BY SYSTEM ORGAN CLASS 
AND PREFERRED TERM AND MAXIMUM 
SEVERITY (SAFETY POPULATION) ................................ 122 
TABLE 14.2.34. SUMMARY OF TREATMENT-EMERGENT 
ADVERSE EVENTS BY SYSTEM ORGAN CLASS 
AND PREFERRED TERM AND STRONGEST 
RELATIONSHIP (SAFETY POPULATION) ........................ 123 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
10/Statistical Analysis Plan ML28964 
TABLE 14.2.35. SUMMARY OF NON-SERIOUS 
TREATMENT-EMERGENT ADVERSE EVENTS 
WITH AN INCIDENCE OF >=5% BY SYSTEM 
ORGAN CLASS AND PREFERRED TERM 
(SAFETY POPULATION) .................................................... 124 
TABLE 14.2.36. SUMMARY OF PATIENTS DEAD OVER 
THE STUDY (SAFETY POPULATION) .............................. 125 
TABLE 14.3.1. SUMMARY OF HEMATOLOGY PARAMETERS 
OVER THE STUDY (SAFETY POPULATION) .................... 126 
TABLE 14.3.2. SUMMARY OF BLOOD CHEMISTRY 
PARAMETERS OVER THE STUDY (SAFETY 
POPULATION) ..................................................................... 127 
TABLE 14.3.3. SUMMARY OF COAGULATION TESTS OVER 
THE STUDY (SAFETY POPULATION) .............................. 128 
TABLE 14.3.4. SHIFT TABLE OF HEMATOLOGY 
PARAMETERS ACCORDING TO NCI CTCAE 
WORST GRADE RECORDED DURING THE 
TREATMENT PERIOD (SAFETY POPULATION) ............... 129 
TABLE 14.3.5. SHIFT TABLE OF BLOOD CHEMISTRY 
PARAMETERS ACCORDING TO NCI CTCAE 
WORST GRADE RECORDED DURING THE 
TREATMENT PERIOD (SAFETY POPULATION) ............... 130 
TABLE 14.3.6. SHIFT TABLE OF COAGULATION TESTS 
ACCORDING TO NCI CTCAE WORST GRADE 
RECORDED DURING THE TREATMENT PERIOD 
(SAFETY POPULATION) .................................................... 131 
TABLE 14.3.7. SUMMARY OF VITAL SIGNS OVER THE 
STUDY (SAFETY POPULATION) ....................................... 132 
TABLE 14.3.8. ECOG PERFORMANCE STATUS (SAFETY 
POPULATION) ..................................................................... 133 
TABLE 14.4.1. TARGET LESION ASSESSMENT AT 
SCREENING (PART #1) (SAFETY 
POPULATION) ..................................................................... 134 
TABLE 14.4.2. TARGET LESION ASSESSMENT AT 
SCREENING (PART #2) (SAFETY 
POPULATION) ..................................................................... 135 
TABLE 14.4.3. POST-SCREENING TARGET LESION 
ASSESSMENT (PART #1) (SAFETY 
POPULATION) ..................................................................... 136 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
11/Statistical Analysis Plan ML28964 
TABLE 14.4.4. POST-SCREENING TARGET LESION 
ASSESSMENT (PART #2) (SAFETY 
POPULATION) ..................................................................... 137 
TABLE 14.4.5. OVERALL LESION ASSESSMENT (SAFETY 
POPULATION) ..................................................................... 138 
TABLE 14.5.1. OVERALL SURVIVAL FROM FIRST DOSE 
OF RITUXIMAB IV (ITT POPULATION) ........................ 139 
TABLE 14.5.2. OVERALL SURVIVAL FROM FIRST DOSE 
OF RITUXIMAB IV: DISTRIBUCTION 
FUNCTION (ITT POPULATION) ....................................... 140 
TABLE 14.5.3. OVERALL SURVIVAL FROM FIRST DOSE 
OF RITUXIMAB IV: DISTRIBUCTION 
FUNCTION CURVE FOR ALL SUBJECTS (ITT 
POPULATION) ..................................................................... 141 
TABLE 14.5.4. OVERALL SURVIVAL FROM FIRST DOSE 
OF RITUXIMAB IV: DISTRIBUCTION 
FUNCTION CURVE by TYPE OF LYMPHOMA 
(ITT POPULATION) .......................................................... 142 
TABLE 14.5.5. PROGRESSION FREE SURVIVAL FROM 
FIRST DOSE OF RITUXIMAB IV (ITT 
POPULATION) ..................................................................... 143 
TABLE 14.5.6. PROGRESSION FREE SURVIVAL FROM 
FIRST DOSE OF RITUXIMAB IV: 
DISTRIBUCTION FUNCTION (ITT 
POPULATION) ..................................................................... 144 
TABLE 14.5.7. PROGRESSION FREE SURVIVAL FROM 
FIRST DOSE OF RITUXIMAB IV: 
DISTRIBUCTION FUNCTION CURVE FOR ALL 
SUBJECTS (ITT POPULATION) ....................................... 145 
TABLE 14.5.8. PROGRESSION FREE SURVIVAL FROM 
FIRST DOSE OF RITUXIMAB IV: 
DISTRIBUCTION FUNCTION CURVE by TYPE 
OF LYMPHOMA (ITT POPULATION) ................................ 146 
TABLE 14.5.9. DISEASE FREE SURVIVAL (ITT 
POPULATION) ..................................................................... 147 
TABLE 14.5.10. DISEASE FREE SURVIVAL: 
DISTRIBUCTION FUNCTION (ITT 
POPULATION) ..................................................................... 148 
TABLE 14.5.11. DISEASE FREE SURVIVAL: 
DISTRIBUCTION FUNCTION CURVE FOR ALL 
SUBJECTS (ITT POPULATION) ....................................... 149 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
12/Statistical Analysis Plan ML28964 
TABLE 14.5.12. DISEASE FREE SURVIVAL: 
DISTRIBUCTION FUNCTION CURVE by TYPE 
OF LYMPHOMA (ITT POPULATION) ................................ 150 
TABLE 14.5.13. EVENT FREE SURVIVAL FROM FIRST 
DOSE OF RITUXIMAB IV (ITT POPULATION)
 ............................................................................................ 151 
TABLE 14.5.14. EVENT FREE SURVIVAL FROM FIRST 
DOSE OF RITUXIMAB IV: DISTRIBUCTION 
FUNCTION (ITT POPULATION) ....................................... 152 
TABLE 14.5.15. EVENT FREE SURVIVAL FROM FIRST 
DOSE OF RITUXIMAB IV: DISTRIBUCTION 
FUNCTION CURVE FOR ALL SUBJECTS (ITT 
POPULATION) ..................................................................... 153 
TABLE 14.5.16. EVENT FREE SURVIVAL FROM FIRST 
DOSE OF RITUXIMAB IV: DISTRIBUCTION 
FUNCTION CURVE by TYPE OF LYMPHOMA 
(ITT POPULATION) .......................................................... 154 
TABLE 14.5.17. SUMMARY OF COMPLETE RESPONSE OR 
COMPLETE RESPONSE UNCONFIRMED (ITT 
POPULATION) ..................................................................... 155 
TABLE 14.6.1. RITUXIMAB IV ADMINISTRATION 
SATIFICATION QUESTIONNAIRE - ITEMS 
FREQUENCY ANALYSIS (SAFETY 
POPULATION) ..................................................................... 156 
TABLE 14.6.2. RITUXIMAB SC ADMINISTRATION 
SATIFICATION QUESTIONNAIRE - ITEMS 
FREQUENCY ANALYSIS (SAFETY 
POPULATION) ..................................................................... 157 
TABLE 14.6.3. SUMMARY OF RITUXIMAB 
ADMINISTRATION SATISFACTION 
QUESTIONNAIRE IV MEAN SCORES (SAFETY 
POPULATION) ..................................................................... 158 
TABLE 14.6.4. SUMMARY OF RITUXIMAB 
ADMINISTRATION SATISFACTION 
QUESTIONNAIRE IV MEAN SCORES (SAFETY 
POPULATION) ..................................................................... 159 
TABLE 14.6.5. SUMMARY OF RITUXIMAB 
ADMINISTRATION SATISFACTION 
QUESTIONNAIRE IV MEAN SCORES (SAFETY 
POPULATION) ..................................................................... 160 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
13/Statistical Analysis Plan ML28964 
TABLE 14.6.6. SUMMARY OF RITUXIMAB 
ADMINISTRATION SATISFACTION 
QUESTIONNAIRE IV MEAN SCORES (SAFETY 
POPULATION) ..................................................................... 161 
TABLE 14.6.7. SUMMARY OF RITUXIMAB 
ADMINISTRATION SATISFACTION 
QUESTIONNAIRE IV MEAN SCORES (SAFETY 
POPULATION) ..................................................................... 162 
TABLE 14.6.8. SUMMARY OF RITUXIMAB 
ADMINISTRATION SATISFACTION 
QUESTIONNAIRE SC MEAN SCORES (SAFETY 
POPULATION) ..................................................................... 163 
TABLE 14.6.9. SUMMARY OF RITUXIMAB 
ADMINISTRATION SATISFACTION 
QUESTIONNAIRE SC MEAN SCORES (SAFETY 
POPULATION) ..................................................................... 164 
TABLE 14.6.10. SUMMARY OF RITUXIMAB 
ADMINISTRATION SATISFACTION 
QUESTIONNAIRE SC MEAN SCORES (SAFETY 
POPULATION) ..................................................................... 165 
TABLE 14.6.11. SUMMARY OF RITUXIMAB 
ADMINISTRATION SATISFACTION 
QUESTIONNAIRE SC MEAN SCORES (SAFETY 
POPULATION) ..................................................................... 166 
TABLE 14.6.12. SUMMARY OF RITUXIMAB 
ADMINISTRATION SATISFACTION 
QUESTIONNAIRE SC MEAN SCORES (SAFETY 
POPULATION) ..................................................................... 167 
TABLE 14.6.13. HEALTHCARE PROFESSIONAL 
QUESTIONNAIRE (PART #1) ........................................... 168 
TABLE 14.6.14. HEALTHCARE PROFESSIONAL 
QUESTIONNAIRE (PART #2) ........................................... 169 
LISTING 16.2.1.1. ANALYSIS SETs ................................................. 170 
LISTING 16.2.1.2. INCLUSION/EXCLUSION CRITERIA 
VIOLATED ........................................................................... 171 
LISTING 16.2.2.1. MAJOR PROTOCOL DEVIATIONS ....................... 172 
LISTING 16.2.2.2. MINOR PROTOCOL DEVIATIONS ....................... 173 
LISTING 16.2.2.3. COVID-19 RELATED PROTOCOL 
DEVIATIONS ....................................................................... 174 
LISTING 16.2.3.1. STUDY DRUG DISCONTINUATION ..................... 175 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
14/Statistical Analysis Plan ML28964 
LISTING 16.2.4.1. INFORMED CONSENT & DEMOGRAPHY .............. 176 
LISTING 16.2.4.2. MEDICAL HISTORY ............................................ 177 
LISTING 16.2.4.3. SURGERY AND PROCEDURES 
HISTORY (CANCER AND NON-CANCER 
RELATED) ........................................................................... 178 
LISTING 16.2.4.4. DLBCL DIAGNOSIS ............................................ 179 
LISTING 16.2.4.5. FOLLICULAR LYMPHOMA DIAGNOSIS .............. 180 
LISTING 16.2.4.6. ECOG PERFORMANCE STATUS, 
FLIPI AND IPI SCORE .................................................... 181 
LISTING 16.2.4.7. VIRAL SEROLOGY AT SCREENING ................... 182 
LISTING 16.2.4.8. CONCOMITANT MEDICATIONS ........................... 183 
LISTING 16.2.5.1. PREVIOUS IV RITUXIMAB DOSE – 
DLBCL .................................................................................. 184 
LISTING 16.2.5.2. PREVIOUS IV RITUXIMAB DOSE – 
FL ........................................................................................ 185 
LISTING 16.2.5.3. INITIAL CHOP ................................................... 186 
LISTING 16.2.5.4. SUBSEQUENT CHOP ............................................ 187 
LISTING 16.2.5.5. SUBSEQUENT cvp ............................................... 188 
LISTING 16.2.5.6. SUBSEQUENT FLUDARABINE ............................. 189 
LISTING 16.2.5.7. SUBSEQUENT CHEMOTHERAPY ........................... 190 
LISTING 16.2.5.8. INITIAL CVP ..................................................... 191 
LISTING 16.2.5.9. INITIAL FLUDARABINE .................................... 192 
LISTING 16.2.5.10. OTHER CHEMOTHERAPY .................................... 193 
LISTING 16.2.5.11. STUDY DRUG ADMINISTRATION ..................... 194 
LISTING 16.2.5.12. ANTI-LYMPHOMA CHEMO/IMMUNO 
THERAPY TREATMENT ........................................................ 195 
LISTING 16.2.5.13. ANTI-LYMPHOMA RADIOTHERAPY 
TREATMENT ......................................................................... 196 
LISTING 16.2.5.14. ANTI-LYMPHOMA TREATMENT ......................... 197 
LISTING 16.2.5.15. CHEMOTHERAPY SELECTION ........................... 198 
LISTING 16.2.6.1. PRE-TREATMENT ADVERSE EVENTS ................. 199 
LISTING 16.2.6.2. ADVERSE EVENTS ............................................... 200 
LISTING 16.2.6.3. SERIOUS ADVERSE EVENTS ............................. 201 
LISTING 16.2.6.4. ADVERSE EVENTS OF SPECIAL 
INTEREST (AESI) ............................................................ 202 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
15/Statistical Analysis Plan ML28964 
LISTING 16.2.6.5. ADMINISTERED ASSOCIATED 
REACTIONS ......................................................................... 203 
LISTING 16.2.6.6. GRADE 3+ ADVERSE EVENTS ........................... 204 
LISTING 16.2.6.7. ADVERSE EVENTS LEADING TO 
RITUXIMAB DRUG INTERRUPTION OR DRUG 
DELAYED ............................................................................. 205 
LISTING 16.2.6.8. ADVERSE EVENTS LEADING TO 
CHEMOTHERAPY DOSE MODIFICATION ............................ 206 
LISTING 16.2.6.9. ADVERSE EVENTS LEADING TO 
CHEMOTHERAPY DISCONTINUATION ................................ 207 
LISTING 16.2.6.10. ADVERSE EVENTS WITHIN THE 
MEDDRA SMQ ANAPHYLACTIC REACTIONS ...................... 208 
LISTING 16.2.6.11. INJECTION SITE REACTIONS ....................... 209 
LISTING 16.2.6.12. DEATH ................................................................ 210 
LISTING 16.2.7.1. HEMATOLOGY ....................................................... 211 
LISTING 16.2.7.2. BIOCHEMISTRY ................................................... 212 
LISTING 16.2.7.3. COAGULATION TESTS ........................................ 213 
LISTING 16.2.8.1. VITAL SIGNS & BODY WEIGHT ....................... 214 
LISTING 16.2.8.2. SERUM PREGNANCY TEST .................................. 215 
LISTING 16.2.8.3. URINE PREGNANCY TEST .................................. 216 
LISTING 16.2.8.4. PHYSICAL EXAMINATION .................................. 217 
LISTING 16.2.8.5. 12-LEAD ECG ..................................................... 218 
LISTING 16.2.8.6. TARGET LESION ASSESSMENT AT 
SCREENING (PART #1) .................................................... 219 
LISTING 16.2.8.7. TARGET LESION ASSESSMENT AT 
SCREENING (PART #2) .................................................... 220 
LISTING 16.2.8.8. TARGET LESION ASSESSMENT 
SUBSEQUENT (PART #1) .................................................. 221 
LISTING 16.2.8.9. TARGET LESION ASSESSMENT 
SUBSEQUENT (PART #2) .................................................. 222 
LISTING 16.2.8.10. OVERALL LESION ASSESSMENT ..................... 223 
LISTING 16.2.8.11. SURVIVAL STATUS .......................................... 224 
LISTING 16.2.8.12. BONE MARROW ASSESSMENT ........................... 225 
LISTING 16.2.8.13. RASQ FOR IV ADMINISTRATION ................... 226 
LISTING 16.2.8.14. RASQ FOR SC ADMINISTRATION ................... 227 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
16/Statistical Analysis Plan ML28964 
LISTING 16.2.8.15. HEALTHCARE PROFESSIONAL 
QUESTIONNAIRE ................................................................. 228 
 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
17/Statistical Analysis Plan ML28964 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation 
Definition 
aaIPI 
AAR 
AE 
ALT (SGPT) 
aPTT 
Age-adjusted International Prognostic Index 
Administration-associated reaction 
Adverse Event 
alanine aminotransferase 
Activated Partial Thromboplastin Time 
AST (SGOT) 
BSA 
BUN 
CEC 
CHO 
CHOP 
 
CHOP-21 
CHOP-14 
CHVP 
 
CI 
CLL 
Aspartate Aminotransferase 
body surface area 
Blood Urea Nitrogen 
Clinical Events Committee 
Chinese hamster ovary 
cyclophosphamide, oncovine (vincristine), doxorubicin, 
prednisone/prednisolone 
CHOP given every 21 days 
CHOP given every 14 days 
cyclophosphamide, doxorubicin, etoposide, 
prednisone/prednisolone 
Confidence Interval 
chronic lymphocytic leukaemia 
CR 
Complete Response 
CRF 
Case Report Form 
CRu  
complete response unconfirmed 
CRO 
contract research organization 
CT 
Computerised Tomography 
CTCAE 
Common Terminology Criteria for Adverse Events 
Ctrough 
Minimal plasma concentration prior to next drug administration 
CVP 
cyclophosphamide, vincristine, prednisone/prednisolone 
DFS 
disease-free survival 
DLBCL 
diffuse large B-cell lymphoma 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
eCRF 
Electronic Case Report Form 
EDC 
Electronic Data Capture 
EFS 
event-free survival 
EGSG 
East German Study Group 
EU 
European Union 
FC 
Fludarabine, cyclophosphamide 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
18/Statistical Analysis Plan ML28964 
Abbreviation 
Definition 
FC 28 
FC given every 28 days 
FDA 
Food and Drug Administration 
FDG-PET 
[18F]deoxyglucose positron emission tomography 
FFS 
failure-free survival 
FL 
follicular lymphoma 
FLIPI 
Follicular Lymphoma International Prognostic Index 
G-CSF 
granulocyte colony-stimulating factor 
GELA 
Groupe d’Etude des Lymphomes de l’Adulte 
GLSG 
German Low-Grade Lymphoma Study Group 
HACA 
human antichimeric antibody 
HAMA 
human anti-mouse antibody 
HBV 
Hepatitis B Virus 
HCV 
Hepatitis C Virus 
HIPAA 
Health Insurance Portability and Accountability Act 
HIV 
Human Immunodeficiency Virus 
IB 
Investigator’s Brochure 
ICF 
informed consent form 
ICH 
International Council for Harmonisation 
iDMC 
Independent Data Monitoring Committee 
IDSMB 
Independent Data Safety Monitoring Board 
IFN 
interferon-α 
IMP 
Investigational Medicinal Product 
INR 
International Normalised ratio 
IPI 
International Prognostic Index 
IRC 
Independent Review Committee 
IRF 
Independent Review Facility 
IRR 
Infusion-related reaction 
IIRR 
infusion/injection-related reaction 
ITT 
Intent-to-treat 
IV 
Intravenous 
IWG 
International Working Group 
LDH 
Lactate Dehydrogenase 
LPLV 
last patient, last visit 
MCP 
mitoxantrone, chlorambucil, prednisone/prednisolone 
MedDRA 
MInT 
Medical Dictionary for Regulatory Activities 
MabThera international trial 
MRI 
Magnetic Resonance Imaging 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
19/Statistical Analysis Plan ML28964 
Abbreviation 
Definition 
NCI 
National Cancer Institute 
NCI CTCAE 
National Cancer Institute Common Terminology Criteria for 
Adverse Events 
NHL 
Non-Hodgkin’s Lymphoma 
NIMP 
Non-investigational medicinal product 
ORR 
Objective Response Rate 
OS 
Overall Survival 
PD 
progressive disease (disease progression) 
PD 
pharmacodynamics 
PET 
positron emission tomography 
PFS 
progression-free survival 
PK 
Pharmacokinetic 
PML 
Progressive Multifocal Leukoencephalopathy 
PR 
Partial Response 
PRP 
patient-reported outcome 
PT 
Prothrombin Time 
PT 
Preferred Term 
RBC 
Red Blood Cells 
RCR 
Roche Clinical Repository 
R-CHOP 
rituximab plus CHOP chemotherapy 
RCT 
randomized controlled trial 
R-CVP 
rituximab plus CVP chemotherapy 
R-CHVP 
rituximab plus CHVP chemotherapy 
R-FC 
Rituximab plus FC chemotherapy 
rHuPH20 
recombinant human hyaluronidase 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 
SAS 
Statistical Analysis System (software) 
SC 
subcutaneous(ly) 
SD 
Stable Disease 
SEER 
Surveillance, Epidemiology, and End Results 
SOC 
System Organ Class 
SPD 
sum of the products of the greatest diameters 
SUSAR 
Suspected Unexpected Serious Adverse Reactions 
SWT 
Satisfaction with Therapy 
TLS 
Tumour lysis syndrome 
TNLT 
time to next lymphoma treatment 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
20/Statistical Analysis Plan ML28964 
Abbreviation 
Definition 
TTF 
time to treatment failure 
TTP 
time to tumour progression 
ULN 
Upper Limit of Normal 
WBC 
White Blood Cells 
WHO 
World Health Organization 
 
 
 
 
 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
21/Statistical Analysis Plan ML28964 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
1. 
BACKGROUND 
The purpose of the analyses outlined in this Statistical Analysis Plan (SAP) is to evaluate 
the safety of Rituximab following subcutaneous administration in patients with CD20+ 
DLBCL or CD20+ follicular NHL grade 1 to 3A. 
This SAP is based on Section 6 (Statistical considerations and analysis plan) of the 
study protocol version 3.1, signed on February 25 h, 2016. 
2. 
STUDY DESIGN 
This is an open-label, single-arm study to evaluate the safety of rituximab SC 
administered during first line treatment for FL (Induction and/or Maintenance), or DLBCL 
(treatment plus 24 months of follow-up). 
This study will include adult patients with CD20+ DLBCL or CD20+ follicular NHL (grade 
1 to 3a; NHL), who have already received at least one full dose of IV rituximab during 
induction or maintenance. Patients receiving Induction therapy must be able to receive 
at least 4 cycles of rituximab SC in addition to standard chemotherapy. FL Patients 
receiving Maintenance therapy must be able to receive at least 6 cycles of rituximab SC. 
During administration of rituximab SC, patients will be assessed for safety and efficacy 
as detailed in the Schedule of Assessments (see Appendix 1 of Study Protocol). RASQ 
(see Appendix 6 of Study Protocol) will be applied to patients at the end of the study 
after rituximab administration. Healthcare Professional (HCP) Questionnaire (see 
Appendix 7 of study Protocol) will be applied at the end of the study to health care 
professionals. 
Induction Therapy: 
Patients receiving Induction therapy prior to entry into the study must be eligible to 
receive at least four further cycles of rituximab SC (i.e., 4 additional months of Induction 
treatment). Patients with follicular NHL who will continue into Maintenance therapy (after 
staging at the end of Induction) can continue to receive rituximab SC during 
Maintenance (see below). 
Maintenance Therapy (patients with follicular NHL): 
Patients receiving Maintenance therapy prior to entry into the study must be eligible to 
receive at least six further cycles of rituximab SC (i.e., 12 additional months of 
Maintenance treatment). Patients who are continuing into Maintenance therapy following 
at least four cycles of rituximab SC during Induction Therapy must also be eligible to 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
22/Statistical Analysis Plan ML28964 
receive at least six cycles of rituximab SC (i.e. 12 additional months of Maintenance 
treatment). 
Post-treatment Follow Up: 
All patients will continue the study with 24 months of follow-up period. 
2.1 
PROTOCOL SYNOPSIS 
The Protocol Synopsis is in Appendix 1. For additional details, see the Schedule of 
Assessments in Appendix 2. 
2.2 
OUTCOME MEASURES 
This study will evaluate safety of Rituximab following subcutaneous administration in 
patients with CD20+ DLBCL or CD20+ follicular NHL grade 1 to 3A. 
2.2.1 
Safety Outcome Measures 
Safety outcome measures will include AARs (defined as all related AEs occurring within 
24 hours of rituximab SC administration, including IIRRs, injection-site reactions, 
administration site conditions and all symptoms thereof), grade ≥ 3 AEs and SAEs. 
Other safety assessments include routine safety laboratory tests, vital signs 
measurements, and changes in concomitant medications. All clinical AEs and SAEs as 
well as laboratory abnormalities will be recorded regardless of their intensity / grading. 
Grading will be completed according to the NCI CTCAE version 4.0 (see Appendix 5 of 
the protocol). 
2.2.2 
Efficacy Outcome Measures  
The efficacy of rituximab will be evaluated at the end of induction treatment for FL 
patients and at the end of the last cycle for DLBCL patients in terms of EFS, PFS, OS, 
CR/CRu and DFS. The endpoints of EFS, PFS and OS will be defined and analysed 
twice using two different starting points for the time-to-event calculations. The first 
starting point will be first dose of rituximab IV and the second will be first dose of 
rituximab SC. 
• 
EFS is defined as the time from first dose of rituximab (analysed using both first 
dose of IV and first dose of SC) to first occurrence of progression or relapse, 
according to the IWG response criteria (Cheson et al 1999, see Protocol 
Appendix 2) or other country standards, or initiation of a non–protocol- specified 
anti-lymphoma therapy or death, whichever occurs first. 
• 
PFS is defined as the time from first dose of rituximab (analysed using both first 
dose of IV and first dose of SC) to the first occurrence of progression or relapse, 
according to the IWG response criteria (Cheson et al. 1999, see Protocol 
Appendix 2) or other country standards, or death from any cause. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
23/Statistical Analysis Plan ML28964 
• 
OS is defined as the time from first dose of rituximab (analysed using both first 
dose of IV and first dose of SC) until death from any cause. 
• 
DFS will be assessed at the end of induction treatment in patients achieving 
CR/CRu and is defined as the period from the date of the initial CR/CRu until the 
date of relapse or death from any cause. 
• 
CR/CRu: Response assessments 4 - 6 weeks after the last dose of Induction 
treatment will be based on the Investigator’s assessment, completed according to 
the original International Working Group (IWG) response criteria for response 
assessment of lymphoma (Cheson et al. 1999; see Protocol Appendix 2). 
Tumour assessments will be based on computed tomography (CT) scans of the neck, 
chest, abdomen and/or pelvis (if detectable by these techniques) or other diagnostic 
means (e.g., magnetic resonance imaging [MRI], PET/CT) where applicable. Other 
methods (e.g., MRI) are acceptable for patients in whom CT scans are contraindicated. 
The CT scan used for eligibility assessments may be performed up to 28 days prior to 
dosing. 
 
2.2.3 
Exploratory Outcome Measures 
Not applicable. 
2.2.4 
 Pharmacokinetic Outcome Measures 
Not applicable. 
2.3 
DETERMINATION OF SAMPLE SIZE 
A sample size of 110 patients is deemed sufficient for this study. In this study, all 
planned statistical analysis will be exploratory in nature as the study will not be powered 
to address any pre-defined statements and only descriptive statistical evaluations will be 
carried out primarily for safety (and efficacy) parameters. Additionally, no published 
reference is available on administration-associated reactions (AARs) following multiple 
doses of subcutaneous (SC) rituximab during induction and/or maintenance therapy in 
patients with CD20+ follicular non-Hodgkin’s lymphoma (NHL) or CD20+ diffuse large B-
cell lymphoma (DLBCL). However, with 110 patients a 95% Clopper-Pearson CI for the 
incidence of AARs will be no wider than +/- 9.7% . This width of interval is deemed 
sufficiently precise to draw valid conclusions around the incidence of ARRs. Additionally, 
enrolment of more than 110 patients within the specified indications could also be 
difficult in participating countries. Due to the fact of exploratory nature of the study, drop 
out patients will not be replaced. 
2.3.1 
Sample Size for the China Extension Period 
Not applicable for this study. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
24/Statistical Analysis Plan ML28964 
2.4 
ANALYSIS TIMING 
This length of the study study is planned according to the type of lymphoma (either FL or 
DLBCL). Since assessments for FL patients are expected to be on-study longer, this 
portion of the study will be determinative for the length of the study. For FL patients the 
study is estimated to take approximately 6 years (68 months) based on an approximately 
12 month of recruitment period, 8 months of induction and 24 months of maintenance 
treatment and 24 months of follow-up period. 
On the other hand, DLBCL patients are expected to be on-study for a shorter period of 
time (approximately in 4 years), based on approximately 12 months recruitment, 8 
months of treatment and 24 months follow up period with a recruitment period of 
approximately 18 months 
The end of the study, defined as last patient last visit (LPLV), will occur 24 months after 
the last SC rituximab treatment for the last FL or DLBCL patient, whichever comes later. 
The statistical analysis will be performed after all patients have completed the study. 
An interim analysis in not planned. 
2.4.1 
Analysis Timing for the China Subgroup Analysis 
Not applicable for this study. 
3. 
STUDY CONDUCT 
3.1 
RANDOMIZATION  
Not applicable. This is an open-label study, non-comparative single arm study. 
3.2 
INDEPENDENT REVIEW FACILITY 
Not applicable for this study. 
3.3 
DATA MONITORING 
Not applicable for this study. 
4. 
STATISTICAL METHODS 
This is not a hypothesis testing study but an exploratory study with predefined precision 
of estimates for key safety parameters for sample size determination; there are no 
formal statistical hypotheses tests to be tested, and there will be no adjustments for 
multiplicity of endpoints or within-subgroups comparisons. 
Descriptive statistics will be provided in summary tables according to the type of variable 
using appropriate descriptive statistics. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
25/Statistical Analysis Plan ML28964 
Continuous variables will be summarized by descriptive statistics (number of cases, 
mean, standard deviation, median, minimum and maximum).  
Categorical variables will be summarized using counts of patients and percentages; 
missing category will be displayed if appropriate. 
Exposure to study treatment (rituximab) and chemotherapy, including the number of 
cycles administered, duration of treatment exposure (calculated from date of first 
treatment date to the last treatment date) and dosing information (e.g., dose 
interruptions, modifications and delays) will be summarized. 
The number of patients who prematurely discontinue study treatment and the number of 
patients who withdrew from the study will be summarized and reasons for withdrawal will 
be displayed 
All data collected will be presented in by-patient data listings. 
All planned analyses identified in this Statistical Analysis Plan (SAP) will be performed 
by SPARC Consulting (Milan) on behalf of IQVIA following Sponsor Authorization of this 
SAP. 
All statistical analyses and data processing will be performed using SAS® Software 
(release 9.4 or higher) under Windows 10 PRO operating system. 
All medical history and AE terms will be assigned to a Low Level Term (LLT), Preferred 
Term (PT) and will be classified by the primary System Organ Class (SOC) according to 
the Medical Dictionary for Regulatory Activities (MedDRA) thesaurus, version 24.1, 
medications will be coded using the INN-1.0V Dictionary, and laboratory values 
converted in Standard Unit (SI) by TCS, Mumbai, India. 
Unplanned visits have been foreseen in the study. Unplanned measurements will not be 
included in by-visit summaries. Listings will include planned and unplanned data. 
4.1 
ANALYSIS POPULATIONS 
4.1.1 
Randomized Population 
Not applicable for this study. 
4.1.2 
Per Protocol Population 
Not defined for this study. 
4.1.3 
Pharmacokinetic-Evaluable Population 
Not applicable for this study. 
4.1.4 
Safety Population 
The Safety data will be summarized based on the safety population (SAF), defined as all 
patients who have received at least one dose of  rituximab. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
26/Statistical Analysis Plan ML28964 
4.1.5 
Intent-To-Treat Population 
The efficacy endpoints will be summarized based on the ITT population (ITT) defined as 
all patients enrolled into the study. 
4.2 
ANALYSIS OF STUDY CONDUCT 
Enrolment, patients’ disposition, and discontinuation from the study will be summarized 
for the ITT population overall and for patients with Diffuse Large B-Cell Lymphoma 
(DLBCL) and patients with follicular Non-Hodgkin’s Lymphoma (FL), separately. The 
reasons for study drug discontinuation will also be tabulated. Protocol deviations, 
including major deviations with regards to the inclusion and exclusion criteria and major 
deviations due to Covid-19 pandemic, will be summarized by deviation category for the 
ITT population. A line listing with all protocol deviations reported over the study will be 
also provided. 
Deviations from the protocol including violations of inclusion/exclusion criteria will be 
assessed definitely as “minor” or “major” by the study clinical team prior to closure of the 
study database. 
4.2.1 
Definition of Baseline 
Baseline is defined as the screening visit. Thus, change from baseline to a specific 
timepoint of a study parameter is calculated as follows: 
Change from baseline to time X = (value at time X) - (baseline value). 
4.3 
ANALYSIS OF TREATMENT GROUP COMPARABILITY 
Demographic and other baseline characteristics (including age, sex, ethnicity, and 
baseline disease characteristics, e.g., DLBCL Diagnosis), as well as the demographic 
profile (height, weight, and BMI), IPI score (according to Shipp et al. 1993) and/or FLIPI 
score and serum pregnancy test at Screening/Baseline will be summarized using 
means, standard deviations, medians, and ranges for continuous variables and 
proportions for categorical variables, as appropriate.  
Summaries will be presented overall and for patients with DLBCL and patients with FL 
separately for ITT population. 
A summary analysis of the DLBCL and FL diagnosis will be presented for the SAF 
population. 
The overall evaluation of a 12-lead ECG tracing at screening will be presented by means 
of a summary analysis on SAF population. 
4.3.1 
Medical History 
Data from “Medical History” form will be summarized for ITT population with descriptive 
statistics. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
27/Statistical Analysis Plan ML28964 
All verbatim terms reported will be assigned to a PT and will be classified by the primary  
SOC.  
Previous diseases are those reported in the “Medical History” form of the eCRF not 
flagged as “Ongoing at study entry”. 
Concomitant diseases are those flagged as “Ongoing at study entry”.  
The following data will be presented:  
• 
A default frequency table showing the number and percentage of patients who 
exhibited at least one previous disease and the previous diseases by primary 
SOC and PT; 
• 
A default frequency table showing the number and percentage of patients who 
exhibited at least one concomitant disease and the concomitant diseases by 
primary SOC and PT. 
Any previous diseases as well as concomitant diseases will be listed. 
4.3.2 
Surgery and Procedures History 
Data from “Surgery and Procedures history (cancer and non-cancer related)” form will be 
summarized for ITT population with descriptive statistics. 
All verbatim terms reported will be assigned to a PT and will be classified by the primary 
SOC.  
The following data will be presented:  
• 
A default frequency table showing the number and percentage of patients who 
exhibited at least one surgery and the surgery by primary SOC and PT; 
All surgery and procedures will be listed. 
4.3.3 
Physical Examination 
Physical Examinations details for each body system will be summarized across each 
visit for safety population. 
4.3.4 
Previous and Concomitant Therapies 
Data from “Concomitant Medication” form will be summarized for safety population with 
descriptive statistics.  
Therapies will be coded using the INN-1.0V dictionary. New anti-lymphoma treatment 
(chemotherapy, radiotherapy, immunotherapy), initiated after the Baseline visit will be 
presented in summary tables. 
Handling of partial dates for prior and concomitant therapies will be performed by TCS, 
Mumbai, India. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
28/Statistical Analysis Plan ML28964 
Previous therapy includes any medication stopped before exposure to study drug. The 
following data will be presented in a unique summary table for previous therapies: 
• 
Total number of patients with at least one treatment (n,%) 
• 
Total number of treatments (n) 
• 
Total number of patients with at least one treatment by ATC class level 2 (n,%) 
• 
Total number of treatments by ATC class level 2 (n) 
• 
Treatments by ATC class level 2 (n,%) 
Concomitant therapy consists of any medication taken during the study, including those 
started before but ongoing at first dose of study drug. The following data will be 
presented overall in a unique summary table for concomitant therapies: 
• 
Total number of patients with at least one treatment (n,%) 
• 
Total number of treatments (n) 
• 
Total number of patients with at least one treatment by ATC class level 2 (n,%) 
• 
Total number of treatments by ATC class level 2 (n) 
• 
Treatments by ATC class level 2 (n,%) 
All previous and concomitant therapies reported over the study will be listed. 
4.3.5 
Viral Serology 
Viral serology at screening including HBcAb, HBsAg, HCV antibody, and HIV antibody 
will be summarized for SAF population with descriptive statistics. 
 
4.4 
EFFICACY ANALYSIS 
The efficacy analysis will be performed in the ITT analysis set. 
Efficacy endpoints include EFS, PFS, OS, DFS, and CR/CRu rate.  
Summaries will be presented overall and for patients with DLBCL and patients with FL 
separately. 
Response assessments will be based on the Investigator’s assessment, completed 
according to the IWG response criteria (Cheson et al 1999, see Appendix 2 of Study 
Protocol) or other country standards. The endpoints of EFS, PFS and OS will be defined 
and analyzed twice using two different starting points for the time-to-event calculations. 
The first starting point will be first dose of rituximab IV and the second will be first dose 
of rituximab SC. 
The analysis of endpoints measured as a time-to-event (e.g., EFS, PFS, OS and DFS) is 
based on the survivor function, which is the probability of remaining event free beyond a 
certain point in time.  


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
29/Statistical Analysis Plan ML28964 
The survivor function will be estimated using Kaplan-Meier methodology and 
summarized using the range, the 25th and 75th percentiles and median survival along 
their 95% confidence interval. 
Patients who have experienced none of these events at the time of analysis (clinical cut-
off) and patients who are lost to follow up will be censored at their last clinical 
assessment date. Patients without post-baseline tumour assessments will be censored 
at the time of their baseline visit except if death occurs prior to their first scheduled 
tumour assessment. 
The survivor function will be displayed graphically using a Kaplan-Meier curve. 
The number and percentage of the patients with event or censored will be also 
presented. Analysis will be performed using the SAS procedure Proc Lifetest. 
4.4.1 
Primary Efficacy Endpoint 
Not applicable. 
4.4.2 
Secondary Efficacy Endpoints 
Event-Free Survival (EFS) 
EFS is defined as the time from first dose of rituximab (analysed using both first dose of 
IV and first dose of SC) to first occurrence of progression or relapse, according to the 
IWG response criteria (Cheson et al 1999, see Appendix 2 of Study Protocol) or other 
country standards, or initiation of a non-protocol-specified anti-lymphoma therapy or 
death, whichever occurs first. Time will be calculated in months as follow: 
EFS = (date of event/censor – date of first dose + 1) / 30.4375 
Progression-Free Survival (PFS) 
PFS is defined as the time from first dose of rituximab (analysed using both first dose of 
IV and first dose of SC) to the first occurrence of progression or relapse, according to the 
IWG response criteria (Cheson et al 1999, see Appendix 2 of Study Protocol) or other 
country standards, or death from any cause. Time will be calculated in months as follow: 
PFS = (date of event/censor – date of first dose + 1) / 30.4375 
Overall Survival (OS) 
OS is defined as the time from first dose of rituximab (analysed using both first dose of 
IV and first dose of SC) until death from any cause. Time will be calculated in months as 
follow: 
OS = (date of event/censor – date of first dose + 1) / 30.4375 
Disease-Free Survival (DFS) 
DFS will be assessed in patients achieving CR/CRu and is defined as the period from 
the date of the initial CR/CRu until the date of relapse or death from any cause. Time will 
be calculated in months as follow: 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
30/Statistical Analysis Plan ML28964 
DFS = (date of event/censor – date of initial CR/CRu + 1) / 30.4375 
Complete Response rate (CR)/Complete Response unconfirmed (CRu) 
CR/CRu rate at 4-6 weeks after the last dose of Induction treatment will be summarized 
and presented with the corresponding 95% two-sided Pearson-Clopper CI by treatment 
group and overall. 
Endpoints resulting in an incidence rate (e.g., CR/CRu) will be summarised with a 95% 
Clopper-Pearson confidence interval. 
4.4.3 
Exploratory Efficacy Endpoints 
Not applicable. 
4.4.4 
Sensitivity Analyses 
Not applicable. 
4.4.5 
Subgroup Analyses 
Demographics and baseline characteristics (age, ethnicity, height, weight, BMI, IPI score, 
FLIPI score and Surgery/Procedure History) will be also presented stratified by gender 
(Male, Female). 
a) PFS and OS   results will be reported for the following l subgroups, in addition to 
the analysis populations described in the document: Gender (Female, Male) 
b) FLIPI score (Low risk, Intermediate risk/High risk) for FL patients only 
c) Grade of FL (1, 2, 3a) 
4.5 
PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSES 
Not applicable. 
4.6 
PATIENT-REPORTED OUTCOME ANALYSES 
Patient satisfaction with administration of treatment will be evaluated using the 
Rituximab Administration Questıonnaıre (RASQ) for safety population. 
The RASQ is a 20-item questionnaire measuring the impact of the mode of treatment 
administration on five domains: Physical Impact, Psychological Impact, Impact on 
Activities of Daily Living, Convenience, and Satisfaction. The Physical Impact domain 
comprises of 3 items (Pain, swelling, and redness (Q2) , Pain experience (Q3), Side 
effects as expected (Q4)), the Psychological Impact domain contains 5 items (Anxious 
about injection/IV (Q5), Worry condition will get worse (Q6), Anxious thinking about 
disease (Q7), Confidence the injection/IV treating disease (Q8), Feeling restricted by 
injection/IV (Q9)), the Impact on Activities of Daily Living domain contains 3 items 
(Interference with usual/daily activities (Q14a), Limit daily activities (Q14b), Lost/gained 
time(Q15)), the Convenience domain contains 3 items (Is it convenient to get injection/IV 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
31/Statistical Analysis Plan ML28964 
(Q10), Length of time to get injection/IV as expected (Q12), Bothered by the amount of 
time to get injection/IV (Q13)) and the Satisfaction domain includes 2 items (How 
satisfied or dissatisfied are you with the injection/IV (Q1), Would you recommend the 
way you received the treatment (Q19). All 16 RASQ items included in the above 
domains have five response options. Reverse-coded response values will be created for 
eight of the RASQ items (Q2, Q3, Q5, Q6, Q7, Q9, Q14a, and Q14b). 
In addition, there are 4 descriptive questions that are not part of the above domains and 
are scored separately. 
For each domain, if there are no missing responses, the domain will be scored using the 
formula: 
Domain score = [(Sum of completed item responses / Number of completed items) - 1] x 
100 / (Maximum possible item response value – Minimum possible item response value) 
However, if there are any missing responses within a domain then the domain will not 
be scored (i.e., a missing value is assigned to the domain). 
Since the maximum possible item response value is 5 and the minimum possible 
response value is 1 for all RASQ items, a simpler way to represent the above formula 
for the RASQ domains is: 
RASQ domain score = (Mean of completed item responses – 1) x 25 
Descriptive statistics will be computed for the RASQ questions assessing patient 
responses regarding convenience, satisfaction and preference for rituximab SC as 
compared to rituximab IV. Specifically, frequencies and percentages will be presented by 
question and timepoint, for the total sample and for patients with DLBCL and patients 
with FL separately.  
In addition, descriptive statistics will be computed by domain (Physical Impact domain, 
Psychological Impact domain, Impact on Activities of Daily Living domain, Convenience 
domain and Satisfaction domain) and timepoint overall and for patients with DLBCL and 
patients with FL separately. 
Listings will present by patient data for individual responses and domain scores. 
 
4.7 
HEALTHCARE PROFESSIONAL REPORTED OUTCOME 
ANALYSES 
Healthcare Professional (HCP) Questionnaire will be evaluated with descriptive statistics. 
Frequencies and percentages will be presented.  
All data reported in Healthcare Professional (HCP) Questionnaire will be listed. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
32/Statistical Analysis Plan ML28964 
4.8 
SAFETY ANALYSES 
All safety analyses will be presented for the Safety population overall and for patients 
with DLBCL and patients with FL separately. 
Safety will be assessed by AEs, AEs of grade ≥ 3, SAEs, AARs including IIRRs, AEs 
within the MedDRA SMQ ”Anaphylactic reactions” (wide), safety laboratory parameters, 
vital signs, concomitant medications, premature withdrawal from the study and from 
study medication due to AEs and ECOG performance status. All clinical AEs and SAEs 
as well as laboratory abnormalities will be recorded and graded according to the NCI-
CTCAE version 4.0. 
4.8.1 
Exposure of Study Medication 
Exposure to study treatment (rituximab) and chemotherapy, including the number of 
cycles administered in induction and maintenance phases, duration of treatment 
exposure (calculated from date of first treatment date to the last treatment date) and 
dosing information (e.g., dose interruptions, modifications and delays) will be 
summarized for the safety population. 
New anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy), initiated 
after baseline visit will be presented in summary tables. 
Summary analysis will be presented overall and for patients with DLBCL and patients 
with FL separately. 
4.8.2 
Adverse Events 
The analysis of AEs will focus on treatment-emergent adverse events (TEAEs), i.e., AEs 
occurring on the day of or after the first administration of study drug and up to 28 days 
after the last dose. Non-treatment emergent AEs (i.e., those occurring before 
commencement of study medication) will only be listed. Adverse events will be coded 
using the Medical Dictionary for Regulatory Activities (MedDRA version 24.1).  
Handling of partial dates for AEs will be performed by TCS, Mumbai, India. Where an AE 
start date is partially or fully missing, and it is unclear as to whether AE started after of 
the study, it will be assumed to be TEAE (worst case). 
The incidence of AARs, AEs, AEs leading to premature discontinuation or interruption of 
study treatment, SAEs, grade ≥ 3 AEs will be computed with 95% Confidence Interval 
(calculated using either the Clopper-Pearson methodology, or the Poisson distribution, 
for frequencies below 10%). The incidence of each AE will be summarized according to 
the primary System Organ Class and by Preferred Term. The incidence of cutaneous 
and soft tissue AARs will additionally be summarised for those that are defined as 
localized and those that are defined as non-localized. The incidence of deaths and 
cause of deaths will be listed and summarized. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
33/Statistical Analysis Plan ML28964 
Counts and percentages will be presented, by primary SOC and PT, overall and for 
patients with DLBCL and patients with FL separately. 
A patient having more than one adverse event with the same PT will be counted only 
once in the incidence calculation for that PT. Similarly, if a patient has more than one AE 
in the same SOC, the patient will be counted only once in the total number of patients 
with an AE for that SOC. 
Where AEs are summarized by relationship or by maximum CTC grade, each patient’s 
maximum CTC grade will be used in the summary. If a patient experiences the same 
adverse event at more than one CTC grade level, or with more than one relationship to 
study drug, the most severe rating or the stronger causal relationship to study drug will 
be used.  
Any missing CTC grade, casualty, or outcome will not be imputed but classified as 
unknown for listing purpose and the worst case will be considered for summarization 
purpose. 
If the severity is missing for a TEAE, the TEAE will be considered as Severe. 
If the relationship to study treatment is missing for a TEAE, the TEAE will be considered 
as related to study treatment. 
If CTG grade is missing, the worst CRT grade will be considered. 
An overview of number of patients with at least one Treatment Emergent Adverse Event 
(TEAE), at least one serious TEAE, at least one AE of special interest (AESI), at least 
one Administration Associated Reaction (AARs), at least one cutaneous and soft tissue 
AARs (localized), at least one cutaneous and soft tissue AARs (non-localized), at least 
one grade ≥ 3 TEAEs, at least one grade ≥ 3 serious TEAEs, at least one grade ≥ 3 
AARs, at least one grade ≥ 3 infusion/injection related reactions, number of TEAEs 
leading to Rituximab drug interrupted/drug delayed, number of TEAEs leading to 
Rituximab dose discontinuation, number of TEAEs leading to chemotherapy dose 
modification, number of TEAEs leading to chemotherapy dose discontinuation and 
number of TEAEs leading to death will be provided. 
The following summary statistical tables including frequencies and percentages, along 
with the 95% CI of the observed proportions (calculated using either the Clopper-
Pearson methodology, or the Poisson distribution, for frequencies below 10%) will be 
provided: 
• 
Proportion of all TEAEs by Primary SOC and PT; 
• 
Proportion of serious TEAEs by Primary SOC and PT; 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
34/Statistical Analysis Plan ML28964 
• 
Proportion of localized AARs by Primary SOC and PT; 
• 
Proportion of non-localized AARs by Primary SOC and PT; 
• 
Proportion of grade ≥ 3 TEAEs by Primary SOC and PT; 
• 
Proportion of grade ≥ 3 serious TEAEs by Primary SOC and PT; 
• 
Proportion of grade ≥ 3 AARs by Primary SOC and PT; 
• 
Proportion of TEAEs leading to Rituximab drug interrupted/drug delayed by 
Primary SOC and PT; 
• 
Proportion of TEAEs leading to Rituximab dose discontinuation by Primary SOC 
and PT; 
• 
Proportion of TEAEs leading to chemotherapy dose modification by Primary SOC 
and PT; 
• 
Proportion of TEAEs leading to chemotherapy dose discontinuation by Primary 
SOC and PT; 
• 
Proportion of TEAEs leading to death by Primary SOC and PT. 
The following groups of adverse events will be summarized: 
• 
All TEAEs; 
• 
All Treatment-Emergent SAEs; 
• 
All AESI; 
• 
All AARs; 
• 
All IRRs; 
• 
Grade ≥ 3 TEAEs; 
• 
Grade ≥ 3 Treatment-Emergent SAEs; 
• 
Grade ≥ 3 AESI; 
• 
Grade ≥ 3 AARs; 
• 
Grade ≥ 3 IIRRs; 
• 
TEAEs within the MedDRA SMQ “Anaphylactic reactions” (wide); 
• 
TEAEs leading to dose modification of Rituximab; 
• 
TEAEs leading to dose modification of chemotherapy; 
• 
TEAEs leading to discontinuation of chemotherapy; 
• 
TEAEs leading to death; 
• 
Cutaneous and soft tissue AARs (localized); 
• 
Cutaneous and soft tissue AARs (non-localized); 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
35/Statistical Analysis Plan ML28964 
• 
TEAEs with an incidence ≥ 5 %; 
• 
TEAEs by maximum severity; 
• 
Non TEAEs by strongest relationship; 
• 
Non serious TEAEs with an incidence ≥ 5 %. 
These groups will be summarized using the following factors by System Organ Class 
and Preferred Term: 
• 
total 
• 
event related to Rituximab 
• 
event related to chemotherapy 
The following individual data listings will be produced: 
• 
A listing of all AEs; 
• 
A listing of all serious AEs; 
• 
A listing of all AESI; 
• 
A listing of all AARs; 
• 
A listing of all AEs related to Rituximab; 
• 
A listing of grade ≥ 3 AEs; 
• 
A listing of all AEs leading to Rituximab drug interruption/drug delay; 
• 
A listing of all AEs leading to Rituximab drug discontinuation; 
• 
A listing of all AEs leading to chemotherapy dose modification; 
• 
A listing of all AEs leading to chemotherapy dose discontinuation; 
• 
A listing of all AEs within the MedDRA SMQ “Anaphylactic reactions”; 
• 
A listing of all Cutaneous and soft tissue AARs (localized); 
• 
A listing of all Cutaneous and soft tissue AARs non-(localized); 
• 
A listing of death 
• 
A listing of all pre-treatment AE. 
AEs of special interest (AESI) include AARs, hepatotoxicity (elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined in Section 
5.3.5.6 of Study Protocol) and suspected transmission of an infectious agent by the 
study drug (see Section 5.2.3 of Study Protocol). 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
36/Statistical Analysis Plan ML28964 
4.8.3 
Laboratory Data 
Summary analysis will be performed in the safety population overall and for patients with 
DLBCL and patients with FL separately. 
Actual values and the changes from baseline to each time-point in hematology, 
biochemistry, coagulation test parameters will be summarized using descriptive statistics.  
Shift tables of NCI CTCAE grade at baseline against worst grade recorded during the 
treatment period will be presented for all laboratory parameters. 
A list of laboratory assessments to be included:  
• 
Haematology: hemoglobin, RBC count, WBC count and differential count 
(neutrophils, eosinophils, basophils, monocytes, lymphocytes, other cells) and 
platelet count; 
• 
Biochemistry at Screening: sodium, potassium, ALT/SGPT, AST/SGOT, total 
bilirubin, serum creatinine, alkaline phosphatase, albumin, blood urea nitrogen 
(BUN), C-reactive protein and LDH. Biochemistry at any further timepoint: 
sodium, potassium, ALT/SGPT, AST/SGOT, total bilirubin, and serum creatinine; 
• 
Coagulation: International Normalized Ratio (INR), Prothrombin Time (PT), 
Activated Partial Thromboplastin Time (aPTT). 
For each laboratory parameter, where appropriate, the reported values will be converted 
into SI units and if needed boundary values for reference ranges will be converted. 
4.8.4 
Vital Signs 
Analysis of vital signs will be performed in the safety population overall and for patients 
with DLBCL and patients with FL separately. 
Vital signs will include measurements of heart rate, systolic and diastolic blood pressure, 
and body temperature.  
A summary of actual values and changes from baseline over the study will be provided 
for each vital sign with default descriptive statistics at each time-point. 
4.8.5 
ECOG Performance Status 
Eastern Cooperative Oncology Group (ECOG) performance status (Grade 0 – Grade 5) 
will be summarized by frequency tables over time for the safety population overall and 
for patients with DLBCL and patients with FL separately. 
4.9 
MISSING DATA 
Imputed values will be included in the analysis set(s), but will not change the original 
clinical database (rawdata). 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
37/Statistical Analysis Plan ML28964 
Missing data in safety parameters will not be replaced except for relationship to study 
medications and severity of AE and partial date in AE and prior/concomitant treatments 
(Sections 4.3.4 and 4.8.2). 
In all efficacy analyses, missing data handling is specific to the efficacy endpoint and 
details are given within Section 4.4 for all efficacy endpoints.  
For analysis of change from baseline endpoints if no baseline value exists for a patient 
at a specific time-point, then the patient will be excluded from the analysis of that time-
point. 
4.10 
INTERIM ANALYSES 
No interim analyses are planned. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
38/Statistical Analysis Plan ML28964 
5. 
CHINA SUBGROUP ANALYSIS  
Not applicable. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
39/Statistical Analysis Plan ML28964 
6. 
REFERENCES 
Badin F, Hayslip J. Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus 
on outcomes and comparative effectiveness. Clinicoecon Outcomes Res 2010;2:37-45. 
Bookbinder LH, Hofer A, Haller MF et al. A recombinant human enzyme for 
enhanced interstitial transport of therapeutics. J Control Release 2006;114(2):230-41. 
Bordeleau L, Berinstein NL. Molecular diagnostics in follicular non-Hodgkin's lymphoma: 
a review. Semin Oncol 2000;27(Suppl 12):42-52. 
Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 
monoclonal antibody rituximab. Ann Oncol 2003;14:520-35. 
Cairo M, Bishop M. Tumor lysis syndrome: new strategies and classification. Br J 
Hematol 2004;127(1):3-11. 
Cartwright RA. Time trends in incidence of haematological malignancies and related 
conditions. Br J Haematol 1999;106:281-95. 
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to 
standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored 
International Working Group. J Clin Oncol 1999;17(4):1244. 
Clarke CA, Glaser SL. Changing incidence of non-Hodgkin’s lymphomas in the United 
States. Cancer 2002;94:2015-23. 
Coiffier B, Altman A, Pui CH et al. Guidelines for the management of pediatric and adult 
tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008 Jun 1;26(16):2767-
78. 
Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with 
CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 
2002;346(4):235-42. 
Coiffier B, Thieblemont C, Van Den Neste E et al. Long-term outcome of patients in the 
LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP 
chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de 
l'Adulte. Blood 2010;116(12):2040-5. 
Cunningham D, Smith P, Mouncey P et al. R-CHOP14 versus R-CHOP21: Result of a 
randomized phase III trial for the treatment of patients with newly diagnosed diffuse large 
B-cell non-Hodgkin lymphoma. J Clin Oncol 2011;29(15, suppl):abstr 8000. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
40/Statistical Analysis Plan ML28964 
Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody 
therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 
2000;18(17):3135-43. 
Davis TA, White CA, Grillo-Lopez AJ et al. Single-agent monoclonal antibody efficacy in 
bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 
1999;17(6):1851-7. 
Delarue R, Tilly H, Salles G et al. R-CHOP-14 compared to R-CHOP-21 in elderly 
patients with diffuse large B-cell lymphoma (DLBCL): Results of the second interim 
analysis of the LNH03-6B GELA study. Ann Oncol 2011;22(suppl 4):117 abstract 106. 
Del Nagro CJ, Mao CP, Brovarney M et al. Comparison of B cell depletion mediated by 
intravenous (IV) Rituxan(R) and Rituxan given subcutaneous (SC) in cynomolgus 
monkeys. Blood (ASH Annual Meeting Abstracts) 2010;116(21): abstract 3980. 
Demidem A, Lam T, Alan S et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody 
sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother 
Radiopharm 1997;12:177-86. 
Eltom MA, Jemal A, Mbulaiteye SM et al. Trends in Kaposi's sarcoma and non- 
Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl 
Cancer Inst. 2002;94:1204-10. 
Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in 
Europe in 2006. Ann Oncol 2007;18:581-92. 
Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the 
treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe 
d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117-26. 
Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with 
three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. New 
Engl J Med 1993;328:1002-6. 
Fisher RI, LeBlanc M, Press OW et al: New treatment options have changed the survival 
of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-52. 
Friedberg JW. Treatment of follicular non-Hodgkin's lymphoma: the old and the new. 
Semin Hematol 2008;45(3 suppl 2):S2-6. 
Friedberg JW, Taylor MD, Cerhan JR et al. Follicular lymphoma in the United States: 
first report of the national LymphoCare study. J Clin Oncol 2009;27(8):1202-8. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
41/Statistical Analysis Plan ML28964 
Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for 
subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4(4):427- 40. 
Habermann TM. Antibody therapy in aggressive lymphomas. Hematology Am Soc 
Hematol Educ Program 2007:257-64. 
Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or 
with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin 
Oncol 2006;24(19):3121-7. 
Herold M, Dölken G, Fiedler F et al. Ongoing clinical studies – randomized phase III 
study for the treatment of advanced indolent NHL and MCL: chemotherapy versus 
chemotherapy plus Rituximab. Ann Hematol 2003;82:77-9. 
Herold M, Haas A, Srock S et al. Rituximab added to first-line mitoxantrone, 
chlorambucil, and prednisolone chemotherapy followed by interferon maintenance 
prolongs survival in patients with advanced follicular lymphoma: An East German study 
group hematology and oncology study. J Clin Oncol 2007;25(15):1986-92. 
Hiddemann W, Kneba M, Dreyling M et al: Frontline therapy with rituximab added to the 
combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) 
significantly improves the outcome for patients with advanced-stage follicular lymphoma 
compared with therapy with CHOP alone: Results of a prospective randomized study of 
the German low-grade lymphoma study group. 
Blood 2005;106:3725-32. 
Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. 
Semin Oncol 1993;20(Suppl 5):75-88. 
Howlader N, Noone AM, Krapcho M et al. (eds). SEER Cancer Statistics Review, 1975-
2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, 
http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data 
submission, posted to the SEER web site, 2012. 
[ILSG] The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the 
International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 
1997;89:3909-18. 
Investigator Brochure MabThera®, Rituxan®, Fifteenth Edition, July 2010 (Rituximab IV), 
and Second Edition, October 2010 (Rituximab SC). 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
42/Statistical Analysis Plan ML28964 
Jaffe ES, Harris NL, Stein H et al. (eds). World Health Organization classification of 
tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. 
Lyon, France: IARC Press; 2001. 
Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low- grade 
or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70(11):1445-76. 
Kornbrot B, Kobayashi RH, Singer A et al. Hypersensitivity to therapeutic murine 
monoclonal antibodies. Nebr Med J 1994;79(12):393-8. 
Landis SH, Murray T, Bolden S et al. Cancer Statistics, 1999. CA Cancer J Clin 
1999;49(1):8-31. 
Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and 
cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves 
response and time to treatment failure, but not long-term outcome in patients with 
previously untreated mantle cell lymphoma: Results of a prospective randomized trial of 
the German low grade lymphoma study group (GLSG). J Clin Oncol 2005;23(9):1984-92. 
Lossos IS. Higher-grade transformation of follicular lymphoma - a continuous enigma. 
Leukemia 2005;19(8):1331-3. 
Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target- 
mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507-32. 
Maloney D, Smith B, Appelbaum F. The anti-tumor effect of monoclonal anti-CD20 
antibody (MAB) therapy includes direct anti-proliferative activity and induction of 
apopthosis in CD20 positive non-Hodgkin’s lymphoma (NHL) cell lines. Blood 
1996;88:637a. 
Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP 
as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417- 23. 
Marcus R, Imrie K, Solal-Celigny P et al. Phase III study of R-CVP compared with 
cyclophosphamide, vincristine, and prednisone alone in patients with previously 
untreated advanced follicular lymphoma. J Clin Oncol 2008;26(28):4579-86. 
McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal 
antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose 
treatment program. J Clin Oncol 1998;16:2825-33. 
Michallet AS, Coiffier B. Recent developments in the treatment of aggressive non- 
Hodgkin lymphoma. Blood Rev 2009;23(1):11-23. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
43/Statistical Analysis Plan ML28964 
Moreau P, Pylypenko H, Grosicki S et al. Subcutaneous versus intravenous 
administration of bortezomib in patients with relapsed multiple myeloma: a randomised, 
phase 3, non-inferiority study. Lancet Oncol 2011;12(5):431-40. Morton LM, Wang SS, 
Devesa SS et al. Lymphoma incidence patterns by WHO subtype in the United States, 
1992-2001. Blood 2006;107(1):265–76. 
Nathwani BN, Harris NL, Weisenburger D et al. Follicular lymphoma. In Jaffe ES, Harris 
NL, Stein H et al. (eds). World Health Organization classification of tumors. Pathology 
and genetics of tumors of haematopoietic and lymphoid tissues. IARC Press: Lyon 
2001;162-7. 
National Cancer Center Network Guidelines, v3 2011 (www.nccn.org) 
Niitsu N. Current treatment strategy of diffuse large B-cell lymphomas. Int J Hematol 
2010;92(2):231-7. 
Pettengell R, Linch D. Position paper on the therapeutic use of rituximab in CD20- 
positive diffuse large B-cell non-Hodgkin’s lymphoma. Br J Haematol 2003;121(1):44-8. 
Pfreundschuh M, Schubert J, Ziepert M et al. German high-grade non-Hodgkin 
lymphoma study group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or 
without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a 
randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9(2):105-16. 
Pfreundschuh M, Trümper L, Osterborg A et al. MabThera international trial group. 
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in 
young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised 
controlled trial by the MabThera international trial (MInT) group. Lancet Oncol 
2006;7(5):379-91. 
Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients 
diagnosed as having non-Hodgkin’s lymphoma from the 1990s to the early 21st century. 
Arch Intern Med 2008;168:469-76. 
Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse 
human monoclonal antibody to CD20. Blood 1994;83:435-45. 
Rituximab Summary of Product Characteristics 
Salar A, Bouabdallah R, McIntyre C et al. A two-stage phase Ib study to investigate the 
pharmacokinetics, safety and tolerability of subcutaneous rituximab in patients with 
follicular lymphoma as part of maintenance treatment. Blood (ASH Annual Meeting 
Abstracts) 2010;116(21): abstract 2858. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
44/Statistical Analysis Plan ML28964 
Salar A, et al. Final Results of the BP22333 Study Demonstrate Non-Inferior 
Pharmacokinetics and Safety of Subcutaneous Administration of Rituximab Compared 
with Intravenous Administration As Maintenance Therapy in Patients with Follicular 
Lymphoma (ASH Annual Meeting Abstracts) 2012. Abstract 1641. Full citation pending. 
Salles G, Mounier N, de Guibert S et al: Rituximab combined with chemotherapy and 
interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. 
Blood 2008;112:4824-31. 
Shipp MA, Harrington DP et al. A predictive model for aggressive non-Hodgkin’s 
lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. N Engl 
J Med 1993;329(14):987-94. 
Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the 
use of white blood cell growth factors: an evidence-based clinical practice guideline. J 
Clin Oncol 2006;24(19):3187-205. 
Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic 
index. Blood 2004;104(5):1258-65. 
Sousou T, Friedberg J. Rituximab in indolent lymphomas. Semin Hematol 
2010;47(2):133-42. 
Stilgenbauer S, Zenz T, Winkler D et al; German chronic lymphocytic leukemia study 
group. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic 
leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the 
German chronic lymphocytic leukemia study group. J Clin Oncol 2009;27(24):3994-4001. 
Swenson WT, Wooldridge JE, Lynch CF et al. Improved survival of follicular lymphoma 
patients in the United States. J Clin Oncol 2005;23:5019-26. 
Swerdlow SH, Campo E, Harris NL et al. WHO classification of tumours of 
haematopoietic and lymphoid tissues, 4th edition, IARC Press, 2008. 
Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. 
Immunol Today 1994;15:450-4. 
Tilly H, Dreyling M; ESMO guidelines working group. Diffuse large B-cell non- Hodgkin's 
lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann 
Oncol 2010;21(suppl 5):v172-4. 
Wynne C, Harvey V, Schwabe C et al. The development of a formulation of trastuzumab 
for subcutaneous administration. Ann Oncol 2010;21(8):viii78–viii95, abstract 218PD. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
45/Statistical Analysis Plan ML28964 
Yin A, Li J, Hurst D et al. Population pharmacokinetics (PK) and association of PK and 
clinical outcomes of rituximab in patients with non-Hodgkin's lymphoma. J Clin Oncol 
2010;28:(suppl; abstract e13108) [Published in conjunction with the ASCO 2010 Annual 
Meeting]. 
SAS Institute Inc., Cary, NC, USA, version 9. 
MedDRA – Medical Dictionary for Regulatory Activities. International Federation of 
Pharmaceutical Manufacturers Associations (IFPMA), c/o TRW, VAR1/8A/MSSO, 12011 
Sunset Hills Road, Reston, VA 20190-3285, USA. 
WHO – Drug Dictionary. World Health Organization Collaborating Center for 
International Drug Monitoring, P.O. Box 26, S-751 03 Uppsala, Sweden. 
EMEA, ICH Harmonised Guideline (1998), Statistical Principles for Clinical Trials. 
Clinical Study Protocol ML28964, version 3.1, 07 February 2016. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
46/Statistical Analysis Plan ML28964 
Appendix 1 - Protocol Synopsis 
TITLE: 
AN OPEN-LABEL, MULTINATIONAL, MULTICENTER, 
PHASE IIIB STUDY TO ASSESS SAFETY OF RITUXIMAB 
FOLLOWING SUBCUTANEOUS ADMINISTRATION IN 
PATIENTS WITH CD20+ DLBCL OR CD20+ FOLLICULAR 
NHL GRADE 1 TO 3A 
PROTOCOL NUMBER: 
ML28964 
VERSION NUMBER: 
3.1 
EUDRACT NUMBER: 
{Number} 
IND NUMBER: 
N/A 
TEST PRODUCT: 
Rituximab (RO 45-2294) 
PHASE: 
IIIb 
INDICATION: 
CD20+ diffuse large B-cell lymphoma or CD20+ follicular non- 
Hodgkin’s lymphoma grade 1 to 3a 
SPONSOR: 
Roche Algeria, 
Objectives 
Primary Objective 
• 
To evaluate the incidence of administration-associated reactions (AARs) following multiple doses of 
subcutaneous (SC) rituximab during Induction and/or Maintenance therapy in patients with CD20+ 
follicular non-Hodgkin’s lymphoma (NHL) or CD20+ diffuse large B-cell lymphoma (DLBCL) who 
have previously received at least one dose of intravenous (IV) rituximab. 
• 
AARs are defined as all adverse events (AEs) occurring within 24 hours of rituximab SC 
administration and which are considered related to study drug. AARs include infusion/injection- 
related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms 
thereof. 
Secondary Objectives 
• 
To evaluate patient-reported outcomes in terms of Rituximab Administration Questionnaire (RASQ) 
• 
To further evaluate the safety of rituximab SC in terms of: 
− Grade ≥ 3 AEs 
− Grade ≥ 3 AARs 
− Serious adverse events (SAEs) 
• 
To evaluate the efficacy of rituximab SC in terms of: 
− event-free survival (EFS) 
− progression-free survival (PFS) 
− Overall survival (OS). 
− disease-free survival (DFS) 
− complete response (CR) rate, including complete response unconfirmed (CRu), 4 weeks after 
the last dose of Induction treatment 
• 
To evaluate healthcare professional outcomes in terms of: 
− HCP (Healthcare Professional) Questionnaire 
 
Other Objectives 
Not applicable 
Study 
Design 
Description of Study 
This is an open-label, single-arm study to evaluate the safety of rituximab SC administered during 
first line treatment for FL (Induction and/or Maintenance therapy plus 24 months of follow up), or 
DLBCL (treatment plus 24 months of follow-up). 
 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
47/Statistical Analysis Plan ML28964 
This study will include adult patients with CD20+ DLBCL or CD20+ follicular NHL (grade 1 to 3a; NHL), 
who have already received at least one full dose of IV rituximab during first-line treatment, induction or 
maintenance. 
During administration of rituximab SC, patients will be assessed for safety and efficacy as detailed in the 
Schedule of Assessments (see Appendix 1). The Rituximab Administration Questionnaire (RASQ, 
Appendix 6) will be applied to patients and Healthcare Professional (HCP) Questionnaire (see 
Appendix 7) will be applied to health care professionals at the end of the study. 
Induction Therapy: 
NHL patients receiving Induction therapy prior to entry into the study must be eligible to receive at least 
four further cycles of rituximab SC (i.e. 4 additional months of Induction treatment). Patients with 
follicular NHL who will continue into Maintenance therapy (after staging at the end of Induction) can 
continue to receive rituximab SC during Maintenance (see below). 
Maintenance Therapy (patients with follicular NHL): 
NHL patients receiving Maintenance therapy prior to entry into the study must be eligible to receive at 
least six further cycles of rituximab SC (i.e. 12 additional months of Maintenance treatment). 
Patients who are continuing into Maintenance therapy following at least 4 (four) cycles of rituximab SC 
during Induction Therapy must also be eligible to receive at least six cycles of rituximab SC (i.e. 12 
additional months of Maintenance treatment). 




Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
49/Statistical Analysis Plan ML28964 
Target Population 
The target population will consist of adults with CD20+ DLBCL or CD20+ follicular NHL grade 1 to 3a, 
according to the World Health Organization (WHO) classification system. 
Inclusion Criteria 
Patients must meet the following criteria for study entry: 
1. Signed, written informed consent form 
2. Age ≥ 18 and ≤ 80 years at time of enrolment 
3. Histologically confirmed, CD20+ DLBCL or CD20+ follicular NHL grade 1 to 3a, according to the 
WHO classification system 
4. Currently being treated with rituximab IV in the Induction or Maintenance setting, having 
received at least one full dose of rituximab IV, defined as standard full dose of rituximab IV 375 
mg/m2 administered without interruption or early discontinuation because of tolerability issues 
5. Expectation and current ability for the patient to receive at least four additional cycles of 
treatment during the Induction phase and six additional cycles of treatment during the 
Maintenance phase (patients with follicular NHL) 
6. Induction only: An International Prognostic Index (IPI) score of 1-4 or IPI score of 0 with bulky 
disease, defined as one lesion ≥ 7.5 cm, or Follicular Lymphoma International Prognostic Index 
(FLIPI) (low, intermediate or high risk) (see Appendix 3) 
7. Induction only: At least one bi-dimensionally measurable lesion defined as ≥ 1.5 cm in its largest 
dimension on computed tomography (CT) scan 
8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3 (see Appendix 3) 
9. Patients with CD20+ DLBCL eligible for R-CHOP regimen 
10. Patients with LVEF ˃55% 
Exclusion Criteria 
Patients who meet any of the following criteria will be excluded from study entry: 
Cancer-Related Criteria 
1. Transformed lymphoma (i.e., histologic evidence of transformation to a Burkitt lymphoma) or 
follicular lymphoma (FL) Grade IIIB 
2. Primary central nervous system lymphoma, primary effusion lymphoma, primary mediastinal 
DLBCL, DLBCL of the testis, or primary cutaneous DLBCL 
3. History of other malignancy that could affect compliance with the protocol or interpretation of 
results. This includes a malignancy that has been treated but not with curative intent, unless the 
malignancy has been in remission without treatment for ≥ 5 years prior to dosing. Note: Patients 
with a history of curatively treated basal or squamous cell carcinoma or melanoma of the skin or 
in situ carcinoma of the cervix are eligible for the study. 
Prior or Concomitant Treatments 
4. On-going corticosteroid use > 30 mg/day of prednisone or equivalent. Note: patients receiving 
corticosteroid treatment with ≤ 30 mg/day of prednisone or equivalent must be documented to 
be on a stable dose of at least 4 weeks’ duration prior to dosing. 
Laboratory Assessments at Screening 
5. Inadequate renal function, defined as: 
− Creatinine > 1.5 times the upper limit of normal (ULN) (unless normal creatinine clearance), or 
calculated creatinine clearance < 40 mL/min (using the Cockcroft-Gault formula) 
6. Inadequate hematologic function, defined as: 
− Hemoglobin < 9 g/dL 
− Absolute neutrophil count < 1.5 x 109/L 
− Platelet count < 75 x 109/L 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
50/Statistical Analysis Plan ML28964 
7. Inadequate hepatic function, defined as: 
− Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN 
− Total bilirubin ≥ 1.5 x ULN. Note: patients with documented Gilbert disease may be enrolled if 
total bilirubin is ≤ 3.0 x ULN 
Other Prior or Current Medical Conditions or Treatments 
8. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal 
antibodies or known sensitivity or allergy to murine products 
9. For patients with FL and DLBCL - Contraindication to any of the individual components of CHOP 
(cyclophosphamide, vincristine, doxorubicin and prednisone), including prior receipt of 
anthracyclines 
10. Other serious underlying medical conditions, which, in the Investigator’s judgment, could impair 
the ability of the patient to participate in the study (e.g., significant cardiovascular disease, 
uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease) 
11. Recent major surgery (within 4 weeks prior to dosing, other than for diagnosis 
12. Active and/or severe bacterial, viral, fungal, mycobacterial, parasitic, or other infection 
(excluding fungal infections of nail beds) or any major episode of infection requiring treatment 
with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics except 
if for tumour fever) within 4 weeks prior to dosing 
13. Active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection (must be ruled out 
during Screening) 
14. History of human immunodeficiency virus (HIV) seropositive status 
General Criteria 
15. Inability to provide informed consent and comply with protocol requirements. 
16. Life expectancy of less than 6 months 
17. A positive serum pregnancy test in women of childbearing potential within 7 days prior to dosing 
or within 14 days if with a confirmatory urine pregnancy test within 7 days prior to dosing. 
Women of childbearing potential are defined as pre-menopausal women or women who are < 2 
years after the onset of menopause and are not surgically sterile. 
18. Fertile men or women of childbearing potential who do not agree to use a highly effective 
measure of contraception (such as oral contraceptives, intrauterine device or barrier method of 
contraception in conjunction with spermicidal jelly or surgically sterile) throughout the study and 
for at least 12 months after the last dose of rituximab. 
Length of Study 
Assessments of this study will be performed according to the type of lymphoma (either FL or DLBCL). 
Since assessments for FL patients are expected to be on-study longer, this portion of the study will be 
determinative for the length of the study. For FL patients the study is estimated to take approximately 6 
years (68 months) based on an approximately 12 month of recruitment period, 8 months of induction and 
24 months of maintenance treatment and 24 months of follow-up period. 
On the other hand, DLBCL patients are expected to be on-study for a shorter period of time 
(approximately in 4 years), based on approximately 12 month recruitment, 8 months of treatment and 24 
months follow up period. 
End of Study 
The end of the study, defined as last patient last visit (LPLV), will occur 24 months after the last SC 
rituximab treatment for the last FL or DLBCL patient, whichever comes later. 
• 
FL patients who complete induction treatment will then enter the maintenance phase. Following 
the last SC rituximab administration, FL patients will be followed up for 24 months. 
• 
DLBCL patients who receive their last SC rituximab treatment will then enter the post- treatment 
follow-up phase. 
• 
Patients with SD or PD at staging will be withdrawn from study treatment and will only be 
followed AEs and for survival until the end of the study. 
• 
Patients who do not complete the Induction treatment per protocol will undergo end-of- 
treatment assessment within 4 weeks after the last dose of Induction treatment and will be 
followed until the end of the whole study according to local practice for AEs, tumour response / 
progression (if PD not yet documented), survival, and documentation of any new anti- 
lymphoma treatment. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
51/Statistical Analysis Plan ML28964 
• 
Patients who complete the study or discontinue from the study early will be asked to return to 
the clinic (after 28 days or at least 5 half-lives of any non-rituximab IMPs, whichever longer) 
after the last dose of study drug for a follow-up visit. 
Safety Outcome Measures 
Safety outcomes will include AARs (defined as all related AEs occurring within 24 hours of rituximab SC 
administration including IIRRs, administration site conditions and all symptoms thereof), grade ≥ 3 AEs, 
and SAEs. Other safety assessments include routine safety laboratory tests, vital signs measurements 
and changes in concomitant medications. All clinical AEs and SAEs as well as laboratory abnormalities 
will be recorded regardless of their intensity / grading. Grading will be completed according to the 
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. 
Efficacy Outcome Measures 
Tumour assessments will be done according to the protocol schedule of assessments (See Appendix 1-
Appendix 2). 
Tumour assessments will be based on CT scans of the neck, chest, abdomen and/or pelvis (if 
detectable by these techniques) or other diagnostic means (e.g. magnetic resonance imaging [MRI]) 
where applicable. Other methods (e.g. MRI) are acceptable for patients in whom CT scans are 
contraindicated. The CT scan used for eligibility assessments may be performed up to 28 days prior to 
dosing. 
Response assessments 4-6 weeks after the last dose of Induction treatment will be based on the 
Investigator’s assessment, completed according to the International Working Group (IWG) response 
criteria (Cheson et al. 1999, see Appendix 2). 
The efficacy of rituximab SC will be evaluated during Induction and/or Maintenance in terms of EFS, 
PFS, OS, CR/CRu, and DFS. 
The endpoints of EFS, PFS and OS will be defined and analysed twice using two different starting 
points for the time-to-event calculations. The first starting point will be first dose of rituximab IV and the 
second will be first dose of rituximab SC. 
EFS is defined as the time from first dose of rituximab (analysed using both first dose of IV and first 
dose of SC) to first occurrence of progression or relapse, according to the IWG response criteria 
(Cheson et al. 1999, see Appendix 2) or initiation of a non–protocol-specified anti-lymphoma therapy 
or death, whichever occurs first. 
PFS is defined as the time from first dose of rituximab (analysed using both first dose of IV and first 
dose of SC) to the first occurrence of progression or relapse, according to the IWG response criteria 
(Cheson et al. 1999, see Appendix 2) or death from any cause. 
OS is defined as the time from first dose of rituximab (analysed using both first dose of IV and first dose 
of SC) to death from any cause. 
DFS will be assessed in patients achieving CR/CRu and is defined as the period from the date of the 
initial CR/CRu until the date of relapse or death from any cause. 
CR/CRu is complete response or complete response unconfirmed and is measured 4 weeks after the 
last dose of Induction treatment. 
Exploratory Outcome Measures 
Not applicable 
Pharmacodynamic and Pharmacokinetic Outcome Measures 
Not applicable 
Pharmacoeconomic Outcome Measures 
Not applicable 
Patient-Reported Outcome Measures 
Patient satisfaction with administration of treatment will be evaluated using the RASQ (see Appendix 6) 
after the rituximab IV administration,after last Rituximab SC in induction and after last Rituximab SC in 
maintenance. The RASQ will be completed immediately after rituximab administration and before 
chemotherapy administration in case the patient will receive chemotherapy. Patients prematurely 
discontinuing treatment during the study should complete the questionnaire at time of 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
52/Statistical Analysis Plan ML28964 
discontinuation, as long as they had been administered at least one dose of treatment via both 
administration routes. 
Healthcare Professional Reported Outcome Measures 
At the end of the study, healthcare professional (HCP) questionnaire (see Appendix 7) will be applied to 
healthcare professionals such as hematologists, internists, nurses or other healthcare professionals 
who administered rituximab SC. 
Study Drug and Study Treatment 
The term "study drug" will be used throughout the protocol to refer to rituximab SC. The term "study 
treatment" will be used to refer to protocol-mandated treatment (also including background 
chemotherapy and/or other pre-medications). 
Investigational Medicinal Products Test Product 
Rituximab SC - The rituximab SC dose is 1400 mg for all patients, independent of patient body 
surface area (BSA). This translates into an injection volume of 11.7 mL. 
Each administration will consist of a single SC injection of rituximab 1400 mg independent of BSA. 
Induction therapy: rituximab SC will always be administered prior to the selected chemotherapy 
regimen (with the exception of the corticosteroid component in CHOP regimens), on average of once a 
month for a minimum of four cycles. 
Maintenance therapy (patients with follicular NHL): rituximab SC will be administered at 2-month 
intervals for a minimum of six cycles, according to local standards of care.  
 
Comparator 
Not applicable. 
Non-Investigational Medicinal Products 
Background therapy: Commercially available chemotherapy will be used in combination with rituximab 
SC, as per standard local practice. For further details, see the local prescribing information for CHOP, 
CVP or FC. 
Concomitant therapy: Patients should receive full supportive care, such as granulocyte colony- 
stimulating factor (G-CSF) support, transfusions of blood and blood products, prophylactic antiviral 
medication, antibiotics, anti-emetics, or local application of radiotherapy for consolidation after induction, 
as applicable and according to institutional standards. Mesna (2-Mercapto Ethane Sulfonate sodium) 
may be used as prophylaxis of haemorrhagic cystitis. 
Pre-medication: In order to reduce the incidence and severity of IIRRs, it is recommended that all 
patients receive the following premedication administered 30-60 minutes prior to each rituximab 
administration: 
• 
paracetamol (acetaminophen) 
• 
diphenhydramine hydrochloride or alternative antihistamine. 
Tumor Lysis Syndrome Prophylaxis: TLS prevention may include hydration and prophylactic 
rasburicase (recombinant urate oxidase) in high-risk patients, hydration plus allopurinol or rasburicase 
for intermediate-risk patients, and close monitoring of electrolyte abnormalities for low- risk patients. 
Primary management of established TLS involves similar recommendations, with the addition of 
aggressive hydration and diuresis, plus allopurinol or rasburicase for hyperuricemia. 
Statistical Methods 
The analysis of this study will be exploratory and will primarily make use of descriptive statistical 
methods. In addition, exploratory statistical testing and modeling will be used to highlight interesting 
aspects of the data. All tests will be two-sided and carried out with a 5% α-error rate without correction 
for multiplicity. 
All enrolled patients who receive at least one dose of study medication will be included in the Safety 
Population, which will be the primary analysis population for safety parameters. All enrolled patients will 
be included in the Intent-to-Treat Population, which will be the primary analysis population for efficacy 
parameters. Other analysis populations may be defined based on more restrictive criteria, such as 
fulfillment of eligibility criteria or a minimum duration of the observation period. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
53/Statistical Analysis Plan ML28964 
Endpoint and Analysis 
Safety will be assessed on the following safety parameters: AARs, including IIRRs, AEs, AEs of 
grade ≥ 3, SAEs, routine laboratory parameters, vital signs, concomitant medications, 
premature withdrawal from the study and from study medication due to AEs or ECOG 
performance status. 
The incidence of AARs AEs, AEs leading to premature discontinuation or interruption of study 
treatment, SAEs, grade ≥ 3 AEs will be estimated with 95%-Clopper-Pearson confidence intervals. 
The incidence of each AE will be summarized by the primary system-organ class and by preferred 
term. The incidence of deaths and cause of deaths will be listed and summarized. 
Laboratory parameters will be summarized and selected laboratory parameters may also be 
displayed graphically. 
Vital signs will be summarized over time. 
ECOG performance status will be summarized by frequency tables over time and percentage 
of patients in different categories will be presented by bar charts at different time points. 
Concomitant medication will be coded according to the WHO DRUG dictionary and tabulated in 
summary tables. 
All safety analyses will be based on the Safety population. 
The analysis of endpoints measured as a time to event (EFS, PFS, OS and DFS) is based on the 
survivor function, which is the probability of remaining event-free beyond a certain point in time. The 
survivor function will be estimated using Kaplan-Meier methodology and summarized using the 
range, the 25th and 75th percentiles and median survival along with a 95% confidence interval for 
median survival. 
Endpoints resulting in an incidence rate (e.g., CR/CRu) will be summarized with a 95% 
Clopper- Pearson confidence interval. 
Determination of Sample Size 
A sample size of 110 patients is deemed sufficient for this study. In this study, all planned statistical 
analysis will be exploratory in nature as the study will not be powered to address any pre-defined 
statements and only descriptive statistical evaluations will be carried out primarily for safety (and 
efficacy) parameters. Additionally, no published reference is available on administration-associated 
reactions (AARs) following multiple doses of subcutaneous (SC) rituximab during induction and/or 
maintenance therapy in patients with CD20+ follicular non-Hodgkin’s lymphoma (NHL) or CD20+ 
diffuse large B-cell lymphoma (DLBCL). However, with 110 patients a 95% Clopper-Pearson CI for 
the incidence of AARs will be no wider than +/- 9.7%. This width of interval is deemed sufficiently 
precise to draw valid conclusions around the incidence of ARRs. Additionally, enrolment of more 
than 110 patients within the specified indications could also be difficult in participating countries. 
Due to the fact of exploratory nature of the study, drop out patients will not be replaced. 
Interim Analyses  
Not applicable  
Study procedures 
See Schedule of Assessments, Appendix 1 and Appendix 2. 






Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
56/Statistical Analysis Plan ML28964 
 
i. 
Women of childbearing potential (defined as pre-menopausal women or women who are < 2 years after the onset of menopause and not surgically sterile) must undergo 
serum pregnancy test within 7 days prior to first dose or within 14 days if with a confirmatory urine pregnancy test within 7 days prior to dosing. 
j. 
Haematology parameters will include haemoglobin, RBC, WBC count and differential, and platelet count. Biochemistry parameters at Screening will include sodium, 
potassium, ALT/SGPT, AST/SGOT, total bilirubin, serum creatinine, alkaline phosphatase, albumin, BUN, C-reactive protein and LDH. Biochemistry parameters at any 
further timepoint during the study will include sodium, potassium, ALT/SGPT, AST/SGOT, total bilirubin, and serum creatinine. Coagulation tests will include: INR, PT, and 
aPTT. The results from the safety laboratory assessments must be available on treatment days, prior to the rituximab administrations. 
k. 
After informed consent has been obtained but prior to dosing, only SAEs caused by a protocol-mandated intervention should be reported (e.g. SAEs related to invasive 
procedures such as biopsies). All clinical and laboratory AEs reported during the study will be documented and graded using the NCI CTCAE criteria, version 4.0. Special 
attention should be given to any acute infusion-related toxicities. After initiation of study drug, all AEs/SAEs, regardless of relationship to study drug, will be reported until 
study closure. 
l. 
Patient reported outcomes: All patients will be required to complete the Rituximab Administration Questionnaire (RASQ, see Appendix 6) at the end of the study. Patients 
prematurely discontinuing study treatment should complete the questionnaire at time of discontinuation, as long as they had taken at least one dose via each treatment 
route (IV and SC) post-randomization. RASQ will be completed immediately after rituximab administration and before chemotherapy administration. 
m. Healthcare Professional (HCP) Questionnaire (see Appendix 7) will be completed at the end of the study by healthcare professionals such as haematologists, internists, 
nurses or other healthcareprofessionals who administered rituximab SC during the study. 






Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
59/Statistical Analysis Plan ML28964 
 
further timepoint during the study will include sodium, potassium, ALT/SGPT, AST/SGOT, total bilirubin, and serum creatinine. Coagulation tests will 
include: INR, PT, and aPTT. The results from the safety laboratory assessments must be available on treatment days, prior to the rituximab 
administrations. 
k. 
After informed consent has been obtained but prior to dosing, only SAEs caused by a protocol-mandated intervention should be reported (e.g. SAEs 
related to invasive procedures such as biopsies). All clinical and laboratory AEs reported during the study will be documented and graded using the NCI 
CTCAE criteria, version 4.0. Special attention should be given to any acute infusion-related toxicities. After initiation of study drug, all AEs/SAEs, 
regardless of relationship to study drug, will be reported until study closure. 
l. 
Patient reported outcomes: All patients will be required to complete the Rituximab Administration Questionnaire (see Appendix 6) at the end of the 
study. Patients prematurely discontinuing study treatment should complete the questionnaire at time of discontinuation, as long as they had taken at 
least one dose via each treatment route (IV and SC) post-randomization. RASQ will be comleted immediately after rituximab administration and before 
chemotherapy administration. 
m. Healthcare Professional (HCP) Questionnaire (see Appendix 7) will be completed at the end of the study by healthcare professionals such as 
haematologists, internists, nurses or other healthcareprofessionals who administered rituximab SC during the study. 
 
 
. 


Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
60/Statistical Analysis Plan ML28964 
Appendix 3 - Table and Listing Shells 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
61/Statistical Analysis Plan ML28964 
TABLE 14.1.1) ENROLLED BY COUNTRY AND SITE (ITT POPULATION) 
__________________________________________________________ 
 
                                          All Patients 
                                           (N=xxx) 
__________________________________________________________ 
          
Country  
  Algeria                                  xx (x.x%) 
  Morocco                                  xx (x.x%) 
  Tunisia                                  xx (x.x%) 
 
Site   
  Site #1                                  xx (x.x%) 
  Site #2                                  xx (x.x%) 
  Site #3                                  xx (x.x%) 
  Site …                                   xx (x.x%) 
  Site n                                   xx (x.x%) 
__________________________________________________________ 
 
 Source: xxx.sas  Run DDMMMYYYY 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
62/Statistical Analysis Plan ML28964 
TABLE 14.1.2) SUMMARY OF PATIENT DISPOSITION (ITT POPULATION) 
 ______________________________________________________________________________________________________________________ 
 
                                                                         All Patients    DLBCL           FL 
                                                              Statistic  (N=xx)          (N=xx)          (N=xx) 
 ______________________________________________________________________________________________________________________ 
 
Intent-to-treat Population                                   n (%)      xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 
 Safety Population                                            n (%)      xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 
 Reason for Discontinuation treatment 
         Progression of Disease                               n (%)      x (xx.x%)       x (xx.x%)      x (xx.x%) 
         Adverse Event                                        n (%)      x (xx.x%)       x (xx.x%)      x (xx.x%) 
         Pregnancy                                            n (%)      x (xx.x%)       x (xx.x%)      x (xx.x%) 
         Patient request/Withdraw consent                     n (%)      x (xx.x%)       x (xx.x%)      x (xx.x%) 
         Investigator decision                                n (%)      x (xx.x%)       x (xx.x%)      x (xx.x%) 
         Lack of compliance                                   n (%)      x (xx.x%)       x (xx.x%)      x (xx.x%) 
         Lost to Follow-up                                    n (%)      x (xx.x%)       x (xx.x%)      x (xx.x%) 
         Death                                                n (%)      x (xx.x%)       x (xx.x%)      x (xx.x%) 
 
 Number of subjects who Continued to Maintenance Phase        n (%)      xx (xx.x%)      xx (xx.x%)     xx (xx.x%) 
_______________________________________________________________________________________________________________________ 
 
 Note(s): Percentages for the reasons for discontinuation are based on the number of subjects who discontinued. Other percentages are calculated based on 
          number of subjects in ITT population. 
 
Source: xxx.sas  Run DDMMMYYYY 
 
  
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
63/Statistical Analysis Plan ML28964 
TABLE 14.1.3) SUMMARY OF PROTOCOL DEVIATIONS (ITT POPULATION) 
 
 _____________________________________________________________________________________________________________________________ 
 
 Category                                                                         All Patients           DLBCL              FL 
      Subcategory                                                    Statistic         (N=xxx)          (N=xx)          (N=xx) 
 _____________________________________________________________________________________________________________________________ 
 
 Number of patients with at least one Protocol Deviation                 n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%) 
 
 Protocol Deviations                                                     n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%) 
      Reason 1                                                           n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%)    
      Reason 2                                                           n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%)                         
      Reason 3                                                           n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%)  
 
Number of patients with at least one major Protocol Deviation            n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%) 
 
Major Protocol Deviations                                                n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%) 
      Reason 1                                                           n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%)    
      Reason 2                                                           n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%)                         
      Reason 3                                                           n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%)  
 
Number of patients with at least one COVID-19 related Protocol Deviation n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%) 
 
COVID-19 Protocol Deviations                                             n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%) 
      Reason 1                                                           n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%)    
      Reason 2                                                           n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%)                         
      Reason 3                                                           n (%)      xx   (xx.x%)    xx  (xx.x%)    xx   (xx.x%)  
_______________________________________________________________________________________________________________________________ 
 
 Note(s): Percentages for the protocol deviations are based on the number of patients in ITT population in each group. 
 Patients with multiple protocol deviations within the same category are counted only once under those categories. 
 The same patient experiencing multiple protocol deviation criterion are counted under each criterion. 
 
Source: xxx.sas  Run DDMMMYYYY 
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
64/Statistical Analysis Plan ML28964 
 TABLE 14.1.4) SUMMARY OF DEMOGRAPHICS (ITT POPULATION) 
 ____________________________________________________________________________________________ 
 
 
                                                  All Patients    DLBCL           FL 
                                    Statistic     (N=xxx)         (N=xx)          (N=xx) 
 ____________________________________________________________________________________________ 
 
 Age (Years) 
                                    n             xxx             xx              xx 
                                    Mean          xx.x            xx.x            xx.x 
                                    SD            xx.xx           xx.xx           x.xx 
                                    Minimum       xx.x            xx.x            xx.x 
                                    Median        xx.x            xx.x            xx.x 
                                    Maximum       xx.x            xx.x            xx.x 
 
 Sex 
         Male                       n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
         Female                     n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 Ethnicity 
         Hispanic (latino)          n (%)         xx (x.x%)       xx (x.x%)       xx (x.x%) 
         Not Hispanic (non-latino)  n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
         Not Applicable as 
         per local regulations      n (%)         xx (x.x%)       xx (x.x%)       xx (x.x%) 
         Other                      n (%)         xx (x.x%)       xx (xx.x%)      xx (x.x%) 
 
 Childbearing potential 
         Yes                        n (%)         xx (x.x%)       xx (x.x%)       xx (x.x%) 
         No                         n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
____________________________________________________________________________________________ 
 
Source: xxx.sas  Run DDMMMYYYY 
  
 
Programming note: 
This table (age and ethnicity variables) to be repeated stratified by sex (Male, Female). 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
65/Statistical Analysis Plan ML28964 
TABLE 14.1.5) SERUM PREGNANCY TEST AT SCREENING (SAFETY POPULATION) 
 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Was the serum pregnancy test performed? 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
Pregnancy test result# 
 
 
 
 
Negative 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Positive 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 Notes: 
 Percentages are calculated relative to the total number of patients in SAF population. 
 # Percentages are calculated relative to the total number of SAF patients who performed a serum pregnancy test at screening visit. 
  
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
66/Statistical Analysis Plan ML28964 
TABLE 14.1.6) SUMMARY OF BASELINE CHARACTERISTICS – PART #1 (ITT POPULATION) 
 ____________________________________________________________________________________________ 
 
                                              All Patients    DLBCL           FL 
                                Statistic     (N=xxx)         (N=xx)          (N=xx) 
 ____________________________________________________________________________________________ 
 
Height (cm) 
                                n             xxx             xx              xx 
                                Mean          xxx.x           xxx.x           xxx.x 
                                SD            x.xx            x.xx            x.xx 
                                Minimum       xxx.x           xxx.x           xxx.x 
                                Median        xxx.x           xxx.x           xxx.x 
                                Maximum       xxx.x           xxx.x           xxx.x 
Weight (Kg) 
                                n             xxx             xx              xx 
                                Mean          xx.x            xx.x            xx.x 
                                SD            xx.xx           xx.xx           xx.xx 
                                Minimum       xx.x            xx.x            xx.x 
                                Median        xx.x            xx.x            xx.x 
                                Maximum       xxx.x           xxx.x           xxx.x 
BMI (Kg/m^2) 
                                n             xxx             xx              xx 
                                Mean          xx.x            xx.x            xx.x 
                                SD            x.xx            x.xx            x.xx 
                                Minimum       xx.x            xx.x            xx.x 
                                Median        xx.x            xx.x            xx.x 
                                Maximum       xx.x            xx.x            xx.x 
____________________________________________________________________________________________ 
 
Source: xxx.sas  Run DDMMMYYYY 
  
 
Programming note: 
This table to be repeated stratified by sex (Male, Female). 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
67/Statistical Analysis Plan ML28964 
TABLE 14.1.7) SUMMARY OF BASELINE CHARACTERISTICS – PART #2 (ITT POPULATION) 
 ______________________________________________________________________________________________________ 
 
 
                                                        All Patients    DLBCL           FL 
                                          Statistic     (N=xxx)         (N=xx)          (N=xx) 
 ______________________________________________________________________________________________________ 
 
IPI Score 
         Low risk                         n (%)         xx (xx.x%)      xx (xx.x%) 
         Low intermediate risk            n (%)         xx (x.x%)       xx (xx.x%)       
         High intermediate risk           n (%)         xx (xx.x%)      xx (xx.x%)       
         High risk                        n (%)         xx (x.x%)       xx (xx.x%)       
 
FLIPI Score 
         Low risk                         n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%)   
         Intermediate risk                n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%)   
         High risk                        n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%)   
 
Surgery/Procedure History 
         General                          n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
         Lymphoma related                 n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
         Both                             n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 Reproductive Status 
         Yes                              n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
         No                               n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 ______________________________________________________________________________________________________ 
 
 Note(s): Percentages for reproductive status are based on the number of female patients in that particular group. 
 
Source: xxx.sas  Run DDMMMYYYY 
  
Programming note: 
This table (IPI Score, FLIPI Score, Surgery/Procedure history variables) to be repeated stratified by sex (Male, Female). 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
68/Statistical Analysis Plan ML28964 
TABLE 14.1.8) DLBCL DIAGNOSIS (SAFETY POPULATION) 
 
 
 
 
Statistic 
 
DLBCL 
(N=xxx) 
 
 
 
How was the histological diagnosis obtained? 
 
 
Fine needle aspiration 
n (%) 
xxx (xx.x%) 
Core needle biopsy 
n (%) 
xxx (xx.x%) 
Excisional/incisional biopsy of peripheral lymph node 
n (%) 
xxx (xx.x%) 
 
 
 
CD20+ expression# 
 
 
Negative 
n (%) 
xxx (xx.x%) 
Positive 
n (%) 
xxx (xx.x%) 
 
 
 
 
 Notes: 
 Percentages are calculated relative to the total number of patients in SAF population. 
 # Percentages are calculated relative to the number of patients with a diagnosis obtained by means of a Fine Needle Aspiration method. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
69/Statistical Analysis Plan ML28964 
TABLE 14.1.9) FOLLICULAR LYMPHOMA DIAGNOSIS (SAFETY POPULATION) 
 
 
 
 
Statistic 
 
FL 
(N=xxx) 
 
 
 
How was the histological diagnosis obtained? 
 
 
Fine needle aspiration 
n (%) 
xxx (xx.x%) 
Core needle biopsy 
n (%) 
xxx (xx.x%) 
Excisional/incisional biopsy of peripheral lymph node 
n (%) 
xxx (xx.x%) 
 
 
 
Grade of FL 
 
 
Grade 1 
n (%) 
xxx (xx.x%) 
Grade 2 
n (%) 
xxx (xx.x%) 
Grade 3a 
n (%) 
xxx (xx.x%) 
 
 
 
CD20+ expression 
 
 
Negative 
n (%) 
xxx (xx.x%) 
Positive 
n (%) 
xxx (xx.x%) 
 
 
 
 
 Notes: 
 Percentages are calculated relative to the total number of patients in SAF population. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
70/Statistical Analysis Plan ML28964 
TABLE 14.1.10) SUMMARY OF BONE MARROW AT BASELINE (ITT POPULATION) 
 ____________________________________________________________________________________________________________________ 
 
 
                                                                      All Patients    DLBCL           FL 
                                                        Statistic     (N=xxx)         (N=xx)          (N=xx) 
 ____________________________________________________________________________________________________________________ 
 
Bone marrow assessment done 
         Yes                                            n (%)         xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
         No                                             n (%)         xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 
 Bone marrow assessment using aspirate 
         Yes                                            n (%)         xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
         No                                             n (%)         xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 
Bone marrow assessment using aspirate result 
         Positive                                       n (%)         xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
         Negative                                       n (%)         xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 
 Bone marrow assessment using biopsy 
         Yes                                            n (%)         xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
         No                                             n (%)         xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 
Bone marrow assessment using biopsy result 
         Positive                                       n (%)         xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
         Negative                                       n (%)         xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
____________________________________________________________________________________________________________________ 
 
Notes: 
Percentages are calculated relative to the total number of patients in ITT population. 
 
Source: xxx.sas  Run DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
71/Statistical Analysis Plan ML28964 
TABLE 14.1.11) LEAD ECG AT SCREENING (SAFETY POPULATION)  
 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Was 12-lead ECG performed? 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
Overall evaluaton of ECG tracing# 
 
 
 
 
Normal 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Abnormal, NCS 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Abnormal, CS 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 Note: 
 CS = Clically Significant. 
 NCS = Not Clinically Significant. 
 Percentages are calculated relative to the total number of patients in SAF population. 
 # Percentages are calculated relative to the total number of SAF patients who performed ECG at screening visit. 
  
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
72/Statistical Analysis Plan ML28964 
TABLE 14.1.12) VIRAL SEROLOGY AT SCREENING (SAFETY POPULATION) 
 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Was the viral serology sample collected? 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
Hepatitis B core antibody (HBcAb) 
 
 
 
 
Negative 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Positive 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Not done 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
Hepatitis B surface antigen (HBsAg) 
 
 
 
 
Negative 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Positive 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Not done 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
HCV antibody 
 
 
 
 
Negative 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Positive 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Not done 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
HCV antibody 
 
 
 
 
Negative 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Positive 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Not done 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
Does the patient have an active viral 
infection with hepatitis B virus (HBV) or 
hepatitis C virus (HCV)? 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 Notes: 
 Percentages are calculated relative to the total number of patients in SAF population. 
 # Percentages are calculated relative to the total number of SAF patients who performed a viral serology test at screening visit. 
  
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
73/Statistical Analysis Plan ML28964 
 
TABLE 14.1.13) SUMMARY OF PREVIOUS DISEASE (ITT POPULATION) 
  __________________________________________________________________________________________________________________ 
 
                                                                All Patients        DLBCL              FL 
  System Organ Class                                            (N=xxx)            (N=xx)             (N=xx) 
    MedDRA Preferred Term 
  __________________________________________________________________________________________________________________ 
 
  Number of patients with at least one previous disease          xx (xx.x%)         xx (xx.x%)        xx (xx.x%) 
 
  <Primary SOC>                                                  xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                      xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                      xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                      xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
 
  <Primary SOC>                                                  xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                      xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                      xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                      xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
 
  <Primary SOC>                                                  xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                      xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                      xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                      xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
 __________________________________________________________________________________________________________________ 
 Notes: 
 Percentages are calculated relative to the total number of patients in the ITT population. 
 Medical History terms were coded using MedDRA thesaurus version 24.1. 
 Previous diseases are those not flagged as “Ongoing at study entry” in the CRF form. 
 Patients can have more than one previous disease. 
 
Source: xxx.sas  Run DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
74/Statistical Analysis Plan ML28964 
TABLE 14.1.14) SUMMARY OF CONCOMITANT DISEASE (ITT POPULATION) 
  _______________________________________________________________________________________________________________________ 
 
                                                                     All Patients       DLBCL              FL 
  System Organ Class                                                 (N=xxx)            (N=xx)             (N=xx) 
    MedDRA Preferred Term 
  _______________________________________________________________________________________________________________________ 
 
  Number of patients with at least one concomitant disease            xx (xx.x%)         xx (xx.x%)        xx (xx.x%) 
 
  <Primary SOC>                                                       xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                           xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                           xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                           xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
 
  <Primary SOC>                                                       xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                           xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                           xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                           xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
 
  <Primary SOC>                                                       xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                           xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                           xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
       <PT>                                                           xx (xx.x%)         xx (xx.x%)         x (xx.x%) 
  _______________________________________________________________________________________________________________________ 
Notes: 
 Percentages are calculated relative to the total number of patients in the ITT population. 
 Medical History terms were coded using MedDRA thesaurus version 24.1. 
 Concomitant diseases are those flagged as “Ongoing at study entry” in the CRF form. 
 Patients can have more than one concomitant disease. 
 
Source: xxx.sas  Run DDMMMYYYY 
 
 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
75/Statistical Analysis Plan ML28964 
TABLE 14.1.15) SUMMARY OF PHYSICAL EXAMINATION (SAFETY POPULATION) 
 ______________________________________________________________________________________________________________________________________ 
 
                                                                                        All Patients    DLBCL           FL 
 Visit                          Body System                                             (N=xxx)        (N=xx)          (N=xx) 
 ______________________________________________________________________________________________________________________________________ 
 
 xxx                           Head Ears Eyes Nose Throat 
                                        Normal                                          xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Abnormal, not clinically significant            xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Abnormal, clinically significant                xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Not applicable                                  xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 
                                Cardiovascular system 
                                        Normal                                          xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Abnormal, not clinically significant            xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Abnormal, clinically significant                xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Not applicable                                  xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 
                                Dermatological 
                                        Normal                                          xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Abnormal, not clinically significant            xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Abnormal, clinically significant                xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Not applicable                                  xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 
                                Musculoskeletal system 
                                        Normal                                          xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Abnormal, not clinically significant            xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Abnormal, clinically significant                xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Not applicable                                  xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 
                                Respiratory system 
                                        Normal                                          xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Abnormal, not clinically significant            xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Abnormal, clinically significant                xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        Not applicable                                  xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 
                                Genitourinary system 
                                        Normal                                          xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        …                                               xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 
                                Gastrointestinal system 
                                        Normal                                          xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        …                                               xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 
                                Nervous system 
                                        Normal                                          xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        …                                               xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 
                                Other 
                                        Normal                                          xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
                                        …                                               xx (xx.x%)     xx (xx.x%)      xx (xx.x%) 
 ______________________________________________________________________________________________________________________________________ 
 
 Note(s): Percentages are based on the number of patients in safety population at the specific visit. 
 
 Source: xxx.sas  Run DDMMMYYYY 
  


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
76/Statistical Analysis Plan ML28964 
TABLE 14.1.16) SUMMARY OF PREVIOUS THERAPIES (SAFETY POPULATION) 
 
ATC Class Level 2 
Other Treatment 
Statistic 
All Patients 
(N=xxx) 
FL 
(N=xxx) 
DLBCL 
(N=xxx) 
Total number of patients with at least one treatment 
n (%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
Total number of treatments 
n 
xxx 
xxx 
xxx 
Class 1 
 
 
 
 
Total number of patients with at least one treatment 
n (%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
Total number of treatments 
n 
xxx 
xxx 
xxx 
Other treatment 1 
n (%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
Other treatment 2 
n (%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
… 
 
 
 
 
Class 2 
 
 
 
 
Total number of patients with at least one treatment 
n (%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
Total number of treatments 
n 
xxx 
xxx 
xxx 
Other treatment 1 
n (%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
… 
 
 
 
 
 
Notes: 
Treatments are coded using the INN-1.0V dictionary. 
Treatments can appear under multiple classes.   
Multiple uses of a specific medication for a patient were counted once in the frequency for the medication. Likewise, multiple uses within a specific medication class for a patient 
were counted once in the frequency for the medication class.  
For frequency counts in “Total number of treatments”, multiple uses of the same medication for a patient were counted separately. 
Patients can have more than one previous therapy. Previous therapy includes any medication stopped before exposure to study drug. 
 
Source: xxx.sas  Run DDMMMYYYY 
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
77/Statistical Analysis Plan ML28964 
TABLE 14.1.17) SUMMARY OF CONCOMITANT THERAPIES (SAFETY POPULATION) 
 
ATC Class Level 2 
Other Treatment 
Statistic 
All Patients 
(N=xxx) 
FL 
(N=xxx) 
DLBCL 
(N=xxx) 
Total number of patients with at least one treatment 
n (%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
Total number of treatments 
n 
xxx 
xxx 
xxx 
Class 1 
 
 
 
 
Total number of patients with at least one treatment 
n (%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
Total number of treatments 
n 
xxx 
xxx 
xxx 
Other treatment 1 
n (%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
Other treatment 2 
n (%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
… 
 
 
 
 
Class 2 
 
 
 
 
Total number of patients with at least one treatment 
n (%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
Total number of treatments 
n 
xxx 
xxx 
xxx 
Other treatment 1 
n (%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
… 
 
 
 
 
Notes: 
Treatments are coded using the INN-1.0V dictionary. 
Treatments can appear under multiple classes.   
Multiple uses of a specific medication for a patient were counted once in the frequency for the medication. Likewise, multiple uses within a specific medication class for a patient 
were counted once in the frequency for the medication class.  
For frequency counts in “Total number of treatments”, multiple uses of the same medication for a patient were counted separately. 
Patients can have more than one concomitant therapy. Concomitant therapy consists of any medication taken during the study, including those started before but ongoing at first dose 
of study drug. 
 
Source: xxx.sas  Run DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
78/Statistical Analysis Plan ML28964 
TABLE 14.1.18) SUMMARY OF PREVIOUS IV RITUXIMAB DOSE FOR DLBCL (SAFETY POPULATION) 
 
 
 
 
Statistic 
 
DLBCL 
(N=xxx) 
 
 
 
 
 
 
Number of previous IV rituximab treatment cycles 
 
 
One 
n (%) 
xxx (xx.x%) 
Two 
n (%) 
xxx (xx.x%) 
Three 
n (%) 
xxx (xx.x%) 
Four 
n (%) 
xxx (xx.x%) 
 
 
 
Dose of most recent IV rituximab cycle 
 
 
 
n  
xxx 
 
Mean (SD) 
xx.x (xx.x) 
 
Median 
xx.x 
 
Min,Max 
xx,xx 
 
 
 
 
Source: xxx.sas  Run DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
79/Statistical Analysis Plan ML28964 
TABLE 14.1.19) SUMMARY OF PREVIOUS IV RITUXIMAB DOSE FOR FL (SAFETY POPULATION) 
 
 
 
 
Statistic 
 
FL 
(N=xxx) 
 
 
 
What phase of IV Rituximab was the patient on for their most recent 
IV cycle? 
 
 
Induction phase 
n (%) 
xxx (xx.x%) 
Maintenance phase 
n (%) 
xxx (xx.x%) 
 
 
 
Number of previous IV rituximab treatment cycles 
 
 
One 
n (%) 
xxx (xx.x%) 
Two 
n (%) 
xxx (xx.x%) 
Three 
n (%) 
xxx (xx.x%) 
Four 
n (%) 
xxx (xx.x%) 
Five 
n (%) 
xxx (xx.x%) 
Six 
n (%) 
xxx (xx.x%) 
Seven 
n (%) 
xxx (xx.x%) 
Eight 
n (%) 
xxx (xx.x%) 
 
 
 
Dose of most recent IV rituximab cycle 
 
 
 
n  
xxx 
 
Mean (SD) 
xx.x (xx.x) 
 
Median 
xx.x 
 
Min,Max 
xx,xx 
 
 
 
Which treatment phase is the subject eligible to enter the study? 
 
 
Induction phase 
n (%) 
xxx (xx.x%) 
Maintenance phase 
n (%) 
xxx (xx.x%) 
 
 
 
 
Source: xxx.sas  Run DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
80/Statistical Analysis Plan ML28964 
TABLE 14.1.20) EXPOSURE TO RITUXIMAB SC – ADMINISTRATION SUMMARY (SAFETY POPULATION) 
 ____________________________________________________________________________________________________ 
 
                                                      All Patients    DLBCL           FL 
                                        Statistic     (N=xxx)         (N=xx)          (N=xx) 
 ____________________________________________________________________________________________________ 
 
 Induction Cycle* 
          Induction Cycle 1             n (%)         x (x.x%)                        x (x.x%) 
          Induction Cycle 2             n (%)         x (x.x%)                        x (x.x%) 
          Induction Cycle …             n (%)         x (x.x%)                        x (x.x%) 
          Induction Cycle n             n (%)         x (x.x%)                        x (x.x%) 
 
 Maintenance Cycle* 
          Maintenance Cycle 1           n (%)         x (x.x%)                        x (x.x%) 
          Maintenance Cycle 2           n (%)         x (x.x%)                        x (x.x%) 
          Maintenance Cycle …           n (%)         x (x.x%)                        x (x.x%) 
          Maintenance Cycle n           n (%)         x (x.x%)                        x (x.x%) 
 
 Treatment Cycle* 
          Treatment Cycle 1             n (%)         x (x.x%)        x (x.x%) 
          Treatment Cycle 2             n (%)         x (x.x%)        x (x.x%) 
          Treatment Cycle …             n (%)         x (x.x%)        x (x.x%) 
          Treatment Cycle n             n (%)         x (x.x%)        x (x.x%) 
 
 Total number of cycles 
                                        n             xxx             xx              xx 
                                        Mean          x.x             x.x             x.x 
                                        SD            x.xx            x.xx            x.xx 
                                        Minimum       x.x             x.x             x.x 
                                        Median        x.x             x.x             x.x 
                                        Maximum       xx.x            x.x             x.x 
____________________________________________________________________________________________________ 
 
 Note(s): *Number of Rituximab SC cycles exposure. 
          Denominator for calculating the percentage is N (Safety population). 
 
Source: xxx.sas  Run DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
81/Statistical Analysis Plan ML28964 
TABLE 14.1.21) EXPOSURE TO RITUXIMAB SC – ADMINISTRATION DETAILS (SAFETY POPULATION) 
 ______________________________________________________________________________________________________ 
 
                                                        All Patients    DLBCL           FL 
                                          Statistic     (N=xxx)         (N=xx)          (N=xx) 
 ______________________________________________________________________________________________________ 
 
 Full Doses 
         Overall                          n (%)         xx (xx.x%)    xx (xx.x%)        xx (xx.x%) 
 
 Full Doses in Induction Cycle 
          Induction Cycle 1               n (%)         x (x.x%)                        x (x.x%) 
          Induction Cycle 2               n (%)         x (x.x%)                        x (x.x%) 
          Induction Cycle …               n (%)         x (x.x%)                        x (x.x%) 
          Induction Cycle n               n (%)         x (x.x%)                        x (x.x%) 
 
 Full Doses in Maintenance Cycle 
          Maintenance Cycle 1             n (%)         x (x.x%)                        x (x.x%) 
          Maintenance Cycle 2             n (%)         x (x.x%)                        x (x.x%) 
          Maintenance Cycle …             n (%)         x (x.x%)                        x (x.x%) 
          Maintenance Cycle n             n (%)         x (x.x%)                        x (x.x%) 
 
 Full Doses in Treatment Cycle 
          Treatment Cycle 1               n (%)         x (x.x%)        x (x.x%) 
          Treatment Cycle 2               n (%)         x (x.x%)        x (x.x%) 
          Treatment Cycle …               n (%)         x (x.x%)        x (x.x%) 
          Treatment Cycle n               n (%)         x (x.x%)        x (x.x%) 
______________________________________________________________________________________________________ 
 
Source: xxx.sas  Run DDMMMYYYY 
 
 
 
 
 
 
 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
82/Statistical Analysis Plan ML28964 
TABLE 14.1.22) EXPOSURE TO RITUXIMAB SC – ADMINISTRATION DETAILS (SAFETY POPULATION) 
 ______________________________________________________________________________________________________ 
 
                                                        All Patients    DLBCL           FL 
                                          Statistic     (N=xxx)         (N=xx)          (N=xx) 
 ______________________________________________________________________________________________________ 
 
 Duration of Injection 
                                          n             xxx             xxx             xxx 
                                          Mean          x.x             x.x             x.x 
                                          SD            x.xx            x.xx            x.xx 
                                          Minimum       x.x             x.x             x.x 
                                          Median        x.x             x.x             x.x 
                                          Maximum       xx.x            xx.x            xx.x 
 
 Dose Injected 
         xxxx mg                          n (%)         xxxx (xx.x%)    xxx (xx.x%)    xxxx (xx.x%) 
         xxxx mg                          n (%)         xxxx (xx.x%)    xxx (xx.x%)    xxxx (xx.x%) 
         xxxx mg                          n (%)         xxxx (xx.x%)    xxx (xx.x%)    xxxx (xx.x%) 
 
 Interruption Duration* # 
                                          n             xxx             xxx             xxx 
                                          Mean          x.x             x.x             x.x 
                                          SD            x.xx            x.xx            x.xx 
                                          Minimum       x.x             x.x             x.x 
                                          Median        x.x             x.x             x.x 
                                          Maximum       xx.x            xx.x            xx.x 
______________________________________________________________________________________________________ 
 
  Note(s): #Interruption due to Serious Adverse Event/ Adverse Event of Special Interest. 
 
Source: xxx.sas  Run DDMMMYYYY 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
83/Statistical Analysis Plan ML28964 
TABLE 14.1.23) TYPE OF CHEMOTHERAPY (SAFETY POPULATION) 
_________________________________________________________________________________________ 
 
                                                All Patients    DLBCL           FL 
 Type of chemotherapy             Statistic     (N=xxx)         (N=xx)          (N=xx) 
 ________________________________________________________________________________________ 
 
 CHOP-14 X 6                      n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
 CHOP-14 X 8                      n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
 CHOP-21 X 6                      n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
 CHOP-21 X 8                      n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
 CVP-21 X 8                       n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
 FC-28 X 6                        n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
 Other                            n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
_________________________________________________________________________________________ 
 
Note(s): Denominator for calculating the percentage is N (Safety population). 
 
Source: xxx.sas  Run DDMMMYYYY 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
84/Statistical Analysis Plan ML28964 
TABLE 14.1.24) EXPOSURE TO CHEMOTHERAPY (SAFETY POPULATION) 
 
 _________________________________________________________________________________________________________________________ 
 
                                                                           All Patients    DLBCL           FL 
 Type                                                        Statistic     (N=xxx)         (N=xx)          (N=xx) 
 _________________________________________________________________________________________________________________________ 
 
 CHOP-14 X 6          Induction Cycle 
                             1 Induction Cycle               n (%)         x (x.x%)                        x (x.x%) 
                             2 Induction Cycles              n (%)         x (x.x%)                        x (x.x%) 
                             n Induction Cycles              n (%)         x (x.x%)                        x (x.x%) 
 
                      Total number of cycles 
                                                             n             xx                              xx 
                                                             Mean          x.x                             x.x 
                                                             SD            x.xx                            x.xx 
                                                             Minimum       x.x                             x.x 
                                                             Median        x.x                             x.x 
                                                             Maximum       x.x                             x.x 
 _________________________________________________________________________________________________________________________ 
 
Note(s): Denominator for calculating the percentage is N (Safety population). 
 
Source: xxx.sas  Run DDMMMYYYY 
 
 
Programming note: 
This table should be also presented for all chemotherapy regimen patient is taking. 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
85/Statistical Analysis Plan ML28964 
TABLE 14.1.25) EXPOSURE TO NEW ANTI – LYMPHOMA TREATMENT CHEMO/IMMUNO THERAPY (SAFETY POPULATION) 
 _________________________________________________________________________________________________________________________ 
 
 
                                                                                All Patients    DLBCL           FL 
 Type                                                             Statistic     (N=xxx)         (N=xx)          (N=xx) 
 _________________________________________________________________________________________________________________________ 
 
 Chemo/Immuno Therapy      Total Number of Cycles 
                                              1 Cycle             n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                              2 Cycles            n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                              n Cycles            n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
 
                           Total number of cycles 
                                                                  n             xx              xx              xx 
                                                                  Mean          x.x             x.x             x.x 
                                                                  SD            x.xx            x.xx            x.xx 
                                                                  Minimum       x.x             x.x             x.x 
                                                                  Median        x.x             x.x             x.x 
                                                                  Maximum       xx.x            x.x             xx.x 
 
                           Duration of Exposure (days) 
                                                                  n             xx              xx              xx 
                                                                  Mean          xx.x            xx.x            xxx.x 
                                                                  SD            xx.xx           xx.xx           xx.xx 
                                                                  Minimum       x.x             x.x             xx.x 
                                                                  Median        xx.x            xx.x            xxx.x 
                                                                  Maximum       xxx.x           xxx.x           xxx.x 
 
                           Response 
                                              CR                  n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                              CRu                 n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                              PR                  n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                              SD                  n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                              PD                  n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                              Unable to assess    n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
__________________________________________________________________________________________________________________________ 
 
 Note(s): Denominator for calculating the percentage is N (Safety population). 
 
Source: xxx.sas  Run DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
86/Statistical Analysis Plan ML28964 
TABLE 14.1.26) INITIAL CHOP REGIMEN DOSAGE (SAFETY POPULATION) 
 
 
Study Treatment 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Cyclophosphamide (mg/m^2) 
 
 
 
 
 
n  
xxx 
xxx 
xxx 
 
Mean (SD) 
xx.x (xx.x) 
xx.x (xx.x) 
xx.x (xx.x) 
 
Median 
xx.x 
xx.x 
xx.x 
 
Min,Max 
xx,xx 
xx,xx 
xx,xx 
 
 
 
 
 
Doxorubicin (mg/m^2) 
 
 
 
 
 
n  
xxx 
xxx 
xxx 
 
Mean (SD) 
xx.x (xx.x) 
xx.x (xx.x) 
xx.x (xx.x) 
 
Median 
xx.x 
xx.x 
xx.x 
 
Min,Max 
xx,xx 
xx,xx 
xx,xx 
 
 
 
 
 
Vincristine (mg/m^2) 
 
 
 
 
 
n  
xxx 
xxx 
xxx 
 
Mean (SD) 
xx.x (xx.x) 
xx.x (xx.x) 
xx.x (xx.x) 
 
Median 
xx.x 
xx.x 
xx.x 
 
Min,Max 
xx,xx 
xx,xx 
xx,xx 
 
 
 
 
 
Prednisone/prednisolone (mg/m^2) 
 
 
 
 
 
n  
xxx 
xxx 
xxx 
 
Mean (SD) 
xx.x (xx.x) 
xx.x (xx.x) 
xx.x (xx.x) 
 
Median 
xx.x 
xx.x 
xx.x 
 
Min,Max 
xx,xx 
xx,xx 
xx,xx 
 
 
 
 
 
 
 
 
 
 
Source: xxx.sas  Run DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
87/Statistical Analysis Plan ML28964 
TABLE 14.1.27) INITIAL CVP REGIMEN DOSAGE (SAFETY POPULATION) 
 
 
Study Treatment 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Cyclophosphamide (mg/m^2) 
 
 
 
 
 
n  
xxx 
xxx 
xxx 
 
Mean (SD) 
xx.x (xx.x) 
xx.x (xx.x) 
xx.x (xx.x) 
 
Median 
xx.x 
xx.x 
xx.x 
 
Min,Max 
xx,xx 
xx,xx 
xx,xx 
 
 
 
 
 
Vincristine (mg/m^2) 
 
 
 
 
 
n  
xxx 
xxx 
xxx 
 
Mean (SD) 
xx.x (xx.x) 
xx.x (xx.x) 
xx.x (xx.x) 
 
Median 
xx.x 
xx.x 
xx.x 
 
Min,Max 
xx,xx 
xx,xx 
xx,xx 
 
 
 
 
 
Prednisone/prednisolone (mg/m^2) 
 
 
 
 
 
n  
xxx 
xxx 
xxx 
 
Mean (SD) 
xx.x (xx.x) 
xx.x (xx.x) 
xx.x (xx.x) 
 
Median 
xx.x 
xx.x 
xx.x 
 
Min,Max 
xx,xx 
xx,xx 
xx,xx 
 
 
 
 
 
 
 
 
 
 
Source: xxx.sas  Run DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
88/Statistical Analysis Plan ML28964 
TABLE 14.1.28) INITIAL FLUDARABINE DOSAGE (SAFETY POPULATION) 
 
 
Study Treatment 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Fludarabine (mg/m^2) 
 
 
 
 
 
n  
xxx 
xxx 
xxx 
 
Mean (SD) 
xx.x (xx.x) 
xx.x (xx.x) 
xx.x (xx.x) 
 
Median 
xx.x 
xx.x 
xx.x 
 
Min,Max 
xx,xx 
xx,xx 
xx,xx 
 
 
 
 
 
Cyclophosphamide (mg/m^2) 
 
 
 
 
 
n  
xxx 
xxx 
xxx 
 
Mean (SD) 
xx.x (xx.x) 
xx.x (xx.x) 
xx.x (xx.x) 
 
Median 
xx.x 
xx.x 
xx.x 
 
Min,Max 
xx,xx 
xx,xx 
xx,xx 
 
 
 
 
 
 
 
 
 
 
Source: xxx.sas  Run DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
89/Statistical Analysis Plan ML28964 
TABLE 14.1.29) EXPOSURE TO NEW ANTI – LYMPHOMA TREATMENT RADIOTHERAPY (SAFETY POPULATION) 
 __________________________________________________________________________________________________________________________ 
 
                                                                                All Patients    DLBCL           FL 
 Type                                                             Statistic     (N=xxx)         (N=xx)          (N=xx) 
 __________________________________________________________________________________________________________________________ 
 
 Radiotherapy              Irradiation Site 
                                       Neck                       n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                       Chest                      n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                       Abdomen                    n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                       Pelvis                     n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                       Other                      n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
 
                           Cumulative Dose of Radiation (Gy) 
                                       xx.xx Radiation            n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                       xx.xx Radiation            n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                       xx.xx Radiation            n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                       xx.xx Radiation            n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
 
                           Cumulative Dose of Radiation (Gy) 
                                                                  n             xx              xx              xx 
                                                                  Mean          xx.xx           xx.xx           xx.xx 
                                                                  SD            x.xx            x.xx            x.xx 
                                                                  Minimum       xx.xx           xx.xx           xx.xx 
                                                                  Median        xx.xx           xx.xx           xx.xx 
                                                                  Maximum       xx.xx           xx.xx           xx.xx 
 
                           Duration of Exposure (days) 
                                                                  n             xx              xx              xx 
                                                                  Mean          xx.x            xx.x            xx.x 
                                                                  SD            x.xx            x.xx            x.xx 
                                                                  Minimum       xx.x            xx.x            xx.x 
                                                                  Median        xx.x            xx.x            xx.x 
                                                                  Maximum       xx.x            xx.x            xx.x 
                           Response 
                                              CR                  n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                              CRu                 n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                              PR                  n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                              SD                  n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                              PD                  n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
                                              Unable to assess    n (%)         x (x.x%)        x (x.x%)        x (x.x%) 
___________________________________________________________________________________________________________________________ 
 
 Note(s): Denominator for calculating the percentage is N (Safety population). 
 
Source: xxx.sas  Run DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
90/Statistical Analysis Plan ML28964 
TABLE 14.2.1) OVERALL SUMMARY OF PATIENTS EXPERIENCING EACH CLASS OF TREATMENT EMERGENT ADVERSE EVENT (SAFETY POPULATION) 
 ____________________________________________________________________________________________________________________________________ 
 
                                                                                      All Patients    DLBCL           FL 
 Events                                                                 Statistic     (N=xxx)         (N=xx)          (N=xx) 
 ____________________________________________________________________________________________________________________________________ 
 
 Treatment Emergent Adverse Events                                      n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 Treatment Emergent Serious Adverse Events                              n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 Adverse Events of Special Interest                                     n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 Administration Associated Reactions                                    n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 Cutaneous and soft tissue AARs (Localized)                             n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 Cutaneous and soft tissue AARs (Non-Localized)                         n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 Grade >=3+ Treatment-Emergent Adverse Events                           n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 Grade >=3+ Treatment-Emergent Serious Adverse Events                   n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 Grade >=3+ Administration Associated Reactions                         n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 Grade >=3+ Infusion/Injection-Related Reactions                        n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 TEAEs leading to rituximab drug interrupted/drug delayed               n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 TEAEs leading to rituximab dose discontinuation                        n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 TEAEs leading to chemotherapy dose modification                        n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 TEAEs leading to chemotherapy dose discontinuation                     n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
 
 TEAEs leading to death                                                 n (%)         xx (xx.x%)      xx (xx.x%)      xx (xx.x%) 
______________________________________________________________________________________________________________________________ 
 
 Note(s): A patient experiencing multiple occurrences of an adverse event was counted, at most, once per Event. 
          TEAE = Treatment-Emergent Adverse Event. 
 
Source: xxx.sas  Run DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
91/Statistical Analysis Plan ML28964 
TABLE 14.2.2) PROPORTION OF TREATMENT EMERGENT ADVERSE EVENT BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
 
 
System Organ Class 
 Preferred Term 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Number of patients with 
Treatment Emergent Adverse 
Event 
 
<Primary SOC> 
 
 
n (%) 
 
n (%) E   95% CI     
 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
 
 
 
 
 
   Note(s): MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
           N = number of patients, % = Observed percentage, E = number of events, CI = Confidence Interval. 
           Percentages are calculated relative to the total number of patients in the SAF population. 
           95% CI of the observed percentage calculated using the Clopper-Pearson methodology, or the Poisson distribution for frequencies below 10%. 
           Each patient is counted at most once within each SOC and PT. 
 
           TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
92/Statistical Analysis Plan ML28964 
TABLE 14.2.3) PROPORTION OF SERIOUS TREATMENT EMERGENT ADVERSE EVENT BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
 
 
System Organ Class 
 Preferred Term 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Number of patients with serious 
Treatment Emergent Adverse 
Event 
 
<Primary SOC> 
 
 
n (%) 
 
n (%) E   95% CI     
 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
 
 
 
 
 
   Note(s): MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
           N = number of patients, % = Observed percentage, E = number of events, CI = Confidence Interval. 
           Percentages are calculated relative to the total number of patients in the SAF population. 
           95% CI of the observed percentage calculated using the Clopper-Pearson methodology, or the Poisson distribution for frequencies below 10%. 
           Each patient is counted at most once within each SOC and PT. 
 
           TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
   
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
93/Statistical Analysis Plan ML28964 
TABLE 14.2.4) PROPORTION OF LOCALIZED ADMINISTRATION ASSOCIATED REACTIONS BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
 
 
System Organ Class 
 Preferred Term 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Number of patients with  
Localized AARs 
 
<Primary SOC> 
 
n (%) 
 
n (%) E   95% CI     
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
 
 
 
 
 
 
   Note(s): MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
           N = number of patients, % = Observed percentage, E = number of events, CI = Confidence Interval. 
           Percentages are calculated relative to the total number of patients in the SAF population. 
           95% CI of the observed percentage calculated using the Clopper-Pearson methodology, or the Poisson distribution for frequencies below 10%. 
           Each patient is counted at most once within each SOC and PT. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
94/Statistical Analysis Plan ML28964 
TABLE 14.2.5) PROPORTION OF NON-LOCALIZED ADMINISTRATION ASSOCIATED REACTIONS BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
 
 
System Organ Class 
 Preferred Term 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Number of patients with  
Non-localized AARs 
 
<Primary SOC> 
 
n (%) 
 
n (%) E   95% CI     
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
 
 
 
 
 
   Note(s): MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
           N = number of patients, % = Observed percentage, E = number of events, CI = Confidence Interval. 
           Percentages are calculated relative to the total number of patients in the SAF population. 
           95% CI of the observed percentage calculated using the Clopper-Pearson methodology, or the Poisson distribution for frequencies below 10%. 
           Each patient is counted at most once within each SOC and PT. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
95/Statistical Analysis Plan ML28964 
 
  
TABLE 14.2.6) PROPORTION OF TREATMENT-EMERGENT ADVERSE EVENTS WITH GRADE >=3+ AES BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
 
 
System Organ Class 
 Preferred Term 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Number of patients with 
grade >=3+ TEAEs 
 
<Primary SOC> 
 
n (%) 
 
n (%) E   95% CI     
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
 
 
 
 
 
   Note(s): MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
           N = number of patients, % = Observed percentage, E = number of events, CI = Confidence Interval. 
           Percentages are calculated relative to the total number of patients in the SAF population. 
           95% CI of the observed percentage calculated using the Clopper-Pearson methodology, or the Poisson distribution for frequencies below 10%. 
           Each patient is counted at most once within each SOC and PT. 
 
           TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
96/Statistical Analysis Plan ML28964 
TABLE 14.2.7) PROPORTION OF TREATMENT-EMERGENT ADVERSE EVENTS WITH GRADE >=3+ SAES BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
 
 
System Organ Class 
 Preferred Term 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Number of patients with   
grade >=3+ serious TEAEs 
 
<Primary SOC> 
 
n (%) 
 
n (%) E   95% CI     
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
 
 
 
 
 
  Note(s): MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
           N = number of patients, % = Observed percentage, E = number of events, CI = Confidence Interval. 
           Percentages are calculated relative to the total number of patients in the SAF population. 
           95% CI of the observed percentage calculated using the Clopper-Pearson methodology, or the Poisson distribution for frequencies below 10%. 
           Each patient is counted at most once within each SOC and PT. 
 
           TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
97/Statistical Analysis Plan ML28964 
TABLE 14.2.8) PROPORTION OF TREATMENT-EMERGENT ADVERSE EVENTS WITH GRADE >=3+ AARS BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
 
 
System Organ Class 
 Preferred Term 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Number of patients with   
grade >=3+ AARs 
 
<Primary SOC> 
 
n (%) 
 
n (%) E   95% CI     
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
 
 
 
 
 
   Note(s): MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
           N = number of patients, % = Observed percentage, E = number of events, CI = Confidence Interval. 
           Percentages are calculated relative to the total number of patients in the SAF population. 
           95% CI of the observed percentage calculated using the Clopper-Pearson methodology, or the Poisson distribution for frequencies below 10%. 
           Each patient is counted at most once within each SOC and PT. 
 
           TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
98/Statistical Analysis Plan ML28964 
TABLE 14.2.9) PROPORTION OF TREATMENT-EMERGENT ADVERSE EVENTS LEADING TO RITUXIMAB DRUG INTERRUPTED/DRUG DELAYED BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
 
 
System Organ Class 
 Preferred Term 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Number of patients with TEAE 
leading to drug  
Interruption/drug delayed 
 
<Primary SOC> 
 
n (%) 
 
n (%) E   95% CI     
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
 
 
 
 
 
   Note(s): MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
           N = number of patients, % = Observed percentage, E = number of events, CI = Confidence Interval. 
           Percentages are calculated relative to the total number of patients in the SAF population. 
           95% CI of the observed percentage calculated using the Clopper-Pearson methodology, or the Poisson distribution for frequencies below 10%. 
           Each patient is counted at most once within each SOC and PT. 
 
           TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
99/Statistical Analysis Plan ML28964 
TABLE 14.2.10) PROPORTION OF TREATMENT-EMERGENT ADVERSE EVENTS LEADING TO RITUXIMAB DOSE DISCONTINUATION BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
 
 
System Organ Class 
 Preferred Term 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Number of patients with TEAE 
leading to dose discontinuation 
 
<Primary SOC> 
 
n (%) 
 
n (%) E   95% CI     
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
 
 
 
 
 
   Note(s): MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
           N = number of patients, % = Observed percentage, E = number of events, CI = Confidence Interval. 
           Percentages are calculated relative to the total number of patients in the SAF population. 
           95% CI of the observed percentage calculated using the Clopper-Pearson methodology, or the Poisson distribution for frequencies below 10%. 
           Each patient is counted at most once within each SOC and PT. 
 
           TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
100/Statistical Analysis Plan ML28964 
TABLE 14.2.11) PROPORTION OF TREATMENT-EMERGENT ADVERSE EVENTS LEADING TO CHEMOTHERAPY DOSE MODIFICATION BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
 
 
System Organ Class 
 Preferred Term 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Number of patients with TEAE 
leading to chemotherapy dose 
modification 
 
<Primary SOC> 
 
n (%) 
 
n (%) E   95% CI     
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
 
 
 
 
 
   Note(s): MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
           N = number of patients, % = Observed percentage, E = number of events, CI = Confidence Interval. 
           Percentages are calculated relative to the total number of patients in the SAF population. 
           95% CI of the observed percentage calculated using the Clopper-Pearson methodology, or the Poisson distribution for frequencies below 10%. 
           Each patient is counted at most once within each SOC and PT. 
 
           TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
101/Statistical Analysis Plan ML28964 
TABLE 14.2.12) PROPORTION OF TREATMENT-EMERGENT ADVERSE EVENTS LEADING TO CHEMOTHERAPY DOSE DISCONTINUATION BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
 
 
System Organ Class 
 Preferred Term 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Number of patients with TEAE 
leading to chemotherapy dose 
discontinuation 
 
<Primary SOC> 
 
n (%) 
 
n (%) E   95% CI     
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
 
 
 
 
 
   Note(s): MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
           N = number of patients, % = Observed percentage, E = number of events, CI = Confidence Interval. 
           Percentages are calculated relative to the total number of patients in the SAF population. 
           95% CI of the observed percentage calculated using the Clopper-Pearson methodology, or the Poisson distribution for frequencies below 10%. 
           Each patient is counted at most once within each SOC and PT. 
 
           TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
102/Statistical Analysis Plan ML28964 
TABLE 14.2.13) PROPORTION OF TREATMENT-EMERGENT ADVERSE EVENTS LEADING TO DEATH BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
 
 
System Organ Class 
 Preferred Term 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Number of patients with TEAE 
leading to death 
 
<Primary SOC> 
 
n (%) 
 
n (%) E   95% CI     
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
xxx (xx.x%) 
 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
<Primary SOC> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 <PT> 
n (%) E   95% CI     xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
xxx (xx.x%) xxx   xx.x%-xx.x% 
 
 
 
 
 
 
 
 
 
 
   Note(s): MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
           N = number of patients, % = Observed percentage, E = number of events, CI = Confidence Interval. 
           Percentages are calculated relative to the total number of patients in the SAF population. 
           95% CI of the observed percentage calculated using the Clopper-Pearson methodology, or the Poisson distribution for frequencies below 10%. 
           Each patient is counted at most once within each SOC and PT. 
 
           TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
103/Statistical Analysis Plan ML28964 
 
  
 TABLE 14.2.14) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Number of patients with 
 Treatment-Emergent                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 Adverse Events 
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
104/Statistical Analysis Plan ML28964 
TABLE 14.2.15) SUMMARY OF SERIOUS TREATMENT-EMERGENT ADVERSE EVENTS BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
 ________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
 ________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Number of patients with serious 
 Treatment-Emergent                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 Adverse Events 
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
105/Statistical Analysis Plan ML28964 
TABLE 14.2.16) SUMMARY OF ADVERSE EVENTS OF SPECIAL INTEREST BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
 ________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
 ________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Number of patients with  
 Adverse Event of                     xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 Special interest 
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
106/Statistical Analysis Plan ML28964 
 TABLE 14.2.17) SUMMARY OF ADMINISTRATION ASSOCIATED REACTIONS BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Number of patients with  
 Administration Associated            xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 Reactions 
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
107/Statistical Analysis Plan ML28964 
 TABLE 14.2.18) SUMMARY OF INFUSION/INJECTION-RELATED REACTIONS BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Number of patients with  
 Infusion/Injection-Related Reaction   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
  
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
108/Statistical Analysis Plan ML28964 
 TABLE 14.2.19) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS WITH GRADE >=3+ AES BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Number of patients with grade 
 >=3+ Treatment Emergent 
 Adverse Event                        xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
109/Statistical Analysis Plan ML28964 
 TABLE 14.2.20) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS WITH GRADE >=3+ SAES BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Number of patients with grade 
 >=3+ Treatment-Emergent Serious 
 Adverse Events                       xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
110/Statistical Analysis Plan ML28964 
 TABLE 14.2.21) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS WITH GRADE >=3+ AESI BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Number of patients with grade 
 >=3+ Treatment-Emergent AESI         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
111/Statistical Analysis Plan ML28964 
 TABLE 14.2.22) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS WITH GRADE >=3+ AARS BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Number of patients with grade 
 >=3+ Treatment-Emergent AARS         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
112/Statistical Analysis Plan ML28964 
 TABLE 14.2.23) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS WITH GRADE >=3+ IIRRS BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Number of patients with grade 
 >=3+ Treatment-Emergent IIRRS         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
113/Statistical Analysis Plan ML28964 
 TABLE 14.2.24) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS WITHIN THE MEDDRA SMQ `ANAPHYLACTIC REACTIONS’ (WIDE)  BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Number of patients with SMQ 
 Anaphylactic reactions               xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
114/Statistical Analysis Plan ML28964 
 TABLE 14.2.25) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS LEADING TO RITUXIMAB DRUG INTERRUPTED/DRUG DELAYED BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Number of patients with  
Treatment-Emergent Adverse Event 
 Leading to Rituximab 
Drug interrupted/delayed              xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
115/Statistical Analysis Plan ML28964 
 TABLE 14.2.26) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS LEADING TO RITUXIMAB DOSE DISCONTINUATION BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
Number of patients with  
Treatment-Emergent Adverse Event 
 Leading to Rituximab 
Dose discontinuation                  xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
116/Statistical Analysis Plan ML28964 
 TABLE 14.2.27) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS LEADING TO CHEMOTHERAPY DOSE MODIFICATION BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
Number of patients with  
Treatment-Emergent Adverse Event 
 Leading to Chemotherapy 
Dose modification                     xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
117/Statistical Analysis Plan ML28964 
TABLE 14.2.28) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS LEADING TO CHEMOTHERAPY DOSE DISCONTINUATION BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
Number of patients with  
Treatment-Emergent Adverse Event 
 Leading to Chemotherapy 
Dose discontinuation                  xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
118/Statistical Analysis Plan ML28964 
 TABLE 14.2.29) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS LEADING TO DEATH BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
Number of patients with  
Treatment-Emergent Adverse Event 
Leading to death                      xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
119/Statistical Analysis Plan ML28964 
 TABLE 14.2.30) SUMMARY OF CUTANEOUS AND SOFT TISSUE AARS (LOCALIZED) BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
Number of patients with  
Cutaneous and soft tissue 
AARS localized                        xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
120/Statistical Analysis Plan ML28964 
 TABLE 14.2.31) SUMMARY OF CUTANEOUS AND SOFT TISSUE AARS (NON-LOCALIZED) BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
Number of patients with  
Cutaneous and soft tissue 
AARS non-localized                        xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
121/Statistical Analysis Plan ML28964 
 TABLE 14.2.32) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS WITH AN INCIDENCE OF >=5% BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
Number of patients with Treatment-Emergent          
Adverse Events with Incidence >=5%    xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
122/Statistical Analysis Plan ML28964 
 TABLE 14.2.33) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS BY SYSTEM ORGAN CLASS AND PREFERRED TERM AND MAXIMUM SEVERITY (SAFETY POPULATION) 
 ________________________________________________________________________________________________________________________________________________________________________________ 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 Maximum    System Organ Class                    ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
 Severity    Preferred Term              n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
Grade x    Number of patients with 
           Treatment-Emergent Adverse 
           Event (Max Grade)           xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
             Primary SOC>             xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
             Primary SOC>             xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
Grade x    Number of patients with 
           Treatment-Emergent Adverse 
           Event (Max Grade)           xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
             Primary SOC>             xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
             Primary SOC>             xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
123/Statistical Analysis Plan ML28964 
 TABLE 14.2.34) SUMMARY OF TREATMENT-EMERGENT ADVERSE EVENTS BY SYSTEM ORGAN CLASS AND PREFERRED TERM AND STRONGEST RELATIONSHIP (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 Strongest      System Organ Class                   ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
 relationship    Preferred Term              n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
Yes    Number of patients with 
           Treatment-Emergent Adverse 
           Event (Max Grade)           xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
             Primary SOC>             xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
             Primary SOC>             xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
No     Number of patients with 
           Treatment-Emergent Adverse 
           Event (Max Grade)           xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
             Primary SOC>             xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
             Primary SOC>             xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
             < PT >                   xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
124/Statistical Analysis Plan ML28964 
TABLE 14.2.35) SUMMARY OF NON-SERIOUS TREATMENT-EMERGENT ADVERSE EVENTS WITH AN INCIDENCE OF >=5% BY SYSTEM ORGAN CLASS AND PREFERRED TERM (SAFETY POPULATION) 
________________________________________________________________________________________________________________________________________________________________________________ 
 
                                                        All Patients                                    DLBCL                                            FL 
                                                        (N=xxx)                                        (N=xx)                                          (N=xx) 
________________________________________________________________________________________________________________________________________________________________________________ 
 System Organ Class                                ______Number of Events____________             ______Number of Events___________         ______Number of Events___________ 
      Preferred Term                       n(%)    Total   TR Rituximab TR Chemotherapy    n(%)   Total TR Rituximab TR Chemotherapy   n(%) Total TR Rituximab TR Chemotherapy 
________________________________________________________________________________________________________________________________________________________________________________ 
 
Number of patients with Treatment-Emergent          
Adverse Events with Incidence >=5%    xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
  
 
 Primary SOC>                         xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
 
 
Primary SOC>                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx                         
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
      < PT >                          xx (xx.x%)    xxx      xxx         xxx              xx (xx.x%)  xxx    xxX         xxx         xx (xx.x%) xxx    xxx         xxx 
________________________________________________________________________________________________________________________________________________________________________________ 
 
 Note(s): n=number of patients with an event. TR=treatment related. 
          MedDRA = Medical Dictionary for Regulatory Activities. SOC and PT are from the MedDRA dictionary, version 24.1. 
          A patient experiencing multiple occurrences of an adverse event was counted, at most, once per System Organ Class and Preferred Term. 
 
         TEAEs are AEs occurring on the day of or after the first administration of study drug and up to 28 days after the last dose. 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
125/Statistical Analysis Plan ML28964 
TABLE 14.2.36) SUMMARY OF PATIENTS DEAD OVER THE STUDY (SAFETY POPULATION) 
 
 
 
Statistic 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Total number of patients dead 
n (%)  
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
Primary cause of death 
 
 
 
 
Progression of disease 
n (%)  
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Adverse event 
n (%)  
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Unknown 
n (%)  
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Other 
n (%)  
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
If cause of death is AE, was the underlying 
cancer a contributing factor#? 
 
 
 
 
 Yes 
n (%)  
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 No 
n (%)  
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
Is there reasonable suspected casual 
relationship to study medication? 
 
 
 
 
 Yes 
n (%)  
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 No 
n (%)  
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
Was an autopsy performed? 
 
 
 
 
 Yes 
n (%)  
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 No 
n (%)  
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 
 
 
Notes: 
Percentages are calculated relative to the total number of patients in the SAF population. 
# Percentages are calculated relative to the total number of patients with primary cause of death = “AE”. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
  
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
126/Statistical Analysis Plan ML28964 
TABLE 14.3.1) SUMMARY OF HEMATOLOGY PARAMETERS OVER THE STUDY (SAFETY POPULATION) 
  ___________________________________________________________________________________________________________________________________________________________ 
 
                                       ____________ All Patients ____________  _______________ DLBCL ________________  _________________ FL _________________ 
  Hemoglobin (g/L)                                    (N=xxx)                                  (N=xx)                                  (N=xx) 
                                                           Change from                             Change from                             Change from 
                        Statistic      Value               Screening           Value               Screening           Value               Screening 
  ___________________________________________________________________________________________________________________________________________________________ 
 
  Screening Visit       n              xxx                                     xx                                      xx 
                        Mean (SD)      xxx.x (xx.xx)                           xxx.x (xx.xx)                           xxx.x (xx.xx) 
                        Median         xxx.x                                   xxx.x                                   xxx.x 
                        Min/Max        xx.x/xxx.x                              xx.x/xxx.x                              xx.x/xxx.x 
 
  Cycle 1 Induction     n              xx                  xx                                                          xx                  xx 
                        Mean (SD)      xxx.x (xx.xx)       x.x (x.xx)                                                  xxx.x (xx.xx)       x.x (x.xx) 
                        Median         xxx.x               x.x                                                         xxx.x               x.x 
                        Min/Max        xxx.x/xxx.x         xx.x/x.x                                                    xxx.x/xxx.x         xx.x/x.x 
 
  Cycle 2 Induction     n              xx                  xx                                                          xx                  xx 
                        Mean (SD)      xxx.x (xx.xx)       x.x (xx.xx)                                                 xxx.x (xx.xx)       x.x (xx.xx) 
                        Median         xxx.x               x.x                                                         xxx.x               x.x 
                        Min/Max        xx.x/xxx.x          xx.x/xx.x                                                   xx.x/xxx.x          xx.x/xx.x 
 
  ... 
 
  Cycle x Induction     n              xx                  xx                                                          xx                  xx 
                        Mean (SD)      xxx.x (xx.xx)       x.x (xx.xx)                                                 xxx.x (xx.xx)       x.x (xx.xx) 
                        Median         xxx.x               x.x                                                         xxx.x               x.x 
                        Min/Max        xx.x/xxx.x          xx.x/xx.x                                                   xx.x/xxx.x          xx.x/xx.x 
  ___________________________________________________________________________________________________________________________________________________________ 
 
  Notes: 
  Change from Screening values includes only those patients with both a screening value and a value for summarized time period. 
  n represents number of patients contributing to summary statistics. 
 
  Source: XXXX.SAS, Run on DDMMMYYYY 
 
Programming note: 
This table to be repeated for all hematology parameters for each visit of induction and maintenance phases. 
Data must be presented according to the International System of Units (SI). 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
127/Statistical Analysis Plan ML28964 
TABLE 14.3.2) SUMMARY OF BLOOD CHEMISTRY PARAMETERS OVER THE STUDY (SAFETY POPULATION) 
 
  ___________________________________________________________________________________________________________________________________________________________ 
 
                                       ____________ All Patients ____________  _______________ DLBCL ________________  _________________ FL _________________ 
  Sodium (mmol/L)                                    (N=xxx)                                  (N=xx)                                  (N=xx) 
                                                           Change from                             Change from                             Change from 
                        Statistic      Value               Screening           Value               Screening           Value               Screening 
  ___________________________________________________________________________________________________________________________________________________________ 
 
  Screening Visit       n              xxx                                     xx                                      xx 
                        Mean (SD)      xxx.x (xx.xx)                           xxx.x (xx.xx)                           xxx.x (xx.xx) 
                        Median         xxx.x                                   xxx.x                                   xxx.x 
                        Min/Max        xx.x/xxx.x                              xx.x/xxx.x                              xx.x/xxx.x 
 
  Cycle 1 Induction     n              xx                  xx                                                          xx                  xx 
                        Mean (SD)      xxx.x (xx.xx)       x.x (x.xx)                                                  xxx.x (xx.xx)       x.x (x.xx) 
                        Median         xxx.x               x.x                                                         xxx.x               x.x 
                        Min/Max        xxx.x/xxx.x         xx.x/x.x                                                    xxx.x/xxx.x         xx.x/x.x 
 
  Cycle 2 Induction     n              xx                  xx                                                          xx                  xx 
                        Mean (SD)      xxx.x (xx.xx)       x.x (xx.xx)                                                 xxx.x (xx.xx)       x.x (xx.xx) 
                        Median         xxx.x               x.x                                                         xxx.x               x.x 
                        Min/Max        xx.x/xxx.x          xx.x/xx.x                                                   xx.x/xxx.x          xx.x/xx.x 
 
  ... 
 
  Cycle x Induction     n              xx                  xx                                                          xx                  xx 
                        Mean (SD)      xxx.x (xx.xx)       x.x (xx.xx)                                                 xxx.x (xx.xx)       x.x (xx.xx) 
                        Median         xxx.x               x.x                                                         xxx.x               x.x 
                        Min/Max        xx.x/xxx.x          xx.x/xx.x                                                   xx.x/xxx.x          xx.x/xx.x 
  ___________________________________________________________________________________________________________________________________________________________ 
 
  Notes: 
  Change from Screening values includes only those patients with both a screening value and a value for summarized time period. 
  n represents number of patients contributing to summary statistics. 
 
  Source: XXXX.SAS, Run on DDMMMYYYY 
 
Programming note: 
This table to be repeated for all blood chemistry parameters for each visit of induction and maintenance phases. 
Data must be presented according to the International System of Units (SI). 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
128/Statistical Analysis Plan ML28964 
TABLE 14.3.3) SUMMARY OF COAGULATION TESTS OVER THE STUDY (SAFETY POPULATION) 
  ___________________________________________________________________________________________________________________________________________________________ 
 
                                       ____________ All Patients ____________  _______________ DLBCL ________________  _________________ FL _________________ 
  PT (sec)                                           (N=xxx)                                   (N=xx)                                  (N=xx) 
                                                           Change from                             Change from                             Change from 
                        Statistic      Value               Screening           Value               Screening           Value               Screening 
  ___________________________________________________________________________________________________________________________________________________________ 
 
  Screening Visit       n              xxx                                     xx                                      xx 
                        Mean (SD)      xxx.x (xx.xx)                           xxx.x (xx.xx)                           xxx.x (xx.xx) 
                        Median         xxx.x                                   xxx.x                                   xxx.x 
                        Min/Max        xx.x/xxx.x                              xx.x/xxx.x                              xx.x/xxx.x 
 
  Cycle 1 Induction     n              xx                  xx                                                          xx                  xx 
                        Mean (SD)      xxx.x (xx.xx)       x.x (x.xx)                                                  xxx.x (xx.xx)       x.x (x.xx) 
                        Median         xxx.x               x.x                                                         xxx.x               x.x 
                        Min/Max        xxx.x/xxx.x         xx.x/x.x                                                    xxx.x/xxx.x         xx.x/x.x 
 
  Cycle 2 Induction     n              xx                  xx                                                          xx                  xx 
                        Mean (SD)      xxx.x (xx.xx)       x.x (xx.xx)                                                 xxx.x (xx.xx)       x.x (xx.xx) 
                        Median         xxx.x               x.x                                                         xxx.x               x.x 
                        Min/Max        xx.x/xxx.x          xx.x/xx.x                                                   xx.x/xxx.x          xx.x/xx.x 
 
  ... 
 
  Cycle x Induction     n              xx                  xx                                                          xx                  xx 
                        Mean (SD)      xxx.x (xx.xx)       x.x (xx.xx)                                                 xxx.x (xx.xx)       x.x (xx.xx) 
                        Median         xxx.x               x.x                                                         xxx.x               x.x 
                        Min/Max        xx.x/xxx.x          xx.x/xx.x                                                   xx.x/xxx.x          xx.x/xx.x 
  ___________________________________________________________________________________________________________________________________________________________ 
 
  Notes: 
  Change from Screening values includes only those patients with both a screening value and a value for summarized time period. 
  n represents number of patients contributing to summary statistics. 
 
  Source: XXXX.SAS, Run on DDMMMYYYY 
 
Programming note: 
This table to be repeated for all blood chemistry parameters for each visit of induction and maintenance phases. 
Data must be presented according to the International System of Units (SI). 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
129/Statistical Analysis Plan ML28964 
TABLE 14.3.4) SHIFT TABLE OF HEMATOLOGY PARAMETERS ACCORDING TO NCI CTCAE WORST GRADE RECORDED DURING THE TREATMENT PERIOD (SAFETY POPULATION) 
 
 
 
 
 
 
 
 
NCI CTCAE Worst Grade During Treatment Period  
 
 
 
 
Statistic 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Not Done 
All 
 
 
 
 
 
 
 
 
 
DLBCL 
Screening 
 
 
 
 
 
 
 
 
 Grade 1 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 2 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 3 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 4 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Not Done 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 All 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 
 
 
 
 
 
 
 
FL 
Screening 
 
 
 
 
 
 
 
 
 Grade 1 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 2 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 3 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 4 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Not Done 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 All 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 
 
 
 
 
 
 
 
All Patients 
Screening 
 
 
 
 
 
 
 
 
 Grade 1 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 2 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 3 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 4 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Not Done 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 All 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 
 
 
 
 
 
 
 
 
 Notes: 
 Percentage are calculated relative to the total number of patients in the SAF population (row percentages). 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
 Programming note: 
 This table to be repeated for all hematology parameters. 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
130/Statistical Analysis Plan ML28964 
TABLE 14.3.5) SHIFT TABLE OF BLOOD CHEMISTRY PARAMETERS ACCORDING TO NCI CTCAE WORST GRADE RECORDED DURING THE TREATMENT PERIOD (SAFETY POPULATION) 
 
 
 
 
 
 
 
NCI CTCAE Worst Grade During Treatment Period  
 
 
 
 
Statistic 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Not Done 
All 
 
 
 
 
 
 
 
 
 
DLBCL 
Screening 
 
 
 
 
 
 
 
 
 Grade 1 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 2 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 3 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 4 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Not Done 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 All 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 
 
 
 
 
 
 
 
FL 
Screening 
 
 
 
 
 
 
 
 
 Grade 1 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 2 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 3 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 4 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Not Done 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 All 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 
 
 
 
 
 
 
 
All Patients 
Screening 
 
 
 
 
 
 
 
 
 Grade 1 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 2 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 3 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 4 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Not Done 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 All 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 
 
 
 
 
 
 
 
 
 Notes: 
 Percentage are calculated relative to the total number of patients in the SAF population (row percentages). 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
 Programming note: 
 This table to be repeated for all blood chemistry parameters. 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
131/Statistical Analysis Plan ML28964 
TABLE 14.3.6) SHIFT TABLE OF COAGULATION TESTS ACCORDING TO NCI CTCAE WORST GRADE RECORDED DURING THE TREATMENT PERIOD (SAFETY POPULATION) 
 
 
 
 
 
 
 
NCI CTCAE Worst Grade During Treatment Period  
 
 
 
 
Statistic 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Not Done 
All 
 
 
 
 
 
 
 
 
 
DLBCL 
Screening 
 
 
 
 
 
 
 
 
 Grade 1 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 2 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 3 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 4 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Not Done 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 All 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 
 
 
 
 
 
 
 
FL 
Screening 
 
 
 
 
 
 
 
 
 Grade 1 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 2 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 3 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 4 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Not Done 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 All 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 
 
 
 
 
 
 
 
All Patients 
Screening 
 
 
 
 
 
 
 
 
 Grade 1 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 2 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 3 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Grade 4 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 Not Done 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 All 
n (%) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
xxx (xx.x) 
 
 
 
 
 
 
 
 
 
 Notes: 
 Percentage are calculated relative to the total number of patients in the SAF population (row percentages). 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
 Programming note: 
 This table to be repeated for all coagulation tests. 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
132/Statistical Analysis Plan ML28964 
TABLE 14.3.7) SUMMARY OF VITAL SIGNS OVER THE STUDY (SAFETY POPULATION) 
  ___________________________________________________________________________________________________________________________________________________________ 
 
                                       ____________ All Patients ____________  _______________ DLBCL ________________  _________________ FL _________________ 
  Heart Rate (bpm)                                   (N=xxx)                                  (N=xx)                                  (N=xx) 
                                                           Change from                             Change from                             Change from 
                        Statistic      Value               Screening           Value               Screening           Value               Screening 
  ___________________________________________________________________________________________________________________________________________________________ 
 
  Screening Visit       n              xxx                                     xx                                      xx 
                        Mean (SD)      xxx.x (xx.xx)                           xxx.x (xx.xx)                           xxx.x (xx.xx) 
                        Median         xxx.x                                   xxx.x                                   xxx.x 
                        Min/Max        xx.x/xxx.x                              xx.x/xxx.x                              xx.x/xxx.x 
 
  Cycle 1 Induction     n              xx                  xx                                                          xx                  xx 
                        Mean (SD)      xxx.x (xx.xx)       x.x (x.xx)                                                  xxx.x (xx.xx)       x.x (x.xx) 
                        Median         xxx.x               x.x                                                         xxx.x               x.x 
                        Min/Max        xxx.x/xxx.x         xx.x/x.x                                                    xxx.x/xxx.x         xx.x/x.x 
 
  Cycle 2 Induction     n              xx                  xx                                                          xx                  xx 
                        Mean (SD)      xxx.x (xx.xx)       x.x (xx.xx)                                                 xxx.x (xx.xx)       x.x (xx.xx) 
                        Median         xxx.x               x.x                                                         xxx.x               x.x 
                        Min/Max        xx.x/xxx.x          xx.x/xx.x                                                   xx.x/xxx.x          xx.x/xx.x 
 
  ... 
 
  Cycle x Induction     n              xx                  xx                                                          xx                  xx 
                        Mean (SD)      xxx.x (xx.xx)       x.x (xx.xx)                                                 xxx.x (xx.xx)       x.x (xx.xx) 
                        Median         xxx.x               x.x                                                         xxx.x               x.x 
                        Min/Max        xx.x/xxx.x          xx.x/xx.x                                                   xx.x/xxx.x          xx.x/xx.x 
  ___________________________________________________________________________________________________________________________________________________________ 
 
  Notes: 
  Change from Screening values includes only those patients with both a screening value and a value for summarized time period. 
  n represents number of patients contributing to summary statistics. 
 
  Source: XXXX.SAS, Run on DDMMMYYYY 
 
Programming note: 
This table to be repeated for Systolic Blood Pressure, Diastolic Blood Pressure, Body Weight and Body Temperature. 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
133/Statistical Analysis Plan ML28964 
TABLE 14.3.8) ECOG PERFORMANCE STATUS (SAFETY POPULATION) 
  _________________________________________________________________________________ 
 
                                     All Patients        DLBCL            FL 
                                        (N=xxx)          (N=xx)         (N=xx) 
  Cycle/Visit          ECOG-PS        n       %         n       %       n      % 
  _________________________________________________________________________________ 
 
  Screening Visit      Grade 1        xxx     x.x       xx     x.x      xx    x.x 
                       Grade 2        xxx     x.x       xx     x.x      xx    x.x 
                       Grade 3        xxx     x.x       xx     x.x      xx    x.x 
                       Grade 4        xxx     x.x       xx     x.x      xx    x.x 
                       Grade 5        xxx     x.x       xx     x.x      xx    x.x 
                       Missing        xxx     x.x       xx     x.x            x.x 
 
  Final Staging        Grade 1        xxx     x.x       xx     x.x      xx    x.x 
                       Grade 2        xxx     x.x       xx     x.x      xx    x.x 
                       Grade 3        xxx     x.x       xx     x.x      xx    x.x 
                       Grade 4        xxx     x.x       xx     x.x      xx    x.x 
                       Grade 5        xxx     x.x       xx     x.x      xx    x.x 
                       Missing        xxx     x.x       xx     x.x      xx    x.x 
  _________________________________________________________________________________ 
 
  Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
134/Statistical Analysis Plan ML28964 
TABLE 14.4.1) TARGET LESION ASSESSMENT AT SCREENING (PART #1) (SAFETY POPULATION) 
 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Were any target lesions identified? 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
Location of lesion 
 
 
 
 
Neck 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Chest 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Abdomen 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Pelvis 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Other 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
CT with contrast 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
CT result 
 
 
 
 
Negative 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Positive 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Not assessed 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
CT without contrast 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
CT w/o contrast result 
 
 
 
 
Negative 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Positive 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Not assessed 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
MRI 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
MRI result 
 
 
 
 
Negative 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Positive 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Not assessed 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 Notes: 
 Percentages are calculated relative to the total number of patients in SAF population. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
135/Statistical Analysis Plan ML28964 
TABLE 14.4.2) TARGET LESION ASSESSMENT AT SCREENING (PART #2) (SAFETY POPULATION) 
 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Clinical assessment 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
Clinical assessment result 
 
 
 
 
Negative 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Positive 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Not assessed 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
FDG-PET 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
FDG-PET result 
 
 
 
 
Negative 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Positive 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Not assessed 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
Other assessment 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
Other assessment 
 
 
 
 
Negative 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Positive 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Not assessed 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 Notes: 
 Percentages are calculated relative to the total number of patients in SAF population. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
136/Statistical Analysis Plan ML28964 
TABLE 14.4.3) POST-SCREENING TARGET LESION ASSESSMENT (PART #1) (SAFETY POPULATION) 
 
 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
 
Study Visit <XXX> 
Was a target lesions assessment done at this visit? 
 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
Were there any changes in the Target Lesions since 
the previous visit assessment? 
 
 
 
 
 
No 
 
 
 
 
 
Yes 
 
 
 
 
 
Not applicable 
 
 
 
 
 
 
 
 
 
 
 
Location of lesion 
 
 
 
 
 
Neck 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Chest 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Abdomen 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Pelvis 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Other 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
CT with contrast 
 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
CT result 
 
 
 
 
 
Increased 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Decreased 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
No change 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
CT without contrast 
 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
CT w/o contrast result 
 
 
 
 
 
Increased 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Decreased 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
No change 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
MRI 
 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
MRI result 
 
 
 
 
 
Increased 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Decreased 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
No change 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 Note: 
 Percentages are calculated relative to the total number of patients in SAF population performing the study visit. 
 
 Programming note: 
 This table should be also presented for all post-screening visits. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
137/Statistical Analysis Plan ML28964 
TABLE 14.4.4) POST-SCREENING TARGET LESION ASSESSMENT (PART #2) (SAFETY POPULATION) 
 
 
 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
 
Study Visit <XXX> 
Clinical assessment 
 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
Clinical assessment result 
 
 
 
 
 
Increased 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Decreased 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
No change 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
FDG-PET 
 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
FDG-PET result 
 
 
 
 
 
Increased 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Decreased 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
No change 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
Other assessment 
 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
Other assessment 
 
 
 
 
 
Increased 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Decreased 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
No change 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
Change in lesion since first assessed 
/previous visit 
 
 
 
 
 
Enlarged 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
No change 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Reduced in size 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Not visible/too small 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Not applicable 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 Note: 
 Percentages are calculated relative to the total number of patients in SAF population performing the study visit. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 Programming note: 
 This table should be also presented for all post-screening visits. 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
138/Statistical Analysis Plan ML28964 
TABLE 14.4.5) OVERALL LESION ASSESSMENT (SAFETY POPULATION) 
 
 
 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
 
Study Visit <XXX> 
Response of target lesions 
 
 
 
 
 
Complete response (CR) 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Complete response unconfirmed (CRu) 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Partial response (PR) 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Stable disease (SD) 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Progressive disease (PD) 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Unable to assess (UA) 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Not applicable 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
Are there any new lesions? 
 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
Investigator's overall assessment of 
response at this visit 
 
 
 
 
 
Complete response (CR) 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Complete response unconfirmed (CRu) 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Partial response (PR) 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Stable disease (SD) 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Progressive disease (PD) 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Unable to assess (UA) 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Not applicable 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 Note: 
 Percentages are calculated relative to the total number of patients in SAF population performing the study visit. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 Programming note: 
 This table should be also presented for all post-screening visits. 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
139/Statistical Analysis Plan ML28964 
 
TABLE 14.5.1) OVERALL SURVIVAL FROM FIRST DOSE OF RITUXIMAB IV (ITT POPULATION) 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Time to event (months) 
25th (95% CI)      xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
 
Median (95% CI)    xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
 
75th (95% CI)      xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
 
 
 
 
 
Number of patients 
 
 
 
 
 Events 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 Censored 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 
 
 
 Notes: 
 Percentages are calculated on the number of patients in the ITT population. 
 Overall survival(months) was estimated using Kaplan-Meier method. 
 
 Patients who are not reported as having died at the time of analysis will be censored at the last contact date.  
 Patients who do not have post-baseline information will be censored at the date of initiation of study treatment. 
 Patients enrolled but not treated will be assigned time = 0.   
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 Programming note: 
 This table should be also presented from the first dose of Rituximab SC. 
 This table should be also presented stratified by: 
a) Gender (Female, Male) 
b) FLIPI score (Low risk, Intermediate risk/High risk) for FL patients only 
c) Grade of FL (1, 2, 3a) 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
140/Statistical Analysis Plan ML28964 
TABLE 14.5.2) OVERALL SURVIVAL FROM FIRST DOSE OF RITUXIMAB IV: DISTRIBUCTION FUNCTION (ITT POPULATION) 
 
Time 
(months) 
 
 
Censoring 
Indicator 
 
Distribution 
Function  
Estimate 
Failure 
Survival 
Standard 
Error 
Number 
Failed 
SDF Lower 
Confidence 
Limit 
SDF Upper 
Confidence 
Limit 
 
 
 
 
 
 
 
 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 Data derived from Kaplan-Meier curve. 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
 Programming note: 
 This table should be presented for All Patients, DLBCL and FL groups. 
 This table should be also presented from the first dose of Rituximab SC. 
 This table should be also presented stratified by: 
a) Gender (Female, Male) 
b) FLIPI score (Low risk, Intermediate risk/High risk) for FL patients only 
c) Grade of FL (1, 2, 3a) 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
141/Statistical Analysis Plan ML28964 
TABLE 14.5.3) OVERALL SURVIVAL FROM FIRST DOSE OF RITUXIMAB IV: DISTRIBUCTION FUNCTION CURVE FOR ALL SUBJECTS (ITT POPULATION) 
 
 
 Note: 
 Data derived from Kaplan-Meier curve. 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
 Programming note: 
 This table should be also presented from the first dose of Rituximab SC. 
 This table should be also presented stratified by: 
a) Gender (Female, Male) 
b) FLIPI score (Low risk, Intermediate risk/High risk) for FL patients only 
c) Grade of FL (1, 2, 3a) 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
142/Statistical Analysis Plan ML28964 
TABLE 14.5.4) OVERALL SURVIVAL FROM FIRST DOSE OF RITUXIMAB IV: DISTRIBUCTION FUNCTION CURVE BY TYPE OF LYMPHOMA (ITT POPULATION) 
 
 
 
 Note: 
 Data derived from Kaplan-Meier curve. 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 Programming note: 
 This table should be also presented from the first dose of Rituximab SC. 
 This table should be also presented stratified by: 
a) Gender (Female, Male) 
b) FLIPI score (Low risk, Intermediate risk/High risk) for FL patients only 
c) Grade of FL (1, 2, 3a) 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
143/Statistical Analysis Plan ML28964 
TABLE 14.5.5) PROGRESSION FREE SURVIVAL FROM FIRST DOSE OF RITUXIMAB IV (ITT POPULATION) 
 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Time to event (months) 
25th (95% CI)      xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
 
Median (95% CI)    xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
 
75th (95% CI)      xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
 
 
 
 
 
Number of patients 
 
 
 
 
 Events 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 Censored 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 
 
 
Notes: 
Percentages are calculated on the number of patients in the ITT population. 
PFS (months) was estimated using Kaplan-Meier method. 
 
PFS is defined as the time from first dose of rituximab to the first occurrence of progression or relapse, or death from any cause, whichever occurs first. 
Patients who have not experienced disease progression or death at the time of analysis and patients who are lost to follow up will be censored at their last clinical assessment 
date. Patients without post-baseline tumour assessments will be censored at the time of their baseline visit except if death occurs prior to their first scheduled tumour 
assessment. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 Programming note: 
 This table should be also presented from the first dose of Rituximab SC. 
 This table should be also presented stratified by: 
d) Gender (Female, Male) 
e) FLIPI score (Low risk, Intermediate risk/High risk) for FL patients only 
f) Grade of FL (1, 2, 3a) 
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
144/Statistical Analysis Plan ML28964 
TABLE 14.5.6) PROGRESSION FREE SURVIVAL FROM FIRST DOSE OF RITUXIMAB IV: DISTRIBUCTION FUNCTION (ITT POPULATION) 
 
 
Time 
(months) 
 
 
Censoring 
Indicator 
 
Distribution 
Function  
Estimate 
Failure 
Survival 
Standard 
Error 
Number 
Failed 
SDF Lower 
Confidence 
Limit 
SDF Upper 
Confidence 
Limit 
 
 
 
 
 
 
 
 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 Data derived from Kaplan-Meier curve. 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
 Programming note: 
 This table should be presented for All Patients, DLBCL and FL groups. 
 This table should be also presented from the first dose of Rituximab SC. 
 This table should be also presented stratified by: 
a) Gender (Female, Male) 
b) FLIPI score (Low risk, Intermediate risk/High risk) for FL patients only 
c) Grade of FL (1, 2, 3a) 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
145/Statistical Analysis Plan ML28964 
TABLE 14.5.7) PROGRESSION FREE SURVIVAL FROM FIRST DOSE OF RITUXIMAB IV: DISTRIBUCTION FUNCTION CURVE FOR ALL SUBJECTS (ITT POPULATION) 
 
 
 
 Note: 
 Data derived from Kaplan-Meier curve. 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 Programming note: 
 This table should be also presented from the first dose of Rituximab SC. 
 This table should be also presented stratified by: 
a) Gender (Female, Male) 
b) FLIPI score (Low risk, Intermediate risk/High risk) for FL patients only 
c) Grade of FL (1, 2, 3a) 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
146/Statistical Analysis Plan ML28964 
TABLE 14.5.8) PROGRESSION FREE SURVIVAL FROM FIRST DOSE OF RITUXIMAB IV: DISTRIBUCTION FUNCTION CURVE by TYPE OF LYMPHOMA (ITT POPULATION) 
 
 
 
 Note: 
 Data derived from Kaplan-Meier curve. 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 Programming note: 
 This table should be also presented from the first dose of Rituximab SC. 
 This table should be also presented stratified by: 
a) Gender (Female, Male) 
b) FLIPI score (Low risk, Intermediate risk/High risk) for FL patients only 
c) Grade of FL (1, 2, 3a) 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
147/Statistical Analysis Plan ML28964 
TABLE 14.5.9) DISEASE FREE SURVIVAL (ITT POPULATION) 
 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Time to event (months) 
25th (95% CI)      xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
 
Median (95% CI)    xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
 
75th (95% CI)      xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
 
 
 
 
 
Number of patients 
 
 
 
 
 Events 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 Censored 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 
 
 
Notes: 
Percentages are calculated on the number of patients in the ITT population. 
DFS (months) was estimated using Kaplan-Meier method. 
 
DFS will be assessed in patients achieving CR/CRu and is defined as the period from the date of the initial CR/CRu until the date of relapse or death from any cause.  
Patients who have not experienced disease progression or death at the time of analysis and patients who are lost to follow up will be censored at their last clinical assessment 
date. 
 
  Source: XXXX.SAS, Run on DDMMMYYYY 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
148/Statistical Analysis Plan ML28964 
TABLE 14.5.10) DISEASE FREE SURVIVAL: DISTRIBUCTION FUNCTION (ITT POPULATION) 
 
 
Time 
(months) 
 
 
Censoring 
Indicator 
 
Distribution 
Function  
Estimate 
Failure 
Survival 
Standard 
Error 
Number 
Failed 
SDF Lower 
Confidence 
Limit 
SDF Upper 
Confidence 
Limit 
 
 
 
 
 
 
 
 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 Data derived from Kaplan-Meier curve. 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
 Programming note: 
 This table should be presented for All Patients, DLBCL and FL groups. 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
149/Statistical Analysis Plan ML28964 
TABLE 14.5.11) DISEASE FREE SURVIVAL: DISTRIBUCTION FUNCTION CURVE FOR ALL SUBJECTS (ITT POPULATION) 
 
 
 
 Note: 
 Data derived from Kaplan-Meier curve. 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
150/Statistical Analysis Plan ML28964 
TABLE 14.5.12) DISEASE FREE SURVIVAL: DISTRIBUCTION FUNCTION CURVE BY TYPE OF LYMPHOMA (ITT POPULATION) 
 
me 
 
 Note: 
 Data derived from Kaplan-Meier curve. 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
151/Statistical Analysis Plan ML28964 
TABLE 14.5.13) EVENT FREE SURVIVAL FROM FIRST DOSE OF RITUXIMAB IV (ITT POPULATION) 
 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
Time to event (months) 
25th (95% CI)      xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
 
Median (95% CI)    xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
 
75th (95% CI)      xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
xxx.x (xxx.x,xxx.x) 
 
 
 
 
 
Number of patients 
 
 
 
 
 Events 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 Censored 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
 
 
 
Notes: 
Percentages are calculated on the number of patients in the ITT population. 
EFS (months) was estimated using Kaplan-Meier method. 
 
EFS is defined as the time from first dose of rituximab to first occurrence of progression or relapse, or initiation of a non-protocol-specified anti-lymphoma therapy or death, 
whichever occurs first. 
Patients who have not experienced disease progression or relapse or initiation of a non-protocol-specified anti-lynphoma therapy or death at the time of analysis and patients who 
are lost to follow up will be censored at their last clinical assessment date. 
 
  Source: XXXX.SAS, Run on DDMMMYYYY  
 
 Programming note: 
 This table should be also presented from the first dose of Rituximab SC. 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
152/Statistical Analysis Plan ML28964 
TABLE 14.5.14) EVENT FREE SURVIVAL FROM FIRST DOSE OF RITUXIMAB IV: DISTRIBUCTION FUNCTION (ITT POPULATION) 
 
 
Time 
(months) 
 
 
Censoring 
Indicator 
 
Distribution 
Function  
Estimate 
Failure 
Survival 
Standard 
Error 
Number 
Failed 
SDF Lower 
Confidence 
Limit 
SDF Upper 
Confidence 
Limit 
 
 
 
 
 
 
 
 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
.. 
xxx 
x 
x.xxxx 
x 
x.xxxx 
xxx 
x.xxxx 
x.xxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 Data derived from Kaplan-Meier curve. 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
 Programming note: 
 This table should be presented for All Patients, DLBCL and FL groups. 
 This table should be also presented from the first dose of Rituximab SC. 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
153/Statistical Analysis Plan ML28964 
TABLE 14.5.15) EVENT FREE SURVIVAL FROM FIRST DOSE OF RITUXIMAB IV: DISTRIBUCTION FUNCTION CURVE FOR ALL SUBJECTS (ITT POPULATION) 
 
 
 
 Note: 
 Data derived from Kaplan-Meier curve. 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 Programming note: 
 This table should be also presented from the first dose of Rituximab SC. 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
154/Statistical Analysis Plan ML28964 
TABLE 14.5.16) EVENT FREE SURVIVAL FROM FIRST DOSE OF RITUXIMAB IV: DISTRIBUCTION FUNCTION CURVE BY TYPE OF LYMPHOMA (ITT POPULATION) 
 
 
 
 Note: 
 Data derived from Kaplan-Meier curve. 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 Programming note: 
 This table should be also presented from the first dose of Rituximab SC. 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
155/Statistical Analysis Plan ML28964 
TABLE 14.5.17) SUMMARY OF COMPLETE RESPONSE OR COMPLETE RESPONSE UNCONFIRMED (ITT POPULATION) 
 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
CR 
n/N1 (%) - 95% CI   xx/XXX (xx.x%) – xx.x,xx.x 
 xx/XXX (xx.x%) – xx.x,xx.x 
 xx/XXX (xx.x%) – xx.x,xx.x 
CRu (unconfirmed) 
n/N1 (%) - 95% CI   xx/XXX (xx.x%) – xx.x,xx.x 
 xx/XXX (xx.x%) – xx.x,xx.x 
 xx/XXX (xx.x%) – xx.x,xx.x 
CR/CRu 
n/N1 (%) - 95% CI   xx/XXX (xx.x%) – xx.x,xx.x 
 xx/XXX (xx.x%) – xx.x,xx.x 
 xx/XXX (xx.x%) – xx.x,xx.x 
 
 
 
 
 
  
  Notes: 
  CR = Complete Response. CRu = Complete Response Unconfirmed. 
  N1=Number of patients have evaluable overall lesion assessment data. 
  Two-sided Clopper-Pearson confidence interval. 
  Tumour assessment measured four weeks after the end of the Induction treatment. 
  Number of patients performing the tumour assessment was used as denominator. 
 
  Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
156/Statistical Analysis Plan ML28964 
TABLE 14.6.1) RITUXIMAB IV ADMINISTRATION SATIFICATION QUESTIONNAIRE - ITEMS FREQUENCY ANALYSIS (SAFETY POPULATION) 
 
 
 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
 
Study Visit <xxx> 
Was the RASQ questionnaire completed? 
 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
1.Thinking about the Rituximab IV infusion, how satisfied or 
dissatisfied are you with the IV infusion? 
 
 
 
 
 
Very satisfied 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Satisfied 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Neither satisfied nor dissatisfied 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Dissatisfied 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Very dissatisfied 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Patient did not answer question 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
2.Thinking about the Rituximab IV infusion, how do you rate the 
pain, swelling or redness you experienced at the site of the drug 
infusion? 
 
 
 
 
 
None 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Mild 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Moderate 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Severe 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Very severe 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Patient did not answer question 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
…  
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 Percentages are calculated relative to the total number of patients in SAF population performing the RASQ questionnaire for Rituximab IV administration. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 Programming note: 
 All items of RASQ questionnaire for Rituximab IV administration must be presented. 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
157/Statistical Analysis Plan ML28964 
TABLE 14.6.2) RITUXIMAB SC ADMINISTRATION SATIFICATION QUESTIONNAIRE - ITEMS FREQUENCY ANALYSIS (SAFETY POPULATION) 
 
 
 
 
 
 
Statistic 
 
All Patients 
(N=xxx) 
DLBCL 
(N=xxx) 
FL 
(N=xxx) 
 
 
 
 
 
 
Study Visit <xxx> 
Was the RASQ questionnaire completed? 
 
 
 
 
 
No 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Yes 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
1.Thinking about the Rituximab SC injection, how satisfied or 
dissatisfied are you with the SC injection? 
 
 
 
 
 
Very satisfied 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Satisfied 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Neither satisfied nor dissatisfied 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Dissatisfied 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Very dissatisfied 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Patient did not answer question 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
 
 
 
 
 
 
2.Thinking about the Rituximab SC injection, how do you rate the 
pain, swelling or redness you experienced at the site of the drug 
infusion? 
 
 
 
 
 
None 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Mild 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Moderate 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Severe 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Very severe 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
Patient did not answer question 
n (%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
 
…  
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 Percentages are calculated relative to the total number of patients in SAF population performing the RASQ questionnaire for Rituximab SC administration. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 Programming note: 
 All items of RASQ questionnaire for Rituximab SC administration must be presented. 
 
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
158/Statistical Analysis Plan ML28964 
TABLE 14.6.3) SUMMARY OF RITUXIMAB ADMINISTRATION SATISFACTION QUESTIONNAIRE IV MEAN SCORES (SAFETY POPULATION) 
  __________________________________________________________________________________________ 
 
  Physical Impact domain 
                                       All Patients        DLBCL               FL 
                        Statistic      (N=xx)             (N=xx)              (N=xx) 
  __________________________________________________________________________________________ 
 
  Visit xx              n              xx               xx                    xx                 
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)       
                        Median         xx.x             xx.x                  xx.x               
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x          
 
  Visit xx              n              xx               xx                    xx                 
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)       
                        Median         xx.x             xx.x                  xx.x               
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x          
 
  Visit xx              n              xx               xx                    xx                 
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)       
                        Median         xx.x             xx.x                  xx.x               
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x          
  __________________________________________________________________________________________ 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
  
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
159/Statistical Analysis Plan ML28964 
TABLE 14.6.4) SUMMARY OF RITUXIMAB ADMINISTRATION SATISFACTION QUESTIONNAIRE IV MEAN SCORES (SAFETY POPULATION) 
  __________________________________________________________________________________________ 
 
  Psychological Impact domain 
                                       All Patients        DLBCL               FL 
                        Statistic      (N=xx)             (N=xx)              (N=xx) 
  __________________________________________________________________________________________ 
 
  Visit xx              n              xx               xx                    xx                 
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)       
                        Median         xx.x             xx.x                  xx.x               
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x          
 
  Visit xx              n              xx               xx                    xx                 
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)       
                        Median         xx.x             xx.x                  xx.x               
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x          
 
  Visit xx              n              xx               xx                    xx                 
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)       
                        Median         xx.x             xx.x                  xx.x               
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x          
  __________________________________________________________________________________________ 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
  
 
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
160/Statistical Analysis Plan ML28964 
TABLE 14.6.5) SUMMARY OF RITUXIMAB ADMINISTRATION SATISFACTION QUESTIONNAIRE IV MEAN SCORES (SAFETY POPULATION) 
  __________________________________________________________________________________________ 
 
  Impact on Activities of Daily Living domain  
 
                                       All Patients        DLBCL               FL 
                        Statistic      (N=xx)             (N=xx)              (N=xx) 
  __________________________________________________________________________________________ 
 
  Visit xx              n              xx               xx                    xx                 
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)       
                        Median         xx.x             xx.x                  xx.x               
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x          
 
  Visit xx              n              xx               xx                    xx                 
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)       
                        Median         xx.x             xx.x                  xx.x               
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x          
 
  Visit xx              n              xx               xx                    xx                 
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)       
                        Median         xx.x             xx.x                  xx.x               
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x          
  __________________________________________________________________________________________ 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
161/Statistical Analysis Plan ML28964 
TABLE 14.6.6) SUMMARY OF RITUXIMAB ADMINISTRATION SATISFACTION QUESTIONNAIRE IV MEAN SCORES (SAFETY POPULATION) 
  ___________________________________________________________________________________________ 
 
 
   
  Convenience domain  
                                       All Patients        DLBCL               FL 
                        Statistic      (N=xx)             (N=xx)              (N=xx) 
  ___________________________________________________________________________________________ 
 
  Visit xx              n              xx               xx                    xx                  
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)        
                        Median         xx.x             xx.x                  xx.x                
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x           
 
  Visit xx              n              xx               xx                    xx                  
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)        
                        Median         xx.x             xx.x                  xx.x                
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x           
 
  Visit xx              n              xx               xx                    xx                  
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)        
                        Median         xx.x             xx.x                  xx.x                
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x           
  ___________________________________________________________________________________________ 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
162/Statistical Analysis Plan ML28964 
TABLE 14.6.7) SUMMARY OF RITUXIMAB ADMINISTRATION SATISFACTION QUESTIONNAIRE IV MEAN SCORES (SAFETY POPULATION) 
  __________________________________________________________________________________________ 
 
   
  Satisfaction domain 
                                       All Patients        DLBCL               FL 
                        Statistic      (N=xx)             (N=xx)              (N=xx) 
  __________________________________________________________________________________________ 
 
  Visit xx              n              xx               xx                    xx                
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)      
                        Median         xx.x             xx.x                  xx.x              
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x         
 
  Visit xx              n              xx               xx                    xx                
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)      
                        Median         xx.x             xx.x                  xx.x              
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x         
 
  Visit xx              n              xx               xx                    xx                
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)      
                        Median         xx.x             xx.x                  xx.x              
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x         
  __________________________________________________________________________________________ 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
163/Statistical Analysis Plan ML28964 
TABLE 14.6.8) SUMMARY OF RITUXIMAB ADMINISTRATION SATISFACTION QUESTIONNAIRE SC MEAN SCORES (SAFETY POPULATION) 
  _________________________________________________________________________________________ 
 
  Physical Impact domain 
                                       All Patients        DLBCL               FL 
                        Statistic      (N=xx)             (N=xx)              (N=xx) 
  _________________________________________________________________________________________ 
 
  Visit xx              n              xx               xx                    xx                
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)      
                        Median         xx.x             xx.x                  xx.x              
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x         
 
  Visit xx              n              xx               xx                    xx                
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)      
                        Median         xx.x             xx.x                  xx.x              
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x         
 
  Visit xx              n              xx               xx                    xx                
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)      
                        Median         xx.x             xx.x                  xx.x              
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x         
  _________________________________________________________________________________________ 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
164/Statistical Analysis Plan ML28964 
TABLE 14.6.9) SUMMARY OF RITUXIMAB ADMINISTRATION SATISFACTION QUESTIONNAIRE SC MEAN SCORES (SAFETY POPULATION) 
  __________________________________________________________________________________________ 
 
  Psychological Impact domain 
                                       All Patients        DLBCL               FL 
                        Statistic      (N=xx)             (N=xx)              (N=xx) 
  __________________________________________________________________________________________ 
 
  Visit xx              n              xx               xx                    xx               
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)     
                        Median         xx.x             xx.x                  xx.x             
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x        
 
  Visit xx              n              xx               xx                    xx               
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)     
                        Median         xx.x             xx.x                  xx.x             
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x        
 
  Visit xx              n              xx               xx                    xx               
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)     
                        Median         xx.x             xx.x                  xx.x             
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x        
  __________________________________________________________________________________________ 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
  
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
165/Statistical Analysis Plan ML28964 
TABLE 14.6.10) SUMMARY OF RITUXIMAB ADMINISTRATION SATISFACTION QUESTIONNAIRE SC MEAN SCORES (SAFETY POPULATION) 
  ___________________________________________________________________________________________ 
 
  Impact on Activities of Daily Living domain  
 
                                       All Patients        DLBCL               FL 
                        Statistic      (N=xx)             (N=xx)              (N=xx) 
  ___________________________________________________________________________________________ 
 
  Visit xx              n              xx               xx                    xx               
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)     
                        Median         xx.x             xx.x                  xx.x             
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x        
 
  Visit xx              n              xx               xx                    xx               
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)     
                        Median         xx.x             xx.x                  xx.x             
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x        
 
  Visit xx              n              xx               xx                    xx               
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)     
                        Median         xx.x             xx.x                  xx.x             
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x        
  ___________________________________________________________________________________________ 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
166/Statistical Analysis Plan ML28964 
TABLE 14.6.11) SUMMARY OF RITUXIMAB ADMINISTRATION SATISFACTION QUESTIONNAIRE SC MEAN SCORES (SAFETY POPULATION) 
  ___________________________________________________________________________________________ 
 
   
  Convenience domain  
                                       All Patients        DLBCL               FL 
                        Statistic      (N=xx)             (N=xx)              (N=xx) 
  ___________________________________________________________________________________________ 
 
  Visit xx              n              xx               xx                    xx                  
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)        
                        Median         xx.x             xx.x                  xx.x                
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x           
 
  Visit xx              n              xx               xx                    xx                  
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)        
                        Median         xx.x             xx.x                  xx.x                
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x           
 
  Visit xx              n              xx               xx                    xx                  
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)        
                        Median         xx.x             xx.x                  xx.x                
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x           
  ___________________________________________________________________________________________ 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
  
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
167/Statistical Analysis Plan ML28964 
TABLE 14.6.12) SUMMARY OF RITUXIMAB ADMINISTRATION SATISFACTION QUESTIONNAIRE SC MEAN SCORES (SAFETY POPULATION) 
  _________________________________________________________________________________________ 
 
   
  Satisfaction domain 
                                       All Patients        DLBCL               FL 
                        Statistic      (N=xx)             (N=xx)              (N=xx) 
  _________________________________________________________________________________________ 
 
  Visit xx              n              xx               xx                    xx              
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)    
                        Median         xx.x             xx.x                  xx.x            
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x       
 
  Visit xx              n              xx               xx                    xx              
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)    
                        Median         xx.x             xx.x                  xx.x            
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x       
 
  Visit xx              n              xx               xx                    xx              
                        Mean (SD)      xx.x (xx.xx)     xx.x (xx.xx)          xx.x (xx.xx)    
                        Median         xx.x             xx.x                  xx.x            
                        Min/Max        xx.x/xx.x        xx.x/xx.x             xx.x/xx.x       
  _________________________________________________________________________________________ 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
168/Statistical Analysis Plan ML28964 
TABLE 14.6.13) HEALTHCARE PROFESSIONAL QUESTIONNAIRE (PART #1)  
 
 
 
 
Statistic 
 
All Healthcare  
Professionals 
(N=xxx) 
 
 
 
Was the HCP questionnaire completed? 
 
 
No 
n (%) 
xxx (xx.x%) 
Yes 
n (%) 
xxx (xx.x%) 
 
 
 
1.Did you personally administer the SC Rituximab in the study? 
 
 
Always 
n (%) 
xxx (xx.x%) 
Sometimes 
n (%) 
xxx (xx.x%) 
Never 
n (%) 
xxx (xx.x%) 
 
 
 
1a. If never, who did administer the SC Rituximab in the study? 
 
 
Other hematologist 
n (%) 
xxx (xx.x%) 
Other internist 
n (%) 
xxx (xx.x%) 
Oncology/chemo nurse 
n (%) 
xxx (xx.x%) 
Other 
n (%) 
xxx (xx.x%) 
 
 
 
2.How many minutes preparation time was required after receiving 
the Rituximab vial from the pharmacy? 
 
 
<5 
n (%) 
xxx (xx.x%) 
6-10 
n (%) 
xxx (xx.x%) 
11-15 
n (%) 
xxx (xx.x%) 
16-20 
n (%) 
xxx (xx.x%) 
>20 
n (%) 
xxx (xx.x%) 
Not sure 
n (%) 
xxx (xx.x%) 
 
 
 
3.How many minutes in total did it usually take to administer the 
Rituximab subcutaneously using the hand held syringe? 
 
 
<5 
n (%) 
xxx (xx.x%) 
6-15 
n (%) 
xxx (xx.x%) 
16-30 
n (%) 
xxx (xx.x%) 
31-60 
n (%) 
xxx (xx.x%) 
61-90 
n (%) 
xxx (xx.x%) 
>90 
n (%) 
xxx (xx.x%) 
Not sure 
n (%) 
xxx (xx.x%) 
 
 
 
4.How long do you think the SC sessions usually lasted from 
patients' arrival until departure 
 
 
<2 hours 
n (%) 
xxx (xx.x%) 
>2 but <3 hours 
n (%) 
xxx (xx.x%) 
>3 but <4 hours 
n (%) 
xxx (xx.x%) 
 
 
 
5.How anxious do you think the SC treatment made patients feel? 
 
 
Not al all 
n (%) 
xxx (xx.x%) 
Fairly 
n (%) 
xxx (xx.x%) 
Very 
n (%) 
xxx (xx.x%) 
 
 
 
 
 Note: 
 Percentages are calculated relative to the total number of healthcare professional performing the HCP questionnaire. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
169/Statistical Analysis Plan ML28964 
TABLE 14.6.14) HEALTHCARE PROFESSIONAL QUESTIONNAIRE (PART #2)  
 
 
 
 
Statistic 
 
All Healthcare  
Professionals 
(N=xxx) 
 
 
 
6.How reliable was using the hand held syringe to give Rituximab 
subcutaneously? 
 
 
Not at all 
n (%) 
xxx (xx.x%) 
Fairly 
n (%) 
xxx (xx.x%) 
Very 
n (%) 
xxx (xx.x%) 
Extremely 
n (%) 
xxx (xx.x%) 
 
 
 
7.Overall how easy did you/your staff find giving Rituximab 
subcutaneously using the hand held syringe? 
 
 
Not at all 
n (%) 
xxx (xx.x%) 
Fairly 
n (%) 
xxx (xx.x%) 
Very 
n (%) 
xxx (xx.x%) 
Extremely 
n (%) 
xxx (xx.x%) 
 
 
 
8.How likely would you be to offer or recommend SC administration 
of Rituximab via a hand held syringe to your patients in the 
future? 
 
 
Not at all 
n (%) 
xxx (xx.x%) 
Fairly 
n (%) 
xxx (xx.x%) 
Very 
n (%) 
xxx (xx.x%) 
Extremely 
n (%) 
xxx (xx.x%) 
 
 
 
9.In general how would you describe your experience regarding the 
Rituximab SC treatment? 
 
 
Satisfactory 
n (%) 
xxx (xx.x%) 
Unsatisfactory 
n (%) 
xxx (xx.x%) 
 
 
 
 
 Note: 
Percentages are calculated relative to the total number of healthcare professional performing the HCP questionnaire. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
170/Statistical Analysis Plan ML28964 
LISTING 16.2.1)1. ANALYSIS SETS 
 
 
Patient 
 
Site 
Intent-To-Treat 
Population 
Safety 
Population 
Reason for Exclusion 
from Safety 
Population 
Type of 
Lymphoma 
 
 
 
 
 
 
xxxx 
xxxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
171/Statistical Analysis Plan ML28964 
LISTING 16.2.1)2. INCLUSION/EXCLUSION CRITERIA VIOLATED 
 
 
Patient 
 
Type of 
Lymphoma 
Failed Criteria 
 
 
 
xxxx 
xxxx 
xxx 
xxxx 
xxxx 
xxx 
xxxx 
xxxx 
xxx 
xxxx 
xxxx 
xxx 
 
 
 
 
 
 
 
Note: 
Only I/E criteria failed are reported in this line listing. 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
172/Statistical Analysis Plan ML28964 
LISTING 16.2.2)1. MAJOR PROTOCOL DEVIATIONS 
 
 
Patient 
 
Type of 
Lymphoma 
Category 
Description of Deviation 
 
 
 
 
xxxx 
xxxx 
xxxxx 
xxxxx 
 
 
xxxxx 
xxxxx 
 
 
 
 
xxxx 
xxxx 
xxxxx 
xxxxx 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxxx 
xxxxx 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
173/Statistical Analysis Plan ML28964 
LISTING 16.2.2)2. MINOR PROTOCOL DEVIATIONS 
 
 
Patient 
 
Type of 
Lymphoma 
Category 
Description of Deviations 
 
 
 
 
xxxx 
xxxx 
xxxxx 
xxxxx 
 
 
xxxxx 
xxxxx 
 
 
 
 
xxxx 
xxxx 
xxxxx 
xxxxx 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxxx 
xxxxx 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
174/Statistical Analysis Plan ML28964 
LISTING 16.2.2)3. COVID-19 RELATED PROTOCOL DEVIATIONS 
 
 
Patient 
 
Type of 
Lymphoma 
Category 
Description of Deviations 
 
 
 
 
xxxx 
xxxx 
xxxxx 
xxxxx 
 
 
xxxxx 
xxxxx 
 
 
 
 
xxxx 
xxxx 
xxxxx 
xxxxx 
 
 
 
 
xxxx 
xxxx 
xxxxx 
xxxxx 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
175/Statistical Analysis Plan ML28964 
LISTING 16.2.3)1. STUDY DRUG DISCONTINUATION 
 
 
Patient 
 
Type of 
Lymphoma 
Study Drug 
Discontinued? 
Date of Trt 
Discontinuation 
Primary Reason 
for trt 
Discontinuation 
If Other, 
Specify 
Date of Last 
Rituximab Dose 
Date of Last 
Chemotherapy 
Dose 
Will the Patient 
Proceed the FUP? 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
176/Statistical Analysis Plan ML28964 
LISTING 16.2.4)1. INFORMED CONSENT & DEMOGRAPHY 
 
 
Patient 
 
Type of 
Lymphoma 
Was IC 
Obtained?  
Date of 
Consent 
Date of 
Birth 
Age 
(yrs) 
Sex 
If Female, 
Childbearing 
Potential 
Ethnicity 
If Other, Specify 
Derived Age from Birth 
Year and ICF Date 
Height 
(cm) 
Weight 
(Kg) 
BMI 
(Kg/m^2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
177/Statistical Analysis Plan ML28964 
LISTING 16.2.4)2. MEDICAL HISTORY 
 
 
Patient 
 
Type of 
Lymphoma No. 
Medical 
History 
Term 
LLT 
PT 
SOC Start Date 
(DDMMMYYYY) 
Stop Date 
(DDMMMYYYY) 
Ongoing at 
Study Entry? 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
DDMMMYYYY 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
178/Statistical Analysis Plan ML28964 
LISTING 16.2.4)3. SURGERY AND PROCEDURES HISTORY (CANCER AND NON-CANCER RELATED) 
 
 
Patient 
 
Type of 
Lymphoma  No. Has patient Any Cancer or 
Non-Cancer Surgeries? 
History Type 
Surgery/Procedure Date of 
Surgery/Procedure 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
179/Statistical Analysis Plan ML28964 
LISTING 16.2.4)4. DLBCL DIAGNOSIS 
 
 
Patient 
 
Type of 
Lymphoma 
Date of 
Histological 
Diagnosis 
How Was Histological 
Diagnosis Obtained? 
If Fine Needle Aspiration, 
Provide Details 
CD20+ Expression 
 
 
 
 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
180/Statistical Analysis Plan ML28964 
LISTING 16.2.4)5. FOLLICULAR LYMPHOMA DIAGNOSIS 
 
 
Patient 
 
Type of 
Lymphoma 
Date of 
Histological 
Diagnosis 
How Was Histological 
Diagnosis Obtained? 
If Fine Needle Aspiration, 
Provide Details 
Grade of FL 
CD20+ Expression 
 
 
 
 
 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
181/Statistical Analysis Plan ML28964 
LISTING 16.2.4)6. ECOG PERFORMANCE STATUS, FLIPI AND IPI SCORE 
 
 
Patient 
 
Type of 
Lymphoma 
Date of 
Assessment 
of ECOG PS 
ECOG PS 
Date of 
Assessment 
of FLIPI 
Score 
FLIPI Score 
Date of 
Assessment 
of IPI Score 
IPI Score 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
182/Statistical Analysis Plan ML28964 
 
LISTING 16.2.4)7. VIRAL SEROLOGY AT SCREENING 
 
 
Patient 
 
Type of 
Lymphoma 
Was Viral 
Serology Sample 
Collected?  
Date of Sample 
Collection 
HBcAb 
HbsAg 
HCV  
Antibody 
HIV 
Antibody 
Viral Infection 
with HBV or HCV? 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
183/Statistical Analysis Plan ML28964 
 
LISTING 16.2.4)8. CONCOMITANT MEDICATIONS 
 
 
Patient 
 
Type of 
Lymphoma No. Medication 
Name 
PT 
SOC Reason for 
Medication 
If Other, 
Specify 
Indication Start Date 
(DDMMMYYYY) Dose Dose 
Unit Freq. Route 
If Other, Specify Stop Date 
(DDMMMYYYY) 
Ongoing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx xxx 
xxx 
xxx 
DDMMMYYYY 
xxx xxx xxx 
xxxxxx 
xxxxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx xxx 
xxx 
xxx 
DDMMMYYYY 
xxx xxx xxx 
xxxxxx 
xxxxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx xxx 
xxx 
xxx 
DDMMMYYYY 
xxx xxx xxx 
xxxxxx 
xxxxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx xxx 
xxx 
xxx 
DDMMMYYYY 
xxx xxx xxx 
xxxxxx 
xxxxxx 
DDMMMYYYY 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
184/Statistical Analysis Plan ML28964 
LISTING 16.2.5)1. PREVIOUS IV RITUXIMAB DOSE – DLBCL 
 
 
Patient 
 
Type of 
Lymphoma 
No. of Previous 
IV Rituximab 
Treatment Cycles 
Dose of Most 
Recent IV 
Rituximab 
Cycle 
Date of 1st 
Rituximab IV 
Administration 
Wich Treatment Cycle is 
the Subject’s First  
on-Study Cycle? 
 
 
 
 
 
 
xxxx 
xxxx 
xxx 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxx 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxx 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxx 
xxx 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
185/Statistical Analysis Plan ML28964 
LISTING 16.2.5)2. PREVIOUS IV RITUXIMAB DOSE – FL 
 
 
Patient 
 
Type of 
Lymphoma 
Phase of IV 
Rituximab 
No. of Cycles 
of IV 
Rituximab 
Recived 
Previously 
Date of 1st 
Rituximab IV 
Administration 
Dose of Most 
Recent IV 
Rituximab 
Cycle 
Eligible Phase 
to Enter the 
Study 
Wich Treatment Cycle is 
the Subject’s First  
on-Study Cycle? 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxx 
xxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxx 
xxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxx 
xxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxx 
xxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
186/Statistical Analysis Plan ML28964 
LISTING 16.2.5)3. INITIAL CHOP 
 
 
Patient 
 
Type of 
Lymphoma 
Start Date 
of CHOP 
Cyclophosphamide 
Fixed Unit 
(mg/m^2) 
Doxorubicin 
Fixed Unit 
(mg/m^2) 
Vincristine 
Fixed Unit 
(mg/m^2) 
Prednisone/Prednisolone 
Fixed Unit 
(mg/m^2) 
 
 
 
 
 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
187/Statistical Analysis Plan ML28964 
LISTING 16.2.5)4. SUBSEQUENT CHOP 
 
 
Patient 
 
Type of 
Lymphoma Cycle 
If Patient Receiving Same 
Regimen as in the Previous 
Cycle? 
Start Date 
If No, Specify Regimen Moved Onto 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
188/Statistical Analysis Plan ML28964 
LISTING 16.2.5)5. SUBSEQUENT CVP 
 
 
Patient 
 
Type of 
Lymphoma Cycle 
If Patient Receiving Same 
Regimen as in the Previous 
Cycle? 
Start Date 
If No, Specify Regimen Moved Onto 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
189/Statistical Analysis Plan ML28964 
LISTING 16.2.5)6. SUBSEQUENT FLUDARABINE 
 
 
Patient 
 
Type of 
Lymphoma Cycle 
If Patient Receiving Same 
Regimen as in the Previous 
Cycle? 
Start Date 
If No, Specify Regimen Moved Onto 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
190/Statistical Analysis Plan ML28964 
LISTING 16.2.5)7. SUBSEQUENT CHEMOTHERAPY 
 
 
Patient 
 
Type of 
Lymphoma Cycle 
If Patient Receiving Same 
Regimen as in the Previous 
Cycle? 
Start Date 
If No, Specify Regimen Moved Onto 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
191/Statistical Analysis Plan ML28964 
LISTING 16.2.5)8. INITIAL CVP 
 
 
Patient 
 
Type of 
Lymphoma 
Start Date 
of CVP 
Cyclophosphamide 
Fixed Unit 
(mg/m^2) 
Vincristine 
Fixed Unit 
(mg/m^2) 
Prednisone/Prednisolone 
Fixed Unit 
(mg/m^2) 
 
 
 
 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
192/Statistical Analysis Plan ML28964 
LISTING 16.2.5)9. INITIAL FLUDARABINE 
 
 
Patient 
 
Type of 
Lymphoma 
Start Date 
Fludarabine  
Fixed Unit 
(mg/m^2) 
Cyclophosphamide 
Fixed Unit 
(mg/m^2) 
 
 
 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
193/Statistical Analysis Plan ML28964 
LISTING 16.2.5)10. OTHER CHEMOTHERAPY 
 
 
Patient 
 
Type of 
Lymphoma Chemotherapy Agent 
Regimen 
Start Date 
Dose 
Unit 
Regimen  
Stop Date 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
194/Statistical Analysis Plan ML28964 
LISTING 16.2.5)11. STUDY DRUG ADMINISTRATION 
 
 
Patient 
 
Type of 
Lymphoma Visit Was Rituximab 
Administered? 
Start Date 
Start 
Time 
Stop Date 
Stop 
Time 
Intended 
Total Dose 
Actual 
 Total Dose 
Was Full 
Dose Given? 
If No, 
Provide 
Reason 
If Other, 
Specify 
If AE, is 
Grade 3-4 
IIRR? 
Drug 
Administered 
on time per 
Schedule 
If No, 
Specify 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
hh:mm 
DDMMMYYYY hh:mm 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
hh:mm 
DDMMMYYYY hh:mm 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
hh:mm 
DDMMMYYYY hh:mm 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
hh:mm 
DDMMMYYYY hh:mm 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
hh:mm 
DDMMMYYYY hh:mm 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
hh:mm 
DDMMMYYYY hh:mm 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
hh:mm 
DDMMMYYYY hh:mm 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
hh:mm 
DDMMMYYYY hh:mm 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
195/Statistical Analysis Plan ML28964 
LISTING 16.2.5)12. ANTI-LYMPHOMA CHEMO/IMMUNO THERAPY TREATMENT 
 
 
Patient 
 
Type of 
Lymphoma 
New Chemo/Immuno 
Therapy for FL 
Seq. Drug Name Cumulative 
Dose 
Unit 
No. 
Cycles 
Start Date End Date 
Response 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxxx 
xxx xxx 
xxx 
xxx 
xxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxxx 
xxx xxx 
xxx 
xxx 
xxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxxx 
xxx xxx 
xxx 
xxx 
xxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxxx 
xxx xxx 
xxx 
xxx 
xxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
196/Statistical Analysis Plan ML28964 
LISTING 16.2.5)13. ANTI-LYMPHOMA RADIOTHERAPY TREATMENT 
 
 
Patient 
 
Type of 
Lymphoma 
New Radiotherapy 
for FL 
Seq. Irradiation 
Site 
If Other, 
Specify 
Cumulative 
Dose 
Unit 
Start Date End Date 
Response 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxxx 
xxx xxx 
xxx 
xxx 
xxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxxx 
xxx xxx 
xxx 
xxx 
xxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxxx 
xxx xxx 
xxx 
xxx 
xxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxxx 
xxx xxx 
xxx 
xxx 
xxx 
DDMMMYYYY 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
197/Statistical Analysis Plan ML28964 
LISTING 16.2.5)14. ANTI-LYMPHOMA TREATMENT 
 
 
Patient 
 
Type of 
Lymphoma 
New Non-Protocol Specified 
Anti-Lymphoma Treatment 
Start Date 
Anti-Lymphoma 
Treatment 
Radiotherapy 
Chemo-Immuno 
Therapy 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
DDMMMYYYY 
xxxxx 
xxxxx 
xxxxx 
xxxx 
xxxx 
x 
DDMMMYYYY 
xxxxx 
xxxxx 
xxxxx 
xxxx 
xxxx 
x 
DDMMMYYYY 
xxxxx 
xxxxx 
xxxxx 
xxxx 
xxxx 
x 
DDMMMYYYY 
xxxxx 
xxxxx 
xxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
198/Statistical Analysis Plan ML28964 
LISTING 16.2.5)15. CHEMOTHERAPY SELECTION 
 
 
Patient 
 
Type of 
Lymphoma 
Chemotherapy 
Regiment 
If Other, Specify 
 
 
 
 
xxxx 
xxxx 
xxxxx 
xxxxx 
xxxx 
xxxx 
xxxxx 
xxxxx 
xxxx 
xxxx 
xxxxx 
xxxxx 
xxxx 
xxxx 
xxxxx 
xxxxx 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
199/Statistical Analysis Plan ML28964 
LISTING 16.2.6)1. PRE-TREATMENT ADVERSE EVENTS 
 
 
Patient 
 
Type of 
Lymphoma  No. Description LLT 
PT 
SOC Start Date 
(DDMMMYYYY) SAE Initial 
Intensity AESI AAR Extreme 
Intensity 
Relation to 
Chemotherapy 
Action  
Taken with 
Chemotherapy 
AE Required 
Treatment 
Outcome End Date 
(DDMMMYYYY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 ARR = Administration-associated reaction. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
200/Statistical Analysis Plan ML28964 
LISTING 16.2.6)2. ADVERSE EVENTS 
 
 
Patient 
 
Type of 
Lymphoma No. Description LLT PT 
SOC Start Date 
(DDMMMYYYY) SAE Initial 
Intensity AESI AAR Extreme 
Intensity 
Relation to 
Rituximab 
Action  
Taken with 
Rituximab 
Relation to 
Chemotherapy 
Action  
Taken with 
Chemotherapy 
AE Required 
Treatment 
Outcome End Date 
(DDMMMYYYY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx xxxx xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx xxxx xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx xxxx xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx xxxx xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 ARR = Administration-associated reaction. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
201/Statistical Analysis Plan ML28964 
LISTING 16.2.6)3. SERIOUS ADVERSE EVENTS 
 
 
Patient 
 
Type of 
Lymphoma No. Description LLT 
PT 
SOC Start Date 
(DDMMMYYYY) SAE Initial 
Intensity AESI AAR Extreme 
Intensity 
Relation to 
Rituximab 
Action  
Taken with 
Rituximab 
Relation to 
Chemotherapy 
Action  
Taken with 
Chemotherapy 
AE Required 
Treatment 
Outcome End Date 
(DDMMMYYYY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 ARR = Administration-associated reaction. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
202/Statistical Analysis Plan ML28964 
LISTING 16.2.6)4. ADVERSE EVENTS OF SPECIAL INTEREST (AESI) 
 
 
Patient 
 
Type of 
Lymphoma No. Description LLT 
PT 
SOC Start Date 
(DDMMMYYYY) SAE Initial 
Intensity AESI AAR Extreme 
Intensity 
Relation to 
Rituximab 
Action  
Taken with 
Rituximab 
Relation to 
Chemotherapy 
Action  
Taken with 
Chemotherapy 
AE Required 
Treatment 
Outcome End Date 
(DDMMMYYYY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 ARR = Administration-associated reaction. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
203/Statistical Analysis Plan ML28964 
LISTING 16.2.6)5. ADMINISTERED ASSOCIATED REACTIONS 
 
 
Patient 
 
Type of 
Lymphoma  No. Description LLT 
PT 
SOC Start Date 
(DDMMMYYYY) SAE Initial 
Intensity AESI AAR Extreme 
Intensity 
Relation to 
Rituximab 
Action  
Taken with 
Rituximab 
Relation to 
Chemotherapy 
Action  
Taken with 
Chemotherapy 
AE Required 
Treatment 
Outcome End Date 
(DDMMMYYYY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 ARR = Administration-associated reaction. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
204/Statistical Analysis Plan ML28964 
LISTING 16.2.6)6. GRADE 3+ ADVERSE EVENTS 
 
 
Patient 
 
Type of 
Lymphoma No. Description LLT 
PT 
SOC Start Date 
(DDMMMYYYY) SAE Initial 
Intensity AESI AAR Extreme 
Intensity 
Relation to 
Rituximab 
Action  
Taken with 
Rituximab 
Relation to 
Chemotherapy 
Action  
Taken with 
Chemotherapy 
AE Required 
Treatment 
Outcome End Date 
(DDMMMYYYY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 ARR = Administration-associated reaction. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
205/Statistical Analysis Plan ML28964 
LISTING 16.2.6)7. ADVERSE EVENTS LEADING TO RITUXIMAB DRUG INTERRUPTION OR DRUG DELAYED 
 
 
Patient 
 
Type of 
Lymphoma No. Description LLT 
PT 
SOC Start Date 
(DDMMMYYYY) SAE Initial 
Intensity AESI AAR Extreme 
Intensity 
Relation to 
Rituximab 
Action  
Taken with 
Rituximab 
Relation to 
Chemotherapy 
Action  
Taken with 
Chemotherapy 
AE Required 
Treatment 
Outcome End Date 
(DDMMMYYYY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 ARR = Administration-associated reaction. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
206/Statistical Analysis Plan ML28964 
LISTING 16.2.6)8. ADVERSE EVENTS LEADING TO CHEMOTHERAPY DOSE MODIFICATION 
 
 
Patient 
 
Type of 
Lymphoma No. Description LLT 
PT 
SOC Start Date 
(DDMMMYYYY) SAE Initial 
Intensity AESI AAR Extreme 
Intensity 
Relation to 
Rituximab 
Action  
Taken with 
Rituximab 
Relation to 
Chemotherapy 
Action  
Taken with 
Chemotherapy 
AE Required 
Treatment 
Outcome End Date 
(DDMMMYYYY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 ARR = Administration-associated reaction. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
207/Statistical Analysis Plan ML28964 
LISTING 16.2.6)9. ADVERSE EVENTS LEADING TO CHEMOTHERAPY DISCONTINUATION 
 
 
Patient 
 
Type of 
Lymphoma No. Description LLT 
PT 
SOC Start Date 
(DDMMMYYYY) SAE Initial 
Intensity AESI AAR Extreme 
Intensity 
Relation to 
Rituximab 
Action  
Taken with 
Rituximab 
Relation to 
Chemotherapy 
Action  
Taken with 
Chemotherapy 
AE Required 
Treatment 
Outcome End Date 
(DDMMMYYYY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 ARR = Administration-associated reaction. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
208/Statistical Analysis Plan ML28964 
LISTING 16.2.6)10. ADVERSE EVENTS WITHIN THE MEDDRA SMQ ANAPHYLACTIC REACTIONS 
 
 
Patient 
 
Type of 
Lymphoma  No. Description LLT 
PT 
SOC Start Date 
(DDMMMYYYY) SAE Initial 
Intensity AESI AAR Extreme 
Intensity 
Relation to 
Rituximab 
Action  
Taken with 
Rituximab 
Relation to 
Chemotherapy 
Action  
Taken with 
Chemotherapy 
AE Required 
Treatment 
Outcome End Date 
(DDMMMYYYY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
xxxx DDMMMYYYY 
xxx xxx 
xxx xxx xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
DDMMMYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 ARR = Administration-associated reaction. 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
209/Statistical Analysis Plan ML28964 
LISTING 16.2.6)11. INJECTION SITE REACTIONS 
 
 
Patient 
 
Type of 
Lymphoma Visit  
Was an Infection 
Assessment Done? 
Active 
Infection 
Was a Rituximab SC 
Injection Site 
Examination Done? 
Date of 
Assessment 
Examination 
Result 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
x 
Xxxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
210/Statistical Analysis Plan ML28964 
LISTING 16.2.6)12. DEATH 
 
 
Patient 
 
Type of 
Lymphoma 
Date of 
Death 
Primary Cause 
of Death 
If cause is AE, was 
Undelying Cancer a 
Contributing Factor? 
If Other, Specify 
Suspected Causal 
Realationship to 
Study Medication 
Was Autopsy 
Performed? 
If Yes, 
Summarize 
Findings 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
211/Statistical Analysis Plan ML28964 
LISTING 16.2.7.1) HEMATOLOGY 
 
 
 
 
 
 
 
 
Original unit 
 
SI 
 
Patient 
 
Type of 
Lymphoma 
Age 
(yrs) 
Gender 
Visit 
Collection 
Date 
(DDMMMYYYY) 
Parameter 
Value 
NRLL 
NRUL 
Reference to 
Normal Range 
 
Value 
Unit 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 NRLL: Normal range lower limit. NRUL: Normal range upper limit.  
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
212/Statistical Analysis Plan ML28964 
LISTING 16.2.7.2) BIOCHEMISTRY 
 
 
 
 
 
 
 
 
Original unit 
 
SI 
 
Patient 
 
Type of 
Lymphoma 
Age 
(yrs) 
Gender 
Visit 
Collection 
Date 
(DDMMMYYYY) 
Parameter 
Value 
NRLL 
NRUL 
Reference to 
Normal Range 
 
Value 
Unit 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 NRLL: Normal range lower limit. NRUL: Normal range upper limit.  
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
213/Statistical Analysis Plan ML28964 
LISTING 16.2.7.3) COAGULATION TESTS 
 
 
Patient 
 
Type of 
Lymphoma 
Age 
(yrs) 
Gender 
Visit 
Collection 
Date 
(DDMMMYYYY) 
Parameter 
Value 
NRLL 
NRUL 
Reference to 
Normal Range 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxx 
xxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: 
 NRLL: Normal range lower limit. NRUL: Normal range upper limit.  
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
214/Statistical Analysis Plan ML28964 
LISTING 16.2.8.1) VITAL SIGNS & BODY WEIGHT 
 
 
Patient 
 
Type of 
Lymphoma Visit 
Was Vital Signs 
Performed? 
Date of 
Assessment 
Pulse 
(bpm) 
SBP 
(mmHg) 
DBP 
(mmHg) 
Body 
Temperature 
(°C) 
Body 
Weight 
(Kg) 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
215/Statistical Analysis Plan ML28964 
LISTING 16.2.8.2) SERUM PREGNANCY TEST 
 
 
Patient 
 
Type of 
Lymphoma 
Was Serum 
Pregnancy Test 
Performed? 
Date of 
Assessment 
Test 
Result 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
216/Statistical Analysis Plan ML28964 
LISTING 16.2.8.3) URINE PREGNANCY TEST 
 
 
Patient 
 
Type of 
Lymphoma 
Was Urine 
Pregnancy Test 
Performed?  
Date of Urine 
Pregnancy Test 
Test Result 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
217/Statistical Analysis Plan ML28964 
LISTING 16.2.8.4) PHYSICAL EXAMINATION 
 
 
Patient 
 
Type of 
Lymphoma Visit 
Date of 
Assessment 
(DDMMMYYYY) 
Body System 
Result  
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
 
 
 
 
xxxx 
xxxx 
 
 
 
 
xxxx 
xxxx 
 
 
 
 
xxxx 
xxxx 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
 
 
 
 
xxxx 
xxxx 
 
 
 
 
xxxx 
xxxx 
 
 
 
 
xxxx 
xxxx 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
 
 
 
 
xxxx 
xxxx 
 
 
 
 
xxxx 
xxxx 
 
 
 
 
xxxx 
xxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
218/Statistical Analysis Plan ML28964 
LISTING 16.2.8.5) 12-LEAD ECG 
 
 
Patient 
 
Type of 
Lymphoma 
ECG Performed? 
 
ECG Date 
(DDMMMYYYY) 
ECG Result 
 
 
 
 
 
xxxx 
xxxx 
xxx 
DDMMMYYYY 
xxxxxxx 
xxxx 
xxxx 
xxx 
DDMMMYYYY 
xxxxxxx 
xxxx 
xxxx 
xxx 
DDMMMYYYY 
xxxxxxx 
xxxx 
xxxx 
xxx 
DDMMMYYYY 
xxxxxxx 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
219/Statistical Analysis Plan ML28964 
LISTING 16.2.8.6) TARGET LESION ASSESSMENT AT SCREENING (PART #1) 
 
 
Patient 
 
Type of 
Lymphoma 
Were Target 
Lesions 
Identified? 
Location If Other, 
Specify 
CT with 
Contrast 
Date of  
CT Scan 
CT Scan 
Result 
CT w/o 
Contrast 
Date of CT 
Scan 
Result 
MRI 
Date of  
MRI 
MRI 
Result 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
220/Statistical Analysis Plan ML28964 
LISTING 16.2.8.7) TARGET LESION ASSESSMENT AT SCREENING (PART #2) 
 
 
Patient 
 
Type of 
Lymphoma 
Clinical 
Assessment? 
Date of  
Assessment Result 
FDG-PET 
Date of 
Scan 
Result 
Other 
If Other, Specify 
Date of  
Scan 
Result 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
xxx 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
221/Statistical Analysis Plan ML28964 
LISTING 16.2.8.8) TARGET LESION ASSESSMENT SUBSEQUENT (PART #1) 
 
 
Patient 
 
Type of 
Lymphoma Visit Were Any 
Changes? 
Location If Other, 
Specify 
CT with 
Contrast 
Date of  
CT Scan 
CT Scan 
Result 
CT w/o 
Contrast 
Date of  
CT Scan 
Result 
MRI 
Date of  
MRI 
MRI 
Result 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
xxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
DDMMMYYYY 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
222/Statistical Analysis Plan ML28964 
LISTING 16.2.8.9) TARGET LESION ASSESSMENT SUBSEQUENT (PART #2) 
 
 
Patient 
 
Type of 
Lymphoma 
Clinical 
Assessment? 
Date of  
Assessment Result 
FDG-PET 
Date of 
Scan 
Result 
Other 
If Other, Specify 
Date of  
Scan 
Result 
Change in Lesion Since 
First Assessed or 
Previous Visit 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
xxx 
DDMMMYYYY 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
xxx 
DDMMMYYYY 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
xxx 
DDMMMYYYY 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxxx 
xxx 
DDMMMYYYY 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
223/Statistical Analysis Plan ML28964 
LISTING 16.2.8.10) OVERALL LESION ASSESSMENT 
 
 
Patient 
 
Type of 
Lymphoma 
Date  
of Assessment 
Response of Target 
Lesions 
New 
Lesions? 
Inv.’s Overall Assessment 
of Response at This Visit 
Date of 
Progression 
 
 
 
 
 
 
 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxx 
xxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxx 
xxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxx 
xxx 
DDMMMYYYY 
xxxx 
xxxx 
DDMMMYYYY 
xxxx 
xxx 
xxx 
DDMMMYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
224/Statistical Analysis Plan ML28964 
LISTING 16.2.8.11) SURVIVAL STATUS 
 
 
Patient 
 
Type of 
Lymphoma 
Was Survival 
Assessment 
Performed? 
Date of 
Assessment 
Survival  
Status 
Date of Last 
Contact 
Has the Patient Started 
New Lymphoma Treatment 
Since Last Contact? 
Start Date 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
xxx 
DDMMMYYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
225/Statistical Analysis Plan ML28964 
LISTING 16.2.8.12) BONE MARROW ASSESSMENT 
 
 
Patient 
 
Type of 
Lymphoma 
Was Bone Marrow  
Assesment Done? 
Date of BM 
assessment 
Was BM Assessment 
Done Using Aspirate? Result 
Was BM Assessment 
Done Using Biopsy? Result 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
x 
DDMMMYYYY 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxx 
xxxx 
x 
DDMMMYYYY 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxx 
xxxx 
x 
DDMMMYYYY 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxx 
xxxx 
x 
DDMMMYYYY 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
226/Statistical Analysis Plan ML28964 
LISTING 16.2.8.13) RASQ FOR IV ADMINISTRATION 
 
 
Patient 
 
Type of 
Lymphoma 
Was RASQ 
Completed? 
Date of 
Assessment 
Item #1 Item 1a 
.. 
Item 20 
Physical 
impact 
domain 
value 
Psychological 
impact domain 
value 
Impact on 
ADL 
Domain 
value 
 
Convenience 
domain 
value 
 
Satisfaction 
 Domain  
value 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY 
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
227/Statistical Analysis Plan ML28964 
LISTING 16.2.8.14) RASQ FOR SC ADMINISTRATION 
 
Patient 
 
Type of 
Lymphoma 
Was RASQ 
Completed? 
Date of 
Assessment 
Item #1 Item 1a 
.. 
Item 20 
Physical 
impact 
domain 
value 
Psychological 
impact domain 
value 
Impact on 
ADL 
Domain 
value 
 
Convenience 
domain 
value 
 
Satisfaction 
 Domain  
value 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
Rituximab - Roche North Africa (Algeria, Morocco & Tunisia) 
Mabrella ML28964 Daughter Protocol 
228/Statistical Analysis Plan ML28964 
LISTING 16.2.8.15) HEALTHCARE PROFESSIONAL QUESTIONNAIRE 
 
 
Site 
 
 
Healthcare 
professional 
 
Was HPQ 
Completed? 
Date of 
Assessment 
Item #1 Item 1a 
.. 
Item 10 
 
 
 
 
 
 
 
 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
xxxx 
xxxx 
xxxx 
DDMMMYYYY 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Source: XXXX.SAS, Run on DDMMMYYYY